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Central insulin resistance is common to both Type 2 Diabetes and Obesity. Magnetic 
resonance imaging (MRI) studies that investigated the effects of intranasally 
administered insulin, have highlighted the involvement of insulin in homeostatic, 
hedonic and to a lesser extent cognitive regulation of appetite control. 
 
This thesis documents a study that set out to explore the effects of intranasal insulin 
on brain function, using a pharmacological MRI protocol that probed the effects of 
insulin on resting state connectivity, resting state cerebral perfusion and the cerebral 
reward response to a food administration paradigm. This study was conducted in a 
group of healthy, male individuals, with normal and overweight participants.  A drug 
delivery device optimised for efficient nasal delivery of insulin, was employed.  
 
A customised, long-label pseudo continuous arterial spin labelling sequence was 
employed. It was shown that intranasal insulin leads to decreases in cerebral blood 
flow in the left insula, putamen, hippocampus and para-hippocampal gyrus. These 
decreases were limited to the overweight group. Furthermore, both hippocampal 
and putamen blood flow responses in the overweight group were associated with 
their dietary intake of saturated fat and sugar.  
 
Functional, blood oxygen level dependent (BOLD) images acquired during a paradigm 
in which participants received glucose and artificial sugar solutions, highlighted group 
differences in response to intranasal insulin in prefrontal, cognitive regions of brain. 
The normal weight individuals showed greater engagement of the anterior cingulate 
cortex, ventromedial prefrontal cortex and nucleus accumbens compared to 
overweight individuals when presented with conditioned stimuli for sweet tasting 
rewards.  
 
Resting state connectivity data was acquired with a novel, multi-echo pulse 
sequence, developed to minimise artefactual sources of temporal variance.  A seed-
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based connectivity analysis showed that connectivity between the left posterior 
hippocampus and the left fusiform gyrus was increased in response to intranasal 
insulin in normal weight individuals. Furthermore, normal weight group connectivity 
between the left posterior hippocampus and prefrontal regions was increased 
compared to overweight individuals following insulin administration.  
 
The results from this pharmacological MRI study indicate differential insulin 
responsiveness in normal weight and overweight individuals. These differences in 
responsiveness show changes in brain function as a result of increased weight in 
otherwise healthy individuals. This work adds to a large body of knowledge on central 
insulin signalling and has provided further supporting evidence of the involvement of 
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Chapter 1 The role of cerebral insulin 
in the modulation of food intake: 
investigations using imaging methods 
 
 
This introductory chapter will outline the basis for the aims of my investigation and 
the experimental procedures conducted and presented within this thesis. 
Throughout this introduction the reader will be given sufficient information with 
which to understand the reasons for conducting this research and also the reasons 
for implementing certain methodologies and protocols. Following this introductory 
chapter, the reader will be guided through the main methods implemented in the 
study, along with their relevant supporting theories. Then the experimental design 
and protocol will be described in detail with reference to the rationale and reasoning 
behind why and how the protocol was created. Following these three chapters 
(introduction, methods and study design) the five main experimental chapters and 
their results will be presented. Each chapter will contain introduction, methods, 
results and discussion sections. The final chapter within this thesis will present a 
summary and discussion of the main findings of each chapter, methodological 











1.1 Type 2 Diabetes Mellitus 
 
Type 2 diabetes mellitus (T2DM) is major global health concern, and has been 
described as one of the “major challenges to human health in the 21st century” 
(Unnikrishnan et al. 2017). T2DM is a metabolic disorder characterised by high blood 
sugar levels and poor blood sugar regulation. Initially considered a ‘western 
population’ disease, T2DM has reached global pandemic status, with widespread 
prevalence in emerging economies in continents such as Asia, Africa and Latin 
America (Unnikrishnan et al. 2017).  In 2017, approximately 425 million people 
worldwide suffered from diabetes and this number is set to increase to 629 million 
by 2045 (Atlas 2017). The prevalence and development of T2DM continues to grow 
due to the combination of a sedentary lifestyle and overconsumption of energy 
dense foods that are high in saturated fat and processed carbohydrates. The risk of 
developing T2DM is associated with a number of other factors; genetic and 
epigenetic (Poulsen et al. 1999), smoking and alcohol consumption (Manson et al. 
2000; Cullmann, Hilding, and Ostenson 2012) and obesity; rendering T2DM a multi-
factorial and highly complex disorder. T2DM causes increased risk of cardiovascular 
disease morbidity and mortality (Martín-Timón et al. 2014), microvascular effects 
that can lead to blindness and neuropathic pain (Fowler 2008), cognitive dysfunction 
and Alzheimer’s Disease (AD) (Sridhar, Lakshmi, and Nagamani 2015) and some 
cancers (liver, pancreatic) (Giovannucci et al. 2010).   
 
1.2 Obesity 
Obesity is characterised and defined by a disproportionate body weight to height 
ratio that is coupled with accumulation of adipose (fat) tissue. Obesity is usually 
assessed by anthropometric measures such as body mass index (BMI) that uses the 
ratio between body mass and the square of the height. A BMI between 25-29.9 kg/m2 
classifies people as overweight and a BMI greater than 30 kg/m2 classifies subjects as 
obese. (Normal weight BMI = 18.5 – 24.9 kg/m2). More than 2 billion people 
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worldwide are classified as overweight or obese based on BMI (Gonzalez-Muniesa et 
al. 2017). Obesity is a complex disorder that is often accompanied by systemic 
inflammation and increased risk for development of T2DM, some cancers (Renehan 
et al. 2010), cardiovascular disease (Nordestgaard et al. 2012), cognitive impairments 
(Jauch-Chara and Oltmanns 2014) and mood impairments and is also a significant 
economic burden (Renehan et al. 2010; Nordestgaard et al. 2012; Wang, McPherson, 
et al. 2011; Jauch-Chara and Oltmanns 2014). In very simplistic terms, the increased 
fat deposition seen in obese individuals results from an imbalance between energy 
intake (in the form of calories); and energy expenditure. This difference is known as 
the ‘energy balance’. In light of this simplistic view, obesity is a result of chronic 
increased food intake coupled with low physical activity.  
 
 
The rise of T2DM and obesity during the ‘modern’ age is primarily a product of the 
changes in lifestyle and diet that have accompanied modern civilisation. Originally 
seen as western diseases, T2DM and obesity continue to affect countries in growing 
economies and even within tribal communities, for example the aboriginal natives of 
Australasia. The environment we live in is changing at an exponential rate, a rate 
much faster than genetics and physiology are capable of. The introduction of 
automation and technology has revolutionised the capabilities of knowledge and 
technical efficiency, but at a cost of a decrease in physical activity and health. The 
diet of the modern age has changed considerably from originally consisting of 
unrefined whole foods to an increase in cheap and highly accessible processed foods 
high in saturated fats and carbohydrates. Common to T2DM and obesity and their 
related diseases and disorders is dysregulation of insulin and the pathways and 









In 1869, Paul Langerhans, a German anatomy student explored the anatomy of the 
pancreas and described “islands of clear cells” that populated this organ. These 
clusters/islands of clear cells are now known as “the Islets of Langerhans” and were 
later found to be responsible for the endocrine properties of the pancreas (Baskin 
2015). The islets boast a highly efficient vascular system and are also innervated by 
autonomic nerve fibres and terminals, that contain neurotransmitters such as acetyl 
choline and noradrenaline. Each islet consists of a mixture of cell types, the main 
types being the insulin secreting beta cells and the glucagon secreting alpha cells 
(Cabrera et al. 2006). 
 
Insulin is a small peptide hormone produced and released into the bloodstream by 
the beta cells of the pancreatic islets of Langerhans. The beta cell functions to both 
store as well as produce and secrete insulin into the peripheral circulatory system, 
where it acts to lower blood glucose concentration (Roder et al. 2016). The beta cells 
are highly specialised to meet the metabolic demands of the body, characterised by 
rapid insulin release into the bloodstream in response to acute physiological changes 
(Song et al. 2013). The alpha cells of the islets of Langerhans secrete glucagon, which, 
in contrast to insulin,  increases blood glucose levels (Goke 2008). Through the 
balanced secretion of both these hormones the pancreas is able to promote and 
maintain blood glucose concentrations between 4-6 mmol/L in healthy humans 
(Roder et al. 2016), despite wide fluctuations in energy availability and expenditure, 
a process known as ‘glucose homeostasis’. 
 
This endocrine system is a key physiological system that requires a finite balance of 
hormone release in order to achieve tightly controlled glucose homeostasis. The 
following sections will focus on insulin’s role in this process, its functions within the 
brain; and novel experimental methods that have been implemented to better 
explore insulin action within the brain.  
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1.3.1 Insulin release 
Insulin is secreted into the circulation from the pancreas in response to circulating 
metabolites (predominantly glucose) but can also be regulated by changes in other 
peripheral hormone species and fatty acids (Fu, Gilbert, and Liu 2013). An elevation 
in blood glucose concentration is known as hyperglycaemia and a low blood glucose 
concentration is known as hypoglycaemia. The beta cells of the pancreas are 
equipped to sense changes in physiological levels of glucose in the blood and to 
respond by releasing appropriate amounts of insulin in order to reach and maintain 
normoglycemia (euglycemia), a state of normal blood glucose concentration.  
 
During an increase in blood glucose, such as after a mixed meal (postprandial state), 
the glucose molecules enter the pancreatic beta cells via glucose transporters (GLUT-
1,2 and 3) along a concentration gradient (Richardson et al. 2007). Inside the beta 
cell, the glucose is phosphorylated by glucokinase, which acts as a glucose sensor and 
controls the subsequent release of insulin. Glucokinase is also found in the liver as 
well as the hypothalamus where it plays a role in hepatic glucose metabolism and 
top down control of glucose intake, respectively (Massa, Gagliardino, and Francini 
2011; Hussain et al. 2015). Insulin release in response to these glucose 
concentrations displays a biphasic profile: a rapid, but transient initial phase shortly 
followed by a more prolonged second phase (Caumo and Luzi 2004). The initial phase 
peaks approximately five minutes after pancreatic glucose sensing characterised by 
a large insulin burst, and the second phase releases the remaining insulin (Roder et 
al. 2016). The instantaneous availability of insulin is permitted through the 
recruitment of insulin storage vesicles close to the plasma membrane which are 






1.3.2 Peripheral insulin effects 
The insulin receptor belongs to the tyrosine kinase family of receptors and is found 
on the plasma membrane of the target cells within the insulin-responsive tissue 
types. The main sites of insulin action comprise skeletal muscle, adipose tissue and 
the liver (Fulop, Larbi, and Douziech 2003). A major anabolic role of insulin in the 
body is to regulate and maintain normal blood glucose levels by promoting cellular 
blood glucose extraction, glucose oxidation and energy storage in skeletal muscle 
and adipose tissue (Wilcox 2005). The rate of glucose uptake into these cell types is 
dependent on the quantity of glucose transporters, predominantly glucose 
transporter type 4 (GLUT-4), present on the cell surface (Kido, Nakae, and Accili 
2001). Insulin signalling at the cell surface, via the insulin receptor, and subsequent 
downstream interactions stimulates the translocation of GLUT-4 from the cytoplasm 
to the cell surface, thus rendering skeletal and adipose tissue glucose uptake, insulin 
dependent (Chang, Chiang, and Saltiel 2004). In the liver, GLUT2 is the predominant 
glucose transporter, and is not insulin responsive. Insulin acts within the liver where 
it stimulates glycogen synthase and inhibits glycogen phosphorylase, promoting 
glucose storage in the form of glycogen and inhibition of   glycogenolysis, respectively 
(Rui 2014). The combination of these effects is key to glucose homeostasis and 
underpins the anabolic effects of insulin.  
 
Aside from glucose stimulated insulin release, the release of pancreatic insulin is 
sensitive to other external factors. For example, the gut hormone glucagon-like 
peptide-1 (GLP-1), which is secreted in response to fructose, free fatty acid and 
glucose ingestion, potentiates pancreatic insulin release (incretin effect) (Kreymann 








1.4 Insulin Resistance 
Peripheral insulin resistance is defined as a pathological state in which the ability of 
insulin to produce its homeostatic effects on normal circulating glucose 
concentrations is reduced (Sears et al. 2009). In other words, peripheral insulin 
resistance is an impairment in the ability of insulin to control hepatic glucose output 
or to maintain uptake of glucose into peripheral target tissues. Insulin resistance 
refers to an inefficient peripheral response to insulin, thus requiring a greater 
concentration of circulating insulin to extract glucose from the blood into the liver 
and muscle cells. This inefficiency leads to a prolongation of the second phase 
pancreatic insulin release which, over time, significantly strains the islet beta cells of 
the pancreas. Insulin resistance precedes the development of T2DM and obesity and 
contributes to many of the complications associated with other metabolic diseases, 
such as the metabolic syndrome (Stears et al. 2012). Insulin resistance is a major risk 
factor for cardiovascular disease (Trevisan et al. 1998) and is known to contribute to 
accelerated ageing (Ryan 2000).   
 
The complexities of both T2DM and obesity are associated with similar dysfunctions 
in the brain and therefore the action of insulin in the brain has been explored in depth 
to understand the central impairments common to both these disorders.  
 
1.5 Insulin in the Brain 
For a long time the brain was considered to be an insulin “insensitive” organ (Gray, 
Meijer, and Barrett 2014). The brain relies predominantly on glucose as a fuel source, 
with the adult human brain, which accounts for only 2% of total body weight, 
consuming roughly 20% of the body’s total glucose and oxygen content 
(Mergenthaler et al. 2013). Glucose, as in the majority of cell types, is metabolised in 
neurons and glial cells to produce adenosine tri-phosphate (ATP), the basis of cellular 
maintenance and energy for neuronal function (Erbsloh, Bernsmeier, and Hillesheim 
1958). As the brain is such an energy demanding organ, there are requirements for a 
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constant glucose supply which is facilitated by the selective permeability of glucose 
through the blood brain barrier (BBB) (Mergenthaler et al. 2013). Blood glucose 
passes through plasma membrane GLUT-1 transporters along a concentration 
gradient into the extracellular fluid of the central nervous system (CNS). Once here, 
cell specific uptake is facilitated by GLUT-3 transporters for neuronal and GLUT-1 for 
glial and endothelial cell uptake, respectively (Ghasemi et al. 2013). These 
transporters, unlike GLUT-4, do not require insulin to initiate uptake and therefore 
glucose uptake within the majority of brain tissue cells can be classified as insulin-
independent. However insulin receptors do exist within the brain and may have a 
different role in the brain in comparison to its actions of peripheral tissue target sites 
(Plum, Schubert, and Brüning 2005).   
 
1.5.1 Insulin receptor distribution  
In humans, insulin receptors are found on neurons within the hypothalamus, 
amygdala, hippocampus, cerebellum and maintain the highest density within the 
olfactory bulb (Schulingkamp et al. 2000). Insulin action within the brain is regionally 
dependent and is involved in a number of key central functions, from metabolism, 
memory and mood to appetite control (Heni et al. 2015; Kullmann et al. 2013; 
Kullmann, Heni, Veit, Scheffler, Machann, Häring, et al. 2015; Guthoff et al. 2010; 
Kroemer et al. 2013; Winocur, Moscovitch, and Bontempi 2010).  
1.5.2 Insulin transport to the brain tissue  
Circulating insulin enters the CNS via a saturable receptor-mediated transport 
mechanism across the blood-brain barrier (BBB) into the cerebrospinal fluid and 
interstitial fluid compartment (Blázquez et al. 2014). Measuring this concentration of 
insulin within the central nervous system (CNS) is not straightforward, however, 
estimations in cerebrospinal fluid (CSF) can be used as a surrogate measure (Banks, 
Owen, and Erickson 2012; Wallum et al. 1987). CSF insulin concentrations are 
considerably lower than those measured from the peripheral circulation but show 
proportional rises following a meal or with peripheral insulin infusion (Kleinridders et 
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al. 2014). The rate of insulin transport across the BBB shows regional variation with 
greatest BBB transport rates occurring in the olfactory bulb (Banks, Kastin, and Pan 
1999). It is also known that some regions of the brain have an inherent reduction in 
BBB integrity, such as the hypothalamus, that renders these regions ‘leaky’ thus 
permitting greater BBB transport of insulin across the BBB (Kleinridders et al. 2013). 
In people with obesity and AD, reduced insulin transport into the CSF has been 
demonstrated, resulting in decreased concentrations of centrally available insulin 
and subsequent reductions in central insulin signalling (Kern et al. 2006; Craft et al. 
1998). Impaired brain insulin signalling is known as central insulin resistance, a 
physiological state that has been observed alongside peripheral insulin resistance 
(Heni, Schöpfer, et al. 2014). Transport of insulin into the brain decreases with age 
(Sartorius et al. 2015) and an association between increased dietary fat intake and 
reduced CNS insulin uptake has been observed in dogs maintained on a high fat diet 
for seven weeks (Kaiyala et al. 2000). The exact mechanism behind this disrupted 
transport across the BBB is not fully elucidated although some have suggested that 
this impairment is thought to occur due to fatty deposits lining the cerebral 
vasculature, physically blocking transport across the BBB (Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015). 
 
1.5.3 Brain insulin resistance 
Much like the description of peripheral insulin resistance, central insulin resistance 
can be defined as the failure of brain cells to respond to insulin (Mielke et al. 2005). 
1.5.3.1 In utero 
As central insulin resistance is largely associated with peripheral insulin resistance, 
some of the causes may be considered common to both types. Studies have shown 
the link between in utero development of brain insulin resistance in fetuses of insulin 
resistant mothers (Linder et al. 2014; Linder et al. 2015). These studies showed that 
administration of an oral glucose solution (the oral glucose tolerance test) in insulin-
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resistant mothers led to a slower fetal post-glucose brain response in comparison to 
insulin-sensitive mothers (Linder et al. 2014; Linder et al. 2015). 
1.5.3.2 Diet 
Saturated fat intake is associated with a decrease in brain insulin sensitivity seen from 
rodent experiments focused on the amygdala (Boghossian et al. 2009; Oh et al. 2013). 
These studies showed that intracerebroventricular (ICV) injection of insulin to the 
amygdala leads to a significant reduction in food intake in wild type rats. These 
animals showed reduced amygdala responsivity to ICV insulin injections after just 3 
days of a high fat diet, which was not coupled with significant changes in peripheral 
insulin sensitivity (Boghossian et al. 2009). Interestingly, this  amygdala specific 
central resistance could be reversed upon switching to a low fat diet, and the rate at 
which sensitivity could be regained was dependent on the duration of the initial high 
fat diet (Boghossian et al. 2009).  
 
1.5.4 Increasing insulin concentrations in the brain 
To understand the effects of insulin resistance in the brain, it is necessary to discuss, 
firstly, the actions of insulin in the brain and secondly, to what extent these actions 
are dysregulated in those with central insulin resistance. To this end, explorations of 
insulin action in the brain have relied upon increasing insulin concentrations in the 
brain, which can be achieved by modulating endogenous pancreatic release or by 
increasing exogenous insulin concentrations. The common methods used are 





In clinical settings the hyperinsulinemic-euglycemic clamp technique is considered 
the gold standard method for assessing insulin sensitivity (Kim 2009); and is a useful 
tool for increasing insulin concentrations whilst avoiding the gustatory response that 
occurs following a meal ingestion. This clamp technique requires maintaining fasting 
blood glucose levels (euglycemia) by glucose infusion, and the amount of glucose 
required to achieve this can be used as a determinant of whole body insulin 
sensitivity (for example, high glucose = high insulin sensitivity). This method involves 
intravenous (iv) infusions, making this an invasive technique which, used as a 
Table 1.5.1 Laboratory methods commonly used to increase insulin concentrations in the periphery 
and the brain in humans. Light grey rows refer to those methods used to increase pancreatic insulin 
secretion, whereas the dark grey rows describe methods used to increase exogenous insulin 
concentrations.  
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research tool, is fairly labour intensive. Furthermore, by increasing peripheral and 
subsequently central insulin concentrations (Kleinridders et al. 2014) simultaneously, 
dissociating peripheral and central insulin effects becomes unachievable. A recent 
addition to the repertoire of methods that can be used to increase central insulin 
concentrations is intranasal administration.  
 
1.6 Intranasal Insulin  
Insulin administered via the nasal cavity is a method that permits direct brain 
administration of insulin, circumventing peripheral blood glucose regulation and 
control (Henkin 2010). This route bypasses the BBB, by diffusion across the olfactory 
epithelia into the subarachnoid space (Dhuria, Hanson, and Frey 2010; Spetter and 
Hallschmid 2015), effectively reaching CSF within 30-60 minutes (Born et al. 2002), 
increasing CNS insulin concentration without going through the peripheral 
circulation. This method requires deposition of insulin, either in solution or as a 
powder aerosol, to the superior-posterior region of the nasal cavity using a nasal 
spray device. The anatomical pathways and mechanical methods used for this 
administration technique will be detailed in Chapter 4.    
 
Following Born’s seminal study profiling intranasal insulin (IN-INS) kinetics (2002), 
research in this area has grown substantially in the last decade (Born et al. 2002). The 
discovery that IN-INS shows beneficial effects on memory and cognition in patients 
suffering from AD (Benedict et al. 2004; Freiherr et al. 2013; Ott et al. 2012; Spetter 
and Hallschmid 2015) was a pivotal factor for the growing application of this 
technique to other basic science and neurophysiological questions. IN-INS is an 
attractive tool for assessing insulin effects on brain function using functional 
magnetic resonance imaging (fMRI) (Schilling et al. 2014; Grichisch et al. 2012). A 
body of behavioural and imaging related published literature has shown a 
modulatory role of insulin in appetite control and food intake. The next sections will 
introduce the mechanism involved in the processes of food intake, that extend 
beyond survival and the detrimental effects that occur as a result of dysregulation of 
these systems.   
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1.7 Food Intake and Appetite Control 
Appetite control and subsequent food intake are complex multi-faceted functions 
that combines a range of dynamic, semi-dissociable mechanisms regulated within 
the brain. The interplay of these systems and mechanisms ultimately control eating 
behaviour from when food intake will occur, through what constituents the meal will 
be comprised of and how much will be consumed in the time between the next meal 
and subsequent meals thereafter. Dysregulation of these systems is likely to lead to 
poor appetite control, seen from the increased body weight and increased fat mass 
that is observed in overweight individuals. A long-term positive energy balance (more 
energy consumed than expended) that may result from poor appetite control is 
coupled with an increase in risk of insulin resistance and development of T2DM and 
obesity (Gonzalez-Muniesa et al. 2017). 
 
Traditional research into appetite control has focused on two main systems; the 
homeostatic and the hedonic system. The homeostatic system can be referred to as 
the metabolic system as it is characterised by a co-ordinated communication 
between peripheral hormonal and nutrient sensing molecules; and the brain, largely 
the hypothalamus and midbrain. The homeostatic system acts to maintain energy 
balance through the dynamic variations in signalling molecule concentrations 
throughout the body, and signals that convey metabolic needs to the brain. In 
contrast, the hedonic system operates and drives desire for food consumption based 
on the palatability of food and the natural rewarding aspects and pleasure associated 
with food consumption. The hedonic system, driven by these potent rewarding 
effects, is capable of overriding the metabolic needs of the body, leading to periods 
of positive energy balance. These two systems are somewhat dissociable but not 
entirely independent due to crosstalk between the neurochemical substrates across 
both systems (Berthoud 2006). For example, the palatability of high calorie energy 
rich foods is increased when hungry in comparison to periods of satiation (Goldstone 
et al. 2009).  
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Recent work into the modulation of appetite control and food intake argues that 
there is a third mechanism involved in this multi-faceted network of appetite control 
and food intake; the cognitive system (Higgs 2016). This cognitive system concerns 
processes such as inhibitory control of food intake, dietary restraint, as well as 
learning value from food rewards, creating memory of foods and driving attention 
towards aspects of eating. This mechanism or system is a relatively new addition to 
the appetite control theories and mounting evidence continues to grow within this 
field regarding the cognitive aspects associated with food appetite and reward.  
 
This thesis explores the role of central insulin in appetite control. The following 
sections will describe the regulation of the three control systems (homeostatic, 
hedonic, cognitive) with an emphasis on intranasal insulin; and research based on 
the use of functional magnetic resonance imaging (fMRI). Furthermore, the known 
dysfunctions associated with these systems, that occur in obesity and T2DM will also 















1.7.1 Homeostatic system 
The complexity of the homeostatic system is beyond the scope of this chapter, but it 
is necessary to explain a selection key metabolic peptide and hormone signals 
involved in homeostatic regulation of food intake. For a thorough review Coll et al., 
is recommended (Coll, Farooqi, and O'Rahilly 2007). As described earlier, the 
homeostatic system works to maintain energy balance (where energy intake equals 
energy expenditure) and body weight by integrating circulating signals that promote 
food intake and those that supress food intake. Peripheral signals originate from the 
gastrointestinal (GI) tract, adipose tissue stores and also from the pancreas and are 
key to sensing changes in nutrient availability such as glucose, fatty acids and amino 
acids. These signals are integrated largely within the homeostatic centre of the brain, 
the hypothalamus, via the arcuate nucleus (ARC) and the connections between 
hypothalamic and extra-hypothalamic regions of the brain, for example the nucleus 
tractus solitarius. For the purpose of describing the homeostatic system within the 
context of this thesis only a selection of signals involved will be described. An 
example of the integrated and dynamic activity of these signals is presented in Figure 




Leptin is released by adipose tissue and is considered an ‘adiposity signal’ or marker. 
In normal weight individuals, leptin levels are relatively stable over time, but they are 
increased in overweight/obese individuals who possess high amounts of adipose 
tissue (Carlson et al. 2009). Leptin supresses food intake by inhibition of the 
neuropeptide Y/Agouti-related (NPY/AgRP) peptide-expressing neurons and 
stimulates the cocaine and amphetamine-related transcript (CART) and the pro-
opiomelanocortin (POMC)-expressing neurons located in the hypothalamus. As 
mentioned, leptin levels are raised during obesity but the sensitivity of leptin as an 
appetite suppressant is significantly reduced in obesity (Myers et al. 2010).Leptin is 
a marker of adiposity and does not show large dynamic variations during low energy 
 46 
(fasting) or high energy (postprandial) states (Korbonits et al. 1997), having little 
impact on food intake.  
 
1.7.1.2 Peptide YY 
Peptide YY (PYY) is an amino acid secreted in response to food ingestion from the 
endocrine L cells of the gut. PYY exists in two forms PYY1-36 and PYY3-36, which are 
both metabolically active. Secretion of PYY rapidly increases during the postprandial 
state but is low during fasting. PYY has anorectic effects, suppressing food intake, by 
inhibition of NPY activity either through penetration across the BBB or through 
activation of the vagus nerve. Overweight and obese individuals show a PYY 
deficiency that is well correlated with reduced satiety (le Roux et al. 2006). 
 
1.7.1.3 Glucagon-like Peptide-1 
Glucagon-like Peptide-1 (GLP-1) is a peptide released by the L cells of the small 
intestine. GLP-1 is released in response to food ingestion. GLP-1 is an incretin peptide 
that stimulates glucose-dependent insulin secretion from the pancreas and acts to 
supress glucagon release. GLP-1 agonists are used in the treatment of T2DM and 
obesity and display glucose lowering effects as well as weight loss effects. There is 
evidence to suggest that GLP-1 exerts its weight loss inducing effects at the level of 
the hypothalamus (Chaudhri et al. 2006). GLP-1 secretion to glucose ingestion is 
attenuated in obese individuals but shows a normal secretory response to oral fat 







In healthy normal weight individuals during periods of negative energy balance, for 
example between meals or following an overnight fast, there is an increase in ghrelin 
secretion from the oxyntic cells of the stomach (Coll, Farooqi, and O'Rahilly 2007). 
Ghrelin is an enteric hormone that stimulates appetite. Peripheral administration of 
ghrelin stimulates food intake through activation of the NPY/AgRP expressing 
neurones of the hypothalamus. Ghrelin levels are highest during fasting and are 
supressed following calorie intake in the postprandial state (Goldstone et al. 2014). 
In obese individuals ghrelin is lower or comparable during fasting conditions vs 
normal weight individuals, however there is a significant delayed response in ghrelin 
level reduction following meal ingestion in obese individuals compared to lean, which 









Figure 1.7.1 Schematic diagram showing a selection of homeostatic signals, described above, before 
and after a meal in normal weight and obese individuals. In normal weight individuals during the 
fasted state, ghrelin levels increase which promotes food intake. Following a mixed meal, ghrelin 
levels will decrease whereas GLP-1, PYY and insulin secretion will be increased. GLP-1 is an incretin 
and promotes pancreatic insulin release. All these signals will eventually reach the hypothalamus to 
supress further energy intake. In obese individuals, both leptin and insulin levels are higher in 
comparison to lean individuals but both brain leptin and insulin sensitivity is decreased. Ghrelin is 
largely unchanged between lean and obese during fasting. Following a mixed meal, there is a high 
increase in peripheral insulin (assuming no T2DM), postprandial ghrelin levels fall much slower in 
obese vs lean. GLP-1 response is attenuated to sugar but not fat. PYY levels remain largely 
unchanged following feeding. Insulin levels are high (during fasting and postprandial) due to 
decreased insulin sensitivity.  
 49 
1.7.1.5 Insulin and its role in the homeostatic system  
The presence of insulin receptors within the hypothalamus initiated the notion that 
insulin is key to the homeostatic control of food intake (Ott et al. 2012; Schulingkamp 
et al. 2000). Brain insulin receptor gene knockout mice (NIRKO mice) show increases 
in body weight and development of diet-sensitive obesity (Bruning et al. 2000), 
demonstrating a role of central insulin signalling in homeostatic weight regulation.  
 
In humans, IN-INS administered four times per day for eight weeks resulted in 
significant weight loss (1.3kg) and a reduction in total adipose tissue in men 
(Hallschmid et al. 2004). However, this effect was not observed in women, which in 
contrast caused a small weight increase as a result of excess fluid retention 
(Hallschmid et al. 2004). However, the same treatment regimen in obese individuals 
did not lead to any differences in weight loss (Hallschmid et al. 2008). A suggested 
explanation for the absent treatment effect in the obese cohort is that obesity is 
associated with chronic endogenous brain insulin resistance and this route of 
administration, although effective in increasing CSF insulin, was not capable of 
increasing sensitivity to the weight reducing effects of insulin (Hallschmid et al. 2008).  
 
Several studies have examined the effect of acute administration of IN-INS on 
responses to food intake. For example, three separate studies probing the 
differential gender effects mentioned above, showed that total food intake was 
reduced following IN-INS administration in men (Jauch-Chara et al. 2012; Benedict et 
al. 2008) but not in women (Hallschmid et al. 2012; Benedict et al. 2008). Firstly, 
following 40 international units (IU) IN-INS, men showed a significant reduction in 
food intake (breakfast ad libitum buffet), predominantly carbohydrate and protein 
based foods, in comparison to IN-PLA (Jauch-Chara et al. 2012). Secondly, in a sperate 
study, 160 IU IN-INS induced significant reductions in total food intake (breakfast 
buffet) in men (Benedict et al. 2008). These results suggest that central insulin in men 
has an appetite suppressant, anorexigenic effect. Benedict et al., further showed that 
the female comparator group were not sensitive to the anorexigenic effects of 
insulin, but, interestingly, presented with IN-INS related cognitive and memory 
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enhancing effects which were absent in the male group (Benedict et al. 2008). These 
differential effects have been seen in rodents, and research has shown that high 
brain oestrogen levels  decrease insulin sensitivity, but in contrast increase leptin 
sensitivity (Clegg et al. 2006). The final study from these three studies mentioned 
showed a selective reduction of energy dense cookies, chocolate chip, in women 
following postprandial administration of IN-INS (160 IU) (Hallschmid et al. 2012). This 
postprandial reduction in cookie consumption was only in the cookies that were 
rated most palatable. This decrease did not result in a reduction in total calorie intake 
as intake of the other snacks available were slightly increased (not significant). These 
effects suggest that insulin may also interact with other satiety signals, thus 
restricting additional eating of palatable foods following a meal. The kinetics of 
endogenous insulin release from the pancreas to the brain CSF are slow (on the scale 
of 4 hours) and hence would render insulin an unlikely satiation hormone (Banks, 
Owen, and Erickson 2012; Wallum et al. 1987; Schwartz et al. 1990); however it can 
be seen that manipulation of central insulin concentration, via exogenous intranasal 
administration, could be an indirect method for reducing food intake in men and 
intensifying selective satiety of palatable foods alongside the plethora of metabolic 
signals released upon food ingestion.   
 
fMRI studies implementing blood oxygen level dependent (BOLD) contrast have 
shown decreases in hypothalamic activity in response to glucose infusion and glucose 
ingestion (Opstal et al. 2017; Smeets et al. 2005). Importantly, the hypothalamic 
decrease in BOLD response is more pronounced followed glucose ingestion as 
opposed to glucose infusion, again suggesting a complementary role for insulin 
alongside other homeostatic signal molecules (Smeets et al. 2007). In keeping with 
this, the decrease in hypothalamic BOLD response (vs baseline) seen in response to 
glucose ingestion is augmented following elevation of central insulin concentrations 
via IN-INS (Opstal et al. 2017). Furthermore, an IN-INS triggered reduction in 
fractional amplitude of low frequency fluctuations (fALFF) (a measure of resting 
neuronal activity), was witnessed in the hypothalamus (Kullmann et al. 2018). 
Accumulation of these findings suggest an insulin-associated role in the 
hypothalamus supporting the role of insulin as a signalling molecule within the 
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homeostatic appetite control system. In contrast to the insulin sensitivity effects 
mentioned, Heni et al., showed measures of insulin resistance (using the homeostatic 
model assessment of insulin resistance (HOMA-IR)) to increase thirty minutes after 
IN-INS administration when compared to intranasal placebo (IN-PLA), which returned 
to comparable levels soon after (Heni et al. 2012). Heni et al., demonstrated that this 
increase in insulin resistance positively correlated with changes in hypothalamic 
fALFF measures (Heni et al. 2012). Insulin sensitivity was assessed by HOMA-IR using 
plasma glucose and plasma insulin concentrations. In this study a significant increase 
in plasma insulin and a significant decrease in plasma glucose was seen as a result of 
residual IN-INS absorption into the central circulation. HOMA-IR is typically used for 
measuring basal insulin sensitivity from fasting blood measures. This study 
implements a pharmacological challenge (IN-INS) and therefore cannot be 
considered basal conditions, especially given the significant changes in plasma 
glucose and insulin concentrations.  
 
 
The BOLD responses reported from a selection of the aforementioned studies 
(Kullmann, Heni, et al. 2017; Kullmann et al. 2018; Heni, Wagner, et al. 2014; Heni et 
al. 2012) were acquired using traditional whole brain T2* weighted gradient echo 
Echo Planar Imaging (EPI) methods, which suffer from susceptibility-related signal 
dropout effects (Deichmann et al. 2003; Ojemann et al. 1997). Signal dropout due to 
magnetic field distortions at air-tissue boundaries, such as the orbitofrontal cortex 
and midbrain regions (hypothalamus), negatively influence image quality and 
therefore one must be slightly sceptical of these reported hypothalamic BOLD 
changes. Furthermore, the correlations reported between hypothalamic BOLD 
responsiveness and measures of insulin sensitivity, do not demonstrate a significant 
hypothalamic response when compared to IN-PLA and so these must also be viewed 
with caution.  
 
In parallel with those investigations, studies using Arterial Spin Labelling (ASL), to 
assess changes in regional cerebral blood flow (CBF), have shown supporting 
evidence for insulin related changes in the hypothalamus. Using a high dose of IN-
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INS (160 IU) Kullmann et al., presented an insulin-dependent decrease in 
hypothalamic cerebral blood flow (CBF) (Kullmann et al. 2018). Decreases in IN-INS 
related hypothalamic CBF have shown correlations with pancreatic insulin secretion, 
as measured with an oral glucose tolerance test (oGTT) performed on a separate day, 
illustrating a strong hypothalamus CBF decrease in individuals that secrete less 
pancreatic insulin to restore normoglycemia (Kullmann, Fritsche, et al. 2017), 
suggesting a link between hypothalamic and peripheral insulin sensitivity. Kullmann 
et al., also showed IN-INS associated decreases in hypothalamic CBF, compared to 
pre-administration measures in both lean (insulin sensitive) and overweight/obese 
(insulin resistant) individuals, highlighting that this insulin related response in CBF is 
also seen in those with peripheral insulin resistance. Furthermore, these significant 
CBF decreases from baseline in the hypothalamus following IN-INS (15 minutes after 
administration) correlated moderately (r=0.37, p = 0.015) with whole body MRI 
measurements of visceral adipose tissue (VAT) (Kullmann, Heni, Veit, Scheffler, 
Machann, Häring, et al. 2015). These findings suggest that those individuals with high 
amounts of visceral fat may have impaired hypothalamic insulin signalling, although 
the trend for this is arguably not very strong. Some ASL image acquisition schemes 
that do not use EPI readouts show good image quality in the regions typically affected 
by tissue susceptibility gradients in gradient-recalled EPI readouts. However, many 
of the ASL based studies did use EPI readouts and therefore the signal of 
hypothalamic change in these areas must also be interpreted with caution. In spite 
of this, the imaging evidence from both BOLD and CBF based studies is, at large, 
compelling; and suggests a role for insulin in the homeostatic control of food intake, 






1.7.2 Hedonic mechanisms 
Hedonic mechanisms underlying appetite and food consumption have been 
classically investigated through a conceptual framework that utilises two distinct 
reward concepts; liking (palatability of food) and wanting (motivation and drive for 
food) (Berridge 2004, 2009). ‘Wanting’ is predominantly governed by the 
dopaminergic (DA) neurotransmitter system which is comprised of midbrain and 
striatal structures and networks; the ventral tegmental area (VTA), substantia nigra 
(SN), nucleus accumbens (NAcc), caudate and putamen (Volkow, Wang, and Baler 
2011; Berridge 2009)  ‘Liking’, in the classical reward sense, can be defined by the 
hedonic properties of stimuli. With food, for example, the hedonic properties would 
be measured as palatability and appeal of certain food stimuli. This liking of food 
stimuli is considered to be underpinned by the opioid and endocannabinoid system 
(Pecina and Berridge 2005). Both systems show widespread receptor profiles that 
cover the striatum, midbrain, insula, thalamus, amygdala and regions of the 
prefrontal cortex too (Karlsson et al. 2015).  
 
The hedonic control of appetite and food intake is posited to reflect the integration 
of these sub-systems and signals within cortical (insula, orbitofrontal cortex) and 
limbic regions (NAcc, caudate, putamen, amygdala, hippocampus). The dysregulation 
of these systems, scholars argue, underpins the disrupted appetite control and 
overeating of energy dense (highly palatable) foods that is associated with obesity 
(Volkow, Wang, Fowler, et al. 2008; Volkow, Wang, and Baler 2011; Drewnowski 
2007). In general, the hedonistic value of food is underpinned by factors such as taste 
and flavour with high fat containing foods correlating with high palatability, which to 
some extent is supported by the overconsumption of fatty foods in obese 
populations (Dagher 2012; Drewnowski 2007). Consumption of palatable foods 
activates the mesolimbic system, a neural circuitry that mediates reward and 
motivation via dopaminergic (DA) neurons and neurotransmitters (Volkow, Wang, 
and Baler 2011). These systems are active when consuming palatable foods as well 
as during anticipation of sensory stimuli (Burger and Stice 2011a; Stice et al. 2008). 
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1.7.2.1 Insulin and the hedonic system 
An intuitive example or argument for the involvement of insulin in hedonic 
processing of food is that during prolonged periods of negative energy balance (food 
deprivation) the responsiveness to food stimuli is increased. From our understanding 
of insulin’s dynamic role in the body, during these times circulating insulin levels 
would be very low (Figlewicz and Benoit 2009) and these low levels could be 
associated with the drive and desire to seek food rewards. Likewise, increases in 
circulating insulin levels (such as that after a mixed meal) could attenuate the reward 
driven desires and motivations, a concept known as motivational salience. In healthy 
individuals, fasting increases motivational salience, whereas during food intake 
motivational salience decreases. In obese individuals, however, this motivational 
salience pattern is dysregulated, described throughout the sections below.   
 
In humans, the hedonic value of food (liking) can be assessed behaviourally through 
questionnaires and ratings of palatability. ‘Wanting’ for food can be assessed by how 
much food is consumed and the amount of effort willing to exert to acquire certain 
food stimuli. Hallschmid et al., performed a study to investigate the effects of IN-INS 
on postprandial snack consumption in women (Hallschmid et al. 2012), which has 
been mentioned previously. In this study they evaluated snack intake (a choice of 
three types of cookies) two and a half hours after a substantial lunch (four mini 
pizzas). Shortly after lunch termination, participants were administered either IN-INS 
(160 IU) or IN-PLA. IN-INS did not show a reduction in total snack intake, however, 
IN-INS did evoke a significant reduction in palatability ratings for the most favoured 
cookie type (chocolate chip - measured under IN-PLA conditions) which was coupled 
with a significant reduction in chocolate chip cookie intake (Hallschmid et al. 2012). 
This result suggests that insulin does not inhibit postprandial intake as there was no 
difference between net snack consumption; but that insulin specifically reduced 
consumption of highly palatable snacks. Results like this might make the dissociation 
of ‘wanting’ and ‘liking’ effects more difficult. In theory, both ‘liking’ and ‘wanting’ of 
the highly palatable chocolate cookies decreased in the presence of central insulin 
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increases; suggested by the decrease in palatability ratings and reduced consumption 
for the chocolate cookies, respectively.  
 
fMRI permits the assessment of behaviour in tandem with changes in neurovascular 
physiology, in response to changes in neuronal activity. ‘Liking’ of food stimuli can be 
assessed through the use of food cue responsiveness when participants are 
presented with a food related stimuli for example pictures of food, smells, tastes etc 
(Dagher 2012). Responsiveness to these cues is often processed by cortical structures 
in the brain; such as the insula, orbitofrontal cortex (OFC), fusiform gyrus and 
occipital regions (LaBar et al. 2001; van der Laan et al. 2011; Verhagen 2007). Food 
cues often engage sensory regions such as the insula, commonly known as the 
gustatory cortex, as well as regions involved in encoding stimulus value, for example 
the OFC (Gottfried, O'Doherty, and Dolan 2003).  
 
Guthoff et al., were the first to show changes in food cue responsivity with increased 
central insulin concentrations, using IN-INS. Administration of IN-INS (160 IU) 
induced reduced cortical activity in comparison to IN-PLA in the fusiform gyrus, 
hippocampus, as well as the superior temporal gyrus (Guthoff et al. 2010). These 
decreases in BOLD contrast were exclusive to food pictures only suggestive of an IN-
INS related decrease in salience or liking of the food picture stimuli presented. 
However, these findings must be carefully considered as the authors report these 
changes at a statistically liberal threshold (p < 0.001, uncorrected for multiple 
comparisons) and therefore these results could be suggestive of a trend, rather than 
a significant finding. Ferreira de Sa et al., did not provide complementary support to 
this finding, publishing a study that showed no central effect of IN-INS on food cue 
processing using an acoustic startle response technique (Ferreira de Sa et al. 2014). 
This study used a lower dose of IN-INS (40 IU) and a different technique and so it is 
difficult to directly compare these two studies. Despite this, with the same low dose 
(40 IU) Schilling et al., presented IN-INS related changes in CBF during the resting 
state (Schilling et al. 2014). They showed regional CBF (rCBF) increases in the insula 
and putamen, two key regions involved in gustatory integration and reward 
processing (Schilling et al. 2014). Although these individuals were not engaged in a 
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functional paradigm, the change in CBF might reflect a change in basal activity which 
could modulate engagement of these areas if recruited by a task. Resting-state fMRI-
BOLD data that probed IN-INS (160 IU) related changes of fALFF in lean women 
observed a decreased in fALFF measures in the hypothalamus as well as the OFC 
(Kullmann et al. 2013). The OFC is a region with well documented involvement in 
palatable food reward valuation (O'Doherty et al. 2002) and could suggest that at 
rest, the sensitivity of this region is reduced following IN-INS, reducing reward 
sensitivity and thus reducing desire for food intake. However, it must be noted that 
both resting state studies (Schilling et al. 2014; Kullmann et al. 2013) were not 
designed to assess insulin related responses to food liking and furthermore there was 
no change in appetite ratings observed in response to IN-INS administration.  
 
‘Wanting’ for food can be assessed by how much food is consumed and the amount 
of effort willing to exert in order to acquire certain food stimuli. Measures of 
motivation for rewarding or salient stimuli and ‘wanting’, are more easily measured 
from pre-clinical neuroscience experiments (Berridge 2009). In humans, however, 
these components of reward are often difficult to dissociate, given the significant 
overlap between liking and wanting, and the commonly self-reported measures used 
to ascertain these metrics (Finlayson, King, and Blundell 2007). Measures of 
motivation or desire for example could be sub-conscious or could be biased by self-
reporting and therefore quantitative tools that use reactive measures, for example 
force grip, are being developed for implementation in neuropsychological research 
environments (Ziauddeen et al. 2014).  
 
In regards to the effects of insulin on reward related behaviour, one must look to pre-
clinical work in order to ascertain the modulatory effects of insulin on the 
dopaminergic system. Converging pre-clinical literature has suggested that insulin 
plays a role in modulating reward related circuitry and thus exerts much of its 
anorexigenic effects through modulation of the mesolimbic pathway. Firstly, in the 
rodent brain, insulin receptors have been found on DAergic neurons of mesolimbic 
regions such as the VTA, SN and also the NAcc, caudate and putamen (Figlewicz et al. 
2003). In rats, direct administration of insulin to the VTA and hypothalamus resulted 
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in a concentration-dependent suppression of DA in the VTA due to an increase in DA 
transporter (DAT) reuptake of DA coupled with decreased sucrose self-
administration (Mebel et al. 2012). This data suggests that insulin reduces DA 
signalling in limbic regions and therefore suppresses the rewarding effects usually 
obtained from eating, reducing the motivation and pursuit of food consumption. This 
data would suggest that ‘wanting’ of food as determined by self-administration is 
modulated via insulin’s effects in the VTA, thus increased central insulin could lead 
to reduced hedonic drive thus terminating feeding. This would support a common 
hypothesis related to obesity, that obese compared to lean individuals, who present 
with lower insulin CSF levels (Kern et al. 2006), experience greater reward from food 
stimuli (hyper-responsivity) and therefore encourages increased food consumption 
(Davis, Strachan, and Berkson 2004; Dawe and Loxton 2004).  
 
1.7.2.2 Hyper-responsivity to food cues 
Some theories propose that greater reward evoked from food intake is a risk factor 
that contributes to the overeating associated with obesity (Stice et al. 2008; Davis, 
Strachan, and Berkson 2004; Rothemund et al. 2007). Evidence to support this theory 
comes from observations of greater activation in limbic (NAcc) and cortical regions 
(insula, OFC) from presentation of food picture stimuli in obese compared to normal 
weight individuals (Rothemund et al. 2007). Developing this further, overweight and 
obese patients with T2DM showed increased BOLD responses in the insula, OFC and 
caudate region upon presentation of food pictures in comparison to age and weight 
matched controls (Chechlacz et al. 2009). As the control group were weight matched 
it could be suggested that these hyper-responsive regions observed following food 
picture stimulation could be as a result of changes in insulin sensitivity both centrally 
and peripherally. An example of this aberrant cue responsivity is highlighted in Figure 




In contrast, there is a corollary hypothesis which postulates that obese individuals 
experience a decrease in mesolimbic reward activation from food intake in 
comparison to lean individuals, driving compensatory overeating and consumption 
(Comings and Blum 2000; Volkow, Fowler, and Wang 2002). This theory is known as 
the hypo-responsivity theory. 
 
1.7.2.3 Hypo-responsivity to food intake 
The hypo-responsivity theory, or sometimes referred to as the reward deficiency 
theory, posits that individuals who experience low reward effects or low engagement 
of reward circuitry are at risk of overeating (Stice et al. 2008). This reward deficiency 
thus drives repeated consumption or increased consumption of palatable foods to 
achieve equivalent reward. Brain regions known to encode reward upon 
consumption of food; insula, VTA, NAcc, caudate and putamen show decreases 
overtime that correlate with satiety (Small et al. 2003). Furthermore, DA levels within 
the NAcc, as measured by C-11 raclopride positron emission tomography (PET) are 
increased upon consumption of a pleasant meal, with the magnitude of release 
showing close association to subjective measures of meal pleasantness (Small, Jones-
Gotman, and Dagher 2003). Support for this theory largely comes from observations 
of low dopamine receptor (D2 receptor) availability and lower DA levels in the NAcc 
in obese vs lean individuals, as measured with C-11 raclopride PET (Volkow, Wang, 
Telang, et al. 2008; Wang et al. 2001). An example of the hypo-responsive system can 






Figure 1.7.2 Simplified schematic models during anticipation of food intake and consumption in 
healthy individuals. Prior to food consumption the metabolic state can influence the hedonic value of 
foods, driving the salience of these foods, increased ‘motivational salience’. Salience and attention 
increases motivation and drive which is essential for food intake. During consumption, homeostatic 
signals will update the metabolic state of the individual and the reward related response acts to 
reduce the salience or hedonic value of palatable foods, reduced ‘motivational salience’. 
Figure 1.7.3 Simplified schematic models during anticipation of food intake and consumption in  obese 
individuals. Prior to food consumption the metabolic state can influence the hedonic value of foods, 
driving the salience of these foods, increased ‘motivational salience’. Salience and attention is hyper-
responsive to food cues which increases motivation and drive for food intake. During consumption, 
aberrant homeostatic signals fail to update the metabolic state of the individual and the reward 
related response from food intake is largely blunted, ‘hypo-responsive’ consummatory reward. As a 
result the ‘stop’ eating signals are not effective or present which results in overconsumption.  
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1.7.2.4 Insulin and the hypo-responsivity theory 
From the literature, there are lines of evidence that show how central insulin 
signalling agrees with this proposed theory. Firstly, Stouffer et al., have recently 
shown that insulin enhances DA release from striatal (caudate and putamen) 
terminals and in the nucleus NAcc via an indirect mechanism involving insulin 
receptor expressing excitatory cholinergic interneurons (Stouffer et al. 2015). They 
further show that in obese mice this DA responsiveness is reduced compared to wild 
types and enhanced in food restricted mice (Stouffer et al. 2015). Finally, a PET study 
using a C-11 raclopride tracer, has shown that people with insulin resistance have 
decreased DA release in the NAcc after drinking a sugary drink in comparison to 
healthy individuals (Wang et al. 2013). This work was presented at a conference of 
which the methodological details cannot be gathered from the abstract. However, 
the data presented are suggestive of an increased modulation of insulin with regards 
to DA neurotransmission and limbic system reactivity.  
 
A product of both the hypo and hyper responsivity theories is what many believe 
drives overeating seen in obese individuals. The increased (hyper) salience of food 
cues drives motivation to eat initially, however, upon receipt of food or consumption 
the rewarding effects are decreased (hypo). It is this discrepancy between the 
predicted reward value and the reward value encoded during consummation that is 
suggested to be a risk factor for overeating in obese individuals. This can be seen in 
Figure 1.7.3. 
 
Limited human imaging studies have shown insulin related effects in the nucleus 
accumbens and striatal regions or explored these mechanisms. However, one study 
has observed functional BOLD responsiveness to food images (mixed high and low 
calorie) vs non-food images in insulin sensitive (normal weight) and insulin resistant 
(overweight and obese) individuals as measured using HOMA-IR (Tiedemann et al. 
2017). This study showed that under placebo conditions the insulin resistant 
individuals displayed significantly lower BOLD responsiveness to food pictures vs 
non-food in the bilateral NAcc and left VTA compared to insulin sensitive individuals 
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(Tiedemann et al. 2017). This opposes the hyper-responsive food cue reward theory 
of obesity but with insulin resistant individuals. In this study, participants were also 
pharmacologically challenged with IN-INS (160 IU) administration. Following IN-INS 
the insulin sensitive group showed an IN-INS related decrease in NAcc and VTA 
activity, while the effect was reversed in the insulin resistant group who presented 
with increased IN-INS related activity of the NAcc and VTA (Tiedemann et al. 2017). 
Interestingly, this study also showed that preference ratings for the food items 
decreased under IN-INS reflecting a decrease in salience for these images in the 
insulin sensitive group. This effect was not seen in the insulin resistant group, but a 
trend (p = 0.09) towards significance was found, which presented a slight increase in 
food preference values following IN-INS. These data suggest that in healthy insulin 
sensitive individuals, insulin works to reduce reward related processing which is 
associated with reductions in palatability ratings of food. Yet, however, in those with 
differential peripheral sensitivity the effects of insulin show an opposing effect. 
Elucidating and exploring these effects in a more rigorous way, as well as 
investigating the opposing effects of changes in central insulin seen in those 
individuals presenting with peripheral insulin resistance, is imperative for future 
research.  
 
The interplay between metabolic state and hedonic mechanism that drives 
overeating can be observed in healthy individuals and at times healthy individuals 
will ‘binge’ or overeat energy dense food or increase calorie intake significantly, in 
certain circumstances. However, the chronic overeating seen in metabolic disorders 
such as obesity or individuals at risk of developing metabolic problems is a result of 
an inherent dysregulation of these systems. Understanding whether this 
dysregulation precedes adverse metabolic manifestations or is an observation seen 
in obese individuals is largely unknown.  
 
Understanding the role of insulin in this interplay has been illuminated in the last 
decade given the introduction of IN-INS and the increasing availability of functional 
imaging access for researchers in the field. The main relevance of hedonic 
dysregulation to T2DM and obesity is that the powerful systems that contribute to 
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hedonic hunger can override homeostatic signals promoting increased food and 
energy consumption. Dysregulation of the hedonic system coupled with a 
dysregulation in the homeostatic system arguably increases the risk of entering a 
pathological cycle of chronic positive energy balance, adipose storage, irreversible 
effects on health, increased risk for CVD and increased mortality. With homeostatic 
eating there are peptide signals such as ghrelin that act to promote eating, but there 
are also inhibitory satiety signals (PYY, GLP-1 etc). In contrast, the hedonic system 
which primarily describes a series of excitatory responses that drive and promote 
overeating does not describe a subset of inhibitory mechanisms. A large amount of 
research in humans has focused on the inhibitory control mechanisms that govern 
the hedonic system and the associated role these systems have in food intake 
dysregulation. These systems together are known as the ‘cognitive mechanisms’.  
 
1.7.3 Cognitive mechanisms 
The homeostatic and hedonic system cannot completely account for all the processes 
involved in appetite control. On a primal level these systems do largely dictate energy 
regulation, which has been demonstrated by elegant animal model experimentations 
(Berridge 2004; Berridge and Kringelbach 2008). As humans operate at a higher 
cognitive level than primates and rodents, there exists an additional component to 
this integrative model of appetite control, which for a long time has been neglected 
by the classical theories of appetite dysregulation. The homeostatic and hedonic 
system present a restricted view on food intake that does not take into account the 
ability for restraint and inhibition of food intake (Higgs 2016). Examples of cognitive 
modulation of appetite control are seen in everyday situations, for example inhibiting 
the consumption of unhealthy, highly palatable foods, in pursuit of long-term 
healthier outcomes (Hare, Camerer, and Rangel 2009). Interestingly, evidence from 
behavioural tasks show that obese individuals display a preference for high 
immediate rewards at a cost of increased risk of future reward loss in comparison to 
normal weight individuals (Weller et al. 2008; Epstein et al. 2010). There is further 
evidence from imaging studies to suggest that high BMI impairs general cognitive 
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functioning, particularly executive function of prefrontal regions of the brain (Sellaro 
and Colzato 2017; Volkow et al. 2009). Regional brain glucose metabolic deficits 
measured with 2-deoxy-2 [18F] fluoro-d-glucose – PET (FDG-PET) negatively 
correlated with BMI in the ventromedial prefrontal cortex (vmPFC) , dorsolateral PFC 
(dLPFC), the anterior cingulate gyrus (ACC)  as well as the medial OFC region (Volkow 
et al. 2009). Examples of cognitive inhibitory control can be seen in Figure 1.7.4. 
 
 
1.7.3.1 Insulin and cognitive control of food intake 
Imaging studies that have investigated the response to IN-INS administration have 
shown that effects within these prefrontal regions to be limited. Kullmann et al., 
showed that in lean women, IN-INS (160 IU) administration gave rise to an increase 
in resting fALFF within the ACC and superior frontal gyrus that was significantly 
associated with BMI (Kullmann et al. 2013). This study was limited to normal weight 
individuals and although the data suggests central insulin sensitivity increases with 
BMI, these interpretations must be restricted to BMI within the ‘normal’ range only. 
Additional resting state investigations, which also investigated the effects of IN-INS 
(160 IU) administration showed increases in regional fALFF within the lateral PFC 
Figure 1.7.4 Simplified schematic highlighting how the cognitive inhibitory control mechanism is 
involved in food intake. In those with strong food inhibition the top down inhibitory effects are 
sufficient to reduce the motivation and drive to palatable, salient food. In those individuals with poor 
inhibitory control, salient food salience and subsequent motivation is too significant to inhibit and 
thus food is ultimately consumed.  
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(Kullmann et al. 2018); and regional increases in CBF within the middle frontal gyrus 
in lean individuals (Kullmann, Heni, Veit, Scheffler, Machann, Häring, et al. 2015). In 
contrast to  the IN-INS related increase in CBF mentioned above, the same study also 
highlighted a significant decrease in middle frontal gyrus CBF in response to IN-INS 
vs IN-PLA in overweight/obese insulin resistant individuals (Kullmann, Heni, Veit, 
Scheffler, Machann, Haring, et al. 2015).  
 
The data from the limited studies presented provide grounds to suggest that IN-INS 
has a modulatory effect on prefrontal cortical regions. The role of insulin within these 
areas and the role of insulin as a central modulator of inhibitory control over the 
hedonic system remains to be elucidated. Higgs et al., provide an interesting 
presentation of when cognitive control and not just inhibitory control mechanisms 
are involved in appetite regulation. They argue that cognitive processes are involved 
in all aspects of food intake, from before a meal, during a meal and also periods after 
and between the next meal or energy intake periods (Higgs et al. 2017).  
 
1.7.4 Cognitive processes involved before feeding  
It is now thought that the cognitive system is required to make valuations of potential 
meal choices on the bases of taste, energy density and the health risks that might be 
associated with those decisions (Hare, Camerer, and Rangel 2009). These valuations 
are encoded within the vmPFC and based on these valuations decisions are made 
within the dLPFC and mOFC (Hare, Camerer, and Rangel 2009; Vassena et al. 2014). 
This prefrontal network provides humans with the ability to engage in goal directed 
behaviour as opposed to cue-driven behaviour. The ability to inhibit confounding 
cues such as palatable foods or smells and the desire for the long-term or short term 
goals must therefore require attention.  
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1.7.5 Cognitive processes involved during feeding  
During a meal or food consumption it is generally well understood that the 
motivation and salience for specific food decreases over time, known as sensory 
specific satiety (Rolls et al. 1981) and also food in general, known as alliesthesia 
(decrease in motivational salience) (Stoeckel et al. 2007). In reality, these two 
mechanisms increase ‘satiation’ as opposed to satiety. These mechanisms are known 
to be associated with reductions in DA transmission, but also with increases in dLPFC 
activity that correlate with measures of satiety (Thomas et al. 2015). Attention also 
seems to form a significant component during the meal consumption phase. Being 
cognitively distracted during meal consumption such as by watching television leads 
to increased food intake (Braude and Stevenson 2014) and suggests the cognitive 
domains are important for selectively inhibiting the hedonic system to induce satiety.  
 
1.7.6 Cognitive processes involved during feeding intervals 
There is evidence to suggest that memory of a previous meal influences further 
eating behaviour (Higgs 2016). As an extreme example, people who suffer from 
amnesia and are unable to remember meal periods will often eat multiple meals with 
relatively short durations between them (Higgs et al. 2008). Within this work Higgs 
et al., also showed that sensory specific satiety was intact in amnesic patients thus 
providing evidence for intact dopaminergic transmission and potentially fully 
functioning hedonic systems (Higgs et al. 2008). In rats, inactivation of dorsal 
hippocampal neurons following a sucrose meal decreases the time interval between 
two meals, suggesting that this cognitive-memory association during postprandial 
and post-absorptive state are modulated by hippocampal-dependent processing 
(Parent 2016).  
 
Taken together, these findings suggest that cognitive processes are a contributor to 
net food intake and that it is the integration of all three systems (homeostatic, 
hedonic and cognitive) that governs and controls food intake. Previous literature has 
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outlined insulin’s involvement in homeostatic and hedonic pathways and to some 
extent the cognitive pathway too. The cognitive benefits of IN-INS on working 
memory, declarative memory in healthy individuals (Benedict et al. 2004; Benedict 
et al. 2008) and also in patients with mild cognitive impairment (MCI) and Alzheimer’s 
Disease (AD) (Freiherr et al. 2013; Craft et al. 2012) suggest that insulin may have an 
important role in the cognitive pathways involved in food intake and appetite 
control. 
 
1.8 Aims of Thesis 
Given the evidence for insulin’s involvement in the three systems engaged in appetite 
control, this thesis aims to explore these components further through a 
pharmacological neuroimaging framework. This investigation employs intranasal 
administration as a method to increase central insulin concentrations, hoping to give 
rise to a limited effect on peripheral hormone and peptide concentrations. This 
investigation has implemented a functional magnetic resonance imaging protocol to 
observe effects of intranasally administered insulin on the brain during rest as well 
as when engaged in a functional task probing the reward system. The studies set out 
to look at the effects of IN-INS in a group of healthy male individuals across a wide 
BMI range that included normal weight and overweight individuals. The study design 
and rationale behind the study are detailed in section 3.1. 
 
The three aims of this thesis and exploratory investigation are: 
 
1) To interrogate changes in Cerebral Blood Flow in response to IN-INS  
2) To interrogate IN-INS related changes in functional connectivity between 
limbic and cortical regions and the rest of the brain 
3) To interrogate the effects of IN-INS during engagement in a task that exposes 
the participant to primary food reward stimuli 
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Chapter 2 General Methods: 
Intranasal Insulin Imaging Study 
Protocol 
 
The study that is being presented in this thesis is a pharmacological investigation of 
the effects of intranasally administered insulin on human brain function. In this study, 
I have implemented a range of functional Magnetic Resonance Imaging (MRI) 
techniques to explore the effects of intranasal insulin in comparison to intranasal 
placebo. This chapter will describe these imaging methods. The fundamental 
processes involved in functional image acquisition will be explained in a generalised 
format. The detailed parameters (and data analysis) of each methodology will be 
















2.1 Nuclear Magnetic Resonance 
The phenomenon of nuclear magnetic resonance (NMR) arises because of the 
quantum mechanical properties of nuclei and its constituent particles.  Below I 
present a description of NMR based mainly on a classical rather than quantum 
mechanical formalism. 
 
NMR refers to the interaction between magnetic moment and angular momentum, 
which occurs in atomic nuclei that possess an odd number of protons, for example 
hydrogen (1H), carbon (13C) and Fluorine (19F). The effect occurs in the presence of an 
external magnetic field (Purcell, Torrey, and Pound 1946). The odd number of 
protons inherent within these nuclei produces a small magnetic character and their 
finite angular momentum around their own axis, is known as nuclear spin. This 
‘rotation’ or spin produces a small magnetic field known as a magnetic dipole 
moment (MDM) (Figure 2.1.1). Although in principle, Nuclear Magnetic Resonance 
(NMR) signals can be obtained from any nucleus with a finite magnetic dipole 
moment;  Magnetic Resonance Imaging (MRI) has predominantly exploited this 
physical property from hydrogen atoms, because their nuclei provide the strongest  
NMR signals and are ubiquitously abundant within the human body (Bloembergen, 
Purcell, and Pound 1948). Hydrogen nuclei are found in water, lipids (-CH2-) and in 
most biological tissue. 
 
Figure 2.1.1 A Magnetic Dipole Moment precessing 
about an external magnetic field B0.  
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When magnetic moments are placed in a strong external magnetic field, B0, such as 
that produced by an MRI scanner, some of these magnetic moments will align with 
the magnetic field direction (B0) and some will align in the opposing direction. For 
conventional MRI scanners and for this description, the main magnetic field direction 
refers to the z-axis and the orthogonal direction is the x-y plane. Exposed to this 
external magnetic field B0, there will be a NET difference between spins that line up 
parallel and anti-parallel with the external field, giving rise to a NET bulk 
magnetisation vector (Mz) along the longitudinal (z) axis.  Because of the angular 
momentum of this magnetisation vector, a finite torque between this vector and the 
external field causes these spins to undergo a motion known as precession, whereby 
the hydrogen spins rotate at a finite angle around the main magnetic field axis, MZ, 
as if describing a ‘cone’.  
 
The precession frequency of the spins is known as the Larmor frequency, ω (Bloch 
1946). The value of the Larmor frequency is governed by the product of the strength 
of the magnetic field (B0, Tesla (T)) and the gyromagnetic ratio of the spin species (g, 
MHz/T), which for hydrogen protons is 42.6 MHz/T (see below). 
 𝜔 = 	𝛾𝐵0	
 
Detection of NMR signals is almost always achieved by establishing a resonance 
condition. In ‘pulsed NMR’ this is achieved by ‘tipping’ the net magnetisation vector 
from the longitudinal axis to the transverse plane, by delivering a radiofrequency 
pulse (RF) at the same frequency as the precessing spins (i.e. the Larmor frequency), 
via a RF transmission coil. The pulse of radio-frequency is delivered to the spins, for 
a time long enough to cause a 90o  rotation of the net magnetisation vector onto the 
axis of detection of the coil.  The signal that is then detected by the coil is known as 
the “free induction decay”. 
 
For any arbitrary angle of rotation (i.e. not necessarily 90 degrees), the magnetisation 
can be defined by two separate components: 1) the remaining magnetisation along 
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the longitudinal axis (which experiences ‘longitudinal’ relaxation) and 2) the 
magnetisation along the transverse axis (which experiences ‘transverse’ relaxation). 
 
2.1.1 Longitudinal relaxation  
Immediately following a 90° flip of the net magnetisation vector into the transverse 
plane, the precessing spins will naturally begin to rotate back to their equilibrium 
state. The process by which this relaxation process takes place can be approximated 
by a simple exponential function: 
 𝑀4(6)8	𝑀9 	:1 −	𝑒6 =$> ? 
 
where Mz(t) is the instantaneous value of the longitudinal magnetisation, M0 is its 
equilibrium value and the time constant of the exponential (T1) is known as the 
‘Longitudinal Relaxation time’.  The process of T1 relaxation is also referred to as spin-
lattice relaxation, during which the spins simply ‘return’ the energy absorbed from 
the RF pulse into the surrounding lattice or environment. T1 relaxation is therefore 
driven by the ability of these spins to emit energy to the tissue and the dynamics of 
this process changes with tissue type.  Therefore, images ‘weighted by’ or sensitive 
to differences in T1 provide a powerful mechanism to obtain T1 contrast in our 
images.  As the magnetisation vector returns to the longitudinal axis, this process 
contributes to the loss of signal in the transverse plane (Figure 2.1.2) 
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2.1.2 Transverse relaxation   
Immediately following a 90° flip, the magnetisation vector is now in the transverse 
plane and the spins are in a higher energy state. The magnetisation is coincident with 
the axis of the detection coil and therefore the signal of the free induction decay is 
at a maximum. Over time, the net magnetisation vector will also decay with what is 
known as T2 relaxation. In the transverse plane the individual spin components will 
rotate around the longitudinal axis. During this rotation the spins will begin to 
dephase with respect to each other resulting in an overall decrease in the magnitude 
of the transverse magnetisation vector; and hence the signal. Two processes 
contribute to this decay (independent of T1).  In this instance, the two main processes 
that contribute to this dephasing are: the interactions between spins and also the 
external magnetic field inhomogeneities.  
Figure 2.1.2 Longitudinal and transverse relaxation. A) Shows the longitudinal magnetisation vector 
(red arrow) and transverse magnetisation vector (blue arrow) in the rotating frame. During 
equilibrium the longitudinal vector Mz is aligned with B0 in the z-axis. Upon excitation by a 90° RF 
pulse the bulk magnetisation vector is flipped into the transverse plane, and MXY is maximal. The 
transverse magnetisation vector will decay exponentially as can be seen in figure (C) known as T2* 
relaxation. The longitudinal magnetisation vector will recover, known as T1 relaxation (B).   
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The former dephasing mechanism is often referred to as spin-spin relaxation and is 
it a result of the interactions between individual spins. These local interactions 
reduce spin phase coherence which in turn reduces the net transverse magnetisation 
vector.  For example, the differing density of tissue types affects the rate at which 
the spins dephase. Spins in dense tissues, that closely interact, dephase at a faster 
rate in comparison to those in less dense tissues. For instance, spins within white 
matter tissue will decay at a much faster rate (short T2) in comparison to spins within 
freely diffusing water, which will dephase more slowly (long T2).  
 
The latter dephasing mechanism is in practice very relevant and describes additional 
spin dephasing in the transverse plane due to inhomogeneities in the external 
magnetic field.  It is easy to see how if the field is different, the Larmor frequencies 
of spins will also be also different and therefore phase coherence between spins is 
reduced and eventually lost.  The combination of both spin-spin interactions and the 
field inhomogeneities leads to a decrease of the free induction decay signal with a 
process that can be approximated by a single exponential function with a time 
constant known as T2* (see Figure 2.1.3) 
 
Figure 2.1.3 Schematic diagram of the rotating frame showing spin dephasing over time in the 
transverse plane following an RF pulse excitation  
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2.1.3 Free induction decay 
In a frame of reference rotating at the Larmor frequency, and following the flip of 
magnetization from MZ to MXY , the spins will appear to be ‘in phase’ and precessing 
at the same frequency in the transverse plane.  However, as the spins begin to 
dephase, the magnetisation vector MXY will begin to decay with a time constant T2*. 
During this time, the magnetization vector rotates around the z-axis inducing an 
oscillating signal in the receiver coil. This oscillating signal is known as free induction 
decay (FID) and oscillates at the Larmor frequency and the amplitude of this FID 
decays exponentially with T2* (𝑒@ %&'∗) (Hoult and Richards 1975).  The FID will decay 
exponentially with respect to T2* as seen in Figure 2.1.4 
 
 
The duration of the FID signal depends obviously on the physical properties of the 
spins in each tissue type and the spatial homogeneity of the magnetic field.  It is 
possible to see how imaging methods can exploit these differences in T2* to obtain 
additional tissue contrast.  The duration of the FID can, in some instances, be very 
short (100ms or less) and in reality measuring the signal only from a single FID is not 
effective.   
Figure 2.1.4 Free induction decay as a result dephasing in the transverse plane and 
external  magnetic field inhomogeneities.   
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As will be explained below, there are methods that allow us to make further 
measurements by manipulating the evolution of the signal. Generally speaking, this 
is conducted using what is known as an MR pulse sequence. An MR pulse sequence 
describes a set of RF and gradient pulses that are applied to the object being scanned. 
Gradient coils are housed within the magnet and will be explained in later sections. 
 
2.1.4 Spin echo 
One of the earliest pulse sequences developed to eliminate the need to depend on 
measurements using the FID, is the spin echo sequence. A spin echo sequence 
consists of a 90° RF pulse that flips the net magnetization vector into the transverse 
plane. As shown in Figure 2.1.5 the spins will begin to dephase over time due to spin-
spin interactions and external field inhomogeneities (T2* decay). However, after a 
short period of time (τ), a 180° RF pulse is applied, which inverts the direction of these 
dephasing spins. Through this inversion, the spins will travel in the opposing 
direction, in the direction they just came from, and begin to rephase. At time 2τ the 
spins will be refocused, in-phase, for a moment before dephasing again through T2* 
Figure 2.1.5 Diagram showing the spin echo sequence in the rotating frame as well as the MR 
signal produced and sampled. Spin echo uses a 180° refocusing RF after the spins have begun 
to dephase (TE/2). Following this refocusing pulse the spins begin to rephase producing an 
echo, with maximal signal intensity at TE. Not that the echo itself decays via T2* as an echo 
of the FID, whereas the peak of the echo decays with T2.  
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relaxation. The rephasing, in-phase (peak) and dephasing components following the 
inversion pulse are known as an ‘spin echo’; and forms the basis behind many of the 
pulse sequences adopted for MRI (Hahn 1950).  
 
As will be seen later, spin echoes are useful because they extend the time available 
for encoding spin frequencies in order to generate an image.  It can also be seen that 
this approach makes the spin echo signals insensitive to the effect of differences in 
magnetic field homogeneity. 
 
2.1.5 Gradient echo 
A gradient echo sequence is another method of producing an echo-like signal, 
however, instead of using an inversion pulse to rephase and create an echo of the 
FID, one or more gradient pulses are used. Following a 90° RF pulse, the FID will begin 
to decay via T2* as the spins in the transverse plane dephase. At this point a finite 
gradient (dephasing gradient) is applied for duration, τ, which acts to accelerate the 
dephasing of the spins. Following this dephasing gradient, another gradient of 
opposite polarity but equal amplitude and duration (rephasing gradient) is applied 
which acts to refocus the transverse evolution of the spins. At time τ of the rephasing 
gradient, the spins will regain the phase evolution they would have had along the 
transverse plane before the application of the gradient pulses.  
 
For both spin echo and gradient echo the time at which the echo peaks is known as 
the echo time (TE). For spin echo acquisition the inversion pulse is applied at TE/2.  
 
2.1.6 Image formation 
The FID and echo signals induced into the RF coil during image acquisition contain 
information regarding the entire brain or region of the brain excited. These signals 
do not contain any spatial information and therefore there are additional steps 
required to localise the origin of the tissue signals in space. This is achieved through 
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the use of external gradient coils that manipulate the magnetic field across the z, x 
and y planes in order to make the Larmor frequencies dependent on position. These 
gradient coils are housed in the MRI scanner. Each gradient coil is required during 
the MRI experiment to obtain spatial information and the gradients are commonly 
referred to as: 
 
• Slice encoding gradient  
• Phase encoding gradient  
• Frequency encoding gradient  
 
The gradient coils change the magnetic field most commonly in a linear manner and 
it is the combination of gradients applied across the imaging object, which imparts 
information about spatial location. Gradients are used to temporarily create non-
uniformity across the magnetic field, which alters the spin frequency precession 
across the imaging object, thus creating spatial inhomogeneity across the magnetic 
field in a controlled manner.  
 
2.1.6.1 Slice encoding gradients 
The slice encoding gradient is used to selectively excite the spins within a finite region 
of space. Slice encoding gradients are applied during excitatory 90° RF pulses, which 
are designed to have a finite excitation bandwidth. In all instances, the excitation 
pulse used to flip the spins covers a range of radiofrequencies referred to as ‘the 
bandwidth of the pulse’. By applying a gradient across the field the spins within the 
imaging object will precess at a range of frequencies above and below the Larmor 
frequency.  A common ‘RF pulse shape’ employed in imaging sequences is the sinc 
function, whose corresponding envelope in the frequency domain is a rectangular 
profile.  By virtue of the applied gradient, application of an excitatory RF pulse with 
a rectangular bandwidth of frequencies, will only excite those spins that correspond 
to a discrete portion of space in the direction of the slice encoding gradient, as 
opposed to the whole object. The thickness of the slice excited can be decreased by 
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increasing the strength of the slice encoding gradient or decreasing the bandwidth 
of frequencies excited by the RF pulse, or a combination of both.  
 
2.1.6.2 Frequency encoding gradients 
The frequency encoding gradient, sometimes referred to as the readout gradient 
creates a linear gradient across a chosen direction. The frequency encoding gradient 
is applied as the signal is captured (usually using an Analogue-to-Digital Converter 
(ADC) and so during this time, as long as the bandwidth of the receiver is sufficiently 
large, the MR signal that is collected contains information from all the frequencies of 
the object encoded by the ‘frequency encoding’ gradient.  
 
The orthogonal dimension of the selected slice could also be encoded and acquired 
using a second frequency encoding gradient, but it turns out practically more difficult 
to achieve this.  This is because magnetic field gradients add as vectors and the result 
of the simultaneous application of two gradients is in fact a single gradient along the 
direction of the vector sum of its components.  Although this is the way in which MR 
imaging was originally achieved (Lauterbur 1973), a practical modification was later 
introduced which made imaging more practically achievable. 
 
2.1.6.3 Phase encoding gradients 
In 1980, Edelstein and colleagues (Edelstein et al. 1980) introduced the use of what 
was later known as ‘phase encoding gradients’.  A phase encoding gradient is a 
gradient across the orthogonal direction of the frequency encoding direction. The 
phase encoding gradient is usually applied any time before the application of the 
frequency encoding gradient. The phase encoding gradient effectively changes the 
phase at which the spins are precessing across its direction, within the slice that has 
been initially excited. Following the application of the phase encoding gradient, from 
the point of view of the frequency encoding axis, the spins will be resonating with 
different phases depending on their location along the phase encoding direction.  
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The combination of phase and frequency encoding gradients on the object being 
imaged provides the ability to now distinguish between individual signals of different 
phase and frequency by creating a measured signal which reflects the summation of 
multiple measurements and frequencies over time. A signal measurement is made 
along the frequency encoding direction for every value of the phase encoding 
gradient. Each of these sampled signals is collected into a data grid, which 
corresponds to the inverse domain of the object.  This ‘inverse space’ of frequency 
encoding temporal signals is known commonly as k-space, because of its analogy 
with X-ray crystallography. 
 
Conventionally, this data grid is filled ‘line by line’, known as Cartesian sampling 
although other methods for sampling trajectories are also used for MRI applications 
(Hennig 1999). Once the entire k-space grid (known as the data acquisition matrix) 
has been sampled, then the signals are reconstructed into an image by means of a 
discrete inverse Fourier transform which transforms the frequency components of 
the measured signal into real (Cartesian) space. In an MRI experiment each slice will 
be encoded by a single plane of its corresponding k-space.  
 
2.1.7 Tissue contrast 
T1 and T2 relaxation are inherent to individual tissue types and these relaxation 
differences are fundamental for differentiating between tissues. This is the basis of 
tissue contrast. Tissue contrast can be modulated and optimised through definition 
of two crucial imaging parameters; the repetition time (TR) and echo time (TE) 
(Damadian 1971). 
 
TR is roughly defined as the time between two RF pulse excitations corresponding to 
different portions of k-space. A long TR will permit spins to relax fully through T1 
relaxation, allowing the net magnetisation vector to align more closely to MZ, 
whereas a shorter TR will prevent the MZ vector for certain tissues to fully relax.  
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TE on the other hand is defined as the time between the excitation RF pulse and 
when the signal measurement from the transverse signal is taken. Dense tissues with 
shorter T2 values (due to increased spin-spin interactions) would require a shorter 
TE to capture the signal before the MXY vector decays, whereas tissues with a longer 




By defining both TR and TE parameters and with prior knowledge of the associated 
T1 and T2 relaxation rates of the tissues of interest, contrast of different tissue types 
within images can be achieved. For example, in a T1-weighted image acquired with a 
short TR (and a short TE), spins with a short T1 will provide a large signal.  On the 
other hand, in a T2-weighted image acquired with a long TE (and long TR), spin 





Figure 2.1.6 An example of how different tissues will decay at 
different exponential rates. By choosing an appropriate TE 




2.2 Functional Brain Imaging 
Functional brain imaging using MRI, known as fMRI, has been vital to the present 
understanding of brain function and its modification in disease. fMRI adopts MRI 
techniques that are sensitive to neurophysiological and neurovascular changes that 
occur in response to neuronal activation (Attwell and Iadecola 2002). Although not a 
description of methods the next section will describe some of the key 
neurophysiological processes that occur during this neurovascular response.  
 
2.2.1 Measuring neuronal activation – neurovascular coupling 
The brain parenchyma is supplied with a fresh supply of oxygenated blood by 
cerebral arteries, arterioles and capillaries, this phenomenon is known as Cerebral 
Blood Flow (CBF) and is also referred to as brain tissue perfusion (Attwell and 
Iadecola 2002). Brain tissue perfusion is maintained at a relatively constant level; and 
as the brain is a highly metabolic organ, producing most of its energy through 
oxidative metabolism, any major disturbances or perturbations to this system can 
lead to severe gross pathology, for example stroke (Girouard and Iadecola 2006). 
Neural information is transferred throughout the brain via conduction along 
neuronal axons. The primary mechanism for information transfer between neurons 
across the synaptic cleft, is by the action of neurotransmitter molecules released 
from the pre-synaptic cleft which bind upon post-synaptic neurotransmitter 
receptors. These neurotransmission events are largely fuelled by oxidative glycolysis 
and therefore lead to metabolic changes within the neurons and surrounding glial 
cells as a result of a higher local demand for oxygen delivery. This close spatial 
relationship between the neurons, glial cells and the vascular system, which allows 
the local energy demands to be met by increasing regional blood flow at a cellular 
level, is known as neurovascular coupling (Attwell et al. 2010).  
 
As previously mentioned, the brain has a very high level of resting metabolism, 
consuming approximately twenty percent of the body’s total oxygen supply (Attwell 
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et al. 2010).  The bulk of oxygenated arterial blood is delivered or supplied by two 
major groups of feeding arteries: the bilateral internal Carotid and Vertebral arteries.  
At the Circle of Willis, these cerebral feeding arteries bifurcate into smaller cerebral 
vessels known as pial arteries. These pial arteries are the anterior, middle and 
posterior cerebral arteries (Cipolla 2009). Pial arteries span across the surface of the 
entire brain parenchyma within the pia-subarachnoid space and perfuse all regions 
of the cerebrum. Surrounded by cerebrospinal fluid (CSF), the pial arteries advance 
into arterioles that ‘penetrate’ the brain tissue via the Virchow-Robin Space (Cipolla 
2009). The vascular wall of arterioles is made of smooth muscle.  Within the tissue 
architecture, the vessels are classified as parenchymal arterioles and are bounded by 
astrocytic end-feet which terminate on the outer layers of these arterioles. 
Downstream of these arterioles is the capillary bed, which forms a highly connected 
and dense network of vessels with a large surface area for efficient vessel to neuronal 
tissue nutrient exchange. Capillaries no longer have smooth muscle in their walls. 
Exchange of nutrients is produced by an intra-capillary pressure gradient that when 
increased leads to enhanced tissue perfusion facilitated by specialised capillary 
endothelial cells (Begley and Brightman 2003). Therefore, an increase in nutrient 
exchange, in most cases oxygen and glucose, requires an increase in intra-capillary 
pressure.  
 
The auto-regulatory control mechanisms that act to maintain sufficient blood flow 
and react in response to increased neuronal metabolism do so at the level of the 
parenchymal arterioles not at the capillary bed. However, this change in flow is 
accompanied by an increase in capillary pressure thus there are several mechanisms 
that must be achieved to increase oxygen supply to meet metabolic demands. These 
arterioles are comprised of three layers; the inner endothelial cell layer, the middle 
smooth muscle layer and the outer collagenous layer. The smooth muscle layer is 
capable of dilating and constricting the vessel walls, permitting increases and 
decreases in flow, respectively. Vascular resistance is governed by Pousille’s Law 
which identifies the vessel radius as the main effective constituent. Vascular 
resistance is inversely proportional to radius (r) to the fourth power and therefore 
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any small change in vessel radius or lumen width is coupled with a dramatic change 
in flow (Washburn 1921).   
 
Increases in synaptic transmission have been shown to directly influence the rate of 
regional brain tissue perfusion (Harris, Reynell, and Attwell 2011). A proposed 
mechanism suggests that, among the milieu of processes that occur during synaptic 
transmission, neuronal-astrocytic messenger molecules are generated that act to 
either modulate calcium (Ca2+) ion channel activity on smooth muscle cells or to 
affect the sensitivity of contractile units to Ca2+ within the parenchymal arteriole 
smooth muscle cells (Attwell et al. 2010). In addition to interactions on Ca2+ channel 
activity there are agents or messenger molecules released during synaptic 
transmission that act on potassium channels (K+) present on the smooth muscle cells 
of the arterioles. Opening of these channels causes cell hyperpolarisation, reducing 
intracellular Ca2+ and consequently leading to smooth muscle relaxation and an 
associated increase in flow (Buxton 2013). Furthermore, nitric oxide (NO) is known 
to interfere with the intracellular sensitivity of contractile units within smooth muscle 
to Ca2+ signalling (Buxton 2013) and is thought to be highly involved in this 
neurophysiological response.  
 
This response to neuronal activity/metabolism can be termed functional hyperaemia 
as the increase in blood flow is coupled with an increase in oxygen supply. The two 
common fMRI techniques, used in the current study of intranasal insulin, and in most 
fMRI studies, are perfusion fMRI and blood oxygenation level dependent (BOLD) 
fMRI. Perfusion fMRI techniques permit assessment of neuronal activity through 
estimation of changes in cerebral blood flow (CBF). Blood Oxygen Level Dependent 
(BOLD) fMRI, however, permits the assessment of neuronal activity primarily by 
being sensitive to changes in the relative concentration of deoxygenated 
haemoglobin in the blood.  This in itself is driven by changes in blood flow, oxygen 
metabolism and the changes in magnetic susceptibility that accompany this 
neurovascular response. The neurophysiology of the BOLD effect along with methods 
used to capture this effect will be outlined in section 2.3.  
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2.2.2 Cerebral blood flow and arterial spin labelling 
Assessment of resting cerebral blood flow (CBF) for the SNIFAR study was conducted 
using a non-invasive perfusion imaging technique known as arterial spin labelling 
(ASL). Using blood water as an endogenous contrast agent ASL is a technique that 
can quantify regional CBF in traditional physiological units of ml / 100g of tissue / min 
(Petersen et al. 2006), it is a measure of the amount of arterial blood delivered to the 
brain tissue regardless of directionality.  
 
In the simplest form, ASL requires the acquisition of a minimum of two images; one 
labelled image and one control image. The labelled image is produced in two steps. 
Step 1: water spins within arterial blood are magnetically labelled (inverted with 
respect to the static signal). Step 2: following this labelling period the spins are 
allowed to travel along the arterial cerebral tree to the capillary bed at which point 
an image is acquired. The control image is an image acquired in the same way as the 
label but without labelling of arterial blood (Detre et al. 1992). The control image 
theoretically contains signal contributions from flowing blood which are 
indistinguishable from the static signal; in turn, the static signal is also largely 
identical to that from the labelled image. Pairwise subtraction of these images 
(control – label) produces a difference image, known as a ‘perfusion weighted image’, 
with signal intensities that arise from the contribution of labelled, inflowing blood 
magnetisation. Acquiring and subtracting images in this manner achieves signal 
differences of approximately 0.5-1.5% (corresponding to the proportion of proton 
spins in the capillary volume relative to those of the rest of each voxel), but with 
multiple average acquisitions, sufficient signal to noise ratio (SNR) can be achieved 
(Alsop et al. 2014). The signal difference obtained from ASL is also dependent on 
factors such as T1 longitudinal relaxation of arterial blood, time taken for labelled 
spins to travel from the labelling plane to the imaging plane as well as haemodynamic 
properties such as cerebrovascular constriction and dilation (Petersen et al. 2006; 
Wang, Chen, et al. 2011a).  
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A huge benefit of ASL is that whole brain physiologically relevant information, CBF, 
can be ascertained that is easily interpretable and applicable to many research and 
clinical applications (Alsop et al. 2014; Wang et al. 2003). Another benefit is that 
unlike Positron Emission Tomography (PET), ASL does not require ionising radiation 
in order to generate perfusion contrast.  In PET, this is normally achieved by injecting 
radiolabelled water (H215O, due to the fact that  15O is a positron emitter). This 
technique is still considered in some quarters as the ‘gold standard’ method for CBF 
quantification (Ramsay et al. 1993; Ye, Berman, et al. 2000). Due to the non-invasive 
character of ASL, serial ASL images and CBF maps can be acquired over the course of 
longitudinal MRI investigations,  which is perhaps one of the main reasons why this 
method has become an attractive alternative in pharmacological investigations. The 
term pharmacological MRI (phMRI), coined by Jenkins et al., describes a 
methodology used to correlate changes in pharmacokinetic data (PK) with changes 
in functional MR signal (Jenkins 2012). Originally implemented with Blood Oxygen 
Level Dependent (BOLD) techniques, this concept has also been adopted with ASL 
through acquisition of serial measurements during an MRI experiment, for example 
in Paloyelis et al., (Paloyelis et al. 2014). 
 
The next section will discuss in detail the fundamental physics of ASL and the evolved 
sophistication that this method has experienced, in order to provide more reliable 
quantitative estimates of CBF. Both the labelling and imaging components will be 
described in general and more specifically with reference to the technique used for 
the SNIFAR study.  
 
2.2.2.1 Labelling  
In general, there are three types of commonly used ASL techniques, classified 
depending on the nature of their labelling methods: pulsed ASL (PASL), continuous 
ASL (CASL) and a variant of CASL called pseudo-continuous ASL (pCASL) (Alsop et al. 
2014). 
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PASL uses a single and relatively short (10-20ms) RF pulse to achieve labelling, 
through inversion of inflowing water spins in the region of the carotid arteries.  CASL, 
which is the original ASL method realised in 1992 (Detre et al. 1992; Williams et al. 
1992) requires application of a continuous RF pulse of 2-4 s duration as a labelling 
mechanism across a plane perpendicular to the feeding carotid arteries in the neck. 
Coupled with this pulse is a constant magnetic field gradient applied in the blood flow 
direction which causes flowing arterial (carotid) spins to experience slow moving 
variations of their resonance frequency as they move along this gradient, ultimately 
resulting in spin inversion (Williams et al. 1992).  
 
The inversion of spins produced by the combination of an applied RF pulse and 
gradient vector in the flow direction is known as ‘adiabatic inversion’ or ‘velocity 
driven adiabatic inversion’, because it works as long as the target spins are moving, 
which is the case for arterial spins. Spins that flow through the labelling plane will 
possess a tendency to follow the slow rotating effective field producing an inversion 
of the magnetisation (Dai et al. 2008). The method works as long as the spins 
experience inversion at a rate faster than that at which they are losing magnetisation 
due to T2 relaxation; but slower than the rate of rotation of the effective field, hence 
the adiabatic character of the process.  This condition can be summarised by the 




where G is the amplitude of the gradient in the direction of flow and v is the flow 
velocity. 
 
pCASL, a variant of CASL developed by Dai et al., achieves flow driven adiabatic 
inversion through application of a series of short (500-100 microsecond) Hanning 
shaped RF pulses coupled with a train of gradients with a small (non-zero) net value, 
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as opposed to a continuous RF pulse (Dai et al. 2008). The net amplitude of RF power 
in the presence of a net, finite magnetic field gradient, achieves flow driven adiabatic 
inversion.  The Hanning shape of each pulse ensures that aliasing planes of the label 
fall outside of the desired image volume.  The phase of each RF unit is incremented 
so that at the end of the RF train, the spins experience a net phase shift of:  
 𝛾𝐺CD6∆4𝐿𝐷 
 
Where Gnet is the net gradient in the direction of flow, Dz is the position of the 
labelling plane relative to the magnet iso-centre and LD is the labelling duration. 
 
In the control condition, the amplitude of each RF pulse unit is inverted and the 
gradient lobes are balanced so as to produce a net gradient of zero in the direction 
of flow.  Therefore, the control condition has the same RF power deposition, the 
same magnetisation transfer contribution but no flow encoding.  
 
The general scheme for a pCASL sequence is displayed in Figure 2.2.1 
 
The net duration of the train of labelling RF pulses (labelling duration-LD) is an 
important parameter included in the CBF quantification calculation. The current 
recommended LD for pCASL, in healthy volunteers is 1800ms (Alsop et al. 2014).  
 
2.2.3 Label duration 
The effect of label duration (LD) has been explored by several groups in an effort to 
increase the ASL signal measured from pCASL experiments. The small amount signal 
provided from labelled arterial blood coupled with low capillary volume in the brain 
makes ASL a relatively low SNR technique (Buxton 2005). Explorative work with 
pCASL label durations has shown evidence that increased SNR can be achieved by 
increasing the labelling duration to 3.5 - 4s seen from both simulated and measured 
pCASL data (Zun et al. 2014). Any further increases are prevented by the hardware 
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constraints of the amplifier, the Specific Absorption Rate (SAR) limit and the need to 
have sufficient fresh inflowing blood for the next TR. Increasing the LD gives rise to a 
linear increase in the bolus width of the arterial label, which leads to greater 
perfusion induced signal difference in the perfusion weighted images. Selectively 
increasing the LD, with no change to the imaging readout parameters, provides an 
increase in contrast to noise ratio. With those values of LD, pCASL can be carried out 





2.2.3.1 Imaging and post labelling delay 
Immediately after labelling, the inverted spins will travel through the arterial 
vasculature to the capillary bed. The time between the end of the labelling pulse and 
the arrival of the labelled bolus to a voxel in brain tissue is known as the Arterial 
Transit Time (ATT) (Qiu et al. 2010); this is an important parameter for CBF 
quantification. In most pCASL protocols, a single delay period between labelling and 
image acquisition is used, sometimes also known as the post labelling delay (PLD). In 
an ideal ASL experiment, the PLD should match the ATT  at every voxel so that image 
acquisition will be performed as the labelled spins are in the capillary bed. In reality 
this is of course impossible to achieve as the ATT is a physiological parameter that 
differs between subjects, it can vary with age, and also differs between brain regions 
and lobes (MacIntosh et al. 2010). If the chosen PLD is too short, labelled spins that 
are still within the arterial compartment will lead to signal hyperintensity in the 
arteries; whereas PLD times that are much longer than the ATT will lead to signal 
Figure 2.2.1 An example of a pCASL sequence. The labelling scheme (green) is applied 
for a set  length, defined by the labelling duration (LD). Following labelling of inflowing 
arterial spins there is a delay period (PLD) to allow the labelled bolus to flow into the 
imaging volume an image is acquired (readout).  
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corresponding to the venous compartment; and because of labelled signal decay via 
longitudinal relaxation (discussed in more detail below), this would lead a 
considerable loss in SNR. An optimal, single PLD for pCASL acquisition is one when 
most of the labelled bolus resides in the capillary domain. This value  is approximately 
1800 ms for young, healthy volunteers (Alsop et al. 2014). 
 
The implementation of multi-PLD ASL acquisition schemes has seen an increase in 
popularity and development over the last few years. Multi-PLD refers to ASL 
acquisitions that acquire perfusion weighted images after more than one PLD time 
(Gonzalez-At, Alsop, and Detre 2000). In doing so, the inflow and outflow of labelled 
spins can be modelled more accurately. From this extra information, estimates of 
ATT can also be performed, in addition to measures of CBF for each voxel. Acquiring 
this additional information incurs a penalty on overall acquisition time. More 
complex methods to remedy this penalty, whilst still providing the gain in additional 
temporal information have been developed.  One such method is known as 
Hadamard encoding ASL sequences (Dai et al. 2012; Wells et al. 2010; Gunther 2007).  
 
2.2.3.2 Hadamard encoding 
Typical pCASL or CASL perfusion weighted image formation requires the acquisition 
of a label image and a control image, which are subtracted to provide a perfusion 
weighted difference image. For Hadamard encoding acquisition the principle is to 
acquire a series of images following implementation of a labelling module that is 
constructed from several control and label sub-blocks (Wells et al. 2010). The 
labelling module oscillates between label and control sub-blocks of a set duration 
which produces an image that is composed of a mixture of control and label signals 
from these sub-blocks. The ordering of sub-blocks is determined by a Hadamard 
matrix which is then applied during image-processing to separate this mixture of 
signals through a linear combination of the images. Following image processing a set 
of perfusion weighted images with differing PLD times is created. To create a set of 
perfusion weighted images of seven different PLD’s an 8 x 8 Hadamard matrix is used 
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that requires eight acquisitions. In comparison to conventional multi-PLD which 
would require fourteen total acquisitions (7 control, 7 label) to achieve seven PLD 
difference images (Dai, Shankaranarayanan, and Alsop 2013). In addition to this 
temporal benefit, Hadamard encoding also boasts an increase in SNR due to the way 
the images are linearly combined and also reduced number of acquisitions (Dai, 
Shankaranarayanan, and Alsop 2013).  
 
For the SNIFAR study, we chose to employ a single-PLD pCASL ASL sequence. 
Following labelling of arterial blood, the inverted spins will decay with T1 during the 
PLD time; leading to a sub-optimal ASL signal difference, even in the presence of high 
RF inversion efficiency. Therefore, the readout imaging modules for ASL should 
ideally possess a high temporal resolution. Both 2D and 3D readouts can be utilised 
with pCASL. The main advantage of 3D readouts over 2D is that the entire imaging 
volume can be acquired during a single excitation permitting a single PLD to be used 
for quantification, as opposed to slice dependent PLDs that need to be adjusted for 
each slice location. Furthermore, suppression of background tissue signal (see below) 
is better executed because the inversion times of the background suppression 
module are relevant to the whole image volume.  
 
2.2.3.3 Background suppression 
Background suppression is a technique used to supress signal from tissues or 
components that are not of interest, to achieve higher contrast between the signals 
of interest (Garcia, Duhamel, and Alsop 2005; Ye, Frank, et al. 2000). In theory the 
perfusion weighted subtraction images should remove the static unwanted tissue 
signal however   subject motion during ASL acquisition produces signal fluctuations 
proportional to the tissue of interest signal prior to this subtraction. By reducing the 
signal from the background, the sensitivity of pCASL can be improved dramatically 
(Garcia, Duhamel, and Alsop 2005). This is done using a combination of saturation, 
spatially selective and non-selective inversion pulses prior to labelling and readout to 
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essentially null the static signal at the start of the readout window (Garcia, Duhamel, 
and Alsop 2005).  
2.2.3.4 Imaging readout 
Readout modules should be considered independent of the labelling modules (see 
Figure 2.2.1). In the SNIFAR study, a single shot 3D fast spin echo (FSE) stack of spirals 
imaging readout was implemented (Ahn, Kim, and Cho 1986). In this sequence, the 
excitation pulse is applied to the entire imaging volume. Following a flip of 
magnetisation into the transverse plane a number of refocusing 180O pulses are 
applied to produce a train of echoes, known as FSE sequence, originally called a Rapid 
Acquisition with Refocused Echoes (RARE) (Hennig, Nauerth, and Friedburg 1986). 
Each echo is sampled with a spiral trajectory, known as a spiral arm, with application 
of a phase encoding gradient along the slice direction between each of the echoes, 
so that each echo is sampled in an ascending slice order. As the peak of each echo 
within this train of sequential echoes (echo train) will decay with T2, there is a 
decrease in signal in the slice encoding direction, which leads to what is known as ‘z-
blurring’ (Figure 2.2.3). A compromise between number of slices (which determines 
the length of the echo train) and the slice thickness must be considered in order to 
avoid deleterious blurring in the slice encoding axis (Glover 2012). This is most visible 
from coronal images.  
 
Spiral imaging is a non-Cartesian method of sampling k-space that follows a spiral 
trajectory as opposed to filling k-space in a rectangular trajectory. This type of 
sampling is temporally efficient as using this trajectory, all the area of the k-space 
plane can be sampled within a single shot (Glover 2012). Spiral imaging sampling 
methods can be used to acquire data from the centre of k-space outwards or from 
the outside inwards. Both of these trajectories can increase the time taken to sample 
k-space by under-sampling the high frequency data points in the corner of k-space 
(Irarrazabal and Nishimura 1995; Glover 2012). Sampling in this way can provide a 
21.5% reduction in overall acquisition time and by oversampling in the centre of k-
space can provide some resistance to subject related movement (Liao et al. 1997). 
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Spiral readouts have been utilised in functional imaging experiments for these 
reasons (Glover 2012).  To create a spiral trajectory in k-space the phase and 
frequency encoding gradients oscillate in a sinusoidal manner during the readout 
window (Ishimaru et al. 2007). This can be seen in Figure 2.2.2. 
 
 
2.2.3.5 Decreasing the voxel size of CBF maps 
 Whilst the spatial resolution of a 2D image in MRI is dictated by the inverse of the 
area sampled in k-space, the ability to resolve the higher spatial detail encoded by 
higher gradient amplitudes, depends on being able to acquire information from 
smaller voxels with sufficient SNR. For spiral acquisitions, this can be achieved by 
increasing the number of points sampled per arm in k-space, and in the orthogonal 
dimension by increasing the number of frequency encoding steps. In the plane of the 
image, higher spatial detail can be obtained in two ways; by increasing the number 
of spiral arms acquired and by also increasing the number of points sampled per 
spiral arm. Increasing the number of arms leads to an associated increase in overall 
scanning time as each additional spiral arm requires an additional TR. Furthermore, 
Figure 2.2.2 Example of a typical k-space trajectory adopted with a spiral readout sequence. A) The 
trajectory sampled in k-space with spiral readout. B) Depicts the Kx and Ky coordinates over time. C) 
The oscillating phase and frequency encoding gradients GX and GY that are required for spiral sampling. 
Gradient amplitude increases over time as the spiral increases in diameter.   
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increasing the number of data points sampled per arm increases the echo spacing; 
and therefore the effective echo time of the through-plane sample, introducing 
greater T2 signal loss across the slice encoding gradient direction and consequentially 







Figure 2.2.3 An example of the 3D spiral sequence trajectory. Each echo is 
sampled along a single spiral arm. In between each echo a slice encoding 
gradient moves to the next plane of k-space to acquire the subsequent echo and 
so on. As the sequence acquires from bottom to top there will be a blurring 





From previous work conducted as part of my MRes project, this 3D-pCASL FSE stack 
of spiral sequence was implemented in a pCASL sequence package that possessed 
the ability to deliver long label durations  (up to 4s, in comparison with the 1.5s 
default duration of the conventional package). In this work, a pCASL sequence was 
optimised using a long LD to increase SNR within the perfusion weighted image 
acquisition. Increasing the LD from a standard label duration (1.5s) to 3-4s displayed 
a significant gain in SNR (approximately 30%, at in plane resolution of 3.4 x 3.4 mm2), 
when compared with identical readout parameters, which turned out to be highly 
beneficial in spite of an overall decrease in temporal resolution (increased TR). Using 
this gain in signal, the project explored the effect of increasing the spatial resolution 
(decreasing the voxel size) in an effort to acquire pCASL images and CBF maps with 
sufficient resolution to better resolve small anatomical structures and better define 
Figure 2.2.4 Examples of k-space spiral trajectories and how the sampling density can 
be increased by additional spiral arms or additional data point per spiral arm. 
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the cortical gyri. As mentioned in the previous chapter, increasing the resolution 
requires increasing the spiral sampling density which was achieved through obtaining 
an optimal combination of spiral arms and points sampled per arm. The optimal 
combination based on image quality and taking into consideration the overall scan 
time, was selected to be an isotropic resolution of 3mm3. This sequence was used 
throughout the pharmacological investigation of intranasal insulin which will be 
presented in this thesis.  
 
2.2.3.6 Partial volume averaging  
The average adult CBF for grey matter (GM) is approximately 55 – 65 ml/100g/min 
whereas the average CBF for white matter (WM) is considerably less, roughly 20 
ml/100g/min (Parkes et al. 2004). CBF tends to show a decline with age independent 
of cerebral GM atrophy (Chen, Rosas, and Salat 2011). From ASL acquisition, a 
measure of CBF for each voxel can be obtained. Voxels at the boundaries between 
grey matter and white matter will contain signal contributions from both of these 
tissue types reflecting a signal average of both tissue (Chappell et al. 2011). This is 
known as a partial volume contamination (PV) effect and is inherent to imaging 
techniques but is accentuated in acquisitions with large signal differences between 
tissue types and techniques with low spatial resolution, such as ASL (Asllani, 
Borogovac, and Brown 2008). Similarly, these PV effects also arise at the GM and 
cerebrospinal fluid (CSF) boundaries. PV effects for CBF mapping leads to an 
underestimation of CBF within these boundary regions which is particularly 
problematic in studies looking at ageing where the cortical GM ribbon is largely 
reduced due to cortical atrophy processes (Creasey and Rapoport 1985). There are a 
number of PV correction methods that are available (Asllani, Borogovac, and Brown 
2008; Chappell et al. 2011) which have struggled to be adopted in general ASL 
processing practices. Given the lack of an accepted and standardised PV correction 
approach we have opted to increase the SNR as much as possible to reduce the voxel 
size to an optimum dimension. 
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2.2.3.7 Cerebral blood flow calculation 
A crucial advantage of ASL as a functional brain imaging tool is the ability to create 
quantitative maps of CBF. Assuming the static tissue signal from control and label 
images has been subtracted effectively the perfusion weighted image signal 
(difference) will be proportional to the efficiency of inversion, the  amount of labelled 
arterial blood delivered to each voxel during the PLD and the specific capillary volume 
at each location.  All these factors contribute to the computed regional value of CBF. 
Quantification of CBF is conducted through a voxel-wise calculation of perfusion 
weighted images (control – label) and also a reference scaling image (commonly a 
proton density (PD) image) along with additional parameters (Buxton 2005; Buxton 
et al. 1998) which depend on the specific pulse sequence employed.  
 
There are several methods and models that can be used for CBF quantification, but 
the simplest model is the single compartment model which will be presented and for 
single PLD ASL data has been shown to be appropriate (Alsop et al. 2014). This model 
of CBF assumes that the entire labelled bolus has entered the target tissue. In healthy 
individuals, this assumption can be largely satisfied by selecting a PLD that is longer 
than both the longest ATT and tissue transit time (Alsop et al. 2014). Liu et al., showed 
that a typical tissue transit time was approximately 1900ms for healthy individuals 
and that a PLD of approximately 2s is hence sufficient to allow for arterial labelled 
spins to completely enter the tissue space (GM) (Liu, Uh, and Lu 2011). Additional 
parameters required in this model are calibration factors that take into account the 
T1 relaxation time of arterial blood (T1blood), the labelling efficiency of the ASL label 
(𝛼) and also the proportion of proton spins in blood vs the proton spins in tissue, 
known as the blood brain barrier partition coefficient  (λ). The model also requires 
the value of the temporal width of the labelled bolus duration (𝜏); which in pCASL 






The formula, for pCASL using a single PLD is presented below:  
 
𝐶𝐵𝐹 =	 6000.		𝜆	.		𝑃𝑊	.		𝑒	 PQR=STUVVW2	.		𝛼	.		𝑇1𝑏𝑙𝑜𝑜𝑑	.		𝑃𝐷	.		(1 − 	𝑒 @]				=STUVVW) 
 
The PLD and 𝜏	are prescribed parameters of the sequences whilst the other 
parameters in the equation can be measured or, are known from reference values. 
For example, the T1blood set to 1650ms at 3T (Lu et al. 2004), α for pCASL is 0.85 
(Dai et al. 2008) but the efficiency of  background suppression also has to be taken 
into account (in our sequence this value was 0.8). λ is 0.9mL/g (Herscovitch and 
Raichle 1985). The PD image, used in the quantification is acquired with the same 
readout parameters as the control and label images, is employed as a scaling factor. 
The 6000 in the above equation is a conversion factor to produce CBF measurements 
as ml of blood per 100g of tissue per minute (Alsop et al. 2014).  
This single compartment tissue model assumes that all labelled spins diffuse from the 
capillary compartment to the tissue compartment immediately, and therefore the 
signal contribution from each tissue voxel is from spins within the tissue space, 
assuming a long enough PLD. In reality this exchange is not immediate and 
furthermore, not all labelled spins will diffuse from vessel to tissue thus leading to 
inaccuracies in CBF estimation. Parkes et al., developed a kinetic CBF model that 
accounts for these two issues, which they call the T1 effect and outflow effect (Parkes 
and Tofts 2002; Parkes 2005).  Although more accurate estimations of CBF can be 






2.3 Blood Oxygen Level Dependent Contrast 
The origin of the BOLD signal stems from the differential magnetic properties of 
haemoglobin which when oxygenated is diamagnetic and when de-oxygenated is 
paramagnetic; and from the uncoupling of blood flow and oxygen utilisation as a 
result of changes in neuronal activity. The paramagnetic properties of 
deoxyhaemoglobin alter the local magnetic susceptibility in its vicinity, both within 
and outside of the venous capillaries, ultimately producing a reduction in the regional 
transverse MR signal, as result of additional loss of phase coherence. As stated above, 
the origin of the BOLD effect exploited in fMRI experiments stems from a 
neurophysiological phenomenon that occurs in response to increased neuronal 
activity.  Increases in neuronal activity are almost always associated with local 
increases in CBF as a result of the phenomenon of neurovascular coupling. Upon 
changes in neural activation this regional increase in CBF is proportionally much 
greater than the relative increase in cerebral metabolic rate of oxygen (CMRO2) and 
this results in a decrease in oxygen extraction fraction (OEF) coupled with a decrease 
in the relative concentration of deoxyhaemoglobin in the venous domain (Fox and 
Raichle 1986). Because the blood, localised to the neuronal activation, is (as a whole) 
now more oxygenated than deoxygenated, the net magnetic field distortions are 
decreased and there is hence an increase in the local transverse MR signal. This 
dependence of the MR signal on the neurophysiological response of the tissue, also 
known as the ‘haemodynamic response’, is more strongly reflected in imaging 
methods that are sensitive to local field distortions, such as the case of gradient echo,  
T2* weighted echo Echo Planar Imaging (EPI) (Mansfield 1977). 
 
The BOLD effect signal is a therefore the result of the sum of contributions from 
changes in CBF, CMRO2 and Cerebral blood volume (CBV) partially mixed over the 
course of this haemodynamic process, and it is known as the ‘haemodynamic 
response function’ (HRF) (Buxton et al. 2004). A detailed description of the 
underlying mechanisms of the neurophysiological phenomenon of the BOLD effect is 
elegantly described in Buxton et al., (Buxton et al. 2004). The next section will guide 
 98 
the reader through the BOLD effect in response to task-based stimulus, common to 
fMRI experiments and how these effects are measured.  
 
Pioneering work by Turner et al., and Ogawa et al., initially showed how decreases in 
the MR signal surrounding cerebral blood vessels (following changes in blood 
oxygenation levels from respiratory gas challenges) could be observed in the cat and 
rodent brain, respectively (Turner et al. 1991; Ogawa et al. 1990). This work 
suggested that deoxygenated blood, in other words rich in deoxygenated 
haemoglobin, could be used as an intrinsic contrast agent when acquired with 
gradient echo imaging sequences. Shortly following these findings, Ogawa et al., 
showed that these MR signal  changes could be observed in the human occipital 
region and calcarine fissure while the subject was presented with a bright visual 
stimulus (Ogawa et al. 1992). This evidence highlighted the sensitivity of rapid 
gradient echo sequences to local changes in deoxyhaemoglobin that could be 
perturbated by external stimuli and opened the door to a new field which we now 
know as BOLD contrast fMRI. Bandettini et al, (1992) also showed how similar 
changes could be measured in primary motor cortex in response to a ‘finger tapping’ 
task (Bandettini et al. 1992).  
 
Fundamental to the ability to observe BOLD contrast changes in the human brain 
during a task requires a gradient echo scanning protocol that fulfils certain 
acquisition qualities. Firstly, to capture these temporal effects, the acquisition needs 
to be conducted rapidly, in order to capture signatures of these neurophysiological 
changes with sufficient accuracy and reliability (Turner et al. 1998). Secondly, images 
need to be acquired with sufficient spatial resolution in order to resolve local changes 
in BOLD contrast that are reflective of the underlying anatomy in small structures. 
And finally, to permit explorations of functional stimuli on the whole brain, an 
acquisition scheme capable of acquiring multiple slices during the BOLD contrast 
event is necessary. As indicated earlier, a rapid acquisition sequence known as 
gradient recalled Echo Planar Imaging (EPI) (Mansfield 1977), possesses these 
qualities and has been the ‘workhorse’ of the fMRI BOLD contrast research 
conducted over the last 26 years. EPI readouts are rapid (~40-100ms) but carry a cost 
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of spatial resolution and therefore a compromise between temporal and spatial 
resolution is required.  
2.3.1 Echo planar imaging 
With this method, it is possible to acquire whole brain data (20-30 T2* weighted 
images) in a  single TR, which is approximately 2s for most conventional fMRI 
protocols. The term TR in this instance refers to the time taken to acquire all the slices 
as opposed to the time between subsequent RF excitations. A readout scheme 
known as blipped EPI is commonly used. This type of readout fills the entirety of k-
space in a rectangular trajectory, following a single RF excitation pulse. As outlined 
in the beginning of this chapter, application of an excitatory RF pulse generates a 
Free Induction Decay  (FID) signal. In the blipped EPI sequence, the FID decay is 
initially accentuated by application of a large phase and frequency de-phasing 
gradient. Following this, the receiver coil is opened and the first lobe in a train of 
frequency encoding gradient is applied, generating a gradient recalled echo from 
which a single line of k-space is sampled. A frequency encoding gradient of the same 
strength and duration is applied in the opposite direction preceded by a small phase 
encoding gradient (blip) to acquire another, the next, line of k-space. This frequency 
encoding gradient switching and blipped encoding sequence is repeated until the 
entire matrix of k-space data is ‘filled’. Once filled, a slice encoding gradient is applied 
to excite the next slice and the same sequence is followed until all data for the next 
slice has been acquired. This process is repeated over an fMRI experiment producing 
a serial collection of T2* weighted images, known as a ‘a functional timeseries’. From 
this time series, the haemodynamic response can be measured by obtaining a 
sufficiently large number of time points for each voxel.  Several analysis methods can 
then be used to model the haemodynamic response function, in response to sensory 
or cognitively induced neuronal activation.  
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2.3.2 Task based fMRI and the haemodynamic response  
Task based fMRI describes an MRI experiment where a participant is required to 
execute a paradigm whilst in the scanner; during which a functional time series of 
MRI data is acquired. Actions can range from basic sensory stimulations such as visual 
stimuli to more cognitively demanding tasks that involve learning, decision making 
or memory related functions (Amaro and Barker 2006). The series of actions within a 
task are known as ‘the paradigm’ and compiled using a pre-defined playlist of actions 
with explicit timings and duration for all the actions.  
 
A convenient property of the HRF is that it is additive when more than one stimulus 
is applied within the temporal width of the HRF.  Hence, a useful design for paradigms 
is what is known as a ‘block periodic design’; in which images collected within periods 
of a certain type of sensory or cognitive engagement are contrasted against those 
collected within a ‘reference’ condition.  
 
In response to a stimulus, the haemodynamic response function (HRF) can be 
observed as a temporal change in MR signal. The HRF can be broken down into three 
parts; the initial dip, the peak and the post stimulus undershoot. (HRF shown in Figure 
2.3.1) 
 
Figure 2.3.1 The haemodynamic response function.  
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2.3.2.1 The initial dip 
A somewhat controversial topic, the initial dip reflects a transient dip in MR signal 
that occurs following neuronal stimulation (Hu and Yacoub 2012). This dip in signal is 
attributed to a transient increase in Oxygen metabolism (CMRO2) in the absence of 
an increase in CBF, that leads to an increase in deoxyhaemoglobin concentration; and 
therefore a decrease in local MR signal (Menon et al. 1995; Hu and Yacoub 2012).  
2.3.2.2 The peak  
The haemodynamic response evolves over time, characterised by a local increase in 
both CBF and in the ratio of oxy to deoxyhaemoglobin concentration; as well as an 
increase in blood volume, which together give rise to an increase in the MR signal. 
The evolution of this response is slow compared with electric and magnetic field 
signatures observed with other techniques; and peaks at approximately six to eight 
seconds following stimulus presentation (Logothetis and Pfeuffer 2004).  
 
As seen in data from block design studies, in which a stimulus or action is preformed 
repetitively over a period of time (for example 20s), the magnitude of this response 
will grow until a plateau is reached (Logothetis and Wandell 2004; Glover 2011). As 
stated earlier, in a block design paradigm the periods of stimulation, known as 
epochs, are contrasted with control epochs where the participant is not engaged 
(rest) or performing a less demanding action (Amaro and Barker 2006). In contrast, 
paradigms in which a single stimulus is presented for a brief period of time (as seen 
in Figure 2.3.1) (but repeated several times with a time interval longer than the full 
width half-maximum of the HRF), are known as event-related paradigms. This type 
of paradigm presentation is possible as a result of the speed at which T2* weighted 
data can be acquired with EPI based techniques. This design permits more cognitively 
demanding paradigms which, for example, involve learning or neuronal responses 
that may change over time, i.e. as a result of  habituation.  
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2.3.2.3 The BOLD signal ‘undershoot’ 
After stimulus evoked neural activity, the BOLD response peak begins to decrease, 
returning to a baseline, eventually passing beyond the baseline level, producing a 
small decrease in MRI signal (Buxton 2013). This is supposed to occur in response to 
a sustained increase in CMRO2 coupled with a reduction in CBF, increasing the 
deoxy/oxy-haemoglobin concentration ratio (van Zijl, Hua, and Lu 2012).  
 
Debate and controversy can be found in the neurophysiological literature regarding 
the physiological underpinnings of both the ‘initial dip’ and the ‘undershoot’. This 
debate exists largely because the BOLD response is a product of at least three 
variables (CBF, CBV and CMRO2); and trying to decipher or disentangle the effects of 
each of these responses is problematic and can lead to discrepancies. Despite this, 
the wealth of knowledge the BOLD contrast phenomenon has provided the 
neuroimaging community with, has been substantial.  
 
2.3.3 Resting BOLD: image acquisition and analysis techniques 
Building on from task based fMRI, BOLD data acquired during the resting-state, or 
better put, in the absence of an administered task of cognitive or sensory 
engagement, has grown in popularity and importance over the last decade. Measures 
of resting functional connectivity, i.e. the identification of regions that show 
synchronous activation (or deactivation), is a very useful alternative to investigate 
brain function. Its application has found utility in pharmacological MRI (phMRI) 
studies, as well as being a complementary tool alongside task-based fMRI 
experimentation (Murphy and Mackay 2010). Resting state connectivity analysis 
permits the interrogation of resting activity at a whole brain network level, allowing 
the researcher to infer and interpret changes beyond those recruited by cognitive 
engaging tasks (Lv et al. 2018). Furthermore, resting fMRI offers a significant 
pragmatic benefit since no task-administration is required, and therefore it is easier 
to make acquisition conditions more consistent across different studies. The main 
requirement from the participant is to stay awake and keep still, removing 
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performance bias or non-compliance often found in task-based studies, which can 
also lead to significant variability (Murphy, Birn, and Bandettini 2013). Biswal et al., 
first reported synchronous fluctuations in the BOLD signal that occurred during rest 
between the left and the right sensorimotor regions and the supplementary motor 
area (Biswal et al. 1995). These synchronous MR signals were observed at 
frequencies below 0.1Hz and since this initial observation considerable work has 
been conducted to better understand, observe and analyse these low frequency 
signal fluctuations during rest. Through this work a number of well-defined low-
frequency networks have been characterised (Smith et al. 2013) and examining the 
modulation patterns on these fluctuations has been and continues to be a great tool 
for pharmacological MRI (Mehta and O'Daly 2011; Jenkins 2012). 
 
2.3.3.1 Functional connectivity 
Functional connectivity is defined by the degree of temporal correlation within the 
BOLD timeseries across different brain regions. Those regions that share a statistically 
significant degree of temporal correlation are labelled as being ‘functionally 
connected’.  The identification of these regions of functional connection is almost 
always made by identifying the independent frequency components of the time 
series and back-projecting those components onto the regions from which they are 
detected (see section 2.3.3.3). The validity and interpretation of this concept remains 
controversial. 
2.3.3.2 Seed based functional connectivity analysis 
There are a number of different ways to assess this degree of functional connectivity 
across the brain (for a review see (Cole, Smith, and Beckmann 2010) but one of the 
simplest in terms of both implementation and interpretation is ‘seed-based 
connectivity’ analysis (Biswal et al. 1995). Seed based analysis requires the selection 
of a ‘functional seed’ region, based on an a priori hypothesis or rationale, for which 
the BOLD time course for this seed is extracted, and used as a regressor within a 
whole brain General Linear Model (GLM) analysis, to derive whole-brain correlation 
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(connectivity) maps (Cole, Smith, and Beckmann 2010).  This type of approach is 
considered hypothesis-driven as the researcher will select a seed or number of seeds 
based on one or more hypotheses.  
 
2.3.3.3 Independent component analysis 
In contrast, independent component analysis (ICA), is a data-driven tool that is also 
commonly used for resting state analysis (McKeown, Hansen, and Sejnowsk 2003). 
ICA for resting-state purposes is used to identify and decompose a functional BOLD 
timeseries into a set of spatially segregated components or maps, combined with the 
time course for each component (Cole, Smith, and Beckmann 2010). This type of 
decomposition processing is popular for defining discrete resting state networks and 
can be used at the single subject level as well as within a group analysis protocol. ICA 
uses the entire dataset in comparison to seed based analysis which restricts the 
analysis to just a single time course selected by the researcher thus is capable of 
finding effects that may be missed. With ICA, constraints can be imposed upon the 
decomposition to reduce the number of components that may be ‘unmixed’ from 
the data.  
2.3.3.4 Resting state data quality 
In contrast to task based fMRI data, with which a model of haemodynamic activity 
can be created and correlated with the time series data, resting state data lacks an 
‘input function’ and has no prior knowledge regarding which signals are related to 
the BOLD contrast and which might be likely to derive from other sources. As the ICA 
method does not use prior information regarding resting state network components, 
the decomposition can also find spatial components that are attributable to non-
neuronal source or noise. The BOLD response originating from neuronal activity 
within resting state data comprises 2-5% of the overall signal measured, which is 
sometimes largely corrupted by artefactual sources of signal change. Artefactual 
signal changes can arise as a consequence of (for example) involuntary head motion, 
cardiac pulsatile motion, breathing related motion, breathing related changes in 
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arterial carbon dioxide, scanner drift and thermal noise (Caballero-Gaudes and 
Reynolds 2017; Murphy, Birn, and Bandettini 2013). The corruption of data through 
artefactual perturbations severely affects the functional connectivity analysis of 
resting-state fluctuations in the BOLD signal, which are typically measured in the 0.01 
to 0.1Hz frequency range. Some of these effects can be removed from the time series 
through temporal filtering processes, for example application of a bandpass filtering 
to restrict the time series data to only a defined frequency range (for example, 
removing those frequencies below 0.01Hz and greater than 0.1Hz) (Murphy, Birn, 
and Bandettini 2013). Given the large number of sources of signal corruption 
observed in resting-state data, there exists a need to perform denoising/cleaning 
methods prior to functional connectivity analysis.  
 
A benefit of ICA is that non-constrained decomposition is useful for spatially defining 
these sources of corruption into spatially independent components (Salimi-Khorshidi 
et al. 2014). Several methods exist to identify nuisance components following ICA 
decomposition, one of which requires a different acquisition approach and therefore 
must be considered prior to protocol commencement (Kundu et al. 2012). ICA based 
denoising methods that use conventional acquisition protocols require identifying 
and defining the decomposed spatial components into neuronal origin (BOLD) or 
artefactual origin (non-BOLD) components. This can be done by subjective operator 
involvement, which is not typically recommended, or by the assistance of algorithms 
based on machine learning classifying techniques; for example:  ICA-based X-
noiseifier (ICA-FIX, ‘Functional MRI laboratory (FMRIB), (Salimi-Khorshidi et al. 2014)) 
and FMRIB’s ICA-based Automatic Removal Of Motion Artefacts (ICA-AROMA, (Pruim 
et al. 2015)). Both of these nuisance component identification methods show good 
denoising capabilities, however a comparative resting state study published in 2017 
(Dipasquale et al. 2017) provided evidence to suggest that a technique known as 
multi-echo ICA (Kundu et al. 2012) was superior for noise removal compared to the 
two former machine learning ICA based methods. This technique requires a different 
acquisition approach to the conventional gradient echo methods described so far; 
and uses ICA coupled with a different signal analysis method for characterising 
components based on the nature of their corresponding T2* decay characteristics 
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(Kundu et al. 2013; Kundu et al. 2012). This technique was implemented in the 
current study of intranasal insulin and is described in detail below.   
 
2.3.4 Multi-Echo ICA: acquisition and processing 
As stated earlier, conventional BOLD contrast fMRI data is commonly acquired using 
gradient-echo echo planar imaging (EPI) using a single echo time (TE) for each image 
volume. BOLD contrast is maximal from gradient echo acquisition when the TE is 
equal to or close to the T2* value of grey matter (Howseman and Bowtell 1999), 
typically found to be 30 -35ms for acquisitions made at 3T. The TE set is a suitable 
compromise value so as to be able to acquire a sufficiently appropriate number of 
slices for the whole brain. However, the T2* of grey matter is not uniform throughout 
the brain and therefore some regions will inevitably display sub-optimal BOLD 
contrast.  For example, gradient echo EPI image acquisition with a long TE will lead 
to susceptibility artefacts and greater signal dropout particularly in prefrontal regions 
(Deichmann et al. 2003), whereas a short TE will be associated with high global signal 
intensity, less signal dropout but a reduction in BOLD sensitivity in those regions with 
larger T2* values (Howseman and Bowtell 1999).  
 
Multi-echo, gradient echo EPI (ME-EPI) acquisition is an acquisition approach that 
acquires multiple whole brain EPI images with increasing TE within a single TR (Posse 
et al. 1999). With this approach, every time point within the time series will have 
multiple whole brain volumes or better put, the data will consist of multiple time 
series each acquired with a different TE. The signal intensity across the echo 
acquisitions in each voxel will typically show an exponential T2* signal decay 
described in Figure 2.3.2.C  and presented visually in Figure 2.3.2.A,B.  
 
The use of this technique has been made possible through the advancement and 
development of rapid functional image BOLD contrast acquisition approaches. ME-
EPI was initially implemented in an effort to reduce susceptibility related signal 
dropout whilst gaining maximum T2* contrast (Posse et al. 1999). This was achieved 
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by firstly, fitting the data to an exponential decay curve to attain the T2* value of 
that of each voxel and with this information average the signal across the different 
echoes together using a weighted approach, optimal for the T2* of the tissue within 






Figure 2.3.2 An example of a multi echo EPI acquisition with three echoes. A) 
for each TR three whole brain EPI images are created. B) The final output can 
be divided into three timeseries each acquired at a different TE. C) the signal 






ME-ICA is a pre-processing technique developed to reduce the impact of noise and 
artefacts present in resting state data (Kundu et al. 2012), made possible through the 
combination of both acquisition and pre-processing techniques. Very simply, the 
multi-echo ICA processing employs a more sophisticated de-noising approach by 
assessing the T2* decay that is observed across the echoes, classifying signals that 
decay in an exponential fashion with T2* as ‘BOLD-like’ and those that do not show 
this relationship as ‘non-BOLD-like’ (Kundu et al. 2012). The appeal of this approach 
is that the independent components are classified based on their inherent T2* 
relaxometry characteristics; and attempts to identify BOLD components as opposed 
to simply identifying only the noise components. For this reason and also the 
superiority compared to other de-noising techniques (Dipasquale et al. 2017) the 
implementation of this technique is growing in the field of resting state functional 
connectivity analysis; as well as in task-based fMRI BOLD (Dipasquale et al. 2017; 
Kundu et al. 2013; Kundu et al. 2017; Lombardo et al. 2016; Power et al. 2018; 
Gonzalez-Castillo et al. 2016).  
 
The method, proposed and developed by Kundu et al., (Kundu et al. 2012), bases this 
approach on the idea that within a small range of TE’s the BOLD signal measured 
from tissue will decay exponentially with  the T2* time constant of that tissue. In 
response to a change in neural activity the change in oxy/deoxy-haemoglobin 
concentration reduces the local susceptibility effects, increasing the apparent T2* 
value of that region and ultimately leading to an increase in MR signal (measured 
with gradient echo EPI). It has been shown that this signal difference increases when 
acquired at longer TE’s (Bandettini et al. 1994) and therefore the change in MR signal 
displays a scaling factor that is dependent on TE. Therefore, confirmation of this type 







On the other hand, observations of a change in MR signal could also arise from non-
BOLD origins, such as those caused by motion. Following head movement for 
example, the tissue signal in the underlying voxel will be different and therefore the 
“spin-history” of the signal, will be also be different. This can be seen in Figure 2.3.3. 
 
In this figure, the two voxels show different levels of steady state magnetisation due 
to differing T1 relaxation rates between voxels, however have a similar T2* value. As 
a result of the different steady state vectors the initial signal intensity (So) in the 
transverse plane will be different between these two voxels and therefore the signal 
within these voxels will decay differently according to the equation presented in 
Figure 2.3.2.C. In response to neural activity in Voxel B, a change in T2* is observed 
and in increase in T2* constant leads to a signal difference measured between 
sequential TR’s if acquired at a suitable TE. However, in response to motion there is 
a displacement of the voxels and now Voxel A is located where Voxel B was. As Voxel 
A had a larger magnetisation vector in the steady state, the initial signal intensity, S0, 
following RF excitation will be greater now that this displacement has occurred. This 
is an example of a ‘spin history’ effect. Given a higher S0, the MR signal sampled at 
the same TE will exhibit very different changes in MR signal between successive TR’s. 
The changes in MR signal between a true change in T2* (BOLD-effect) and those 
coming from a change in S0, are essentially indistinguishable when using a single TE.  
In this scenario, spurious changes in MR signal are likely to be observed as a result of 
motion and changes in S0 , thus corrupting the data.  
 
Interestingly, the MR signal change produced from this change in S0 does not show a 
linear relationship with increasing TE, therefore it becomes TE-independent. This 
crucial element therefore permits the use of fitting to model the TE dependence of 
the time series (or independence) and to use it as the basis for identifying 












Figure 2.3.3 A diagram showing the effects of neural activity and motion on T2* decay and MR signal. 
Top panel shows two voxels, the associated steady state magnetisation curves and the T2* decay 
profile for both voxels when acquired with gradient echo EPI. Note the two voxels have differing S0. 
Middle panel shows that in response to neural activity in Voxel B there is a change in T2* constant 
which could be observed if detecting changes between TRs. Bottom panel shows how if there is a 
motion displacement that shifts voxel A to Voxel B location then a change in S0 will show a MR signal 
increase of measured with a single TE. This is known as a spin-history effect. 
 
 111 
The ME-ICA approach has been widely used and has several steps which will be 
described in sequence: 
 
Step 1: 
An average T2* map is produced based from the echo signal intensities at each voxel, 
averaged over the entire time series. Based on this T2* value, the signal intensities 
from each voxel and each echo are combined using a weighting scheme that is 
optimal for the T2* value assigned for that voxel (Posse 2012). The combined echo 
time series is thus optimal for the T2* value of each voxel (Posse et al. 1999) with 
optimal contrast to noise ratio (CNR). In their software, this is known as the ‘optimally 
combined’ dataset.  
 
Step 2:  
The optimally combined dataset is run through a spatial ICA. The ICA algorithm is 
unconstrained, so the total number of components extracted can range between 
subjects.  
 
Step 3:  
Within each identified component, the algorithm assesses the degree to which the 
signal intensity represents T2* decay (by characterising its TE-dependence) or 
whether the signal change across echoes does not arise from an exponential T2* 
decay (TE-independence). This process is conducted at each time point by fitting the 
TE signal change as a function of TE to a TE-dependence model and also to a TE-
independent model. For each time point a goodness of fit value is assigned for both 
of the models and a summary measure for the TE-dependence and TE-independent 
models is assigned for the component. These summary measures are defined as 
kappa, 𝜅, and rho, 𝜌. A high 𝜅 value signifies a component that correlates well with 
TE-dependence in an exponential fashion. A low 𝜌 value signifies a component that 
correlates well with the TE-independence model. A component defined with a high 𝜅 and low 𝜌 value would be deemed to correspond to signal decay indicative of a 
‘true- BOLD’ origin (of greater probability of arising from genuine changes in neuronal 
activity). Conversely, a low 𝜅  and high 𝜌 component is deemed to exhibit signal 
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changes that are likely to arise from non-neuronally driven sources (e.g. motion or 
physiological nature) and likely to be artefactual.  
 
Step 4:  
Based on the distribution of the 𝜅 and 𝜌 values, the ME-ICA algorithm defines 
thresholds for each component; and those components that show 𝜅 and	𝜌 values 
greater and lower, respectively, (than the calculated thresholds) are then classified 
as having the appropriate TE-dependence. Those that fall outside of an established 
range of 𝜅 and 𝜌 values,  are classified as TE-independent and some that fall in the 
middle are classified as “unidentified” (Kundu et al. 2012).  
 
Step 5: 
Timeseries of components classified as non-BOLD (low 𝜅 and high 𝜌)  are then 
regressed from the optimally combined echo time series in a similar way to which 
motion parameters are regressed in a General Linear model. The regressed time 
series is considered to be “de-noised”. The main output from the ME-ICA de-noising 
process is therefore a single time series of functional volumes that have been 
optimally combined based on the T2* value and in principle ‘cleaned’ of non-BOLD 
components as described above (Kundu et al. 2012). 
 
The next chapter will describe the application of these techniques for a 
pharmacological MRI study that explored the effects of intranasal insulin in healthy 











Chapter 3  Study Design 
 
3.1 Investigation of the Effects of Intra-nasally Administered 
Insulin on Food Appetite and Reward: The SNIFAR study 
This is a double-blind, placebo controlled, crossover MRI study to investigate the 
effects of insulin in the central nervous system (CNS), using intranasal administration. 
This study was designed to evaluate the effects of intranasal insulin on both 
homeostatic appetite control and also hedonic food reward.  A good proportion of 
investigations using intranasally administered insulin literature have focused on its 
effects on cognition, mood and also food related neural processing. This study aims 
to extend our understanding of the effects of this important compound by using a 
food administration paradigm that has not been reported in previous studies. This 
study also intends to contribute to the limited literature on resting state perfusion in 
response to intranasal insulin, through the implementation of an optimised arterial 
spin labelling sequence. Finally, the study reported here builds upon the current 
insulin related connectivity literature through the use of an artefact noise removal 
T2* weighted image acquisition and processing technique called multi-echo 
independent component analysis denoising  (Kundu et al. 2012). Also included within 
this thesis is a chapter focused on work that was conducted to optimise a 
commercially available nasal pump, to provide optimal insulin delivery to the CNS.  In 
this work (conducted using active insulin) I carried out key in vitro measurements 







This study was approved the King’s College London Psychiatry Nursing and Midwifery 
Ethics Committee (ethics no. RESCM-17/18-2282). Participants for this study were 
predominantly recruited through the King’s College recruitment website although 
some were recruited through word of mouth. Participants liaised with the head 
researcher through email initially and also a short phone conversation to filter out 
participants who did not fulfil the immediate inclusion criteria. The study consisted 
of three visits in total. Visit one was a screening session and the remaining two 
sessions were experimental imaging sessions.  
 
3.1.2 Screening and inclusion criteria 
This study evaluated drug effects in healthy right-handed male volunteers (aged 
between 20-36 years of age). All participants provided informed written consent.  
Participants were screened to ensure they had no history of psychiatric illness or 
diabetes assessed by clinical interview, no cardiac-related complications (assessed at 
the screening visit by means of a 12-lead electrocardiogram (ECG)), no history of 
eating disorders, asthma or allergies associated with breathing difficulties and did 
not adhere to a vegetarian or vegan diet. During the screening, height and weight 
measurements were taken, as well as resting blood pressure and heart rate 
measurements in the supine and standing position.  
 
During the screening session, participants answered three questionnaires to assess 
eating behaviours, to obtain an indication of weekly food intake and to assess how 
stable their eating behaviours were, using a three-factor eating questionnaire 
(Stunkard and Messick 1985), the dietary free fat and sugar subscale questionnaire 
(Francis and Stevenson 2013) and the council of nutritional appetite questionnaire 
(Wilson et al. 2005). These questionnaires are based on general eating behaviours 
and are highly unlikely to change during the length of the study; therefore, they were 
completed during the screening visit only. The council of nutritional appetite 
questionnaire (CNAQ) was used a screening tool. The CNAQ is commonly employed 
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to assess the likelihood of future weight loss, typically implemented in anorexia 
research (Wilson et al. 2005). The CNAQ consists of eight questions using a 5-point 
scale (1-5), total scores range from 8-40. Scores greater than 28 indicate a normal or 
good appetite, whereas scores  ≤ 27.9 reflect poor appetite. Participants with scores 
representative of poor appetite were deemed not eligible for this study (Wilson et al. 
2005).  
 
The three factor eating questionnaire (TFEQ) and dietary free fat and sugar subscale 
questionnaire (DFS) was also used in the data analysis of the study. The TFEQ is 
commonly employed in obesity related research and measures three factors: dietary 
restraint, disinhibition and hunger (de Lauzon et al. 2004). The TFEQ is a 36 part 
questionnaire that uses both true and false questions as well as 4-point and 5-point 
Likert scales. TFEQ scores for each factor are calculated and severity ratings of ‘low’, 
’medium’ and ‘high’ for each factor can be ascertained.  
 
Dietary restraint has an impact on weight control and how this can be achieved, for 
example by reducing food portions or restricting eating (Bryant, King, and Blundell 
2008). High dietary disinhibition is reflected by a tendency to overeat, particularly at 
opportunistic moments within obesogenic environments. The final factor, hunger, 
explores the feelings of hunger and how these feelings can evoke food intake 
(Stunkard and Messick 1985).  
 
The dietary fat and sugar (DFS) questionnaire provides an approximate guide to 
examine how often meals or food that contain high amounts of saturated fat and 
sugar are consumed. From the DFS the overall frequency of foods high in saturated 
fat, sugar as well as food that contains both high levels of fat and sugar can be 
calculated (Francis and Stevenson 2013). This questionnaire contains 26 food types 
for which the participant must mark on a scale how often that food type is consumed. 
The scale ranges from “less than once per month” to “5 + times per week” on a 5 
point scale. The questionnaire is quick to complete and has been shown to produce 
valid and reliable measures of saturated fat and free sugar consumption when 
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compared with weekly food diaries which are also more arduous on the participant 
(Francis and Stevenson 2013).  
 
During the screening session participants were given full details on what was 
required from them, familiarised with the study protocol, scanner paradigms as well 
as shown how to correctly operate the nasal administration pump.  
3.1.3 Study cohort stratification 
Participants with a body mass index (BMI) between 18 and 30 kg/m2 were included.  
These subjects were then subdivided into two groups: below and above 25 kg/m2   to 
examine differences between healthy and near-obese individuals. 
 
This division allowed us to study individuals in a metabolic state between normal 
weight and obese, who are at risk of evolving into a condition of obesity along with 
its associated risks (González-Muniesa et al. 2017). In the UK approximately 40% of 
adult males are overweight as assessed by BMI, with 33% normal weight and 26% 
obese, therefore the majority of males in the UK are classified as overweight 
according to BMI (Barker 2018). Regarding the study of intranasal insulin, some 
reports have shown a lack of effectiveness in weight loss via long term intranasal 
insulin administration in obese men but not in normal weight men (Hallschmid et al. 
2008). Therefore, the study of this group of individuals is important for establishing 
possible markers of brain function that may be associated with this ‘at risk’ 
population. Furthermore, overweight individuals represent an interesting study 
group as they are essentially healthy albeit ‘less so’ then normal weight individuals 
(González-Muniesa et al. 2017).  
 
Furthermore, this study recruited men only. As described in the introduction central 
insulin has some differential gender effects as a result of interactions of central 
oestrogen on insulin anorexigenic effects (Clegg et al. 2006; Benedict et al. 2008). To 
avoid or limit these potential confounding effects of oestrogen males were 
exclusively recruited in this study.  
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For this repeated-measures design a sample size of sixteen was required to detect 
changes in cerebral blood flow (CBF) of 3 ml/100g/min, based on a standard 
deviation of 4 ml/100g/min and an effect size of 0.75 with a two tailed, paired t-test 
(α = 0.05, 1-β= 0.8). (G*Power, (Faul et al. 2007)). Therefore, this study aimed to 
recruit sixteen subjects within each group for a total of thirty-two subjects in the 
entire study (lean plus overweight). This specific change in CBF was used as a guide 
for this power calculation based on research by Kullmann et al., who presented 
changes in the hypothalamus of this magnitude from this dose of intranasal insulin 
(Kullmann et al. 2018) 
 
3.1.4 Post absorptive state 
Participants were instructed to follow an overnight fast, with their last meal to be 
consumed no later than 10pm the night before (approximately a 12-hour fast). As 
this study probed the effects of insulin on homeostatic and hedonic food related 
processing, it was important for the participants to be in a fasted/post absorptive 
state. Participants were allowed to drink water throughout the morning.  
 
By skipping breakfast, participants entered into a negative energy balance thus 
promoting hunger. Previous functional imaging research comparing the fed and 
fasted state has shown that in the fasted state the appeal of food imagery is 
increased (LaBar et al. 2001) and is also associated with increased preferences or bias 
towards foods high in calories in comparison to low calorie food pictures (Goldstone 
et al. 2009). Findings from studies like these have provided a methodological 
foundation for investigating functional brain responses to food cues and food stimuli 
by placing the participant or patient in a state of negative energy balance and 
therefore increasing responsiveness to task based paradigms focused on appetite 
and reward (Dagher 2012). We implemented an overnight fast as the goal was to 
observe how this negative energy balance would affect brain responsiveness 
following intra-nasal administration of insulin compared to placebo. By 
implementing an ‘overnight’ fast rather than a prolonged fasting period (> 24 hours) 
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the effect of ketone bodies on brain metabolism was avoided (Cahill 1970). Following 
all scanning procedures a ‘standard’ lunch was administered to the participants. 
3.1.5 Abstinence of vasoactive substances  
Participants were further instructed not to consume alcohol 24 hours prior to 
scanning and also not to have caffeinated drinks on the morning of scanning, only 
water was allowed. Both caffeine and alcohol are vasoactive substances leading to 
global decreases and increases in cerebral perfusion, respectively (Vidyasagar et al. 
2013; Gundersen, van Wageningen, and Gruner 2013) and therefore would introduce 
significant variability in the study.  
3.2 Imaging Sessions 
The first imaging session was conducted no later than thirty days following the 
screening session and the second imaging session no later than 15 days following the 
first imaging session. The protocol for each imaging visit is shown in Figure 3.2.1.  
 
 
The next sections will discuss the non-imaging related components of the protocol 
using Figure 3.2.1 as a reference.  
 
Figure 3.2.1 Protocol for the imaging sessions. All black boxes are considered non-imaging and the 
blue box will be referred to as the imaging component.  
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3.2.1 Participant arrival and physiological measurements  
Participants arrived at the centre for neuroimaging sciences at 9am or 9:30am to 
begin scanning at either 10 or 10:30am, respectively. Upon arrival participants were 
required to fill out the necessary MRI safety forms and to relax before any 
physiological measurements were taken. After 20 minutes, seated blood pressure 
(BP) and heart rate (HR) were recorded. These vital physiological measurements are 
necessary to ensure that it is safe for the participant to start the full imaging session 
protocol.  
 
Blood sampling was performed at two time points; before drug administration (pre-
dose) and after scanning (post-scan).  Using venepuncture techniques, blood samples 
were collected by filling one grey top (2.5 ml, Fluoride/Oxalate – for plasma glucose) 
and one gold top (serum separator tube – for serum insulin and C-peptide) 
Vacutainer (Becton, Dickinson U.K. Limited, Berkshire). In addition, a drop of blood 
from the butterfly needle was used to measure blood glucose concentration using a 
portable blood glucose monitor (FreeStyle Optium, Medi Sense, MPT Pharma Ltd, 
Walsall, UK). This measurement was recorded for safety reasons so that the 
researcher could be aware of the approximate baseline blood glucose concentration 
and if the participant felt unwell or showed signs of hypoglycaemia a second sample 
could be taken (via a pin-prick approach) and used to compare against the baseline 
measure permitting appropriate action to be taken in response to any adverse 
effects.  
 
Samples were separated into plasma and serum by spinning the samples in a 
centrifuge at 4°C and 3000 rpm for 10 minutes. Plasma and serum were separated 
into 2.5ml aliquots and stored at -20°C until processed. These samples were 
processed and analysed for plasma glucose, serum insulin and serum C-peptide 
concentrations at the King’s College Hospital clinical biochemistry department. All 
assays were conducted by a commercial contractor called ViaPath located within 
King’s College Hospital site (King's College Hospital, Bessemer Wing, Denmark Hill, 
London, SE5 9RS).  
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3.2.2 Plasma and serum assays  
Plasma glucose was determined using the glucose-oxidase method using an ADVIA 
2400 Chemistry system (Siemens Healthcare Diagnostic Ltd, Newton House, Surrey, 
UK).  Serum insulin and C-peptide concentrations were determined using a 
chemiluminescence assay using an ADIVA centaur system (Siemens Healthcare 
Diagnostic Ltd, Newton House, Surrey, UK).  
3.2.3 Drug preparation and administration protocol  
Twenty minutes prior entering the scanner, participants received a total dose of 160 
IU insulin (Humulin®, 500 IU/ml, Eli Lily) or placebo (0.9% saline solution, Fresenius 
Kabi) by means of four intranasal applications (see details in the next section).  
 
Insulin and placebo solutions were provided by KCL pharmacy department on the 
morning of each imaging session, in a plain white nasal pump device (SP270+ pump 
with 3959 actuator)(Nemera, La Verpillière, France), these contained 2ml of either 
insulin or saline solution.  
 
The dosing protocol closely followed previous intranasal insulin dosing protocols 
reported in the literature (Guthoff et al. 2010). We employed a total of four nasal 
sprays over a four-minute period with each spray containing 40 IU of insulin (total 
dose = 4 x 40 IU = 160 IU). To employ this protocol, the insulin solution provided by 
pharmacy required dilution by the researcher. A single spray of the nasal pump 
contains 0.1ml solution. The insulin solution (500 IU/ml) dispensed by pharmacy was 
diluted with 0.5ml of saline solution to create a 2.5ml insulin solution with a new 
concentration of 400 IU/ml and the resulting insulin concentration per 0.1ml spray 
was 40 IU as per the protocol requirements. As this study was double blinded the 





Nasal spray administration was performed approximately thirty minutes prior to 
functional data acquisition (resting-state BOLD acquisition) in an effort to acquire 
data after insulin concentrations in the central nervous system have increased, in line 
with the pharmacokinetics of intranasal insulin previously reported(Born et al. 2002). 
 
Participants were familiarised with the intranasal application procedure at the 
screening sessions and were then able to self-administer the dose under instruction 
from the head investigator at each of the imaging sessions. Participants received a 
total of 4 sprays, alternating between nostrils and leaving one minute between each 
spray to allow for sufficient diffusion time and to avoid the dose running out of the 
nostrils. Participants assumed a bent forward position and used their left hand to 
administer to the right nostril and vice versa (presented in Figure 3.2.2). Following 
each administration spray, participants were instructed to hang their head down and 
forward to prevent any fluid ‘run out’ and also to take advantage of gravitational 
forces, in an effort to facilitate droplets to travel towards the posterior regions of the 









Figure 3.2.2 Nasal Self Administration process. The nasal administration process starts with 
the participant holding the spray between the thumb and fingers. The nasal pump nozzle is 
then inserted into the nose using the opposite hand, the image shows the right hand being 
used for the left nostril. The participant then bends forward, keeping the spray bottle upright 
and administers a single dose (spray). Immediately after administration the participant hangs 
there head down to prevent the dose running out of the nose and also to help the dose travel 
to the posterior region of the nasal cavity with the pull of gravity. Participants would only hang 
for 15-20 seconds or so, as instructed by the researcher.  
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The insulin solution carried a strong scent which was not replicated by the placebo 
solution. Prior to nasal administration the pump required ‘priming’. Priming requires 
spraying the pump 3-4 times in the air in order to fill the pump and pump feeding 
tube with the solution. To avoid scent detection and potential unblinding by either 
the participant or the researcher a distraction protocol was implemented. 
Immediately before dosing the participant was given a ‘dummy’ pump defined as a 
“practice pump” which was filled with diluted TCPä solution. The participant was 
instructed to spray the pump into the air 5-6 times with both right and left hands in 
preparation for dosing and to ‘warm up’ their hands. At the same time the researcher 
primed the nasal pump that was to be used for the study by spraying in the air 3-4 
times. By spraying both fluids simultaneously, the scent of the solution under 
investigation was masked by the strong smelling TCP and thus both the researcher 
and participant remained blinded to the treatment.  
 
3.2.4 Visual analogue scale (VAS) scores 
Prior to entering the scanner and also imminently after scanning had terminated the 
participants completed visual analogue scales (VAS) to assess subjective hunger. This 
type of subjective rating is reproducible and a powerful marker of subjective appetite 
and hunger (Flint et al. 2000).  
 
The question was “how hungry do you feel right now?” and each participant 
answered by placing a mark on a 10cm scale from “not at all” to “very”. The first of 
the hunger score VAS assessments was performed after dosing and therefore these 







3.3 Imaging Protocol 
The SNIFAR study adopts a multi-modal MR imaging approach to investigate the 
effects of intranasal insulin on brain function. The following sections will provide the 
methodologies used for each component of the imaging protocol, the principles of 
each of these techniques are described in chapter 2. In an effort to aid the reader, 
the individual analysis techniques for each component will be detailed in each 
chapter. The following sections will highlight the main acquisition techniques and 
give information on the tasks that were implemented, and the equipment used in 
the functional paradigm. Furthermore, pre-processing that was common to all the 









Figure 3.3.1 Imaging protocol for the SNIFAR study. Different colours refer to a different category of 
image acquisition, Blue = structural, Green = resting-state, Dark blue and purple = task based fMRI 
BOLD. * Food Picture fMRI data was collected for another study.   
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3.4 Image Acquisition 
All scanning was conducted using a MR750 3 Tesla GE Discovery Scanner (General 
Electric, Waukesha, WI, USA) with a 32-channel receive only head coil. Each 
participant was provided with a button box (2 buttons, left and right), this device was 
placed in their right hand to allow for selections during task performance. 
Physiological data for each participant was also recorded for each participant using 
bellows (for breathing rate) wrapped around the diaphragm and a pulse oximeter 
(for heart rate) placed on the index or middle finger of the left hand. 
3.4.1 Anatomical image acquisition  
Structural images were acquired for each participant at the beginning of the scanning 
protocol. T2 and Fluid Attenuated Inversion Recovery (FLAIR) images were acquired 
during the first imaging session. The Centre for Neuroimaging Science’s local policy 
requires acquisition of a T2 weighted and FLAIR image for every participant studied, 
these are assessed by a radiologist in the event of any incidental pathological 
findings.  
3.4.2 T2 weighted 
For each participant an axial T2 weighted fast recovery fast spin echo (FR-FSE) image 
was acquired with the following parameters: slice thickness (∆𝑧)=2mm, slices = 72, 
slice gap = 2mm, TR = 4380ms, TE = 65ms, flip angle = 111°, matrix size (DM) = 
320x256 with a Field of View (FOV) = 24cm. Acquisition time 2:03 min. 
3.4.3 FLAIR 
For each participant an axial T2 FLAIR image was acquired with the following 
parameters: slice thickness (∆𝑧)=4mm, slices = 36, slice gap = 4mm, TR = 8000ms, TE 
= 65ms, Inversion Time (TI) = 2000ms, flip angle  = 111°, DM = 256x128 with a FOV = 
24cm.  Acquisition time 2:33 min. 
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3.4.4 T1 weighted  
At the second imaging session a high resolution (1.1 x 1.1 x 1.1 mm) T1 weighted 
image was acquired at the beginning of the protocol. The T1 weighted image was 
used in the SNIFAR study for co-registration and normalisation of functional imaging 
data to Montreal Neurological Institute (MNI) standardised space.  
 
This sequence used a T1 weighted 3D Magnetisation Prepared Rapid Acquisition 
Gradient Recalled Echo (MP-RAGE) with the following parameters: slice thickness 
(∆𝑧)=1.2mm, slices = 196, TR = 7.312ms, TE = 3.016ms, inversion time (TI) = 400ms, 
flip angle (FA) = 11°, matrix size (DM) = 256x256 with a FOV = 27cm.  Acquisition time: 
5:37 min. 
 
3.4.5 Resting state BOLD 
For each participant a resting state BOLD timeseries was acquired using a multi-echo 
EPI sequence. The multi-echo EPI sequence was chosen for this part of the study due 
to documented effects of artefact removal that can be achieved through the 
implementation of the multi-echo independent component analysis (ME-ICA) 
denoising algorithm proposed by this approach (Kundu et al. 2012).  
 
For the acquisition of these data in SNIFAR study participants were instructed to look 
at a white ‘fixation’ cross presented to them on a black projector screen. Participants 
were instructed to keep still for the duration of the scanning and to let their mind 
wander naturally. The projector screen was situated at the back of the scanner bore. 
 
3.4.6 Resting state perfusion - Arterial Spin Labelling 
Resting state Cerebral Blood Flow (CBF) data was acquired using a 3D-pseudo 
continuous (3D pCASL) sequence. The sequence was used with a long label duration 
of 3500ms to maximise the signal-to-noise-ratio of this measurement (see details of 
long labelling in section 2.2.3.  
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As in the case of the resting state BOLD scan, participants were instructed to look at 
a white ‘fixation’ cross presented to them on a black projector screen. Participants 
were instructed to keep still for the duration of the scanning.  
 
3.4.7 Taste task  
The taste paradigm was performed as the second functional task in the SNIFAR 
protocol. The taste task was designed to evaluate the effects of receiving three 
different taste stimuli whilst in the scanner. This task employed an MR compatible 
system capable of delivering a pre-defined volume (0.5mL) of liquid to the 
participants during fMRI-BOLD acquisition.  
 
3.4.7.1 Taste delivery system   
The taste delivery system is known as the “MR Fluid Liquid Automatic Vendor (MR-
FLAV) and was designed and built by the Engineering Section of the Department of 
Neuroimaging, KCL. The device is an automated, high speed liquid delivery system 
that dispenses a calibrated bolus of 0.5mL. The dose is restricted to 0.5mL to 
minimise any swallowing difficulties that may occur with a larger bolus whilst laying 
down; and to prevent the possibility of the fluid blocking the subjects’ airways. The 
MR FLAV system can be broken down into three constituent parts: 1) the Pneumatic 
control device which resides in the scanner control room, 2) the dispensing unit 
which houses the liquid reservoirs and calibrated dose syringes and 3) the delivery 
tube which extends from the main unit to the subject’s mouth (see Figure 3.4.2 and 
Figure 3.4.1). 
 
The pneumatic control device is located in the MR control room and is the driving 
force behind the delivery pump system. This unit translates the paradigm commands 
into a pneumatic programmed sequence. The device receives air inflow and pumps 
this out as pressurised air along the 4-metre long piping tubes to the dispensing unit 
which is located in the scanner room, at the foot of the scanner bed.  
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The dispensing unit itself is MR safe and for this study was situated under a pillow, 
underneath the participants’ legs. The dispending unit contains four separate 
reservoirs linked to 4 different syringes. Upon a taste delivery trigger, the syringe 
which is calibrated to 0.5ml is pneumatically pushed from the pressurised air, 
expelling a 0.5mL bolus of fluid along the delivery tube (see Figure 3.4.3.B). After 
delivery the syringe mechanism retracts via pneumatic suction which draws up the 
next 0.5 mL bolus from the reservoir, ready for the next administration.  
 
The delivery tube extends from the dispensing unit to the head coil. In the internal 
part of the head coil there is a custom designed cradle/holder that holds the delivery 
tube during the taste task. At the end of the delivery tube is a solid mouthpiece 
shaped like a baby bottle teat which is purposefully designed to fit disposable rubber 
baby bottle teats over its surface (see Figure 3.4.1). 
 
The system requires filling each reservoir with the experimental taste liquids and 







Figure 3.4.1 The pneumatic controlled device is not MR compatible and is located in the control 
room. The Dispensing unit is located in the scanner room and was placed underneath the 
participants legs in this study. The dispensing unit contains the calibrated syringes and 
reservoirs. The delivery tube extends from the dispensing unit into the bore of the scanner to 
the participants mouth. 
  
Figure 3.4.2 Taste bolus delivery mouthpiece. The mouthpiece is shaped like a baby-bottle teat 
and perfectly fits rubber disposable teats (left). The mouthpiece is an outlet for the three taste 
stimuli and has a separate outlet for each taste solution (right). 
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3.4.7.2 Taste stimuli 
 
The taste stimuli used for this paradigm were selected to examine the primary taste 
response to sweet stimuli. Two sweet stimuli were used; a sucrose solution and a 
non-nutritive, low calorie, sweetener solution. In addition, a control mineral water 
solution was the third taste stimulus. Each taste stimulus was prepared the evening 
before scanning and was kept at 4°C in the fridge overnight. On the morning of 
scanning each taste stimulus was loaded in the designated reservoir prior to subject 
arrival, approximately an hour before scanning. The taste stimuli maintained a cool 
temperature by being in the reservoirs. For every visit, this protocol was followed 
and therefore one can assume that the temperature of stimuli was similar across all 
scanning sessions.  
 
Water (control): 
Bottled water (‘Harrogate mineral water’) was used as a control solution for this 
paradigm. Water is not tasteless and has been shown to activate the taste cortex 
(Zald and Pardo 2000). The taste of water however is markedly less intense in 
comparison to the two sweet stimuli, and therefore it is suitable in this instance as a 
non-sweet control stimulus.  
 
Sucrose: 
The sucrose solution was produced by diluting 12.5g (approximately 3 teaspoons) of 
table sugar (99.99% sucrose) (Caster Baking Sugar, Tate and Lyle) into 150ml of the 
mineral water (bottled Harrogate water - vehicle). This produced a 0.08g/ml 
(sucrose/water) stock solution. Each 0.5ml sucrose bolus delivered contained 0.04g 
of sucrose.  
 
Stevia: 
Stevia solution was created using a granulated sweetener made from the stevia leaf 
marketed as TruviaÒ (The Truvia Company LLC).  In reference to the manufacturer’s 
notes, TruviaÒ is three times sweeter than sugar. Therefore, stevia solution, the 
name that will be used herein, was produced by diluting 4.2g (approximately 1 
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teaspoon) of TruviaÒ into 150ml of bottled water. Each stevia solution stimuli 
contained 0.014g of TruviaÒ from a stock stevia solution of 0.028g/ml.  
 
Stevia is a natural sweet-tasting non-nutritive (calorie free) extract from the Stevia 
rebaudiana  leaves indigenous to South America (Goyal, Samsher, and Goyal 2010). 
Extracts from the stevia leaf are being used more regularly as alternative sweeteners 
to sugar. Interestingly, stevia has shown beneficial effects on postprandial blood 
glucose and plasma insulin concentration in humans (Anton et al. 2010). 
Furthermore, meals sweetened with stevia showed comparable satiation effects 
when compared with sucrose sweetened meals, in conjunction with decreased 
postprandial glucose and insulin responses (Anton et al. 2010). The main constituent 
of TruviaÒ is erythritol, a non-sugar carbohydrate that belongs to the family of 
polyols.  Steviol glycoside and extract from the stevia leaf, is the other constituent 
within TruviaÒ. TruviaÒ is FDA approved and is one of the leading stevia based 
products on the market in the US with Companies such as Coca-Cola using stevia 
based extracts and sweeteners like TruviaÒ in some of their products as sugar free 
alternatives. 
 
3.4.7.3 Taste dispenser setup in situ 
The taste task occurs midway through the imaging protocol and therefore the 
researcher had to enter the scanner room for the setup of this paradigm. The 
participant was informed to remain as still as possible whilst the researcher 
positioned the MR compatible taste dispenser for the task. 
 
The taste outlet mouthpiece was positioned into the right hand-side of the 
participant’s mouth between the teeth and cheeks. This position ensured comfort 
for the participant for the duration of this paradigm. The taste outlet positioning was 
similar for all participants to ensure taste bud stimulation remained similar across all 




3.4.8 Experimental paradigm 
Participants became familiar with the experimental procedure at the screening 
session and completed a mock run of the paradigm outside the scanner without the 
taste stimuli. Furthermore, participants were reminded of the details of the paradigm 
prior to scanning by the researcher. The details of the paradigm and the three 
different trials are shown in Figure 3.4.4. 
 
This was an ‘event-related’ paradigm.  At the start, one of three abstract, arbitrary 
fractal images were presented at the beginning of each trial, with each fractal image 
being associated with either the water, sucrose or stevia stimulus. This relationship 
Figure 3.4.3 Schematic drawings of the taste dispenser in situ and during bolus delivery. A) The 
taste paradigm requires the taste dispenser box to be situated close to the bore of the scanner, 
either on a side table (seen from this picture) or under the participant’s legs. The outlet tube and 
dispenser mouthpiece are positioned in the participant’s mouth, inside the scanner. B) Schematic 
drawings of the syringe pumps that are used to administer the taste bolus, calibrated to 0.5ml. The 
three pictures (from left to right) show the evolution of a single taste bolus delivery. 
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between presented image and taste stimuli remained constant throughout the entire 
paradigm. This visual stimulus, referred herein as ‘the cue’, was presented for 2s 
either on the left or the right hand side a white fixation cross, positioned in the 
middle of the screen. Upon cue presentation, the participant was required to signal 
the direction of the cue presentation using an MR compatible button box. The period 
between the cue and impending taste stimulus delivery consisted of a white fixation 
cross and was set to 3s for every trial. Following this, the cross went from white in 
colour to green which signalled delivery of the taste stimulus. The delivery signal was 
present for 3s, however the taste stimulus (0.5ml delivery bolus) itself was delivered 
over the first 1.5s of this event. Following bolus delivery the participants were 
required to keep the liquid bolus in their mouth until the presentation of a “swallow 
now “ prompt, known as a paired trial (Figure 3.4.4). The time spent with the stimulus 
in the mouth varied from 3 to 6s and began when the fixation cross returned to white 
in colour from green. The “swallow now” cue was presented for 2s which was 
followed by a fixed inter trial interval of 1.5s. Trials were presented in a pseudo-
random order, so that each taste trial was never followed by the same taste. On 40% 
of the trials the taste stimulus was not delivered. This event is termed ‘withheld 
delivery’. In these instances, the visual cue was presented, however when the cross 
turned green the taste stimulus was withheld, referred to as ‘withheld delivery’. As 
there was no stimulus delivered the swallow prompt was not presented/required 
and the next trial started following the inter-trial interval (see Figure 3.4.4) 
 
An entire run of this paradigm consisted of 45 trials, 9 delivery trials and 6 delivery 
withheld trials for each of the three taste stimuli. This paradigm consisted of 2 runs 
in total, performed in succession. 
 
The first time each taste stimulus was delivered and swallowed two questions 
followed: “how much do you like the taste?” and “how sweet did you find this 
taste?”, for which the visual analogue scale (VAS) ranged from “not at all” to “very” 
(0 to 100, respectively).  The participant responded by pressing the left and right 
buttons of the button box, using their index and middle fingers, respectively, thus 
placing their chosen score in a visual analogue scale (VAS).  These questions were 
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also presented following the final stimulus, at the end of the second run (VAS trial – 
see Figure 3.4.4), Fractal cues were different between visits and the paradigm 
playlist, which determined the order of presentation of the stimuli, also differed 






Figure 3.4.4 A diagram to show the three different trial types of the taste paradigm. Black 
boxes represent the events that are modelled as events of interest (cue, delivery and 
withheld delivery, respectively). Grey boxes represent events that are modelled in the 
first level model but not of interest or used for contrast creation (swallow and VAS scoring 
periods). A paired trial is the most common trial type and involves the delivery of a 0.5ml 
bolus/stimulus following visual cue presentation. An unpaired trial does not deliver the 
0.5ml bolus as expected, instead nothing is delivered. A VAS trial is when the delivery of 
the bolus is followed by two VAS questions, this happens for each taste at the very 
beginning of the first run and at the very end of the second run. 
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3.5 Image Processing  
3.5.1 Co-registration and normalisation of T1 weighted images  
All the T1 weighted images from all subjects were used to create a group template 
using Advanced Normalisation Tools (Avants et al. 2014; Avants et al. 2011) (ANTs, 
templatecreate), which was registered to standardised MNI space using the FLIRT 
routine  (Jenkinson and Smith 2001; Jenkinson et al. 2002) of the Functional Software 
Library (FSL, FMRIB, Oxford University, version 3.2, http://www.fmrib.ox.ac.uk/fsl ).  
The parameters for co-registration of the T1 weighted image to the group template 
(T1 to template) and also from the template to MNI space (template to MNI) were 
saved as text files to be later used for functional image registration (see Figure 3.5.1). 
The MNI template had an isotropic resolution of 2mm3.  
 
All functional imaging datasets were pre-processed prior to group level analysis. 
Specific details for image pre-processing differed between pCASL, multi-echo EPI and 
single echo EPI task-based datasets and therefore the individual pre-processing 
pipelines will be outlined in the respective chapters. However, all images whether 
CBF maps or time series data were co-registered and normalised to standard space 
Montreal Neuroimaging Institute (MNI) co-ordinates to facilitate group level 
inferences . 
 
This involved creating a functional image to subject T1 co-registration (functional to 
T1) transform. And then the final stage involved application of three transformation 
parameters to the T1-weighted image using ANTs (Avants et al. 2011). The three 
transform parameters are defined as: 
• Functional to T1 
• T1 to Template 






3.6 Lunch and Discharge 
Following the final blood sample collection, participants were given a lunch meal 
which consisted of a sandwich, ‘crisps’ and a piece of fruit. The volume of food 
consumed was not assessed in this study.  Participants discussed elements of the 
scanning with the researcher and after a final Blood Pressure and Heart Rate 




Figure 3.5.1 Pre-processing pipeline for co-registration and normalisation of images to MNI. The 
transformation files created at each point in the pipeline are outlined in blue. These three steps show 
the last of the pre-processing steps that would be taken for all the functional image acquired. The 
functional image datasets were pre-processed differently for each modality and is not shown in this 
diagram.  
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Chapter 4  Nasal Pump 
characterisation 
 
Nasal administration of insulin has been utilised as a drug delivery method and 
research tool to supply insulin directly to the brain; in order to study its effects with 
limited interference from systemic insulin-glucose interactions. Nose-to-brain 
delivery bypasses the blood brain barrier (BBB), by diffusion across olfactory epithelia 
and effectively reaches brain tissue within 30-60 min (Banks, Owen, and Erickson 
2012). Thus, nasal insulin administration can be utilised as a tool for research in 
patients with diabetes, obesity and Alzheimer’s disease where regular receptor 
mediated transport of insulin across the BBB to the brain tissue is disrupted (Craft et 
al. 1998; Kullmann, Heni, Veit, Scheffler, Machann, Häring, et al. 2015). For optimum 
delivery to the brain via this route, insulin must be deposited in the upper and 
posterior regions of the nasal cavity. Nasal cavity anatomy varies considerably 
between subjects and thus achieving maximal delivery for every subject is not always 
feasible using a single device. However, previous studies using both in vitro nasal cast 
experiments and computational modelling methods (Inthavong et al. 2006; 
Inthavong et al. 2008) have provided a general framework about nasal pump 
performance characteristics to achieve appropriate drug deposition in this region. 
This chapter will introduce the reader to some general aspects of nasal 
administration for drug brain delivery and the process by which I characterised and 








4.1 Introduction  
Delivery of therapeutic agents via the nasal cavity has long been utilised for 
treatment and research purposes alike (Ghori et al. 2015). The nasal cavity is a largely 
accessible route of drug administration and is well tolerated in most people and 
patient populations (Guastella et al. 2013). The nose is the main entrance point for 
inhaled air in humans and majority of land animals (Phalen 1976). The nasal cavity, 
which is situated just beyond the nostrils is the first anatomical landmark within the 
mammalian respiratory system. The nasal cavity acts primarily to filter and also 
modify inhaled air for efficient gas exchange within the lower airway structures. In 
addition to this air conditioning role, the nasal cavity contributes to many other 
functions such as olfaction, speech production and also taste which is permitted via 
the complex architecture and physiological functioning of the nasal cavity (reviewed 
thoroughly in (Geurkink 1983)).   
 
The nasal cavity is a large structure that spans lengthways from the nasal vestibule 
to the nasopharynx (»120-140 mm in length) and from the cavity floor to the cavity 
ceiling (cribriform plate) (»40 mm in height) in adults (see Figure 4.1.1 and Figure 
4.1.2). The nasal cavity is subdivided into two chambers by a cartilage wall called the 
nasal septum (Ghori et al. 2015). Within each of these chambers there are three 
further regional subdivisions: the vestibular, turbinate and olfactory regions, 
respectively (Cheesman and Burdett 2011). The vestibular region acts primarily to 
filter and remove large particles (10𝜇𝑚) within ambient air during inhalation. More 
posteriorly resides the turbinate region, which consists of upper, middle and lower 
turbinates’ and are comprised of mucus secreting epithelial cells which serve to 
humidify incoming air and create flow turbulence effects for efficient gas exchange 
in the lower respiratory system (Kim, Kim, and Kwon 2018). The olfactory region, 
which is positioned just below the ethmoid bone and cribriform plate is responsible 
for odour recognition and comprises only 8% of the nasal cavity surface area (Ghori 
et al. 2015). The olfactory region consists of a mixture of cell types that have discrete 
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functionality which form several layers to bridge the gap between the nasal cavity 
and the CNS.  
 
 
The olfactory bulb sits on top of the cribriform plate which is a sieve like structure at 
the most superior region of the nasal cavity and has olfactory nerve endings that 
protrude through into the olfactory region of the nasal cavity.  
 
 
Figure 4.1.1 The anatomy of the nasal cavity. A) Schematic showing the nasal cavity from a sagittal 
view. Labelled are the vestibular, turbinate and olfactory regions of the nasal cavity as well as the 
olfactory nerve endings and air flow passage. B) Representative sagittal T1 anatomical MRI image 
showing the nasal cavity and the three nasal regions (vestibular, turbinate and olfactory, respectively). 
 
Figure 4.1.2 Representative MRI images showing the olfactory bulb and cribriform plate 
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The exact mechanisms of drug delivery via the nasal cavity to the CNS are not yet 
entirely understood, or agreed upon amongst the nose-to-brain drug delivery 
community. However, there is substantial agreement that the nerve cells and 
bundles connecting the nasal passages to the CNS (olfactory and trigeminal nerves) 
are heavily involved in this process (Pardeshi and Belgamwar 2013). It is most likely 
that nose to brain delivery is possible via several routes (olfactory nerve, trigeminal 
nerve, lymphatic and CSF pathways) and that specific drug delivery characteristics 
such as mode of delivery and formulation dictate which of these routes may 
dominate (Pardeshi and Belgamwar 2013). To this end, this chapter will briefly 
discuss the relevant olfactory and trigeminal nerve pathways as these are considered 
the most prominent and significant pathways for CNS drug delivery via the nasal 
cavity (Agrawal et al. 2018; Dhuria, Hanson, and Frey 2010).   
 
 
4.1.1 Nose to brain drug penetration via nerve pathways 
Whether through the olfactory or trigeminal nerve pathway, nasal drug delivery to 
the brain can be broken down into three distinct steps: 
1. Drug transport across the nasal epithelial barriers 
2. Drug transport to brain tissue entry points  
3. Drug transport from brain tissue entry points to other brain tissue areas  
 
For each of these steps there exist several potential mechanisms of which some are 
more validated and accepted than others. A thorough explanation of all the possible 
mechanisms is beyond the scope of this chapter and so the next sections will highlight 
only the most significant and accepted mechanisms. The reader should be aware that 
the majority of these mechanistic studies have been conducted in animal models 
which do not necessarily translate well to human models especially those conducted 
in rodents (Lochhead and Thorne 2012).     
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4.1.2 Olfactory nerve pathway 
The olfactory nerve is comprised of the olfactory nerve endings, olfactory bulbs and 
olfactory tracts Figure 4.1.3 which connect the olfactory regions of the nasal cavity 
with the olfactory cortex (inferior pre frontal cortex) as well as the amygdalae and 
hippocampal structures (Dhuria, Hanson, and Frey 2010).  
 
Olfactory nerve cells project from the olfactory bulb through the cribriform plate to 
the olfactory epithelium of the nasal cavity and are crucial for odour sensing. In 
combination with the columnar supporting cells and basal cells the olfactory nerve 
cells help to form the a blood brain barrier (BBB) at the level of the olfactory 
epithelium (Agrawal et al. 2018). Direct contact with peripheral toxins within the 
nasal cavity requires these olfactory nerve cells to regenerate every 3-4 weeks. This 
dynamic nature and constant regeneration results in immature cell formations (see 

























Figure 4.1.3 Olfactory bulb, nerves and epithelium. 
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considered a ‘leaky’ barrier (Balin et al. 1986). Furthermore, within this highly 
innervated region of the olfactory region there are myelinated cells, called olfactory 
ensheathing cells which wrap over the protruding olfactory nerve cell axons. As well 
as myelination, these ensheathing cells create fluid filled spaces between the 
olfactory nerve cells, peri-neuronal spaces, even during olfactory nerve cell 
regeneration (Lochhead and Thorne 2012).  
4.1.2.1 Drug transport across the nasal epithelial barriers 
Drug transport across the olfactory epithelium can occur via two mechanisms: the 
intra-neuronal and extra-neuronal route. The intra-neuronal route is extremely slow 
(up to 24 hours) and involves the transport of drug molecules along nerve bundles 
via intracellular and transcellular transport mechanisms (Kristensson and Olsson 
1971). The extra-neuronal route on the other hand, is recognised as the predominant 
mechanism for nose to brain drug delivery of therapeutic agents. If sufficient drug 
molecules are deposited at the region of the olfactory epithelium these molecules 
can diffuse through the leaky barrier permitted by the creation of peri-neuronal 
spaces by olfactory ensheathing cells. Access via these peri-neuronal openings has 
been shown in rodents as well as non-human primates (Balin et al. 1986). Once 
successfully past the olfactory epithelium the molecules will have to cross the lamina 
propria to reach the subarachnoid space and CSF.  
4.1.2.2 Drug transport to brain tissue entry points  
Once in the lamina propria these molecules and substances could be absorbed or 
drained into the nasal vascular system or cervical lymph nodes, as a result of the rich 
vasculature and nasal lymphatics within the lamina propria (Dhuria, Hanson, and Frey 
2010). Those substances that avoid uptake at this level can proceed through the peri-
neuronal spaces from the lamina propria into the subarachnoid space and CSF 
beyond the cribriform plate. Furthermore, it has been shown that once in this space 
there are small openings for which some substances can enter into nerve bundle 
sheaths from the subarachnoid/CSF space (Faber 1937). Diffusion into the outer 
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nerve bundle compartments is thought to be established via a diffusion gradient and 
that sufficient quantities of substances can enter via these bulk movement effects 
(Jansson and Bjork 2002).  
4.1.2.3 Drug transport from brain tissue entry points to other brain tissue areas 
The peri-neuronal spaces connecting to nerve bundles are also surrounded by large 
amounts of blood vessels and can also provide suitable perivascular spaces for drug 
transport. The theory for drug molecule movement from the olfactory site to other 
regions on the brain relies on bulk flow within these perivascular and peri-neuronal 
spaces. This bulk movement is enhanced by the pulsatile motion of cerebral arteries 
(Ying 2008). Once at these more distal regions within the brain, substances can either 
diffuse into brain tissue or bind to cell receptors for cell mediated transport or as an 
agonist/antagonist. Studies have suggested that utilisation of this extra-neuronal 
route can produce adequate drug concentrations within the CNS in roughly 30 mins 
in rodents (Ichimura, Fraser, and Cserr 1991). With regards to insulin delivery to the 
brain via intranasal administration Born et al., showed that a low dose of insulin 
(40IU) administered with a nasal spray device could produce an increase in insulin 
concentrations measured from CSF within 30 minutes in humans compared to 
baseline measures (Born et al. 2002). This seminal paper showed for the first time 
that intranasal delivery of neuronal active peptides show increased levels in the CNS 
compartment as measured via CSF (Born et al. 2002).   
4.1.2.4 Trigeminal nerve pathway 
In addition, the trigeminal nerve, which is the largest cranial nerve, has connections 
with the nasal cavity, oral cavity and eyelids via the V1, V2 and V3 branches of the 
trigeminal nerve, respectively. The ophthalmic nerve bundle (V1) and maxillary nerve 
bundle (V2) have processes that connect from the midbrain to the olfactory region 
and also the turbinate regions of the nasal cavity, respectively (Kamel and Toland 
2001). The turbinate region of the nasal cavity is rich in ciliated mucous producing 
cells crucial for toxin clearance and so, it is unlikely that large amounts, if any, of drug 
molecules can enter the CNS at this entry point. It is therefore suggested that the 
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mechanisms of entry via peri-neuronal spaces at the olfactory epithelium and 
superior regions are present for this route also (Lochhead and Thorne 2012). Bulk 
movement of substances and pulsatile motion enhancements, as mentioned with the 
olfactory route, is likely to drive movement alongside the trigeminal nerve route. The 
overall trigeminal route, from nerve endings to midbrain entry sites, is greater in 
length than the olfactory route  and is predicted that this route will take longer for 
compounds to travel along.  
 
For both of these complex nose to brain administration routes the active 
pharmaceutical must first traverse beyond the vestibular and turbinate regions and 
deposit sufficient dose content in the olfactory region. Diffusion through these extra-
neuronal pathways relies heavily on bulk movement and it is essential that these 
active substances have enough residence time within the olfactory region to facilitate 
movement into central nervous system compartments (Agrawal et al. 2018). 
4.1.2.5 Nose to brain delivery considerations 
This study formally characterises three commercially available nasal spray devices 
using the same dose of insulin solution that was implemented in the imaging phase 
of the study. Intranasal delivery of insulin solution in humans has previously been 
used in other research projects due to the quick onset of action in the CNS coupled 
with a limited effect on peripheral glucose concentrations (Born et al. 2002; 
Kullmann, Heni, Fritsche, et al. 2015). Most of these studies have used a nasal spray 
device and liquid solution which when sprayed (termed ‘actuated’), produces a 
plume of liquid droplets that travels through the nasal cavity. Some of these droplets 
will deposit on the vestibular, turbinate and olfactory regions or if small enough can 
pass through to the lungs. Hopefully, the mechanistic definitions above illustrate the 
complexity of this administration to the reader. The next sections will highlight the 
relevant nasal anatomy, device mechanisms and formulation properties that must be 
considered for nose to brain drug delivery of insulin and will give the reader sufficient 
knowledge to understand the rationale and methodological aspects behind this 
characterisation study. 
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4.1.2.6 Nasal anatomy considerations 
Firstly, the nasal cavity is architecturally complex with thin air filled passages that 
twist and turn from the nostrils through to the trachea. The narrowest region of the 
nasal cavity is called the nasal valve and is situated roughly 2-3 cm beyond the nostril 
entrance (Ghori et al. 2015). The nasal valve is the narrowest and most difficult of 
obstacles for any nasal delivery device to overcome (Haight and Cole 1983). Nasal 
valve cross sectional area is at its smallest during sharp inhalation through the nose 
and thus nasal administration is sub-optimal when sniffing or inhaling sharply 
through the nose. Optimal administration should be performed during light 
inhalation when the nasal valve is not minimal and there is a nasal air flow present 
(Djupesland 2013).  
 
The nasal cavity undergoes dynamic cleaning and congestive swelling every 2-4 
hours, alternating between the left and right sides, known as the nasal cycle. This 
autonomic mechanism results in one side being more congested (see Figure 4.1.4) 
and thus leads to a reduced cross sectional area within that nasal cavity passage, 
adding further hurdles for nasal spray droplet delivery (Djupesland 2013). There is 
little that can be done to avoid this, practically. However, implementing an 
administration protocol that alternates between nostrils will help to avoid either 
problems that might be encountered by using a single nostril.  
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4.1.2.7 Nasal pump 
In this experiment, three commercial nasal spray devices were characterised. All the 
devices are known as ‘metred nasal pumps’, which means that the pump itself will 
dispense a pre-determined, fixed volume of liquid (dose) for every spray/actuation, 
permitted if actuation is performed correctly. All devices were metred to 0.1ml per 
spray, which is common for most nasal spray applications and is at the top end of the 
absorption capacity of the nasal cavity. Figure 4.1.5 shows a typical nasal spray  
pump, very similar to the pumps characterised in this study. The nasal device consists 
of three parts: The actuator, pump mechanism (and dip tube) and the bottle. To 
actuate the device, the actuator is squeezed down which produces a spray/plume 
that is released from the orifice at the tip of the actuator. After actuation, the pump 
will release naturally due to spring mechanism and will simultaneously draw up the 
next dose via the dip tube. Generation of a plume is key to the success of any nasal 
pump. Upon actuation the metred dose volume inside the pump (0.1ml in this 
instance) is put under sufficient pressure causing the dose to be propelled into 
Figure 4.1.4 Coronal View of Nasal Cavity in a healthy 
volunteer. Notice the congestion on the right hand side, which 
would be due to the nasal cycle. 
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streams that run up the side of the nozzle. At the top of the nozzle these streams 
enter into a small cylindrical compartment called the swirl chamber via inlets. Within 
this chamber a vortex is created which is expelled into the air through an orifice at 
the tip of the nozzle. The plume itself goes through several stages of development: 
initial phase, stable phase and end phase, with the stable phase being the most 




Figure 4.1.5 Nasal spray pump and actuation process. The nasal spray pump assembly consists of an 
actuator, the pump mechanism, dip tube and bottle. Pumps are actuated by applying a downward 
force onto the actuator which propels the liquid from the pump mechanism upwards. The liquid enters 
a swirl chamber and through this process produces sufficient force to propel out through the orifice, 
located at the top of the actuator, in the shape of a plume. Upon release, once a plume has been 
created, a spring mechanism returns the actuator back to its normal position and simultaneously a 
metred dose is drawn up via the dip tube.  
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Assessment of nasal cavity deposition pattern from nasal administration devices  can 
be conducted in vivo, in vitro and in silico, using radiolabelled isotope imaging, human 
nasal cast model studies and advanced computational modelling, respectively 
(Suman et al. 2002; Inthavong et al. 2006; Pu et al. 2014). These types of evaluations 
are valuable for nasal delivery system assessment pipelines and observations from 
these datasets has provided a generalised framework of nasal pump characteristics 
that that are optimal for olfactory drug deposition leading to efficient nose-to-brain 
drug delivery with a typical nasal spray (Cheng et al. 2001; Inthavong et al. 2006; 
Newman, Moren, and Clarke 1988). Assessment of device characteristics such as the 
size of the droplets and plume shape can be assessed using more accessible in vitro 
techniques and therefore are useful as surrogate measures prior to or in the absence 
of nasal device deposition pattern analysis. These type of measures are also the first 
point of call for any device pipeline and are useful for determining reliability of spray 
performance.  
 
A nasal pump plume will contain a mixture of small and large droplets. For nasal 
delivery of any kind, droplets must be between 30 and 120𝜇𝑚. Larger droplets will 
show very poor nasal cavity penetration and tend to deposit in the anterior regions 
of the nasal cavity due to the inability to travel with the air flow (Dayal, Shaik, and 
Singh 2004). Smaller droplets on the other hand, will travel and deposit within the 
olfactory regions whereas very small droplets (< 10𝜇𝑚) can travel beyond this and 
penetrate into the distal regions of the respiratory tract and lungs, which can be very 
harmful (Agrawal et al. 2018). The distance and degree a droplet or particle can travel 
is dependent on the interactions with the environment in which it is situated and the 
inertial components of that droplet within that environment. Smaller droplets have 
less inertia than large droplets and therefore will follow airflow streamlines and are 
more likely to  avoid obstacles within the nasal cavity compared to large droplets 
(Inthavong et al. 2006). For olfactory epithelium deposition it is therefore crucial for 
a device to produce a consistent plume comprised of smaller droplets to reach this 
anatomically distal region within the nasal cavity.  
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The FDA released a guidance and recommendation document in 2003 that 
highlighted necessary parameter measurements and methodologies for in vitro 
characterisation of nasal sprays (FDA 2003). This was used as a reference for this 
study, and all methods were conducted to the standards set out in this guidance 
document.  
 
Laser diffraction is a method recommended to measure droplet size (FDA 2003). This 
is an optical method that measures the size of droplets in flight (following actuation) 
(see Figure 4.1.6). A plume is actuated through a horizontal laser beam that runs 
between a laser source and detector. The plume will cause the laser light to diffract 
as it passes through the beam, reducing the signal detected (obscuration). Following 
this, a distribution of obscuration is measured from which the droplet size 
distribution can be calculated over the lifetime of a single actuation or during the 






Figure 4.1.6 Schematic of the laser diffraction method setup.  
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Another aspect that needs to be considered for drug deposition inside the nasal 
cavity is the plume itself following actuation (Cheng et al. 2001). The plume is often 
cone shaped and a typical measure to assess the geometry of the plume is plume 
angle. This measure, which is conducted in vitro, is thought to be a useful 
determinant of penetration within the nasal cavity, particularly how much of the 
plume will penetrate past the nasal valve. One study showed that a narrow plume 
angle of 35° shows greater penetration beyond the nasal valve in comparison to a 
wider spray with a plume angle of 70° (Newman, Moren, and Clarke 1988).  
 
Measuring plume angle requires a sagittal image of the plume (side view) during the 
stable phase, when the plume is at its largest. Recommendations for plume angle 
methodology is through the use of a high speed digital camera and laser light sheet 
combination. For this, a high speed digital camera is positioned to capture the nozzle 
pump and the impending plume. A laser light sheet is projected across the space 
above the nozzle. During actuation the plume is sprayed upright and is dissected by 
the laser sheet thus becoming illuminated and captured by the high speed digital 
camera (see Figure 4.1.7).    
 
 
Figure 4.1.7 Schematic of the light sheet photography method setup. 
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Both droplet size and plume angle can be modified through the combination of the 
nasal delivery device and drug formulation (Dayal, Shaik, and Singh 2004). The drug 
formulation in this instance was the concentration of insulin that was to be used in 
the imaging phase of the SNIFAR study and therefore this aspect was not investigated 
or characterised in this study. In this study the primary objective was to characterise 
three nasal spray devices using in vitro measures of droplet size and plume angle with 
insulin formulation. Following this characterisation, the pump with the properties 
that best reflected olfactory deposition in humans would be adopted in this 
pharmacological investigation. Pump performance was compared to the generalised 
framework: a plume with a spray angle between 30° and 45° and droplets between 
20 and 50 µm (Cheng et al. 2001; Inthavong et al. 2006; Newman, Moren, and Clarke 
1988). The pump that has characteristics most similar to the generalised framework 
would be used in the SNIFAR study. In addition, testing a device is fit for purpose is 
very important and the current literature would suggest that this step is not routinely 
performed. This study is the first to report a preliminary nasal device testing stage 


















4.2 Materials and Methods 
Human Insulin (Humulin®, 500 IU/ml) was purchased from Eli Lilly, USA (Eli Lilly and 
Company, Cambridge, MA). Three nasal spray pumps (100 µL) were provided by 
Nemera (La Verpillière, France), the SP270+® with two crimp on actuator types (3959 
and 4290; Figure 4.2.1 A and B, respectively) and a new prototype device with a single 
crimp on nasal actuator (5701; Figure 4.2.1 C). An insulin stock solution was prepared 
by diluting the insulin with saline to create an insulin solution of 400IU/ml. The two 
SP270+® pump configurations and the prototype device were filled with 2.5 mL and 
4.5 mL of insulin solution (400 IU/mL), respectively, due to different length dip tubes. 
With this stock solution there was enough to fill 5 bottles for each pump 
configuration. For ease of differentiation, the tested pump combinations will be 
labelled pump 1, 2 and 3: 
• Pump 1 — SP270+® pump with 3959 actuator (n=5) 
• Pump 2 — SP270+®  pump with 4290 actuator (n=5) 










All characterisation steps were performed in accordance with the Food and Drug 
Administration (FDA) guidance for industry document, that was designed to ensure 
nasal device analytical assessments were conducted to the highest quality (FDA 
2003). The analytical procedures were performed personally at Intertek Melbourn, 
(Intertek, Melbourn, Cambridge, UK) according to good manufacturing practices as 
part of a collaboration with King’s College London Institute of Pharmaceutical 
Sciences, Intertek Melbourn and Nemera.    
 
4.2.1 Droplet size measurement 
Droplet size was determined by laser diffraction using a Malvern Spraytec ® system 
(Malvern Instruments, Inc, Southborough, MA). A Proveris Vero® (Proveris  Scientific 
Corporation, Malborough, MA) automated actuator was also used for reliable and 
automated actuation of each pump configuration and is recommended over manual 
actuation by hand (FDA 2003). Actuation force was kept constant for all experiments 
and pump configurations at 6.8 kg. The automated actuator was placed between the 
Figure 4.2.2 A schematic showing the nasal pump characterisation pipeline that was implemented.  
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laser emitter and the detector lens at 90° to achieve vertical spray actuation. Data 
was collected at a single distance from the tip of the actuator to the middle of the 
laser beam (30mm) and a single actuation at this distance for each pump was tested. 
Data was processed and analysed using the Malvern software (Malvern Instruments, 
Inc, Southborough, MA). Plots of obscuration over time were used to manually 
identify the stable phase of each actuation, when the plume is most constant, which 
was selected for analysis. From this phase the point in the size distribution up to and 
including 10, 50 and 90% of the total sample volume ( known as Dv10, Dv50 and 
Dv90) , as well as the respirable droplets (<10 µm) were estimated for each pump 
and sample. Furthermore, a cumulative size distribution plot was created to help 
visualise the droplet size distribution and used to calculate the percentage of 
droplets that were in the range of 20-50 µm for each pump type.  
 
4.2.2 Plume geometry and spray pattern measurement 
A Proveris SprayView® setup and Proveris Vero® automated actuator (Proveris  
Scientific Corporation, Malborough, MA), actuation settings as above, were used to 
assess plume angle. The SprayView® setup couples a high-speed camera and a pulsed 
laser light sheet to capture high quality images of the insulin plume as it is emitted 
from the pump. For plume angle, the light sheet is positioned to dissect the centre of 
the plume, parallel to the plume flow. A single actuation is required for each pump 
sample.  
 
For image assessment the Proveris software was used (Viota Software, Proveris  
Scientific Corporation, Malborough, MA). Axial plume images with maximal image 
intensity, i.e. when the plume is at its largest, were identified from signal over time 
plots and were used for analysis. From this image the tip of the nozzle was located 
and defined as the origin point. From this origin, two lines were aligned along the left 
and right edges of the plume using a manual threshold selection process. The angle 
(plume angle) created by these two arms was measured in degrees (°). 
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4.2.3 Statistical analysis 
All processing and analysis for both droplet size and plume angle were measured 
individually for each pump sample (n=5) and then averaged together for each pump 
type. Data are presented as mean ± standard deviation. Unpaired t-tests were 
performed between data from all pump configurations for the measures obtained 
from droplet size, spray pattern and plume geometry analysis. P values were judged 
to p < 0.05 and p < 0.01 significance. All analysis was performed using R statistical 












4.3.1 Droplet size distribution 
Mean droplet size values for Dv10, 50 and 90 are presented in Figure 4.3.1. No 
significant differences in Dv10, 50 or 90 were seen between pump 1 or pump 2. 
Significant differences were seen between pump 1 – pump 3 (mean difference         = 
-5.9, -22.9 and -50.8, for Dv10 (p < 0.05), 50 (p < 0.05) and 90 (p < 0.001), 
respectively). Significant differences were also seen between pump 2 –and pump 3 
(md=-7.8, -26.2 and -55.6, for Dv10 (p < 0.001), 50 (p < 0.001) and 90 (p < 0.001), 
respectively). Respirable droplets (data not shown) for all pump configurations were 




Figure 4.3.1 Bar graph displaying the droplet size measures recorded. All measures were taken 
at a 30mm distance. Values plotted are mean ± SD (n=5, for each pump). * p < 0.05, ** p < 






From the droplet size distributions the proportion of droplets between 20-50𝜇𝑚 was 
measured and has been presented in Table 4.3.1. Although not statistically tested, 
pump 3 showed the smallest proportion of droplets in this range (29.76 ± 11.58%) 
with pump’s 1 and 2 showing larger proportions (48.88 ± 2.06% and 51.38 ± 5.32%, 
respectively) (this can also be seen graphically in Figure 4.3.2).  
Table 4.3.1 Median droplet size values for each pump as well as the % of 
droplets that are between 20-50 µm. Values shown are mean  SD.  
Figure 4.3.2 Droplet size distribution curves for each pump. This graph shows the cumulative frequency 
(%) of droplet sizes created from each pump. The grey shaded area represents the desired size range 
of droplets (20-50 µm). From the graph it is clear that both pumps 1 and 2 have a greater proportion 
of droplets that fall within this range compared to pump 3. Values plotted are mean ± SD at each point 
(n=5, for each pump).  
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4.3.2 Plume angle 
Plume angle was measured for each device using light sheet high speed photography. 
Mean angle values are presented in Figure 4.3.3 as well as some representative 
images displaying the spray profile Figure 4.3.3. No significant differences were seen 
between pump 1 (37.8 ± 3.9°) or pump 2 (42.7 ± 3.7°). Plume angle was significantly 
different between pumps 1 and 3 (p < 0.05)  as well as pumps 2 and 3 (p < 0.01) 
(pump 3: 27.5 ± 7.8°).  
 
 
Figure 4.3.3 Bar graph displaying mean plume angle values and example images of plumes generated 
by each pump taken using light sheet high speed photography. A) The bar graph displays the mean ± 
SD plume angle calculated for each pump (n=5). The red dashed lines represent the desired plume 
angel range. * p < 0.05, ** p < 0.01, unpaired t-test. B) High speed photography images of 
representative plumes acquired during maximal plume creation. Pump 3 visibly creates a narrower 








This was a comparative study that analysed the performance of three commercial, 
nasal pump delivery devices and configurations with insulin solution. This study has 
provided information on pump performance that can be used to help predict the 
nasal deposition profile that may be achieved for the SNIFAR MRI study. The data 
reported here was collected to, firstly, see if any of the tested commercial nasal spray 
devices with insulin solution were capable of producing deposition suitable for nose 
to brain delivery in humans. And, secondly, to provide sufficient information for the 
researcher to make an informed decision about which pump, if any, to implement in 
the SNIFAR study. From previous flow dynamic modelling and in vitro cast model 
results, the optimal pump should have the following characteristics: small droplets 
(between 20µm and 50µm), contained in a narrow plume (between 30° and 45°) 
(Cheng et al. 2001; Inthavong et al. 2006; Newman, Moren, and Clarke 1988).  
 
The respirable fractions for all the pumps were very low and therefore any of these 
could be implemented in a human study. From droplet size data it was clear that both 
pumps 1 and 2 had smaller droplets within the stable phase of the plume when 
compared with pump 3. Pumps 1 and 2 were not statistically dissociable from any of 
the droplet size measures assessed. All measures were assessed from the stable 
phase, when the plume is fully developed, based on obscuration thresholds. Within 
this stable phase, roughly 50% of that volume contained droplets that were within 
the desired range (20-50 µm) for pumps 1 and 2. Pumps 1 and 2 were comprised of 
the same pump mechanism but with different actuators, which would suggest that 
although physically quite different, these two actuators have similar plume creation 
properties. This is slightly surprising given that published data show changes in orifice 
size as well as actuator shape and length have significant impact on the size of the 
droplets produced (Dayal, Shaik, and Singh 2004).  
 
The analytical data reported here with insulin further showed significant differences 
in plume angle between the three tested pumps. Pumps 1 and 2 both produced wider 
plumes as shown by both a larger angle from the nozzle orifice compared to pump 3. 
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It is known from previous work that increased droplet size leads to a narrower plume 
generation and given the smaller droplets produced from pumps 1 and 2 the 
associated wider plume was expected (Trows et al. 2014). No significant differences 
were seen between pump 1 and 2, a similar result as seen from the droplet size data. 
After gathering and analysing this data it can be concluded that pump 1 and pump 2 
both displayed characteristics that were closest to the a priori metrics identified to 
be important for nose to brain delivery. The large droplets generated by pump 3 
coupled with a very narrow plume < 30°, would be unable to penetrate past the 
anterior portion of the nasal cavity and thus not fit for purpose in this instance. A 
very narrow plume with big droplets acts more in the fashion of jet/hose then a mist 
which is sub-optimal for nasal cavity dispersion and likely lead to drug run out of the 
nose and would not be efficient for olfactory drug delivery. Both pump 1 and pump 
2 produced more favourable results in comparison. Both of these pumps would be 
suitable for the SNIFAR study, however are not dissociable following this simple 
characterisation of each. Therefore, the physical and ergonomic characteristics of the 
two pump actuators were used to help decide between these two pumps. The term 
‘fit for purpose’ in this context covers more than just the plume profile. A major 
consideration is that the device has to be user friendly for first time nasal spray users 
and have sufficient design flexibility to cater for individual differences, in for example 
nasal anatomy and hand sizes. The user friendliness was not explored through by a 
quantitative experimental approach and so has been based on qualitative 
assessments and backed by rationale specific to the intended use: a pharmacological 
MRI study in humans.  
 
The actuator for pump 1 is narrow in shape and boasts lateral finger grips to aid 
manual actuation and manoeuvrability. Pump 2 has a slightly shorter and thicker 
actuator nozzle compared to pump 1, and does not have such obvious finger grips, 
rather a thick ring at the base of the nozzle.  
 
In this study actuation of nasal sprays were controlled using an automated device, 
which is recommended for in vitro characterisation of nasal devices. The actuation 
force used was set to 6.8kg as per standard operating procedures (SOP) within the 
 161 
laboratory this analysis was conducted at. Interestingly, this setting is slightly higher 
than the average adult actuation force, which was recorded as 5.82kg (range = 2.44- 
8.64kg) from a group of 20 inexperienced adults (Doughty et al. 2011). Actuation 
force has been shown to affect the size of droplets emitted within the generated 
plume, with stronger forces producing smaller droplets (Dayal, Shaik, and Singh 
2004). Therefore, the finger grips in the case of the pump 1 would hopefully provide 
the participant to actuate with sufficient force, close to the 6.8kg described by the 
automated actuator implemented during characterisation.  
 
Furthermore, as mentioned in the Chapter 3 (section 3.2.3), the participants 
administered the nasal spray in a ‘forward leaning’ position to aid olfactory 
deposition whilst keeping the nasal pump bottle upright. The participants will be 
required to insert the nozzle at least 1.5cm into to the nostril and roughly at a 60° 
angle, as recommended for olfactory deposition (Guastella et al. 2013). The slightly 
narrower and longer actuator would be beneficial in this situation due to increased 
insertion depth and degree of angular movement once inside the nostril compared 
to pump 2.  
 
The ergonomic benefits of pump 1 is believed to have greater translatability for the 
use in the SNIFAR study. Therefore pump 1, the SP270+ and 3959 actuator, was 













Chapter 5 Demographics, blood 
analysis, ratings and questionnaires  
 
This chapter will present demographic data from the cohort investigated during the 
SNIFAR study as well as results from peripheral blood samples taken during each 
scanning session and questionnaires conducted both at screening and during 
scanning visits. Every participant enrolled in the SNIFAR study completed all three 
visits, however, four participants were excluded entirely from the analysis due to 
protocol non-compliance and other issues that warranted exclusion, which will be 
discussed in this chapter. The format of this chapter will present methods and results 
together followed by explanations of the findings for each component in the 
discussion section. This chapter will touch on how the findings impacted the SNIFAR 















5.1 Methods and Results 
5.1.1 Participants 
Forty one healthy male participants attended screening sessions for this 
neuropharmacological MRI investigation. Of these, thirty one fulfilled all the 
eligibility criteria, could commit to the study and were recruited for the imaging 
phase of the SNIFAR study. Those participants who were not eligible were excluded 
as a result of either baseline blood pressure issues (hypertension), electrocardiogram 
irregularities, logistically unavailable or deemed unsuitable for the research 
investigation by the researcher due to poor punctuality and communication 
difficulties. Participants were recruited in two groups, based on body mass index 
(BMI), in order to explore the effects of intranasal insulin (IN-INS) compared to 
intranasal placebo (IN-PLA) in both normal weight, referred herein as lean, and 
overweight (OW) individuals (lean BMI = 18.5 – 24.9 kg/m2, overweight BMI = 25 — 
29.9 kg/m2). 
5.1.2 Screening questionnaires 
Three questionnaires based on eating behaviours and diet composition were 
completed by each participant at the screening session, which was at least seven days 
prior to the first imaging session.  
5.1.2.1 Council for nutrition appetite Questionnaire 
One of these questionnaires was used primarily as a screening tool: the council of 
nutrition appetite questionnaire. All of the forty one participants who attended the 
screening session scored above the threshold score (score = 28) for exclusion from 
the council of nutrition appetite questionnaire. The council of nutritional appetite 
questionnaire is used predominantly to look for poor nutrition, and from this 
questionnaire a low score (< 28) gives an indication of poor nutrition and appetite as 
well as a risk of at least 5% weight loss within six months (Wilson et al. 2005). This 
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test was used as a screening tool as the SNIFAR study aimed to assess central insulin 
effects within a cohort of male individuals that had a stable weight and appetite.   
The two remaining questionnaires (three factor eating questionnaire and dietary fat 
and sugar questionnaire) were implemented in order to assess eating behaviour  and 
diet composition between groups as opposed to a screening tool, the results of which 
are presented below.  
 
All statistical analysis performed was conducted using R statistical analysis software 
(Rstudio - Version 1.1.453, Boston, MA, http://www.rstudio.org/).   
 
5.1.2.2 Three factor eating questionnaire 
The three factor eating questionnaire (TFEQ) provides an assessment of dietary 
restraint, disinhibition and hunger as explained in Chapter 3 (section 3.1.2). Upon 
questionnaire marking a score for each factor is ascertained. The higher the mark the 
greater the severity, which ranks low, moderate and high. To test differences 
between BMI groups, unpaired t-tests were performed across groups for each factor 
using the factor scores as opposed to the severity category (judged to p > 0.05 






Table 5.1.1 TFEQ scores for lean and OW groups and associated  p values 
produced from unpaired t-tests comparing groups.  
 165 
 
There were no significant group differences between the dietary restraint, 
disinhibition or hunger factors. For each factor the OW group displayed a higher 
score compared to the lean group with the biggest difference seen for the 
disinhibition factor (see Figure 5.1.1) In terms of severity category both lean and OW 
groups showed medium severity for dietary restraint and low severity for 
disinhibition. For the hunger factor, the lean group averaged a low severity score, 
whereas the OW group averaged a medium severity score.  
  
5.1.2.3 The dietary fat and sugar questionnaire 
The dietary fat and sugar (DFS) questionnaire provides an approximate guide to 
examine how often meals or food that contain high amounts of saturated fat and 
sugar are consumed, within an average week. From the DFS the overall frequency of 
foods high in saturated fat, sugar as well as food that contains both high levels of fat 
and sugar can be calculated. For each food category unpaired t-tests were conducted 
to interrogate group differences between the lean and OW groups.  
 
Data are presented in Figure 5.1.2. There were no statistically significant group 
differences found for any of the three food categories tested (saturated fat, p = 0.27, 
Figure 5.1.1 Three factor eating questionnaire scores. Scores for each factor are 
presented as mean ± SEM for lean (n=12) and OW (n=15) groups. 
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sugar p = 0.31, sugar and fat p = 0.26). However, similar to the TFEQ scores there was 
a slight group trend seen for all food types, that showed the OW group displaying 
slightly higher frequency scores for all three food categories; saturated fat, sugar and 
both sugar and fat, respectively.  
Figure 5.1.2 Dietary fat and sugar scores. Intake scores describe the frequency with which food 
containing saturated fat and sugar are consumed per week. Presented are scores for both lean (n=12) 
and OW (n=15). Data is presented as mean ± SEM. 
5.1.3 Pre scan requirements 
Participants were required to undergo an overnight fast and instructed to consume 
their last meal, which should be a regular size meal, no later than 10pm the night 
before. Furthermore, they were instructed to abstain from alcohol use the evening 
before and to avoid caffeinated drinks on the morning of scanning.  
 
5.1.4 Blood analysis: as a screening tool 
Blood samples were taken prior to dosing (defined as the pre-dose sample), once 
acclimatised, and immediately following the conclusion of the scanning protocol 
(post-scan sample) on both visits. Blood samples were spun and plasma separated  
on-site, for analysis conducted in batches off-site. Subject blood samples were 
collected to primarily measure the effects of IN-INS on plasma glucose, serum insulin 




Having attained these particular metabolite and hormone measures, additional 
analyses were conducted to benefit the study. Firstly, blood samples were used to 
assess participant compliance with the study protocol. For example, abnormally high 
‘pre-dose’ blood metabolite and hormone concentrations suggested the subject was 
not fully fasted. In this instance, a serum insulin concentration of > 50 mIU/L was 
used as a marker of non-compliance and any participant who exceeded this 
threshold, pre-dose, was excluded from the analysis. Using pre-dose insulin 
measures as a  compliance measure was added to the SNIFAR protocol following data 
collection completion. In many cases blood analysis results were not analysed until 
the participant had completed both of the imaging sessions and therefore exclusion 
based on compliance was performed retrospectively at the data analysis stage. 
 
As a result of high fasting insulin, three participants were removed from the analysis 
due to non-compliance with the fasting protocol. Furthermore, a fourth participant 
was excluded entirely from the analysis as a result of attending the final scanning 
session with only 1-2 hours sleep as a result of work related activity and stress. This 
lack of sleep was highlighted and coupled with a very low appetite rating from 
subjective measures of appetite. Thus the revised total number of participants 
included in the analysis of the SNIFAR study was twenty seven (n=27). Of those 
included twelve were normal weight (lean), fourteen were overweight (OW) and one 
was obese (BMI=31.4) but was included in the OW group. The two groups differed 
significantly for BMI but did not differ in age as assessed through unpaired t-tests 
(p<0.05 significance). Mean BMI and age are presented in Table 5.1.2 .  
Table 5.1.2 Age and BMI for the whole cohort and for the lean and overweight group. *** p < 
0.0001, unpaired t-test. 
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Whole body peripheral insulin resistance was ascertained using the homeostasis 
model assessment of insulin resistance (HOMA-IR) (Levy, Matthews, and Hermans 
1998; Matthews, Hosker, et al. 1985). 
 
5.1.5 Blood analysis: as a measure of insulin resistance 
Baseline measures (pre-dose) of insulin sensitivity/resistance for each participant 
were calculated using the HOMA-IR 2 model (Matthews, Hosker, et al. 1985) for each 
visit. HOMA-IR can be calculated using plasma glucose and serum insulin 
concentrations or plasma glucose with serum C-peptide concentrations. Given that 
there was a significant difference in baseline (pre-dose) serum insulin levels within 
the lean group, but C-peptide levels were highly comparable between sessions, the 
HOMA-IR calculation using serum C-peptide was used. The online, publicly available 
HOMA-IR 2 calculator v2.2.3 was used (https://www.dtu.ox.ac.uk/homacalculator/). 
Measures of HOMA-IR were calculated for both visits. The average HOMA-IR score 
for each participant (visit 1 + 2 / 2) was calculated and compared between groups 
(unpaired t-test). Furthermore, a correlation analysis was performed to look at the 
association between HOMA-IR and BMI for each group, using Pearson’s correlation 
coefficient. Correlation coefficients (r) greater than 0.4 or less than -0.4, with an 
associated p value < 0.05 were deemed significant. Correlation coefficient thresholds 
were set to only look for ‘moderate to very strong’ correlations (i.e. 0.4 to 1.0) based 
on Evans’ guide to correlational analysis (Evans 1995).  
 
Participant HOMA-IR values did not significantly differ between groups (lean: 0.88 ± 
0.22, OW: 1.07 ± 0.37, p = 0.12). Pearson’s correlation analysis did not reveal a 
relationship between BMI and HOMA-IR in the lean group, however, a significant 
strong positive correlation was identified between BMI and HOMA-IR in the OW (r = 
0.70, p = 0.003, Pearson’s)(presented in Figure 5.1.3). 
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Figure 5.1.3 BMI vs HOMA-IR scores. The OW group HOMA-IR scores (averaged pre-dose across visits) 
show a strong positive correlation with BMI.  
 
Through observing Figure 5.1.3, it can be seen that the lean group display a fairly 
tight range of HOMA-IR scores ranging from approximately 0.6 to 1.2, whereas the 
OW group display a much larger variation ranging from approximately 0.5 to 1.7. The 
strong positive correlation seen between OW BMI and OW HOMA-IR scores is 
interesting.  There appears to be a BMI threshold of approximately 28 kg/m2 at which 
HOMA-IR scores split into ‘lower’ and ‘higher’ HOMA-IR groups. This observation 
suggests that while BMI across the entire range does not correlate well with HOMA-
IR, the  increases in peripheral insulin resistance are observed from the upper end of 
the overweight BMI strata.   
5.1.6 Blood analysis: to assess the effects of IN-INS 
Plasma and serum blood concentrations were assessed to document the effects of 
IN-INS on plasma glucose concentration. Measuring serum C-peptide simultaneously 
with serum insulin permits the assessment of whether increases in serum insulin are 
attributed to endogenous pancreatic insulin release, which would be coupled with 
an increase in C-peptide, or from exogenous insulin increases, i.e. from overspill of 
IN-INS into the systemic circulation (Kullmann et al. 2018).   
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Pre-dose and post-scan blood concentrations for both placebo and insulin conditions 
were entered into a within-group repeated measures analysis of variance model 
(ANOVA), to look for main effects of treatment and time as well as interaction effects 
for plasma glucose, serum insulin and serum C-peptide concentrations separately. In 
light of a significant main effect of drug or time (p < 0.05), two planned comparison 
t-tests (paired) were conducted to ascertain from which time point or which 
treatment was driving this main effect, respectively, as post hoc tests (using a p < 
0.05 statistical threshold). In response to an interaction effect, a post hoc Tukey test 
was performed to assess where the differences lay (applying a p < 0.05 statistical 
threshold). In the OW group, one participant did not provide a full set of blood 
samples, due to blood sampling issues that were encountered and therefore the OW 
blood analysis was conducted on fourteen participants.  
 
Data are presented graphically in Figure 5.1.4. Within both groups there was a slight 
decrease in plasma glucose concentrations over time on both the placebo and IN-INS 
visit. The decrease in glucose following IN-INS was, in both BMI groups, visually 
greater compared to placebo albeit did not yield any significant effects of time or 
treatment on ANOVA. Within the lean group there was an IN-INS related decrease in 
glucose of 0.21 ± 0.22 mmol/L and in the OW group a decrease of 0.17 ± 0.46 mmol/L. 
In the lean group there was a significant main effect of treatment (F1,23 = 5.75, p = 
0.021, ANOVA). Planned comparison t-test revealed a significant difference in serum 
insulin concentrations between placebo and IN-INS pre dose (t(11)= -2.28, p = 0.04, 
paired t-test, placebo (pre): 5.18 ± 2.51, IN-ins (pre): 13.98 ± 12.18) but no significant 
treatment effects from post-dose serum insulin measurements (p = 0.14).  In the OW 
group there was significant main effect of treatment (F1,27 = 9.15, p = 0.003, ANOVA). 
Planned comparison, post hoc t-tests showed significantly higher post-scan serum 
insulin levels in the IN-INS condition compared to IN-PLA (t(13) = -3.13, p = 0.008, 





Figure 5.1.4 Lean and OW Blood analysis plots. A) Blood analysis shown for the lean group show the 
measured concentrations of plasma glucose, serum insulin and serum C-peptide for both IN-PLA and 
IN-INS sessions over time (n=12). B) Blood concentrations for the OW group are plotted (n=14). A 
significant increase in post scan serum insulin for IN-INS vs IN-PLA, as tested using paired t-test. Plots 
illustrate a significant decrease over time of serum C-peptide concentration.  * p < 0.05, ** p < 0.01, 




In both groups there were significant main effects of time (pre-dose – post-scan) on 
serum C-peptide concentration (lean: F1,23 = 9.70, p = 0.003; OW: F1,27 = 5.47, p = 0.02, 
ANOVA). In the lean group planned comparison t-tests revealed a significant effect 
of time in both treatment conditions (IN-PLA: t(11) = 3.17, p = 0.009, IN-INS: t(11) = 
4.47, p = 0.001, paired t-test). Similarly, in the lean group significant differences over 
time were found in both conditions (C-peptide: IN-PLA: t(13) = 2.79, p = 0.015; IN-




Table 5.1.3 Blood analysis values for both lean and OW groups. Data are displayed as mean 
± SD lean (n=12), OW (n=14). a,b – significant treatment effect lean (p < 0.025) and OW (p < 
0.01), respectively. c,d and e,f – significant effect of time lean (p < 0.01) and OW (p < 0.001).   
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5.1.7 Subjective hunger scores 
Prior to entering the scanner (but after dosing, pre scan) and also imminently after 
scanning had concluded (post scan) participants completed visual analogue scales 
(VAS) to assess subjective hunger. This type of subjective rating has been shown to 
be a reproducible and powerful marker of subjective appetite (Flint et al. 2000). 
These appetite ratings were an additional point of assessment within the protocol 
that was implemented after the first four participants had completed all sessions and 
therefore only available for twenty three participants. The appetite scores were 
assessed individually for each group; firstly, within treatment appetite ratings were 
compared over time (pre vs post) and, secondly, changes in hunger over time (post 
minus pre), were compared across treatment (insulin vs placebo) using paired t-tests 
(p < 0.05, significance).  
 
Within the lean group there were no significant differences between pre and post 
measurements of appetite following either IN-PLA or IN-INS. There was a trend 
towards significance (p = 0.06, paired t-test) for an increase in appetite over time in 
the placebo condition. There were no significant differences seen from comparing 
the changes over time following each drug treatment within the lean group.  
 
In the overweight group, there was a significant increase in appetite ratings over time 
between the pre and post scan measurement within the placebo condition (pre: 55.0 
± 16.5, post: 73.85 ± 15.25, t(7) = -2.94,  p = 0.01, paired t-test). No drug related 
differences were observed within the OW group between any of the hunger change 





Figure 5.1.5 Pre and post-scan hunger VAS ratings for lean and OW groups. A) Lean hunger ratings 
did not show a statistically significant increase in hunger over time under both treatment 
conditions (n=8). B) Within the OW group, following IN-PLA administration there was an increase 
in hunger over time (n=12) (pre vs post-scan). C) Change in hunger over time following each 
treatment. There was no difference in change in hunger between treatment conditions. * p < 0.05, 
bars represent mean ± SEM. Light grey bars = pre scan, Dark grey bars = post scan, black bars = 
IN-PLA change in hunger and red bars = IN-INS change in hunger over time.  
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5.2 Discussion  
The results from the non-imaging data are very informative and even within such a 
small sample there are some trends that can be observed. It is worth initially 
mentioning that the exclusion of four participants was unfortunate and even more 
unfortunate that both visits had been completed before this exclusion decision was 
made. In retrospect, issues of non-compliance such as fasting could be avoided by 
either bringing participants in to stay overnight or by conducting studies later in the 
day and controlling their meals or lack thereof. However, implementation of study 
protocols like this are time-consuming and more labour intensive for both the 
researcher and the participant and is not always feasible as was the case for this 
study, which was conducted predominantly by a single researcher.   
5.2.1 HOMA - Insulin Resistance  
HOMA-IR scores are useful for assessing peripheral insulin sensitivity and often used 
to correlate with some other physiological measure such as BMI (Vogeser et al. 2007). 
The HOMA is a tool to asses pancreatic beta cell function as well as IR  (Wallace, Levy, 
and Matthews 2004) and as it is based on fasting measures, the latter primarily 
reflects hepatic insulin sensitivity rather than peripheral. It has been suggested that 
implementing C-peptide alongside glucose concentrations for HOMA calculations is 
better for predicting beta cell function, whereas predicting IR or insulin sensitivity is 
better conducted with glucose and insulin entered into the calculation (Wallace, 
Levy, and Matthews 2004). However, the scores in this case were calculated using 
the pre dose C-peptide blood measurements for the following reasons. There was a 
large amount of variability within the serum insulin data, as seen from the large 
standard deviation values (see Table 5.1.3). Furthermore, several participants had 
levels below the lower limit accepted by  the HOMA-IR 2 online calculator used (Levy, 
Matthews, and Hermans 1998). These two points reflect the inherent variability in  
the insulin assay adopted in this study. Concerns regarding insulin assay 
standardisation do exist (Robbins et al. 1996), which is beyond the scope of this 
discussion but do support the justification in using C-peptide in this measurement. 
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Furthermore, these measures were not used clinically  and were purely for research 
purposes and supplementation.  Even with the more reliable c-peptide measure, 
there were no formal differences in HOMA-IR scores between the lean and the OW 
group. HOMA-IR has been shown to positively correlate with BMI (Vogeser et al. 
2007) as well as many other factors, including age (Karakelides et al. 2010). The 
cohort enrolled and investigated as part of the SNIFAR were young, and otherwise 
healthy, which may explain the lack of difference between these two groups. A strong 
positive correlation was observed however between HOMA-IR and BMI which was 
exclusive to the OW group. From the BMI x HOMA-IR plot (Figure 5.1.3) a trend can 
be seen that shows a slight group separation in HOMA-IR at approximately a BMI of 
28 m/kg2. The absence of a correlation in the lean group may reflect a narrow range 
of BMI measures in this group, but may also reflect a healthy phenotype across the 
range of lean values, while a phenotype above the BMI threshold of 28 shows an 
impact of BMI on insulin sensitivity.    
 
Previous imaging studies have assessed HOMA-IR in an effort to stratify study cohorts 
into insulin sensitive and insulin resistant groups in order to make inferences based 
on peripheral insulin sensitivity (Tiedemann et al. 2017). This was not possible in this 
case and therefore pre dose HOMA-IR scores primarily benefited the study through 
providing these values as ‘covariates of interest’ into the design matrix for whole 
brain second level random effects statistical models for functional imaging data 
analysis, as will be presented in the chapters to follow. This additional physiological 
information may in some cases help to account for some of the between subject and 
also within-subject variance inherent to the functional imaging data collected.  
 
Blood was sampled on only two occasions during the present protocol. Sampling 
serial blood measurements throughout the duration of the scanning protocol might 
have been preferable and is used for pharmacological fMRI research, as drug activity 
can be closely correlated with pharmacokinetic data (Mehta and O'Daly 2011). In this 
instance, however, temporally rich blood sampling was not feasible and was also not 
a primary aim of this study. Furthermore, it was considered desirable not to disturb 
the participant during scanning. As such, only pre-scan (before dosing) blood 
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concentrations and HOMA-IR measures were employed as covariates for imaging 
data analysis. The addition of blood concentration and HOMA-IR covariates was 
purposely restricted to the resting state blood oxygen level dependent and the 
resting state cerebral blood flow data, which were acquired at the beginning of the 
functional imaging protocol. 
 
5.2.2 Effects of IN-INS on blood glucose and hormone concentration 
An acute 160 IU dose of IN-INS was implemented in this study via two nasal 
administrations in each nostril. A recent meta-analysis (Schmid et al. 2018) has 
formally looked at the safety aspects and concerns regarding hypoglycaemia and 
other adverse events in response to IN-INS. This meta-analysis reports 17 separate 
research papers that have studied the acute effects of a single dose of 160IU of IN-
INS. From all of these studies there were no reports of severe hypoglycaemia 
(although not explicitly defined by the authors (Schmid et al. 2018)) but there were 
reports of IN-INS related decreases in blood glucose of approximately 0.24 mmol/L 
(Benedict et al. 2008), 0.2 mmol/L (Heni et al. 2012) and 0.48 mmol/L (Santiago and 
Hallschmid 2017) in response to a 160IU dose. For the SNIFAR study an explicit 
definition for a ‘hypoglycaemia alert’ was set to £ 3.9 mmol/L as defined in Seaquist 
et al., (Seaquist et al. 2013). From the data reported above a mean IN-INS related dip 
in plasma glucose concentrations of 0.21 mmol/L and 0.17 mmol/L in lean and OW 
groups, respectively, similar to those reported previously (Benedict et al. 2008; Heni 
et al. 2012; Santiago and Hallschmid 2017).  
 
The trend towards a decrease in plasma glucose levels is very likely due to increased 
peripheral insulin concentrations from the IN-INS administration. In the OW group 
IN-INS administration was coupled with a significant increase in post scan serum 
insulin concentrations in comparison to IN-PLA. This increase was, however, not 
coupled with a rise in C-peptide levels which suggests that this increase detected is a 
result of exogenous insulin increases in the periphery from IN-INS administration. In 
the lean group however, there is a surprising statistically significant difference 
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between pre dose serum insulin levels between the IN-INS session and IN-PLA 
session. One might suspect that this difference has resulted from some participants 
not having been fasting on the IN-INS sessio . However, the increased pre dose serum 
insulin concentration seen on IN-INS sessions vs IN-PLA is not coupled with an 
associated increase in serum C-peptide. In fact the serum C-peptide levels between 
sessions are very similar pre dose and as alluded to before the discrepancy may be a 
consequence of an unreliable assay. Nevertheless, although all participants 
confirmed verbally to the researcher that they were fasted at the start of each study, 
the very high insulins of three participants did lead to their exclusion from the data 
analysis, on the basis that a non-fasted state could not be ruled out.   
 
As mentioned the OW group displayed an increase in serum insulin concentrations 
after IN-INS compared to IN-PLA. Interestingly this increase was coupled with a slight 
but insignificant decrease in plasma glucose concentration. This lack of significant 
blood glucose decrease given the insulin rise may be reflective of a BMI related 
peripheral insulin insensitivity. Even though none of the OW participants were 
classified as IR this lack of significant glucose decrease could be an early sign of 
decreased peripheral insulin sensitivity within the OW group. The increase in post 
scan serum insulin seen within the OW group is strongly suggested to be as a 
consequence of drug absorption into the peripheral circulation. This is a consequence 
of using a high dose of insulin (160 IU) and also the route of administration. As 
described in detail in Chapter 4; the nasal cavity epithelium is highly vascularised. The 
nasal pump carefully selected for the SNIFAR study was superior to the comparator 
pumps tested against, but is arguably not fully optimal pump for nose to brain insulin 
delivery. In fact, given the complex architecture of the nasal cavity and large surface 
area of the nasal epithelium (Djupesland 2013) even a purposefully designed nose to 
brain nasal pump would lead to some residual drug deposition within the nasal 
epithelium which would subsequently be absorbed into the circulatory system. This 
spill over effect of IN-INS into the circulation was not however, coupled with any 
hypoglycaemic events or adverse reactions, similar to that observed from previous 
reports (Schmid et al. 2018). An exogenous insulin dose of 160 IU delivered 
intravenously would lead to severe hypoglycaemia. As there was a limited effect on 
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peripheral glucose levels following IN-INS there is strong evidence to suggest that a 
large majority of the 160 IU dose was delivered to the central nervous system (CSF) 
via olfactory and trigeminal nose to brain delivery routes (Djupesland 2013). It will 
be argued therefore, that imaging data differences seen within the SNIFAR data are 
due to central increases of insulin within the central nervous system (CNS) from nose 
to brain delivery of insulin solution.  
 
C-peptide in all cases significantly decreased over time. The understating of this is 
that being in the fasted state for the duration of the protocol would not require 
pancreatic insulin release and subsequent C-peptide levels would drop over time as 
a result of C-peptide degradation (Matthews, Rudenski, et al. 1985). The larger drop 
after IN-INS is compatible with the systemic action of some of the exogenous insulin, 
presumably through a direct effect, as importantly the plasma glucose did not fall in 
any subject to or below 3.9mmol/l, the levels associated with the onset of the 
pancreatic homeostatic responses of reduced pancreatic insulin and increased 
pancreatic glucagon responses (Seaquist et al. 2013).   
 
5.2.3 Hunger ratings 
From subjective hunger ratings taken outside of the scanner it can be seen that there 
is an insulin related hunger blunting effect. In all cases hunger increased over time 
but was only significant in the OW group from the IN-PLA session. This may suggest 
the OW group are more susceptible to feelings of hunger during fasting. Comparing 
the change in hunger over time between intranasal treatments did not reveal any 
treatment related differences. The application of 160 IU IN-INS has been previously 
shown to reduce calorie consumption in healthy young men compared to IN-PLA 
(Benedict et al. 2008). Although ratings of hunger are physically different from food 
consumption it still serves as a good reflection of energy balance. One study looking 
at the effects of IN-INS on cerebral perfusion additionally reported no effect of IN-
INS on self-reported subjective hunger following 40 IU IN-INS (Schilling et al. 2014) 
suggesting that the anorexigenic appetite reducing effects of IN-INS may be dose 
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dependent. These hunger ratings nonetheless showed a general trend towards an 
IN-INS related effect on hunger suppression in the OW group. These effects were 
subtle and do not suggest that IN-INS induces satiety but these observations are 
useful when interpreting the results from the functional imaging data collected which 
are subsequently analysed in the following chapters.  
 
5.2.4 Questionnaires 
Previous research has found that BMI correlates positively with both TFEQ 
disinhibition and hunger factor scores, but not dietary restraint (Zimmerman et al. 
2017). These correlation results previously reported are in support of the trend seen 
from the data presented from the SNIFAR study. As the TFEQ questionnaire was 
completed at screening there are no drug related effects that can be attained from 
these scores. From previous research, the TFEQ has been used to good effect as a 
statistical regressor against functional imaging related data. For example, Kullmann 
et al., showed that TFEQ disinhibition scores correlated with cerebral blood flow 
(CBF) responses to IN-INS within the prefrontal cortex (Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015). The TFEQ scores gathered from screening 
may benefit and help to compound the understanding of imaging data collected via 
correlational analysis as has been described previously (Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015) and were applied in this way when possible.  
The DFS is a rough marker of diet composition. The two groups differed by only one 
BMI category and therefore this might explain why a general trend was seen as 
opposed to formal statistical differences between the two groups. For all food 
categories the OW group showed slightly higher intake frequency scores suggesting 
that the OW group in general consume slightly more foods containing saturated fats, 
sugar and a combination of both sugar and fat. Similarly to the TFEQ scores, the use 
of these DFS scores will benefit the imaging data acquired through implementation 
of explorative correlational analyses. The SNIFAR study did not assess adiposity and 




All questionnaires performed at the screening were done so as to reduce the 
workload for the participants during the imaging visits of the study. Although the 
results from the questionnaires do not reveal differences between lean and OW 
groups, the information from these scores will be important additions to the imaging 
data analysis. The scores for the questionnaires were used within exploratory 
correlation analyses, particularly to supplement region of interest based analysis.  
In conclusion, there are some interesting results from the demographic, 
questionnaire and blood concentration data. The SNIFAR study was implemented in 
an age matched group of healthy male volunteers who were stratified into two BMI 
groups; normal weight/lean and overweight. Differences in questionnaire scores 
were subtle and not statistically significant, as was also true of measures of insulin 
resistance. Therefore, these two matched cohorts were also matched for diet 
composition, dietary restraint, disinhibition and hunger permitting strong inferences 















Chapter 6 The modulatory effects of 
intranasal insulin on cerebral 
perfusion  
 
This chapter will document the measurements of cerebral perfusion that I carried out 
in this study. Resting perfusion weighted imaging data were acquired using a ‘work 
in progress’ arterial spin labelling sequence that permitted the use of long labelling 
durations  (> 1.5s). The sequence parameters chosen for this investigation of the 
effects of intranasal insulin on resting perfusion were chosen derived from a previous 
sequence optimisation project that I conducted during the MRes phase of this 
program, prior to the beginning of this PhD (Wingrove et al. 2015). The main focus of 
this chapter, therefore, will be the data analysis and results for the perfusion-related 
component of the SNIFAR study which will be presented and discussed with 















Arterial spin labelling (ASL) is an ideal imaging technique to explore regional changes 
in cerebral perfusion, or cerebral blood flow (CBF), in response to a pharmacological 
challenge (Wang, Chen, et al. 2011b). CBF measured through ASL is both quantitative 
(ml/100g of brain tissue/min) and physiologically relevant when examining drug 
induced effects in the brain (Mehta and O'Daly 2011). Regional CBF changes can be 
reflective of direct compound interactions on the cerebral vasculature, for example 
caffeine (Perthen et al. 2008), or as a result of increased metabolic demand required 
from neuronal populations due to neuroactive effects (see section 2.2.1). Previous 
work in humans using ASL has provided some evidence to suggest that exogenous 
insulin has little direct interaction with the cerebral vasculature (Grichisch et al. 2012) 
and that insulin-associated effects on CBF are driven by neuronal origins.  
 
A small number of experiments looking at the modulatory effects of intranasal insulin 
have employed ASL to explore regional perfusion changes in healthy lean, obese, 
insulin resistant and also healthy elderly individuals (Schilling et al. 2014; Kullmann, 
Heni, Veit, Scheffler, Machann, Häring, et al. 2015; Akintola et al. 2017). The present 
study, however, is the first to explore these effects in a group of overweight 
individuals in comparison to an age matched normal weight group. Furthermore, 
within this interrogation, a pseudo-continuous ASL (pCASL) sequence with long 
labelling abilities was implemented, in an effort to acquire quantitative images of CBF 
with a voxel size adequate to resolve cortical and sub-cortical features with limited 
partial volume effects. CBF measurement with ASL is prone to image degradation 
effects, known as partial volume effects, as a result of the combined signal 
contribution from both grey matter (GM) and white matter (WM) (Asllani, 
Borogovac, and Brown 2008; Chappell et al. 2011). More often than not, an 
investigator is interested in GM perfusion, which is typically three times greater than 
that of WM. Voxels at GM/WM boundaries will inevitably comprise signal 
contributions from both tissue types, thus the WM contribution may introduce an 
underestimation of CBF. The sequence aims to limit the effects caused by partial 
volume through acquisition of images with smaller voxels in an effort to reduce CBF 
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underestimation. There have been no reported studies that have adopted a pseudo-
continuous ASL (pCASL) sequence with long labelling abilities for use in a 
pharmacological MRI (phMRI) experiment. The sequence used has been optimised 
to achieve a balance between in-plane spatial resolution, temporal resolution, signal 
to noise ratio and blurring in the slice encoding direction (z-axis).  
 
The aim of this experiment is to identify CBF changes in response to intranasal insulin 
administration in both lean and overweight individuals. The use of this pCASL 
sequence will permit the resolution of cortical and sub-cortical structures known to 
be insulin responsive and be sensitive to resolve significant insulin associated 
changes in regional CBF. We hypothesise that 160 IU IN-INS will produce significant 
changes in CBF within the limbic and cortical structures that possess insulin 
receptors. We predict that these changes will be decreases in CBF based on previous 
CBF literature with this dose (Kullmann et al. 2018) and that these decreases will be 


















6.2.1 Participants and study protocol 
As mentioned previously in Chapter 5 (see section 5.1.4) of the 31 participants 
scanned, 27 were included in the analysis of cerebral perfusion Three of these were 
removed due to possible non-compliance of the overnight fast and one was excluded 
due to a lack of sleep the evening before one of the scanning sessions. In total there 
were 12 lean participants (BMI = 22.40 ± 1.89 (mean ± standard deviation)) and 15 
OW participants (BMI = 27.76 ± 1.92) that were included in this analysis of cerebral 
perfusion (groups did not differ in age, as mentioned in Chapter 5 (see section 5.1.1)).   
 
6.2.2 ASL acquisition 
Resting state ASL was performed directly after the acquisition of resting-state blood 
oxygen level dependent (BOLD) data and was the final resting acquisition within the 
SNIFAR protocol (see section 3.4.6). Given previous literature on intranasal insulin 
pharmacokinetics (Born et al. 2002) it is likely that CSF and interstitial brain insulin 
concentrations would be close to peak elevation levels at this time point.  
 
All scanning was conducted using a MR750 3 Tesla GE Scanner with a 32 channel head 
coil. Whole brain resting cerebral perfusion images were collected using a 3D pseudo-
continuous arterial spin labelling (pCASL) sequence acquired with a fast spin echo 
(FSE) stack of spiral readout. The following parameters were used; 10 spiral arms, 
600 points per arm, in plane resolution 2.94 x 2.94 mm2, slice thickness = 3mm, 54 
slices, label duration (LD) = 3500 ms, post label delay (PLD) = 2025 ms, echo time/ 
repetition time (TE/TR) = 11.8 / 7325 ms, number of averages = 2, total time of 
acquisition = 5.22 mins. A background suppression module was applied, to null static 
signal, using default scanner calculated pulses. This consisted of one single selective 
saturation pulse applied to the imaging volume and an imaging selective inversion 
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pulse prior to labelling followed by four non-selective inversion pulses between the 
end of the labelling block and the readout window. 
 
The labelling plane for this pCASL sequence is automatically set to 2 cm below the 
imaging volume. The imaging volume was positioned on the inferior surface of the 
cerebellum for all subjects to allow for both optimal labelling plane positioning and 
labelling efficiency, perpendicular to the carotid and vertebral arteries just below the 
Circle of Willis. The pCASL sequence automatically acquires a 3D proton density (PD) 
image using identical readout parameters for cerebral blood flow quantification 
purposes and was also used to aid co-registration. During resting pCASL acquisition 
participants were instructed to keep their eyes open and look at a fixation cross 
displayed to them via a projector screen.   
  
6.2.3 Cerebral blood flow quantification  
CBF maps were computed from perfusion weighted (PW) and PD images using the 
single compartment model using online GE scanner software, by performing the CBF 
calculation at each voxel, defined in section 2.2.3.7, of the acquisition methods 
chapter (chapter 2). 
 
6.2.4 Image processing 
PD images, which boast higher tissue contrast compared to both CBF maps and PW 
images were co-registered to 3D T1 images using epi_reg (FMRIB software Library, 
version 3.20, University of Oxford, UK, www.fmrib.ax.ac.uk/fsl - FSL (Jenkinson et al. 
2002)). Subject CBF maps were registered to MNI space by applying the saved 
transformations (from the T1 normalisation steps, see section 3.5.1, in the study 
design chapter (chapter 3)) and warps using Advanced Normalisation Tools software 
(ANTs) (Avants et al. 2014). Normalised CBF maps were smoothed using a full width 
half maximum (FWHM) Gaussian kernel of 6 x 6 x 6mm3 using the Statistical 
Parametric Mapping smooth function (SPM-12, Wellcome Trust Centre for 
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Neuroimaging, University College London, UK, www.fil.ion.ucl.ac.uk/spm ). This 
smoothing kernel, approximately twice the acquired spatial resolution, was 
implemented in reference to recommendations for group statistical inferences with 
functional BOLD data (Worsley and Friston 1995). 
 
6.3 Group level CBF Image Analysis 
6.3.1 Whole brain analysis 
Pre-processed CBF maps were analysed at the second-level using SPM. These maps 
were entered into a random effects second level voxel-wise repeated measures 
factorial model analysis with the three factors; subject, Drug (PLA, INS) and Group 
(LEAN, OW) (known in SPM as a flexible factorial model). The inclusion of the subject 
factor as an explanatory variable to encode the between subject-variability helps to 
reduce the amount of unexplained variance within the data and has been shown to 
increase detection sensitivity within pharmacological experiments (Mehta and 
O'Daly 2011). Mean grey matter (GM) CBF values, calculated from a liberal GM mask, 
were added to this model as a covariate to account for within-subject between 
session GM CBF variability. Analysis was constrained to those voxels within the GM 
by applying an implicit GM mask. Contrast T-maps for the main effect of PLA and INS 
were created as well as interaction effect contrasts (Drug X BMI) (see Figure 6.4.2). 
Voxel wise whole brain analysis results were set to a cluster forming threshold of p < 
0.01. Significant clusters were classified based on cluster correction for multiple 
comparisons using a family wise error threshold (FWE) of p < 0.05. In response to  a 
significant interaction effect (p < 0.05 FWE) or an interaction trend (0.05 < p < 0.1 
FWE) 2nd level whole brain paired t-tests were created for each group for both main 
drug effects, INS > PLA and INS < PLA, using the same cluster forming threshold as 




To assess changes in global CBF whole brain median grey matter (GM) CBF values, 
constrained to a standardised GM mask, were extracted from the pre-processed 
maps  using Analysis of Functional Neuroimage (Cox 1996) (AFNI, 3dmaskave) 
software. GM CBF values were entered into a repeated measures analysis of variance 
(ANOVA) model to test for main effects of drug group and interaction effects. 
Following a significant main effect of drug two paired t-tests were conducted to see 
if drug related changes were significant within the lean or overweight group, or both.  
Following a significant group effect two unpaired t-tests were conducted to explore 
whether these group differences in CBF were detected following placebo or insulin 
administration, or both. These t-tests will be referenced as planned comparisons and 
formed a post hoc analysis as opposed to testing all possible combinations. To correct 
for these two planned comparisons a Bonferroni multiple comparison correction was 
applied providing a significance threshold of p < 0.025. Following a significant 
interaction effect a Tukey test was performed post hoc to test all possible 
comparisons. Tukey tests inherently adjust for multiple comparisons and thus a 
significance threshold of p  < 0.05 was employed. 
 
Blood analysis results presented in Chapter 4 showed a degree of variability in 
baseline serum insulin concentrations in the lean group between imaging visits. This 
variability proved sufficient to produce significant differences in pre-scan serum 
insulin concentrations between the two imaging visits in the lean group only. In an 
effort to account for some of this variability, HOMA-IR scores, calculated and 
presented in chapter 4 for both INS and PLA, were added to the paired t-test model 
as a regressor of no interest (nuisance regressor) in the lean group only. The whole 
brain paired t-test was run both with and without the addition of the nuisance 
regressor. 
6.3.2 Region of interest analysis 
Small volume correction (SVC) analysis was conducted on whole brain t-maps to 
permit a more thorough exploration within pre-defined regions of interest (ROI). 
Bilateral anatomical regions were selected, as ROIs for this analysis. These regions 
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were defined a priori based on high insulin receptor density profiles and also from 
previous publications that have shown insulin induced responses within these ROIs 
and potential functions in food intake and behaviour (detailed in Table 6.3.1) 
(Schulingkamp et al. 2000; Schilling et al. 2014). Insulin receptor dense regions were 
defined as the hippocampus and amygdala (Schulingkamp et al. 2000) and the ROIs 
based on previous intranasal insulin literature were the insula and the putamen 
(Schilling et al. 2014).  
 
 
All subcortical bilateral ROIs were defined in SPM-12 using the Functional MRI tool 
of the Wake Forest University School of Medicine (http://www.ansir.wfubmc.edu) 
known as ‘WFU pick atlas’, implemented with automated anatomical labelling (AAL). 
The insula is a relatively large cortical structure with well-established functional roles 
in the processing of appetite related cues and reward (Frank, Kullmann, and Veit 
Table 6.3.1 Regions of interest used in this cerebral perfusion analysis of IN-INS. 
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2013). As a result of the size and diverse neural functionality of the insula was 
subdivided into the posterior and anterior subdivision in an effort to infer more 
specificity in reference to CBF related effects seen within the insula. These 
subdivisions used were based on publicly available cytoarchitecture data (Kurth, 
Eickhoff, et al. 2010). All ROIs are visually displayed in Figure 6.4.4. 
 
SVC was applied to whole brain maps of both the main effects and interaction effects 
for the five ROIs described above. A significance threshold was calculated to correct 
for multiple comparisons by dividing the p < 0.05 by the number of ROIs used (ROIs 
= 5). The significance was set to p < 0.01 for SVC analysis.  
 
Furthermore, median CBF values were extracted from the five bilateral ROIs defined 
above (Cox 1996) (AFNI, 3dmaskave). Median CBF values for each ROI were entered 
into a repeated measures ANOVA factorial model with two factors drug and group. 
Five ANOVA models were created to assess the five different ROIs. Main effects of 
drug and group were explored as well as drug by group interactions. Main effects and 
interactions were assessed to a significance threshold of p < 0.05. Following a 
significant main effect of drug two paired t-tests were conducted to see if drug 
related changes were significant within the lean or overweight group, or both.  As 
with the median GM CBF analysis described earlier, following a significant group 
effect two unpaired t-tests were conducted to explore whether these group 
differences in CBF were detected following placebo or insulin administration, or both. 
A Bonferroni multiple comparison correction for two planned comparisons was 
applied providing a significance threshold of p < 0.025 (0.05/2). Following a 
significant interaction effect a Tukey test was performed post hoc to test all possible 
comparisons. Tukey tests inherently adjust for multiple comparisons and thus a 
significance threshold of p  < 0.05 was employed.  
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6.3.2.1 Correlational analysis 
As an additional exploratory analysis, drug induced changes in regional CBF within 
each group were assessed for correlations with dietary saturated fat intake and sugar 
intake measured through the dietary fat and sugar (DFS) subscale questionnaire that 
each participant completed during the screening. Insulin induced CBF changes from 
the five ROIs (∆%) were defined as PLA – INS / PLA * 100,  and self-reported dietary 
saturated fat and also sugar intake scores were in arbitrary units. ∆% CBF changes for 
each ROI were examined for associations with fat and sugar intake using Pearson’s 
correlation coefficient. A relevant correlation was defined as rho (r)=  > 0.4 or <  - 0.4 
with a p value < 0.05.  
 
6.3.2.2 Statistical analysis 
Descriptive parametric statistics were used to describe the results and noted as mean 
± standard deviation unless stated otherwise. All ROI analysis was conducted using R 
statistical analysis software (Rstudio - Version 1.1.453, Boston, MA, 
http://www.rstudio.org/).  Repeated measure ANOVA models were used to look for 
main effects of group and drug as well as interaction effects from the median 
extracted CBF values extracted from each of the ROIs defined. For within group and 














6.4.1 Grey matter cerebral blood flow 
Median CBF (ml/100g/min) values extracted from GM voxels (presented in Table 
6.4.1) revealed no significant effect of drug, BMI or interaction effect on global GM 
CBF. 
 
6.4.2 Repeated measures factorial model analysis 
For the repeated measures factorial model four contrasts were created (Figure 
6.4.2): 
• INS > PLA 
• INS < PLA 
• Interaction 1 (LEAN INS > PLA, OW INS < PLA) 
• Interaction 2 (LEAN INS < PLA, OW INS > PLA) 
Table 6.4.1 Median Grey Matter CBF. Data are presented as the average  ± SD.  
Figure 6.4.1 Axial CBF map slices from a representative volunteer acquired using the long 
label pCASL FSE stack of spiral readout sequence. The perfusion weighted data for this map 
was acquired with an in-plane spatial resolution 2.94 mm2 with a 3mm slice thickness.  
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This model was employed at the second level to identify clusters of significant change 
in regional CBF associated with the main effects of INS on CBF in both the lean and 
OW groups combined, and to search for any interaction effects or trends between 
these groups. The main effect of drug  (INS > PLA), provided no significant clusters 
when corrected for multiple comparison (FWE p <0.05 at the cluster level). Similarly, 
the opposite drug effect contrast, INS < PLA, did not reveal any significant clusters 
(FWE p < 0.05).  
Figure 6.4.2 Repeated measures factorial model design matrix and contrasts. A) The design matrix for 
the repeated measures factorial model that was implemented for the 2nd level random effects analysis. 
Three factors (subject, drug and BMI) were used and the mean GM CBF (Global GM) was added as a 
regressor of no interest. B) Four contrast vectors were tested with this model, shown graphically.    
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Two interaction contrasts were tested to look for any differential responses between 
lean and OW groups, noted above. Neither of these interaction contrasts revealed 
any significant clusters, when corrected for multiple comparisons at the whole brain 
level. However, for interaction 1 (Lean INS > PLA, OW INS < PLA) a trend towards 
significance was seen from a large  cluster (1399 voxels) situated within the right 
middle temporal gyrus (p = 0.052, FWE-corrected) (MNI co-ordinates: x = 52, y = -60, 












Five a priori defined anatomical ROIs (see Figure 6.4.4) were used for small volume 
correction (SVC) analysis on all contrast maps created from the factorial model 
analysis. All contrast maps were evaluated at a significance cluster forming threshold  
of p < 0.01 prior to SVC .  A significance threshold for SVC of p < 0.01 was applied to 
correct for type I error inflation from multiple comparisons.  
 
For main effects of drug defined as “INS > PLA” and “INS < PLA” none of the 
anatomical bilateral ROIs survived the significant threshold following SVC. For the 
interaction 1 contrast (see Figure 6.4.2) the bilateral posterior insula showed an  
interaction effect (p = 0.04) but did not survive Bonferroni correction.   The origin of 
the interaction effect was the left posterior insula at MNI coordinates x = -38 y = -6 z 
= -6, and, x = -38 y = -14 z = -6, respectively (p = 0.040 and p = 0.041, t = 3.86, 3.85, 
respectively). Interaction 2 contrast did not provide any significant changes from SVC, 
from any of the five anatomical ROIs tested.  
Interaction 1 
y = -60 x= 48 
z = 0 z = 5 
Figure 6.4.3 Interaction 1 trend (p=0.052, FWE) cluster seen within the 
middle temporal gyrus. Group level statistical parametric t-map overlaid 
onto an MNI template. Cluster forming threshold p < 0.01, cluster extent 
threshold 1000 voxels.   
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6.4.3 Whole brain, lean and OW voxel wise paired t test analysis  
Whole brain results from the repeated measures factorial model showed a trend 
towards an interaction effect (interaction 1) within the right middle temporal gyrus 
(p = 0.052, FWE-corrected). As a result of this trend whole brain within-group paired 
t-tests were conducted post hoc to further interrogate this trend.  
 
For the lean group both INS and PLA CBF images were entered into a whole brain 
paired t-test in SPM-12. Linear contrasts for drug effects were created (INS > PLA and 
INS <  PLA). Mean GM CBF values were entered into the model, as described before, 
as a regressor of no interest. An additional paired t-test was created which added an 
additional regressor to the model. Measures of pre scan insulin sensitivity (HOMA-
IR) calculated in chapter 5 (section 5.1.5) were entered into the model as a regressor 
of no interest for the lean group only.  
 
For the OW group a whole brain paired t-test model was created and linear contrasts 
for both drug effects were created. Mean GM CBF values were entered in the model, 
as described before, as a regressor of no interest. Blood concentration covariates 
were not entered into the model as one participant did not have a complete blood 
sample profile.  
Figure 6.4.4 Regions of interest used for further analysis. 
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Both paired t-tests had a cluster forming threshold of p < 0.01 applied. Clusters that 
survived a FWE-corrected significance threshold of p < 0.05 were reported as 
significant.  
 
Finally, SVC analysis was employed using the five anatomical ROIs as described 
previously, with a significant threshold p > 0.01 for multiple comparison.  
 
6.4.3.1 Insulin effects on CBF – lean  
Whole brain voxel wise paired t-tests for both, INS > PLA and INS < PLA, contrasts 
revealed no significant changes in CBF at the whole brain level. Additionally, inclusion 
of HOMA-IR scores as a regressor of no interest did not yield any significant effects.  
SVC analysis was applied to the two contrasts with and without the additional insulin 
sensitivity regressor. No significant changes were seen in any of the ROIs tested for 
the paired t-test model without HOMA-IR scores for either of the contrasts. With 
HOMA-IR added as a nuisance regressor an effect was seen within the amygdala from 
the INS < PLA contrast created t map but did not survive the statistical significance 
threshold for multiple comparison correction (t(11) = 5.02, p = 0.025, paired t-test, 
MNI coordinates x = 24  y = 2  z = -20).  
 
6.4.3.2 insulin effects on CBF - overweight 
Voxel wise paired t-test for the INS > PLA contrast, revealed no significant CBF 
differences at the whole brain level. The INS < PLA contrast, however, revealed a 
large (1848 voxels) significant cluster of significant CBF change ((t14) = 6.00, p = 
0.017, FWE-corrected, paired t-test). The spatial extent of the cluster was large and 
comprised three peaks within the left temporal lobe, corresponding to the left 
hippocampus, posterior insula/putamen and para-hippocampal gyrus (MNI co-
ordinates and t-values are presented in Table 6.4.2,  thresholded T-maps are 

























Figure 6.4.5 T maps overlaid onto structural images, illustrating insulin related perfusion decreases 
in overweight individuals. A) Coronal and axial sections displaying the left hippocampal region t-map 
cluster associated with an insulin induced decrease in CBF. B) Sagittal sections displaying both the 
left hippocampal and insula related decreases in CBF. C) Coronal sections showing insulin induced 
perfusion decreases localised to the left insula and putamen regions.  D) Axial sections highlighting 
left putamen and posterior insula decreases in CBF in response to insulin compared to placebo. 
 
Table 6.4.2 Significant cluster found from whole brain paired t-test analysis in the OW group (INS < 
PLA) which comprised of three peak regions.  
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For the contrast, INS < PLA, SVC  revealed CBF differences within all five ROI regions 
(see Table 6.4.3). From these five regional differences in CBF only two were 
statistically significant when corrected for multiple comparisons, these were the 














6.4.4 Regional CBF assessment 
SVC takes into account the model used at the second level and the regressors of no 
interest added (for example mean GM CBF and HOMA-IR). As an additive analysis 
method median CBF values were extracted from the five previously defined 
anatomical ROIs. These values (one value per subject) were compared across 
different drug conditions and also across groups to examine regional perfusion 








Table 6.4.3 Table showing the results from small volume correction analysis in the overweight group 
only. P values in bold correspond to ROIs that survived multiple comparison correction (p < 0.01). 
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6.4.4.1 Insulin effects 
No interaction effects were reported from any of the five ROIs tested and no drug 
effects were reported from any of the ROIs tested either.  
 
6.4.4.2 Group Effects 
Significant main group effects in CBF were seen within the insula cortex for both 
anterior (F(1,26) = 12.53, p = 0.001, ANOVA) and posterior regions (F(1,26) = 8.96, p = 
0.004, ANOVA).  
 
For the anterior insula CBF significant differences were reported from planned 
comparison t-tests following placebo (t(25) = 2.45, p = 0.0022, unpaired t-test) and 
insulin administration (t(25) = 2.48, p = 0.023, unpaired t-test). In both cases median 
anterior insula CBF was lower in the lean group in comparison to the overweight 
group (see Figure 6.4.6).  
 
For the posterior insula, planned comparison t-tests reported significantly greater 
CBF in the overweight group compared to the lean group following placebo 
administration only (t(25) = 2.78, p = 0.0023, paired t-test) but not following 
intranasal insulin administration (see Figure 6.4.6). 
 
Figure 6.4.6  Regional CBF measures extracted from the insula A) Under placebo conditions both the 
anterior and posterior insula show increased rCBF in the OW group compared to the lean group. B) 
Under insulin conditions the anterior insula rCBF is significantly greater in the OW group compared to 
the lean group. * p < 0.025, ** p < 0.01, average median rCBF values plotted, error bars = SD, lean n=12, 
OW n=15.  
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6.4.5 CBF correlations with dietary measures 
An assessment of the association between regional changes in CBF in response to INS 
vs PLA and self-reported saturated fat and sugar intakes were assessed as part of an 
exploratory correlational analysis. 
 
Within the lean group, % regional CBF changes in response to insulin did not report 
any associations between any of the intake scores for any of the ROIs. 
 
Within the OW group, the % change in hippocampal and putamen CBF had a strong 
negative linear correlation with saturated fat score (r = -0.58, p = 0.025 and r = -0.59, 
p = 0.020, Pearson’s correlation coefficient, respectively) (see Figure 6.4.7). 
Additionally, % CBF changes in response to insulin measured from the hippocampus 
and putamen showed strong negative correlations with self-reported sugar intake 
scores (r = -0.58, p = 0.022 and r = -0.57, p = 0.026, Pearson’s correlation coefficient, 
respectively).  
 
No other ROI % change in CBF correlated with fat or sugar intake that survived the 




















Figure 6.4.7 Association between % change in CBF and saturated fat and sugar scores within the OW 
group. A) % change in CBF in the hippocampus negatively correlates with saturated fat score 
(arbitrary units) 𝑦 = 	−0.94𝑥 + 59.71. B) % change in CBF in the putamen is also modulated by 
saturated fat intake levels, 𝑦 = 	−0.92𝑥 + 58.80. C) % change in CBF within the hippocampus 
negatively correlates with sugar intake (arbitrary units) 𝑦 = 	−3.07𝑥 + 38.84, D) % change in CBF 
within the putamen negatively correlates with sugar intake 𝑦 = 	−2.85𝑥 + 36.93, Significance was 
set to p< 0.05 and rho > 0.4 or < -0.4, n=15 (OW).  
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6.5  Discussion 
The aim of this component of the study was to look at the effects of intranasal insulin 
administration on resting cerebral perfusion using arterial spin labelling. A 3D pCASL 
technique was used to acquire quantitative cerebral perfusion maps in a cohort of 
healthy males who had a range of BMI scores and were stratified into normal weight 
(lean) and overweight groups. The pCASL sequence implemented in this study 
adopted a long label duration (3.5s), to increase signal to noise ratio within the 
perfusion weighted images. To this end the voxel size of the acquired images was 
decreased to make use of this increase in signal from the larger labelled bolus. All 
other parameters used were in line with those recommended by the recent ASL 
consensus paper (Alsop et al. 2014). The sequence was successfully implemented and 
characterised for use in this pharmacological investigation. This study was able to 
provide observations of insulin induced decreases in CBF within the hippocampus, 
which has not been reported previously; as well as decreases in the insula and 
putamen, in contrast to regional CBF increases within these regions as previously 
reported (Schilling et al. 2014). Furthermore, this study showed that hippocampal 
and putamen CBF responses to nasal insulin are associated with self-reported dietary 
saturated fat intake and sugar intake in overweight subjects. 
 
This study showed that long label pCASL provides sufficient sensitivity to detect 
changes in cerebral perfusion following intranasal insulin administration. Changes in 
perfusion were most apparent in the overweight group of individuals examined in 
this study, in comparison to the lean group who did not display a statistically 
significant or detectable change in response to intranasal insulin, at the whole brain 
level, but did show a reduction in the amygdala from small volume correction 
analysis, albeit did not survive statistical threshold applied for multiple comparisons. 
In this overweight group intranasal insulin also reduced CBF within the left 
hippocampus, left posterior insula, left putamen and also the left para-hippocampal 
gyrus, observed in the voxel-wise whole brain analysis. Post hoc analysis through the 
use of small volume correction also showed insulin induced CBF reductions within 
the amygdala and anterior insula, albeit these did not survive more stringent 
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statistical threshold (Bonferroni multiple comparison correction for the number of 
ROIs).  
 
As detailed in previous chapters, cerebral perfusion is a surrogate marker for 
neuronal activity, due to the dynamic relationship between neuronal activity and 
neuronal vascular supply, known as neuronal coupling (Attwell and Iadecola 2002). 
Changes in CBF can be observed after administration of compounds that elicit direct 
effects on the vasculature. For example, caffeine an adenosine receptor (A2A) 
antagonist, elicits vaso-constrictive actions within the cerebral vasculature, reducing 
global CBF (Perthen et al. 2008; Liau, Perthen, and Liu 2008; Grichisch et al. 2012). 
There is compelling evidence to suggest that insulin has little direct vasoactive effect 
within the CNS (Grichisch et al. 2012) and therefore any perfusion differences seen 
from this reported experiment can be interpreted as very likely to be driven by 
changes in regional neuronal activity.   
 
From an anatomical perspective the changes in perfusion presented are relatable to 
both previous literature from investigations of the effects of centrally acting insulin 
and also insulin receptor distribution in the brain. The decreases in CBF presented 
here are in contrast to the limited number of studies reported that have examined 
the effects of intranasal insulin on cerebral perfusion. These have reported both 
insulin induced decreases and increases which will be used in reference to the 
findings reported here (Grichisch et al. 2012; Schilling et al. 2014; Akintola et al. 2017; 
Kullmann et al. 2013; Kullmann, Heni, Veit, Scheffler, Machann, Haring, et al. 2015; 
Kullmann et al. 2018).  
6.5.1 Hippocampus 
The hippocampus is an area with a high density of insulin receptors (Plum, Schubert, 
and Brüning 2005). Subjects with conditions such as Alzheimer’s disease (AD) and 
type 2 diabetes (T2DM) display central insulin resistance which is associated with 
cognitive and memory impairments, highlighting the role of central insulin in these 
cognitive functions and in hippocampal physiology (Ott et al. 2012; Benedict et al. 
2004; Craft et al. 2012; Craft et al. 1998). 
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Whole brain statistical parametric maps in the overweight group displayed a large 
cluster of insulin induced CBF decreases with a peak in the left hippocampus. 
Visualisation of these maps shows that the cluster extends beyond the boundaries of 
the left hippocampus and encompasses regions of the para-hippocampal gyrus. 
These temporal lobe features are particularly important in memory related activity 
and formation (Braak et al. 1996). This is the first study that has examined CBF 
changes within the hippocampal formation following intranasal insulin 
administration. At the neuron receptor level, understanding how insulin exerts its 
central effects is becoming better understood. Electrophysiology studies in cultivated 
rat hippocampal slices and CA1 neurons show that an acute increase in insulin 
concentration induces recruitment of GABAergic receptors (GABAAR) to these CA1 
synaptic formations (Wan et al. 1997). In addition, insulin’s effects on hippocampal 
neurons have previously shown an overall reduction in neuronal excitability through 
opening GABAA channels and thus establishes a state similar to tonic inhibition (Jin 
et al. 2011) within these cells. Furthermore, insulin action within the hippocampus 
has been shown to hyperpolarise neurons, reducing neuronal firing rate through 
interaction with potassium channels (O'Malley and Harvey 2007; O’Malley, Shanley, 
and Harvey 2003). An increase in GABA related activity and reduced firing rate within 
the hippocampus would arguably be sufficient to produce regional decreases in CBF 
as shown using pCASL in this report, and hence provide a mechanism for the results 
presented in the current study.  
 
To complement these cerebral effects, this study also identified a relationship 
between insulin induced CBF changes within the hippocampus; and both dietary 
saturated fat and sugar intake, separately, in the overweight group. Saturated fat and 
sugar intake measured using the ‘dietary fat and sugar subscale’ questionnaire 
correlated with insulin related decreases in CBF. The relationship was negatively 
correlated implying that lower levels of saturated fat and sugar intake are related to 
greater insulin responses (decreases in CBF) within this overweight group. The 
modern western diet, characterised by high levels of saturated fats and refined 
carbohydrates, contributes significantly to weight gain and metabolic disease 
prevalence (Kanoski et al. 2010; Hu, van Dam, and Liu 2001). Overconsumption of 
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saturated fat in comparison to poly-unsaturated fat results in higher visceral adipose 
tissue deposition (Rosqvist et al. 2014). A previous cerebral perfusion imaging study 
which examined intranasal insulin responses showed that after insulin application a 
stronger decrease in hypothalamic CBF was witnessed in those individuals with lower 
levels of visceral adipose tissue (Kullmann, Heni, Veit, Scheffler, Machann, Häring, et 
al. 2015). High dietary saturated fat intake is associated with impairments in 
hippocampal memory related functioning (Pasinetti and Eberstein 2008) and an 
increase in metabolic disorders and incidence of Alzheimer’s Disease (Pasinetti and 
Eberstein 2008). Some reports suggest that the modern western diet impacts blood 
brain barrier (BBB) integrity and that these memory related impairments are 
consequential to this process (Persidsky et al. 2006). From this collection of findings 
and the results reported in this study there is evidence to suggest an association 
between dietary fat intake and central insulin sensitivity within the hippocampus. 
Within this overweight cohort the sensitivity to insulin signalling in the hippocampus 
is decreased in those who consume higher amounts of saturated fat. Decreased 
hippocampal responsiveness to insulin signalling could be a marker of central insulin 
resistance that precedes peripheral insulin resistance, although more extensive 
research would need to be conducted to further explore this finding.  
 
Furthermore, from studies looking at high sugar based diets, an accumulation of 
evidence has shown that peripheral insulin sensitivity is reduced in response to diets 
high in refined sugar (Macdonald 2016). A cross sectional study showed that a high 
fat and high sugar ‘western diet’ exhibited poor hippocampal-dependent memory 
function coupled with a reduction in sensitivity to interoceptive signals in humans 
(Francis and Stevenson 2011). Mice fed on a high fat and high sugar ‘western diet’ 
displayed BBB leakages in the hippocampus and dorsal striatum which was 
associated with poor performance in a learning task compared to chow fed mice 
(Hargrave et al. 2016). Findings like this support the correlation between increased 
sugar intake and reduced insulin responsiveness seen within the hippocampus and 




6.5.2 Insula  
In the overweight group there was a large cluster of significant CBF change at the 
boundary between the left putamen and the left posterior insula cortex. A study of 
intranasal insulin in lean individuals showed a CBF increase in both the bilateral insula 
and the bilateral putamen (Schilling et al. 2014). The insula is known for its role as a 
hub for integration of visceral stimuli such as taste and odour, and commonly 
referred to as the primary gustatory cortex (Rolls 2006). Previous cerebral perfusion 
studies using 15O-labelled water positron emission tomography (PET) have shown a 
relationship between hunger state and regional CBF within the insula, hippocampus, 
para-hippocampal gyrus and putamen (Tataranni et al. 1999). More specifically they 
showed regional perfusion increases in these areas following long fasting periods 
(36hrs), much longer than those implemented in this study (Tataranni et al. 1999). 
The data being reported here show decreases in these areas in response to increased 
central insulin concentrations. Centrally increased insulin concentrations in the brain 
has been shown to have anorexigenic effects, reducing food intake acutely and 
subsequent weight gain over time in mice (Air et al. 2002). Intranasal administration 
of insulin in humans has been shown to reduce appetite acutely (Jauch-Chara et al. 
2012; Benedict et al. 2008). If cerebral blood flow in these limbic regions is closely 
linked to hunger states then the decreases seen from this ASL imaging study under 
an intranasal insulin challenge could be as a result of a mild change in appetite or 
hunger. A trend for an insulin associated change in hunger was seen from hunger 
questionnaires recorded prior to and after scanning in the overweight group. As 
described in chapter 4, subjective hunger ratings significantly increased during 
placebo sessions but there was no difference in hunger ratings pre and post scanning 
following intranasal insulin administration, suggestive of an appetite blunting 
response of insulin. To this end, Tataranni et al., also showed that induction of satiety 
following a calorie dense liquid meal was associated with a selective reduction in 
perfusion within the insula, hippocampus, para-hippocampal gyrus and putamen 
(Tataranni et al. 1999). Although the results from the pCASL study being reported 
here did not show a satiation effect of intranasal insulin there is evidence of a hunger 
blunting effect seen from the intranasal insulin visits (reported in chapter 5 (see 
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section 5.1.7). Furthermore, Tataranni et al showed that decreases in CBF during 
satiety correlated with both plasma levels of insulin and plasma free fatty acid levels, 
which were increased and decreased following liquid meal ingestion, respectively  
(Tataranni et al. 1999). This is suggestive of modulatory metabolic mechanisms on 
neuronal activity within the insula region. It can therefore be proposed that insulin 
acts as a satiety signal, and that following meal consumption pancreatic increases in 
insulin reach the CNS where they impart an inhibitory effect on further food 
consumption. Insulin may have a direct effect on the hypothalamus or an indirect 
effect through its interactions with other hubs within the limbic system and 
prefrontal cortex and thus intranasal administration of insulin would mimic this 
effect.  
 
It is also important to discuss the pharmacodynamics of insulin within the insula 
region, similar to the hippocampal mechanisms mentioned above. The insula boasts 
a high density of insulin receptors (Werther et al. 1987) and receives neuronal  input 
from both the hypothalamus and amygdala (Allen et al. 1991). Electrophysiology 
studies have shown that acute insulin application to rat insula pyramidal neurons 
leads to an increase in repetitive spike firing rate (Takei et al. 2010) in comparison to 
control neurons. This increase was not however an increase in spontaneous firing but 
rather insulin had a neuromodulatory effect on neuronal firing. The authors propose 
that insulin increases neuronal excitability within the insula via sodium channel 
sensitivity changes and postulate that during times of increased insulin CSF 
concentrations, such as after eating, this increased firing rate is in response to 
increased interoception (Takei et al. 2010). Intranasal insulin related increases in the 
insula have been previously reported using a continuous ASL sequence (Schilling et 
al. 2014) in lean individuals. That study references Takei et al., in support of the 
regional perfusion increase seen in the insula. Although the continuous ASL study 
mentioned and the present study used a similar imaging technique and analysis 
approach, there are several differences between experimental protocols which may 
explain the contrasting results. In the current study, a dose of 160IU was used in 
comparison to the 40IU used by Schilling et al. A dose dependent intranasal insulin 
effect has been identified previously from a multi-modal MR imaging investigation in 
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humans (Kullmann et al. 2018). CBF decreases within the hypothalamus showed a 
strong dose dependent effect on CBF with decreases being most prominent following 
160IU administration vs placebo (Kullmann et al. 2018). Interestingly, following 40IU 
administration no significant changes in any of the imaging related measures (CBF or 
fractional amplitude of low frequency fluctuation) were  identified in comparison to 
placebo. However, highly significant and opposing changes were seen between 40IU 
and 160IU, suggestive of intranasal insulin not only having a dose dependent effect 
but a differential dose dependent effect which may explain the opposing effects seen 
in this current study in comparison to Schilling et al., (Schilling et al. 2014). These 
differential effects were most prominent in the caudate, a region most commonly 
involved in dopamine signalling and closely connected to the putamen, often 
referenced together as the dorsal striatum (Kullmann et al. 2018).  
 
6.5.3 Putamen 
Putamen perfusion decreases were seen both at the whole brain level and also when 
assessed with small volume correction in the overweight group exclusively. Insulin 
plays a key role in reward behaviour and particularly food related reward (Figlewicz 
and Benoit 2009). As mentioned previously, the putamen has been shown to exhibit 
increases in CBF following nasal administration of insulin in humans (Schilling et al. 
2014). As mentioned earlier, the results reported here differ in the direction of the 
perfusion change and could be as a result of the higher dose used in this study (160 
IU) (Kullmann et al. 2018). The putamen, similar to the hippocampus, revealed a 
similar relationship between insulin induced changes in CBF and saturated fat and 
sugar intake. The association was negatively correlated, such that putamen 
decreases in CBF in response to insulin were higher in those who consumed less 
saturated fat and less sugar composed foods. In the absence of a rewarding stimulus, 
it is hard to make assumptions about how this change in putamen activity would be 
associated with reward. However, pre-clinical rodent work has shown reduced BBB 
integrity, more susceptible to leakage, at the level of the striatum in response to a 
high fat and sugar western diet (Hargrave et al. 2016). Furthermore, given that a high 
fat diet induces central insulin resistance (Arnold et al. 2014) it is perhaps intuitive 
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that this correlation between fat intake and IN-INS response exists. One can possibly 
suggest that the putamen and likewise the hippocampus are particularly susceptible 
to this high fat induction of central insulin resistance.  
 
6.5.4 Amygdala 
From whole brain paired t-tests, both lean and overweight groups showed a trend 
towards insulin related decreases in amygdala CBF from small volume correction. In 
both cases the difference was not sufficient to survive multiple comparison 
correction, but with a larger sample size this insulin associated effect on CBF within 
the amygdala may become apparent. The amygdala is an insulin receptor dense 
region and is a major component of the limbic system, commonly involved in fear 
and anxiety processing (Ohman 2005; Ressler 2010). However, there are several lines 
of research that support the notion for amygdala involvement with food intake and 
appetite control (Figlewicz, MacDonald Naleid, and Sipols 2007). Administration of 
insulin via injection to the amygdala in rats shows an acute decrease in food intake 
couple with a reduction in appetite (Boghossian et al. 2009). Insulin receptors in the 
central nucleus of the amygdala (CeA) are abundantly expressed and insulin binding 
within the CeA selectively increases both the amplitude and frequency of 
spontaneous inhibitory postsynaptic currents (sIPSCs) (Korol et al. 2018).  It could be 
through this insulin-mediated mechanism in which the decrease in CBF seen in this 
study was realised. The amygdala is known to be responsive to visual food cues. 
Several studies have shown that in response to satiation the amygdala shows a 
decrease in responsiveness to food cue paradigms (Morris and Dolan 2001; Gottfried, 
O'Doherty, and Dolan 2003). Given that these decreases were seen during sensory 
manipulation, they might not be directly relatable to this study but highlight an 




6.5.5 Lean vs overweight 
From the results reported in this study it is evident that there is a response within 
the overweight group to IN-INS which is not replicated within the lean/normal weight 
group. There was very little effect on CBF following intranasal insulin administration 
in the lean group, and to that extent there was no significant results to report from 
any of the whole brain analyses performed in the lean group. The failure to see an 
insulin induced response could be as result of the variability in baseline insulin levels 
witnessed in this weight group between sessions. Given this, pre-dose HOMA-IR 
measurements helped to account for some of this variability and highlighted a trend 
towards an insulin related reduction in CBF within the amygdala from small volume 
correction analysis.  
 
Pharmacological decreases in CBF during rest are not entirely intuitive in comparison 
to increases in CBF which can be somewhat explained by an increase in neuronal 
activity, as a result of the neurovascular coupling phenomena, in the absence of 
direct effects on cerebral vasculature. Given the CBF differences in this study were 
selectively observed in the overweight group, it could be argued that this group 
showed an aberrant or increased CBF in the left hippocampus, insula, putamen and 
para-hippocampal gyrus. And that in response to insulin this aberrant activity was 
reduced. Given this study was placebo controlled it offered an opportunity to 
examine some differences between these two groups under both insulin and placebo 
conditions. To this extent the ROI extracted values were utilised to evaluate inter-
group differences. There were no differences in global grey matter perfusion 
between groups from either placebo or insulin sessions. At a regional level, resting 
perfusion data showed CBF differences within both the bilateral posterior and 
anterior insula within the placebo condition. In both these insula regions, rCBF was 
higher in the overweight group in comparison to the lean group. Furthermore, 
following insulin administration the group differences in CBF within the anterior 
insula remained but were no longer observable in the posterior insula. Food cue tasks 
have highlighted the insula as a region involved in processing of high calorie visual 
food cues, and have also illustrated increases in insula BOLD activity in obese 
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individuals compared to normal weight (Rothemund et al. 2007). Furthermore, pre-
meal resting state fMRI-BOLD data also supports an overactive insula in obese 
individuals vs normal weight individuals (Hogenkamp et al. 2016). The insula, as well 
as a region involved in gustation is also heavily involved in interoception. Perhaps not 
surprising is the finding that interoception sensitivity is reduced in overweight and 
obese individuals compared to normal weight individuals (Herbert and Pollatos 
2014). The lack of an observable group difference within the posterior insula 
following intranasal insulin administration suggest that insulin may act to inhibit the 
overactivity of the insula in the overweight group. More work will need to be 
conducted to make more informative inferences from these results.  
 
The results gathered from this interrogation of intranasal insulin’s effects on cerebral 
perfusion has shown that insulin is centrally active in this group of overweight 
individuals eliciting regional decreases in perfusion. A lack of observable effects 
within the lean group was surprising given the profound effects seen within the 
overweight group. We cannot exclude that the lack of effect is possibly due to the 
variability seen within the baseline blood concentration measures and inclusion of 
these into the statistical model did help to reveal some insulin related effects but the 
alternative explanation, that in lean subjects these regions are already optimally 
active/inactive, remains attractive. These findings pose the question as to whether 
the regional perfusion observed in the lean group is fully (in)activated during fasting 
conditions, so the insulin challenge makes no difference, whereas in the overweight 
group the pathway is active and capable of being deactivated by intranasal insulin, 
and that this effect is impaired by poor dietary indiscretion.  
 
This is the first time that insulin related changes in CBF have been reported in the 
hippocampus. The long label sequence implemented in this study was sensitive to 
demonstrate insulin induced changes within key regions of the brain involved in 





Chapter 7 Taste task paradigm  
 
This chapter will present the results from the taste paradigm that was employed 
within the SNIFAR protocol. The taste paradigm is a complex functional task that was 
conducted following the food pictures functional task. Participants were given clear 
instructions during the screening visit and also again on each scanning morning 
regarding the paradigm. In an effort to aid the reader the results for this paradigm 
have been divided into four separate sub-chapters. This first sub-chapter will provide 
the reader with detailed functional data acquisition parameters and overall paradigm 
details. The following sub-chapters will reference the specific analytical methods 
used firstly to, assess these functional data in an effort to best describe the main 
whole brain effects of the paradigm within each group and treatment, respectively; 
secondly, to examine whole brain treatment effects and group effects for each 
component of the paradigm and finally, to assess treatment effects through a 
thorough interrogation of the data with region of interest analysis and accounting for 
subjective changes in taste over time. I hypothesise that IN-INS will reduce the 
rewarding effects of each of the sweet taste stimuli and that these reductions will be 
greatest in lean individuals in comparison to the overweight group.  Furthermore, in 
response to viewing the cue, I hypothesise that, the overweight will display a hyper-
responsivity to these cues in comparison to the lean group, which will be reduced 











7.1 Introduction  
Intranasal insulin administration in humans has shown appetite reducing effects. In 
imaging studies using acute administration, significant reductions in food cue (food 
image viewing) responsiveness have also been observed  (Guthoff et al. 2010). It is 
well established that there are three systems that interact to modulate energy 
intake: the homeostatic, hedonic and cognitive pathways (Volkow, Wang, Fowler, et 
al. 2008; Volkow, Wang, and Baler 2011; Berridge 2009; Berridge and Kringelbach 
2008; Higgs 2016; Higgs and Spetter 2018; Higgs et al. 2017). Dysregulation of these 
systems is thought to be key to the development of obesity, insulin resistance and 
type 2 diabetes and therefore understanding this dysregulation is of great 
importance. 
 
The homeostatic system controls energy intake and energy balance in response to 
metabolic demands and energy store levels in the body (see section 1.7.1). This 
pathway is regulated largely by peripheral hormones such as leptin, ghrelin, insulin 
and intestinal peptide YY 3-36 (PYY) that relay metabolic information from the 
periphery to the hypothalamus which processes and acts on these signals (Lutter and 
Nestler 2009; Karra, Chandarana, and Batterham 2009). Overproduction or 
underproduction of appetite inducing and appetite reducing hormones, respectively, 
has been associated with the weight gain seen in obesity (Goldstone 2006).  
 
Additionally, there is a large body of empirical evidence suggesting that aberrant 
hedonic responses (supported by its corresponding functional networks) also 
contribute greatly to the dysregulation of energy intake associated with obesity 
(Volkow, Wang, and Baler 2011). ‘Hedonic feeding’, also known as ‘non-homeostatic 
feeding’, is characterised by the consumption of palatable food for its potent 
rewarding effects, as opposed to satisfying the metabolic demands of the body (see 
section 1.7.2). The hedonic system incorporates regions of the meso-limbic system 
(amygdala, hippocampus, nucleus accumbens (NAcc)) involved in learning and 
reward processing, as well as cortical regions (anterior cingulate cortex, orbital 
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frontal cortex, and insula) involved in motivation, decision making and gustatory 
processing, respectively (Volkow, Wang, and Baler 2011).  
 
Finally, the cognitive systems involved in appetite control and top down modulation 
of inhibitory and valuation of food choices is an important and often neglected aspect 
in this discipline (Higgs 2016) (see section 1.7.3). Particularly, as a large amount of 
evidence regarding food consumption and the mechanisms that govern this action 
have been observed in pre-clinical animal models.  
 
Insulin has been shown to be centrally active and a large amount of evidence shows 
that insulin has effects on both ‘homeostatic feeding’ and ‘hedonic feeding’ 
(Figlewicz and Benoit 2009), with much of this support coming from animal model 
literature. This investigation  therefore seeks to examine the effects of increased 
central insulin concentrations on hedonic and cognitive brain responsivity to 
food/liquid stimuli administration in a cohort of normal weight and overweight 
individuals. This experiment will also probe the anticipatory effects, described as the 
time immediately before receiving a primary food stimulus, as well as the 
consummatory response, defined as the response to actual receipt of a primary food 
stimulus. Anticipation responses to receiving food reward stimuli have been shown 
to be increased in obese compared to lean individuals (hyper-responsivity) (Burger 
and Stice 2011b). In contrast, BOLD effects seen from the consummation response 
to food stimuli are decreased in obese compared to lean (hypo-responsivity) (Stice 
et al. 2008). Given these observations, some have hypothesised that these 
differential effects seen in lean and obese individuals are key features of obesity and 
may contribute to the development of this metabolic disease.   
 
This experiment looks at two discrete responses, anticipation and consummation, for 
two sweet solutions, one of which contains calories (in the form of sucrose) and the 
other a non-nutritive artificial sweetener, (‘stevia’). The use of non-nutritive 
sweeteners as replacements for calorie dense sweeteners such as sucrose has 
increased over the last decade (Anton et al. 2010). Many suggest non-nutritive 
sweeteners can provide a sweet palatable taste whilst negating the sugar load and 
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postprandial increase in insulin associated with many energy dense sweeteners. 
Some suggest that non-nutritive sweeteners may be useful for promotion of weight 
loss or weight gain prevention (Mattes and Popkin 2009), although this remains 
largely debated, with limited long term empirical evidence to support the former. 
Stevia (previously described in section 3.4.7.2), a relatively recent addition to the 
non-nutritive sweetener market, is thought to have beneficial effects on insulin 
sensitivity (Chang et al. 2005) and postprandial glucose and insulin levels in 
comparison to other popular sweeteners and sucrose (Anton et al. 2010). The 
hedonic effects of stevia however, have yet to be reported and this study sets out to 




















7.2 Methods  
7.2.1 Participants 
Thirty one participants took part in this study. As mentioned in chapter 4, three of 
these were excluded due to evidence of non-compliance with the fasting protocol. 
Furthermore, two of the normal weight participants (lean, as stratified by BMI 
(kg/m2)), were excluded from this analysis due to technical problems encountered 
with the scanner and taste dispenser apparatus. As a result, the sample size for this 
analysis has been reduced to 10 normal weight (BMI = 22.01 ± 1.81 kg/m2, mean 
± SD) and 15 overweight individuals (BMI = 27.76 ± 1.92 kg/m2).  
 
7.2.2 Taste dispenser setup  
The researcher had to enter the scanner room for the setup of this paradigm. The 
participant was informed to remain as still as possible whilst the researcher 
positioned the MR compatible taste dispenser for the task. The taste outlet head was 
positioned into the right hand-side of the participant’s mouth between the teeth and 
cheeks.  
 
The taste paradigm has been described in detail in chapter 3 (see section 3.4.7). The 
participants were reminded of the details of the paradigm prior to the paradigm 
commencing by the researcher. The details of the paradigm and the three different 






















Figure 7.2.1 The fractal cue images that 
were used for the taste paradigm. 
Figure 7.2.2 A diagram to show the three different trial types of the taste paradigm. Black boxes 
represent the events that are modelled as events of interest (cue, delivery and withheld delivery, 
respectively). Grey boxes represent events that are modelled in the first level model but are not of 
interest or taken through to the second level analysis (swallow and VAS scoring periods). A paired 
trial is the most common trial type and involves the delivery of a 0.5ml bolus/stimulus following 
visual cue presentation. An unpaired trial does not deliver the 0.5ml bolus as expected, instead 
nothing is delivered. A VAS trial is when the delivery of the bolus is followed by two VAS questions, 
this happens for each taste at the very beginning of the first run and at the very end of the second 
run. 
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7.2.3 Image acquisition  
Whole brain functional images were acquired using a single-shot 2D T2* weighted 
gradient echo echo-planar imaging (EPI) sequence using parallel imaging (Array coil 
Spatial Sensitivity Encoding, ASSET). Slices were acquired in a sequential top down 
direction in the near- axial plane parallel to the anterior-posterior commissure (AC-
PC) line (approximately 30°) with the following parameters: TR = 2000 ms, TE = 30 
ms, flip angle = 75°, matrix size = 64 x 64, FOV = 211 x 211, slice thickness = 3 mm, 
slice gap = 0.3 mm, no. of slices = 41, in-plane voxel size = 3.3 x 3.3 mm2. Four dummy 
acquisitions were acquired to achieve steady state magnetisation which were 
discarded, prior to analysis. The total number of imaging volumes was 324 acquired 
in 10:56 mins for each run. This experiment was conducted, as mentioned earlier, 
using two consecutive runs. 
 
7.2.4 Image processing  
Image processing was performed using a combination of neuroimaging software 
packages. Firstly, outliers were removed from the time series using 3dDespike 
(Analysis of Functional Neuroimages (AFNI) (Cox 1996)). To correct for subject motion 
images were realigned to a base volume using 3dVolreg (AFNI) and all volumes were 
subsequently corrected for slice timing differences using 3dTshift (AFNI). The base 
volume was co-registered to the subject specific T1 anatomical image using epi_reg 
(FSL, FMRIB, version 3.20, University of Oxford, UK, http://www.fmrib.ox.ac.uk/fsl). 
Normalisation warping parameters for the anatomical to standard MNI template 
were then applied using Advanced Normalisation Tools (ANTs)(Avants et al. 2011; 
Avants et al. 2014). Finally, spatial filtering of the images was applied using a full 
width half maximum (FWHM) gaussian kernel of 8 x 8 x 8 mm using the Statistical 
Parametric Mapping smoothing function (SPM-12, Wellcome Trust Centre for 
Neuroimaging, University College London, UK, http://www.fil.ion.ucl.ac.uk/spm). 
Furthermore, a high-pass temporal filter (filter width of 128s) was also applied as part 
of the first level model design.  
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7.2.5 Image analysis 
Several different analyses were performed on this dataset. For ease of interpretation 
and to allow the reader to follow the results found from this task more clearly, this 
chapter has been broken into the following three sections. 
 
A. Interrogating the functional effects of the taste paradigm 
Within this section the reader will be guided through the BOLD response profiles to 
this complex paradigm for each taste and each event (cue and receipt of taste), 
respectively. This section will explore these responses through whole brain voxel 
wise analysis and also small-volume correction (SVC) from a priori selected regions 
of interest (ROIs). Within this section it is also appropriate to look at any group 
related differences using two sample t-tests at the whole brain level and also to 
further interrogate these through SVC analysis.   
 
B. Formal comparisons between intranasal insulin and intranasal placebo 
Within this section the main effects of intranasal insulin on brain modulation within 
this paradigm will be assessed. The analysis was conducted using both whole brain 
analysis and ROI analysis (not small volume correction) using extracted beta 
estimates. In addition to drug related effects, ROI analysis permitted the exploration 
of group related (BMI) differences in BOLD response for each taste and condition.  
 
C. Time dependent effects of intranasal insulin: separate analysis of each 
functional series 
Functional data for this paradigm was acquired over two runs. The temporal 
dynamics associated with this paradigm attributed through learning conditioned 
stimuli and due to sensitisation effects over time, were acknowledged and therefore 
analysis was conducted to evaluate any differences between runs. This analysis was 




Each section will have a short introduction followed by the specific data analysis and 
statistical techniques implemented. This multiple analysis strategy was conducted in 
an effort to fully interrogate the vast amount of functional data that can be examined 
using this paradigm. 
 
 
















Within this subchapter the analysis methods and results used to explore the main 
task effects within each treatment will be described. Furthermore, with this 
methodology, the differences between BMI stratified groups within treatment were 
also interrogated from whole brain analysis.  
 
In addition, the VAS rating analysis and results will be reported.  
7.3.1 Analysis of VAS ratings 
VAS ratings were collected at the beginning of run 1 and at the end of run 2.  
Average run likeness VAS ratings for each taste were entered into a repeated 
measures ANOVA, with two factors drug (insulin vs saline) and substance (water, 
sucrose, stevia) for the whole group (n=25), to assess differences in ratings between 
substances and any drug related effects. Similarly, to assess the effect of drug or 
substance on sweetness, average run sweetness VAS ratings for each taste were 
entered a repeated measures ANOVA, with two factors drug and substance for the 
whole group (n=25). For each ANOVA model there were three taste stimuli, so 
statistically significant main effects and interaction effects were inspected using a 
Tukey post hoc test to look for significant comparisons. 
 
Two further repeated measures ANOVA models were created that included just the 
two substances, sucrose and stevia, to examine drug and substance effects, for 
likeness and sweetness, which may have been missed from including water in the 
repeated measures ANOVA model described above. Following a statistically 
significant interaction effect a post-hoc Tukey test was implemented and following a 
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main effect of either drug or substance two paired t-tests, within substance and 
within drug, were conducted, as respective planned comparison tests. All ANOVA 
main effects and interaction effects were assessed at p < 0.05 significance. Tukey 
tests adjust for multiple comparisons and so were assessed to p < 0.05. Planned 
comparisons were assessed to p < 0.025 for multiple planned comparisons (0.05/2).  
7.3.2 1st level model designs  
For statistical analysis of whole brain data, SPM-12 software was used. A random 
effects analysis was implemented through creation of 1st level contrast images from 
a standard general linear model analysis. These contrast images were taken through 
to the 2nd level to interrogate group level effects.  
For this paradigm each trial was modelled as having three conditions of interest: 
• Cue presentation 
• Stimulus (taste) delivery  
• Stimulus delivery withheld 
The paradigm was modelled as an event-related task with condition onsets and 
durations defined from the task. The duration of the cue presentation was set to 2s 
and both the stimulus delivery and withheld conditions were set to 3s, respectively. 
Each condition was modelled separately for each of the three taste stimuli, water, 
sucrose and stevia (see Figure 7.3.1). In addition, the swallowing periods were 
implicitly modelled with onsets defined when the swallow cue was presented, 2s 
duration. The swallow cue was modelled as a single condition as opposed to a taste 
specific swallow condition. Each condition was convolved with SPM’s canonical 
haemodynamic response function (Worsley and Friston 1995). Furthermore, the six 
‘scan-to-scan’ affine head motion parameters produced during motion correction 
were included as nuisance regressors in the model to account for subject head 
motion (see Figure 7.3.1.A).  
 
This paradigm was acquired through two functional runs, with identical scanning 




Figure 7.3.1 Diagram showing the first level model design matrix setup and an 
example output from this general linear model design. A) displays the three events 
of interest for each taste (water, sucrose and stevia) that were entered into the 
model along with the swallow, VAS and the six motion regressors included in this 
model. B) Both runs are combined into the design matrix. An example linear 
contrast vector applied to both runs is shown at the top of the design matrix. C) 
From the general linear 1st level model a single contrast image for each of the 
contrasts is created. An example of a single contrast image is displayed for the 
contrast vector applied to this model. 
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Linear contrasts were generated to examine the differences in BOLD response 
between each taste for the cue presentation. These linear contrasts were replicated 
for run 1 and run 2 so that a single contrast statistical parametric map was created 
for each contrast (Figure 7.3.1.C).  
7.3.2.1 Cue presentation contrasts:  
Contrast images were created by comparing the BOLD response to presentation of 
the cue assigned to one taste against the cue assigned to another. To be clear, the 
taste cues refer to the fractal images that are presented prior to the taste being 
delivered, or withheld, depending on trial type. In all cases the cue is 100% predictive 
of the taste that will be delivered, but is not predictive of whether the taste will be 
delivered or withheld. All cue presentation contrasts are shown in Figure 7.3.2.  
 
 





7.3.2.2 Stimulus Receipt contrasts: 
Statistical contrast images were generated for the BOLD response to stimulus receipt 
for each taste, respectively. These images were created by contrasting the delivery 
event against the delivery withheld event. Contrasts were created independently for 
each taste and thus three taste dependent contrasts were created from 1st level 
statistical modelling: 
 
• Water delivery > Water delivery withheld  
• Sucrose delivery > Sucrose delivery withheld 
• Stevia delivery > Stevia delivery withheld 
 
7.3.3 Group level inferences 
Random effects second level models were created to examine: 
• Task related effects within each group and treatment; using one sample t-
tests.  
AND 
• Group effects within treatment; using two sample t-tests.  
 
Contrast estimate images for each contrast of interest created at the 1st level were 
entered into these group level models (lean (n=10) and OW (n=15). 
 
7.3.4 Whole brain analysis 
For both the one sample and two sample t-test models, whole brain analysis was 
carried out using a cluster defining threshold of p < 0.001 uncorrected. Significant 
clusters were deemed significant if p < 0.05 following a family wise error (FWE) 
correction for multiple voxel comparisons, using what SPM defines as the cluster 
extent threshold.   
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7.3.5 Small Volume Correction (SVC) 
SVC was also employed for this analysis using a priori regions of interest (ROIs).  For 
the cue event, four ROIs were used. These were the anterior cingulate cortex (ACC), 
the ventro-medial prefrontal cortex (vmPFC), nucleus accumbens (NAcc), and medial 
orbitofrontal cortex (mOFC). These regions were selected according to previous work 
which had examined the response to cues associated with conditioned primary 
rewards (O'Doherty et al. 2002) and have been also linked with insulin-related 
reward signals (Tiedemann et al. 2017). Bilateral ACC and mOFC masks were designed 
in SPM-12 using the Functional MRI tool of the Wake Forest University School of 
Medicine (http://www.ansir.wfubmc.edu) known as ‘WFU pick atlas’, implemented 
with automated anatomical labelling. The bilateral NAcc was defined from the 
Harvard probabilistic brain atlas in FSL (Desikan et al. 2006). The vmPFC was defined 
from Manning et al., (Manning et al. 2015) as two 10mm radius spheres centred at 
MNI coordinates, x = 6, y = 30, z= -9 and x = -6, y = 24, z =  -21. A multiple comparison 
correction was used to assess significance from SVC results. For the four 
comparisons/ROIs tested for BOLD responses during the cue presentation, a p value 
of 0.0125 was used (0.05/4 = 0.0125).  
 
For the delivery phase, four bilateral anatomical regions of interest were used: the 
caudate + putamen (CPu), NAcc, anterior insula and the amygdala. Both the NAcc and 
CPu are part of the striatum and are involved in reward processing through 
dopaminergic neurotransmission (Schultz 2001). The amygdala is a region of the 
limbic system also involved in response to taste and heavily involved in the gustatory 
response (Breslin 2013). Finally, the anterior insula is heavily involved in taste 
processing, commonly referred as the gustatory cortex (Frank, Kullmann, and Veit 
2013). The CPu structures and amygdala were defined using the WFU pick atlas tool. 
The CPu was created by combining the caudate head and body mask with the 
putamen mask. The anterior insula mask was defined using publicly available 
cytoarchitecture segmentations (Kurth, Eickhoff, et al. 2010). For four 
comparisons/ROIs assessed for BOLD responses during the stimulus delivery, a p 
value of 0.0125 was used (0.05/4 = 0.0125) to correct for multiple comparisons. 
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7.3.6 Correlation analysis with BMI 
The effect of BMI on BOLD response for both cue and delivery conditions was 
assessed using a linear regression correlational analysis. Each ROI, defined above, 
was used as a mask to extract mean BOLD contrast estimates (from 1st level contrast 
maps) for each treatment condition (3dmaskave function, AFNI) for every 
participant. These mean values were regressed against BMI as part of a 
supplementary exploratory analysis.  
 
Contrast estimates extracted from the ACC, vmPFC, mOFC and NAcc ROIs for the 
sucrose > water and stevia > water contrasts were correlated against BMI. 
 
For the delivery > delivery withheld contrasts, only the two sweet delivery tastes 
were interrogated. Extracted values from the insula, amygdala, CPu and  NAcc, under 
insulin and placebo conditions were regressed against BMI and correlations were 
estimated. 
 
Correlations were estimated using Pearson’s correlation coefficient. Correlation 
coefficients (r) greater than 0.4 or less than -0.4, with an associated p value < 0.05 
were reported. Correlation coefficient thresholds were set to only look for ‘moderate 
to very strong’ correlations (i.e. 0.4 to 1.0) based on Evans’ guide to correlational 
analysis (Evans 1995). However, within this exploratory analysis a total of 32 
correlations were tested. Therefore, an adjusted statistical threshold of p < 0.00156 
(0.05/32) was used to correct for multiple comparison testing and therefore 
correlations that fulfilled both the coefficient threshold and the p value significance 
will be reported as significant. 
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7.4 SECTION A. Results  
7.4.1 VAS ratings 
7.4.1.1 Likeness ratings 
VAS ratings used to assess how much the participants liked each flavour revealed 
highly significant main effect of substance (F2,24 = 45.85, p < 0.001, ANOVA). Post hoc 
Tukey test showed that following both placebo and insulin administration there was 
a significant difference between sucrose and water as well as stevia and water 
(p<0.001, adjusted for multiple comparisons Tukey test) for all within drug sweet 
taste vs water comparisons (see Figure 7.4.1). In all cases water was the least 
palatable substance. There were no differences between sucrose and stevia from this 
ANOVA analysis or drug related effects.  
 
Furthermore, excluding the water scores from the ANOVA model did not reveal any 
significant differences between sucrose and stevia likeness or any treatment related 
effects on palatability.  
 
 
Figure 7.4.1 VAS likeness ratings averaged across runs for each taste and condition. A) VAS ratings 
recorded during the placebo session show that both sucrose and stevia solutions were ‘liked’ more in 
comparison to water. B) similarly, sucrose and stevia solution were liked more than water under 
insulin conditions. Mean ± SD  *** p < 0.001, Tukey test for multiple comparisons, n =25 (whole group).  
 230 
7.4.1.2 Sweetness ratings 
With water included in the ANOVA model there was a significant substance effect 
(F2,24 = 176.01, p < 0.001, ANOVA). Post-hoc analysis showed that across drug 
conditions both sucrose and stevia were rated sweeter than water (p<0.001, 
adjusted for multiple comparisons, Tukey test) for all within drug sweet taste vs 
water comparisons (see Figure 7.4.2).  
 
Exclusion of water related sweetness scores from the ANOVA model provided a 
significant main effect of substance (F1,24 = 4.47, p = 0.037, ANOVA). Within drug 
paired t-tests showed that sucrose (77.46 ± 10.42) was rated as sweeter than stevia 









Figure 7.4.2 VAS sweetness ratings averaged across runs for each taste and condition. A) VAS 
ratings recorded during the placebo session show that both sucrose and stevia solutions were 
perceived to be sweeter in comparison to water. B) similarly, sucrose and stevia solution were 
reported as sweeter vs water under insulin conditions. Mean ± SD *** p < 0.001, Tukey test for 





7.4.2 Cue presentation contrasts 
Both ‘sucrose < water’ and ‘stevia < water’ contrasts revealed no significant clusters 
following both one sample and two sample t-tests.  
7.4.2.1 Sucrose cue > water cue 
Within the placebo session, both lean and OW groups showed activation within the 
visual cortex in response to the sucrose cue compared to the water (control) cue, see 
Figure 7.4.4 and Table 7.4.1. 
 
There were no further significant regions after applying small volume correction with 
each bilateral ROI. 
 
Within the insulin session, both groups showed areas of BOLD response within the 
visual cortex from whole brain analysis (see Figure 7.4.4 and Table 7.4.2). After 
applying small volume correction (SVC) to the lean group one sample t-test statistic 
maps there were significant areas of activation within the ACC, NAcc and mOFC. Only 
the NAcc and mOFC survived correction for multiple ROI comparisons (p = 
0.0125)(results are shown in Table 7.4.3).  
Figure 7.4.3 VAS sweetness ratings show an increase in sweetness for sucrose vs stevia under 
insulin conditions only. Mean ± SD , * p < 0.025 (multiple test correction), paired t-test,  n=25 
(whole group). 
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Furthermore, contrasting lean vs OW revealed no significant differences at the whole 
brain level or following small volume correction within the placebo session. Likewise 
the insulin session did not provide any whole brain differences between lean and 
OW groups. However, from SVC performed for the ‘lean > OW’ contrast there was a 
significant difference within the ACC, which did not survive multiple comparison 















Figure 7.4.4 Statistical T-maps overlaid onto structural MNI images of one sample t-test statistical 
clusters for the sucrose > water cue contrast, following placebo administration for both lean (n=10) 
and OW (n=15) individuals. Both groups show statistically significant areas of activation within the 





Table 7.4.1 Whole brain statistics from one sample t-tests performed in lean (n=10) and OW 
groups (n=15) following intranasal placebo administration. All p values presented have been 





Table 7.4.2 Whole brain statistics from one sample t-tests performed in lean (n=10) 
and OW groups (n=15) following intranasal insulin administration. All p values 
presented have been corrected for multiple voxel comparisons.  
Figure 7.4.5 Statistical T-maps overlaid onto structural MNI images of one sample t-test statistical 
clusters following insulin administration for both lean (n=10) and OW (n=15) individuals. Both 
groups show statistically significant areas of activation within the primary visual cortex. OW maps 




7.4.2.2 Stevia cue > water cue 
 
For placebo, the stevia cue > water cue contrast provided significant increases in the 
BOLD response compared to water within the visual cortex and Crus I region of the 
cerebellum both within lean and OW groups (see Figure 7.4.6 and Table 7.4.4). 
Furthermore, the lean group also showed areas of significant activation within the 
right anterior pre-frontal cortex/lateral OFC.  
 
SVC revealed significant effects which survived multiple comparison correction 
within all tested ROIs for the lean group. In the OW group the ACC and NAcc survived 
multiple correction significance but the mOFC did not (Table 7.4.5)  
 
Under placebo conditions, there were no significant group differences from whole 






Table 7.4.3 Statistical results from small volume correction (SVC) analysis 
performed on one sample t-test parametric maps in the lean group. p values in 
bold indicate regions that survived correction for multiple ROI comparison. NA 
















Figure 7.4.6 Statistical T-maps overlaid onto structural MNI images of one sample t-test statistical 
clusters following placebo administration for both lean (n=10) and OW (n=15) individuals for the stevia 
cue > water cue contrast. Both groups show regional BOLD related activity within the occipital cortex. 
The lean group further displayed cluster activation towards the right lateral OFC and left middle 
temporal gyrus. The OW showed increased BOLD activity within the right middle temporal gyrus in 
addition to the occipital regions.     
Table 7.4.4 Whole brain statistics from one sample t-tests performed in lean (n=10) and OW groups 
(n=15) following intranasal placebo administration for the stevia cue > water cue. All p values 























Under insulin conditions, whole brain analysis revealed significant activation in 
response to the stevia cue vs water cue presentation within the visual cortex, 
anterior cingulate cortex and precuneus regions in the lean group (see Figure 7.4.7 
and Table 7.4.6). In the OW group, BOLD responses seen from this cue presentation 
contrast were found within the bilateral visual cortex.  
 
For both groups, the ACC showed significant recruitment for the stevia cue but only 
survived small volume correction in the lean group (p =0.008, t = 4.20) and not in the 
OW group (p = 0.020, t = 4.35) following insulin administration. None of the 
remaining ROIs tested with SVC showed any statistical effects (data not tabulated). 
Furthermore, there were no significant group differences seen in the insulin 
condition for this contrast.   
Table 7.4.5 Statistical results from SVC analysis performed on one 
sample t-test parametric maps in the lean and OW group in response 
to presentation of the stevia cue > water cue. p values in bold indicate 
regions that survived correction for multiple ROI comparison.  
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Table 7.4.6 Whole brain statistics from one sample t-tests performed in lean (n=10) 
and OW groups (n=15) following intranasal insulin administration for the stevia cue > 
water cue. All p values presented have been corrected for multiple voxel comparisons 
using a family wise error Bonferroni correction. 
Figure 7.4.7 Statistical T-maps overlaid onto structural MNI images of one sample t-test 
statistical clusters following insulin administration for both lean (n=10) and OW (n=15) 
individuals for the stevia cue > water cue contrast. Both groups show regional BOLD related 
activity within the occipital cortex. The lean group further displayed cluster activation within 
the ACC. 
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7.4.2.3 Sucrose vs stevia cue 
There were no significant changes in BOLD response when contrasting the cue for 
sucrose vs stevia under both placebo and insulin conditions for either sucrose > 
stevia or stevia < sucrose. Furthermore, there were no group effects for either 
placebo or insulin contrasts assessed at the whole brain level or through SVC.  
7.4.3 Stimulus delivery contrasts 
7.4.3.1 Water delivery vs water withheld  
Under placebo conditions delivery of water stimulus contrasted with when the water 
bolus was withheld showed increases in the BOLD response within the 
somatosensory cortex, supplementary motor area and the cerebellum in the lean 
group (see Figure 7.4.8 and Table 7.4.7). In the OW group significant clusters were 
produced within somatosensory cortex, frontal operculum as well as in the VI region 
of the cerebellum (see Figure 7.4.9 and Table 7.4.7) 
Figure 7.4.8 Whole brain statistical t-map overlaid onto a structural MNI image for the water 
delivery > water withheld contrast in the lean group (n=10). A) Sagittal sections display 
significant clusters within left middle insula cortex. B) Coronal sections illustrate significant BOLD 
related activity within bilateral somatosensory cortical regions, extending to the insula region. 
C) Axial images highlighting the bilateral insula and somatosensory BOLD increases for this 
contrast.  
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SVC analysis was performed and revealed significant BOLD responses contained 
within the anterior insula, CPu and amygdala for both groups (Table 7.4.8). No group 
















Table 7.4.7 Whole brain statistical results from one sample t-tests performed in lean and OW 
groups for the water delivery contrast. Cluster size = no. of voxels within the significant cluster. 
Figure 7.4.9 Whole brain statistical t-map clusters overlaid onto an MNI structural image for the OW 
group (n=15) from water delivery contrast. A) Sagittal sections and B) coronal sections show insula 





Under insulin conditions, the delivery of water yielded significant increases in the 
BOLD response within the left and right somatosensory cortex for both lean and 
overweight groups. In the overweight group these large clusters centred around the 
somatosensory cortex and also span to cover the operculum cortex on the left side 
in the OW group (see Figure 7.4.10 and Table 7.4.9).  
 
From lean group statistics, only the anterior insula survived SVC (p = 0.001, t = 5.58). 
In the OW group, the anterior insula (p < 0.000, t = 8.53), CPu (p = 0.003, t = 5.88) and 
amygdala (p = 0.010, t = 3.86) survived SVC (see Table 7.4.10).   




Table 7.4.8 SVC statistical results in the lean and OW group for the water delivery contrast 
following placebo administration. BOLD p values represent regions that survived multiple 


















Figure 7.4.10 Lean and OW whole brain t-maps overlaid onto structural images following insulin 
administration. A) and D) display insula activity. B) and E)coronal sections highlighting bilateral 
somatosensory and insula significant clustering. C) and F) highlight similar patterns of insula 
activity in both lean and OW groups for this contrast. 
Table 7.4.9 Whole brain statistical results from one sample t-tests performed in lean and OW 


















7.4.3.2 Sucrose delivery vs sucrose withheld  
Under placebo conditions, the effect of sucrose solution delivery against withheld 
showed increases in BOLD response within the left somatosensory cortex in lean 
individuals. In the OW group there were significant responses in the left and right 
somatosensory cortex, as well as in the left operculum cortex (see Figure 7.4.11 and 
Table 7.4.11) .  
 
Within the lean group the anterior insula survived SVC (p = 0.001, t=4.56). Within the 
OW group the anterior insula (p = 0.001, t = 6.05) and amygdala (p = 0.003, t=4.50) 
survived SVC analysis (Table 7.4.12).  
 
There were no group differences found within the placebo session.  
 
 
Table 7.4.10 SVC results from the water delivery contrast 
following intranasal insulin administration, for both lean 
and OW. BOLD p values represent those regions that 









Figure 7.4.11 Statistical t-maps created from one sample t-test overlaid onto structural MNI 
images for the lean and OW groups following placebo administration for the sucrose delivery > 
withheld contrast. A) and D) sagittal sections for lean and OW respectively display large BOLD 
activation clusters within the left insula region for the OW group, with this observation being 
absent in the lean group. B) and E) coronal sections showing bilateral somatosensory and insula 
BOLD cluster recruitment in the OW group which is much reduced and lateralised to the left 
somatosensory cortex in the lean group. C) and F) show axial activation within the insula and 









Table 7.4.11 Whole brain statistics produced from one sample t-tests in both the 
lean and OW groups. 
 
Table 7.4.12 SVC results for lean and OW groups following placebo administration 
for the sucrose delivery > withheld contrast. BOLD indicates regions where the p 
value calculated was less than the threshold for multiple ROI comparison.  
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Following insulin administration, the effect of sucrose solution delivery against 
withheld delivery, showed increases in BOLD response within the left and right 
somatosensory cortex in lean individuals. In the OW group there were significant 
responses in the left and right somatosensory cortex, right anterior insula cortex and 
also in the left and right cerebellum VI region (see Figure 7.4.12 and Table 7.4.13).   
Within the lean group the anterior insula (p < 0.001, t = 6.51) and CPu (p = 0.002, t = 
5.53) showed significant changes. Within the OW group the anterior insula (p = 0.001, 
t = 4.61), CPu (p < 0.000, t = 6.51) and amygdala (p = 0.007, t = 4.01) survived SVC 
analysis (Table 7.4.14).  
 
Figure 7.4.12 Whole brain statistical t-maps overlaid onto structural MNI images from one sample 
t-tests performed in lean and OW groups following insulin administration for the sucrose delivery 
> withheld contrast. A) and D) show sagittal sections with BOLD clusters within the insula region 
for lean and OW, respectively. B) and E) are coronal sections that display on both lean and OW 
groups somatosensory BOLD activity from this contrast. The OW group (E) display greater BOLD 
responses within subcortical regions around the putamen and caudate region. C) and F) axial slices 
that illustrate increased BOLD activity within the insula for the lean and OW groups, as well as 






There were no group differences seen following insulin administration.  
Table 7.4.13 Whole brain statistics from one sample t-tests performed in lean and 
OW groups following insulin administration. 
Table 7.4.14 SVC results for lean and OW groups following 
insulin administration for the sucrose delivery > withheld 
delivery contrast. 
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7.4.3.3 Stevia delivery vs stevia withheld  
Under placebo conditions, the effect of receiving stevia solution was contrasted 
against not receiving it.  This gave rise to increased BOLD response within the left and 
right somatosensory cortex in lean individuals. In the OW group there were 
significant responses in the left and right somatosensory cortex, as well as in the left 
operculum cortex and left and right cerebellum VI (Figure 7.4.13 and Table 7.4.15). 
 
Figure 7.4.13 Whole brain statistical t-maps overlaid onto structural MNI images from one 
sample t-tests performed in lean and OW groups following placebo administration for the 
stevia delivery > withheld contrast. A) and D) show sagittal sections for lean and OW, 
respectively. The OW group show a large degree of BOLD related activity within the insula 
region which is absent in the lean group. B) and E) are coronal sections that display on both 
lean and OW groups somatosensory BOLD activity from this contrast. The OW group (E) display 
greater BOLD responses within subcortical regions around the putamen and caudate region 
also. C) and F) axial slices that illustrate a reduced response in the right insula of the lean group 
in comparison to the OW group who show bilateral increased BOLD activity within the insula, 
as well as BOLD responses in the putamen and cerebellum. 
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None of the ROIs tested survived SVC in the lean group. Within the OW group the 
anterior insula (p < 0.001, t = 6.32), CPu (p = 0.002, t = 65.60) and amygdala (p = 0.002, 
t = 4.48) survived SVC analysis.  
 
There were no group differences within the placebo session for this contrast.   
 
 
Table 7.4.15 Whole brain results for the stevia delivery condition under placebo 
conditions for both lean and OW groups.  
Table 7.4.16 SVC results from the OW group under placebo 
conditions for the stevia delivery > withheld contrast. 
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Under insulin conditions (Figure 7.4.14 and Table 7.4.17) the effect of stevia solution 
delivery against withheld delivery, showed increases in BOLD response within the left 
and right somatosensory cortex, left and right cerebellum VI, left and right lingual 
gyrus as well as the supplementary motor area in lean individuals. In the OW group 
there were significant responses in the left and right somatosensory cortex, right 
operculum cortex, the left and right cerebellum VI region, left and right lingual gyrus 
and also the right putamen.   
 
Figure 7.4.14 Whole brain statistical t-maps overlaid onto structural MNI images from one sample t-
tests performed in lean and OW groups following insulin administration for the stevia delivery > 
withheld contrast. A) and D) show sagittal sections for lean and OW, respectively. Both groups show 
a large degree of BOLD related activity within the insula region and somatosensory cortex. B) and E) 
are coronal sections that display both lean and OW groups somatosensory BOLD activity from this 
contrast. The lean group (B) also shows increased BOLD related activity within the supplementary 
motor cortex. C) and F) axial slices that illustrate a reduced response in the right insula in comparison 
to the left in both lean and OW groups. Both groups display BOLD related increases in the 




Within the lean group the anterior insula (p = 0.002, t = 5.56), CPu (p = 0.003, t = 5.50) 
and amygdala (p = 0.10, t = 3.95) showed statistically significant changes. Within the 
OW group the anterior insula (p = 0.002, t = 5.56), CPu (p = 0.001, t = 5.97) and 
amygdala (p = 0.001, t = 4.96) survived SVC analysis (Table 7.4.18).  
 





Table 7.4.17 Whole brain statistic results from one sample t-tests performed in lean 





7.4.3.4 Correlation analysis with BMI 
An exploratory correlational analysis was performed to examine the relationship 
between regional BOLD contrast estimates for cue presentation and stimulus 
delivery contrasts for both insulin and placebo sessions. From this analysis very few 
regional extractions correlated with BMI. However, a strong negative correlation 
between BMI and BOLD contrast estimates from the vmPFC during the stevia cue > 
water cue for the placebo session was observed (t = -4.1, p = 0.0005; r=-0.65, 
Pearson’s) (see Figure 7.4.15). This correlation suggests that as BMI increases, BOLD 
related activity within the vmPFC upon presentation of the stevia cue decreases. For 
the same contrast (stevia cue > water cue), but following insulin administration the 
vmPFC extracted values regressed against BMI provided a negative correlation but 
did not fulfil the statistical threshold criteria for this analysis (t = -2.0, p = 0.055, r = -
0.39, Pearson’s, Figure 7.4.16). Finally vmPFC extracted contrast estimate values for 
Table 7.4.18 SVC results for both lean and OW groups 
under insulin conditions for the stevia delivery > 
withheld contrast.  
 253 
the sucrose > water cue presentation event provided a moderate negative 
correlation with BMI (t = -2.57, p = 0.017, r = -0.47, Pearson’s). This negative 
correlation, however, did not satisfy the multiple comparison statistical threshold set 
for this analysis. No other correlations were observed that survived the threshold of 
significance set for this exploratory correlation analysis.  
 
Figure 7.4.16 Plot of BMI vs vmPFC extracted contrast estimates for the stevia > 
water cue following insulin administration for comparison against. The plot shows 
an insignificant negative correlation between vmPFC BOLD estimation from this 
contrast vs BMI. 
Figure 7.4.15 Plot of BMI vs vmPFC extracted contrast estimates for the stevia > 
water cue following placebo administration. Each black dot is a single participant 
(n=25) and the black line is the line of best fit. The plot shows a strong negative 
correlation and that vmPFC BOLD estimation from this contrast decreases as BMI 
increases.  
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7.5 SECTION B. Formal Comparisons Between Intranasal 
Insulin and Intranasal Placebo  
 
Within this section the analytical methods used to assess the effects on intranasal 
insulin compared to intranasal placebo will be detailed along with the results. To 
explore these drug-related effects a whole brain analysis method and also a ROI 
based analysis method have been employed.  
7.5.1 Whole brain analysis 
A random effects repeated measures factorial model was constructed at the second 
level for each contrast to explore both the main effect of drug and the interaction 
between drug and group. Following the task related effects the analysis was focused 
on three cue contrasts of interest: sucrose > water, stevia > water and sucrose > 
stevia. Furthermore, only the two sweet taste delivery contrasts were assessed: 
sucrose delivery > sucrose withheld and stevia delivery > stevia withheld. Subject-
specific contrast images created from the 1st level model for each condition were 
entered into a repeated measures factorial model with three factors; subject, drug 
and group using SPM-12 software. Four t-test comparisons (contrasts) were created 
from this 2nd level model; two drug effects and two interactions (see below).  
 
1. Insulin > Placebo (Main effect of drug) 
2. Insulin < Placebo (Main effect of drug) 
3. Lean Insulin > Placebo, OW Insulin < Placebo (Interaction 1) 
4. Lean Insulin < Placebo, OW Insulin > Placebo (interaction 2) 
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The resulting statistical parametric t-maps created from this second level model were 
set to a cluster forming voxel threshold of p < 0.001. Clusters which survived a FWE-
correction for multiple comparisons (p < 0.05 FWE-corrected) were reported as 
significant. Following the detection of significant clusters in the interaction contrast 
a post hoc analysis was performed using two, whole brain, within group paired t-
tests. Single linear contrasts within these paired t-tests were created depending on 
the directionality of the interaction contrast (interaction 1 or 2). Following significant 
cluster formations seen from main drug effect contrasts, within group whole brain 
paired t-tests were performed. Cluster forming thresholds and significant cluster 
thresholds were implemented as described above for all of the post hoc whole brain 
tests.  
7.5.2 ROI analysis 
ROI analysis was performed separately to look at regional effects of drug, group and 
also drug by group interactions. Mean parameter estimates  for each contrast were 
extracted at the subject level within each ROI mask using 3dmaskave (AFNI). ROI 
mean BOLD estimates for each contrast were entered into a repeated measures 
Analysis of Variance (ANOVA) factorial model with two factors, drug and group. 
Significance, for either main effects of drug or group and also drug*group interaction 
effects was set to p < 0.05 from the ANOVA. Following a drug*group interaction a 
post-hoc Tukey test was used to assess which comparisons were driving the 
interaction effect. The Tukey post hoc analysis tests every possible comparison and 
adjusts the outcome accordingly for the number of comparisons. For significant main 
effects of drug and group, planned comparisons to explore this effect were 
conducted as post hoc tests. Therefore, a significant main effect of drug or group was 
interrogated through the use of two t-tests within group (paired) or within drug 
(unpaired), respectively. Significance for t-tests was set to p < 0.025, to correct for 




Bilateral ACC, vmPFC, mOFC and NAcc ROI masks, which have been defined and 
selected a priori, were used to assess drug and group differences during cue 
presentation conditions. Furthermore, for delivery contrasts, the anterior insula, 
CPu, NAcc and amygdala ROI masks were used to assess both drug and group 
differences, again previously defined. 
 
7.5.3 Statistical analysis  
All statistical analysis was conducted using R (Rstudio). Mean and standard deviation 






















7.6 SECTION B. Results 
In a similar structure to the previous results section (section A), the whole brain and 
ROI analysis results will be considered for each contrast separately.  
7.6.1 Sucrose cue > water cue 
No significant drug related BOLD changes were seen assessed at the whole brain 
level. Furthermore, there were no differential drug related responses from either of 
the interaction contrasts.  
 
ROI analysis revealed a significant group effect within the ACC (F1,24 = 5.07, p = 0.029). 
Un-paired t-tests showed a greater contrast estimate in the lean group (0.73 ± 0.49 
arbitrary units) compared to the OW group (-0.16 ± 0.87) following insulin 
administration (t(23) = -3.28, p = 0.003) but not in the placebo session (t(23) = -0.44, 
p = 0.67) (presented in Figure 7.6.1). Furthermore, ANOVA results from the vmPFC 
revealed a significant drug by group interaction effect (F1,24 = 4.64, p = 0.037). Tukey 
test post-hoc analysis did not produce any significant comparisons, adjusted for 
multiple comparisons.  
 
Figure 7.6.1 Plot showing extracted contrast estimates from the ACC in both groups and 
under both pharmacological conditions for the sugar > water cue contrast. Estimates are 
from contrast images. Unpaired t-test revealed a significant difference between lean and 
OW group contrast estimates in this region, exclusively under insulin conditions. Values 
are mean ± SEM, * p < 0.025, corrected for multiple comparisons.   
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7.6.2 Stevia cue > water cue 
Whole brain voxel wise analysis produced no significant insulin effects or interaction 
effects.  
 
ROI analysis showed a significant group effect within the ACC (F1,24 = 5.62, p = 0.022). 
Unpaired t-test post-hoc analysis showed that this group effect was evident within 
the insulin session. Lean individuals showed significantly greater ACC BOLD 
responsiveness (0.88 ± 0.82) compared to OW individuals (0.15 ± 0.24) (t(23) = -2.27, 
p = 0.036)(Figure 7.6.2.A). Group effects were also seen in the NAcc (F1,24 = 4.90, p = 
0.032, ANOVA) which was significant within the insulin condition (t(23) = -2.66, p = 
0.014, unpaired t-test) as a result of greater contrast estimates in lean individuals vs 
OW (0.29 ± 0.19 vs 0.06 ± 0.24, respectively) (Figure 7.6.2.C). Furthermore, significant 
group effects were seen within the vmPFC (F1,24 = 12.02,  p = 0.0012, ANOVA). Within 
the vmPFC these group effects (lean > OW) were significant in the placebo condition 
(lean: 0.23 ± 0.25, OW: 0.02 ± 0.21, t(23) = -2.63, p = 0.018 , unpaired t-test) but did 
not survive multiple correction for the insulin condition (lean: 0.29 ± 0.24, OW: 0.04 




Figure 7.6.2 Plots showing contrast estimates and group differences for the stevia > water cue 
contrast for the ACC, vmPFC and NAcc. A) ACC - unpaired t-tests show a significant increase in the 
lean group vs the OW group under insulin conditions. B) vmPFC - unpaired t-tests show differences 
under both placebo and insulin conditions, and in both cases lean estimates are greater. C) NAcc - 
under insulin conditions the lean group display greater estimates under insulin conditions compared 
to the OW group. Values are mean ± SEM, * p < 0.025, corrected for multiple comparisons. 
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7.6.3 Sucrose cue  > stevia cue   
No whole brain effects of drug were seen from this contrast. ROI analysis showed a 
significant group effect within the vmPFC (F1,24 = 6.38, p = 0.015), which was only 
significant within the placebo condition (t(23) = 3.30 , p = 0.005, unpaired t-test), with 
the OW group displaying a greater response in comparison to the lean group (lean: -
0.23 ± 0.29, OW: 0.12 ± 0.19). 
7.6.4 Sucrose delivery > sucrose withheld 
No drug related effects were produced at the whole brain level or from ROI analysis 
from the delivery of sucrose solution.  
7.6.5 Stevia delivery > stevia withheld  
Receipt of stevia solution contrasted with when stevia was withheld, resulted in a 
significant interaction effect from the whole brain analysis (interaction 1). A single 
significant cluster was formed over Brodmann area 11 and Brodmann area 32, which 
covers parts of the mOFC, rostral ACC (rACC) and vmPFC anatomy (see Table 7.6.1 
and Figure 7.6.3). To explore this interaction whole brain paired t-tests in lean (Insulin 
> Placebo) and OW (Insulin < Placebo) groups were computed. Neither of these 
whole brain comparison revealed any significant clusters that survived FWE 
correction for multiple comparisons.  
 
ROI analysis did not reveal any other significant drug or group related effects, for any 
























Table 7.6.1 Whole brain statistic results from the interaction effect observed from the repeated 
measures ANOVA analysis conducted for the stevia delivery > withheld contrast. A significant cluster 
was identified following Bonferroni correction for multiple comparisons. Cluster size refers to the 
number of voxels within this significant cluster. Lean (n=10), OW (n=15).   
Figure 7.6.3 Whole brain statistical t-map overlaid onto an MNI structural template showing the 
statistical interaction effect cluster that was observed from a repeated measure whole brain ANOVA 
model for the stevia delivery > withheld condition. The significant cluster as seen from sagittal and 
axial slices is located within the region of the rACC and mOFC. This T-map has been cluster corrected 
using FWE threshold of p < 0.05. 
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To aid the interpretation of this result, the significant cluster seen in Figure 7.6.3 was 
used as a mask to extract contrast estimates from all participants under both placebo 
and insulin conditions for the stevia delivery contrast. The contrast estimates for 
each group (plotted as the mean) under both pharmacological conditions were 
plotted in Figure 7.6.4. These values are only used for observational purposes and no 
further statistical analysis was made on these extracted values. The plot in Figure 
7.6.4 does display this interaction effect very clearly as the lean activity, measured 
via contrast image estimates, increases in response to insulin, whereas the OW group 













Figure 7.6.4 Sagittal view from a 3D rendered image showing the location of a cluster that 
survived the statistical significance threshold for the stevia delivery contrast. Plotted are the 
contrast estimates extracted from this cluster for both lean and OW groups for each treatment.  
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7.7 SECTION C. Time Dependent Effects of Intranasal Insulin: 




The functional data collected for this paradigm were acquired over two runs. The 
previous analysis of this dataset has been conducted using both of these runs 
combined into a single 1st level model. The effects seen from the previous analysis 
are valid, however, it is necessary to address and explore the effects that might be 
seen across runs or from the individual executions of the paradigm. This paradigm 
was designed in a way that required the participant to learn the relationship between 
a visual cue and presentation of a taste stimulus. Previous work using predictive 
learning and temporal difference paradigms have shown that dopaminergic 
responsiveness shifts from the presentation of the reward stimulus to the cue 
presentation, once learnt (Gottfried, O'Doherty, and Dolan 2003; O'Doherty et al. 
2003; O'Doherty et al. 2002). This shift has also been shown from fMRI studies, which 
demonstrate the BOLD response shifts from the stimulus presentation to stimulus 
cue, once learnt (O'Doherty et al. 2003), although not as clearly as that from single 
cell recordings in primates (Schultz 1998). Furthermore, the participants are 
presented with repeated taste stimuli which will likely to lead to either habituation 
and desensitisation effects within the primary taste receptors of the tongue (Li et al. 
2002). Under these considerations, analysing the effect of each run is appropriate 





7.7.1 VAS ratings 
Subjective ratings of likeness and sweetness for sucrose and stevia were evaluated 
separately for differences between runs using paired t-tests within drug for the 
whole cohort (n=25). These paired comparisons were conducted within treatment.  
Within group comparisons were made to explore differences between the sweetness 
and likeness of sucrose and stevia across runs. A 2 x 2 within drug ANOVA was created 
to look at the effects of substance and run for ratings of likeness and sweetness. Main 
effects of run or substance were explored further with planned comparison t-tests 
and interactions using Tukey tests, respectively. Planned comparisons for main effect 
of run employed two within substance paired t-tests, for example sucrose likeness 
run 1 vs run 2, whereas planned comparisons for main effect of substance employed 
two within run paired t-tests, for example sucrose likeness run 1 vs stevia likeness 
run 1.  
 
All planned comparisons were deemed significant if p < 0.025, adjusted for two 
comparison tests. Tukey tests were judged to p < 0.05 statistical threshold as this test 
automatically adjusts for multiple comparisons.  
7.7.2 1st level model design 
To assess BOLD related effects of both run and drug, two separate 1st level models 
were created in SPM-12; one for the first run and one for the second run. As before 
1st level models were modelled with nine regressors of interest (cue, taste delivery 
and taste withheld for each taste), a swallow cue regressor (participant visually 
instructed to swallow) and also a VAS regressor. Six additional head motion 
regressors, saved following motion correction during pre-processing, were entered 
into the model Figure 7.7.1. For each run, there were 324 whole brain EPI images. 
Linear contrast images were created at the first level . Three contrasts were created 
for the cue presentation event: sucrose > water, stevia > water and sucrose > stevia. 
Two contrasts were created for the delivery minus withheld event for each sucrose 







Figure 7.7.1 A) the 1st level model design matrix included all events of interest 
(cue, delivery and withheld) for each taste, as well as swallow, VAS periods and 
head motion parameters. B) in this analysis each run was modelled separately 
with the general linear model and therefore individual contrast images for each 
run are generated.  
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7.7.3 Whole brain group level analysis 
A second level factorial model was constructed to examine the main effect of run 
within treatment. To answer this question a paired t-test was created for the whole 
cohort (n=25) to look for differences between runs for each contrast of interest 
individually.  
 
Furthermore, for each contrast, 1st level contrast images for each run were entered 
into a repeated measures factorial model (SPM-12, ‘flexible factorial model’) with 
three factors; subject, drug and group, to look for main effects of drug as well as 
interaction effects. For both of the whole brain analyses the cluster forming 
threshold was set to p < 0.001 uncorrected. As before, clusters with p < 0.05 following 
FWE - Bonferroni correction for multiple comparisons (using the cluster extent 
criterion), were reported as significant.  
7.7.4 ROI analysis 
The main interest of this study is to interrogate the effects of insulin on this complex 
paradigm. An ROI analysis was performed within each BMI group to look at main drug 
effects, main run effects and also interaction effects. Mean values were extracted 
from subject contrast images created at the 1st level using 3dmaskave (AFNI) for each 
contrast, drug session and run. The ROIs used in this analysis of drug and run were 
identical to the ROIs previously defined. Similarly, the bilateral ACC, vmPFC, mOFC 
and NAcc ROI masks were used to assess dug and run differences during cue 
presentation conditions. For delivery contrasts the amygdala, anterior insula ,CPu 
and NAcc ROI masks were used to assess both drug and run differences. 
 
The main aim of this analysis is to explore drug effects within these ROIs from 
individual runs that may have been missed or unable to be teased apart in the 
previous analysis in which the runs were combined. To increase the power to detect 
these drug effects, a within group analysis was conducted in OW and lean groups 
separately to look at the main effects of drug and run as well as the associated 
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interaction effects. This was done by constructing a factorial repeated measures 
ANOVA model for each contrast with the factors drug and run. Main effects of drug, 
main effects of run and interaction effects were assessed for significance using a p 
value of 0.05 from the ANOVA. Following significant main drug effects, planned 
comparison paired t-tests were conducted within run and similarly, following main 
run effects, paired t-tests were conducted within drug, as a post-hoc analysis judged 
to p < 0.025 significance to correct for multiple planned comparisons. Significant 
Interaction effects were interrogated using a Tukey post-hoc test, judged to p < 0.05 






















7.8 SECTION C. Results 
7.8.1 VAS ratings 
Effects of likeness over time for the whole cohort for sucrose and stevia are 
presented in Figure 7.8.1. 
7.8.1.1 Whole Group – likeness ratings 
Under placebo conditions, no differences in likeness ratings for stevia or sucrose 
between runs were identified following placebo administration (Figure 7.8.1.A).  
 
Following insulin administration subjective VAS ratings showed significant 
differences between runs for likeness ratings of the stevia solution. Ratings of how 
much stevia was liked, decreased over time (run 1: 73.28 ± 11.99, run 2: 67.28 ± 





Figure 7.8.1 Whole group VAS likeness ratings for sucrose and stevia recorded during run and 
run 2 for placebo and insulin conditions. A) No difference between how much these two 
tastes are liked for either run under placebo, however, note the greater variability in the 
sucrose ratings as seen by the larger error bars compared to stevia scores. B) under insulin 
conditions there was a significant difference between likeness ratings over time for stevia. 
Stevia likeness ratings decreased over time (paired t-test). Data is showing mean ± SD, * p < 
0.025, paired t-test, n=25 (whole group).  
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7.8.1.2 Whole Group – sweetness ratings 
Whole group analysis (n=25) of subjective VAS scores showed that under placebo 
conditions the VAS sweetness ratings for stevia significantly decreased from run 1 to 
run 2 (run 1: 74.96 ± 10.59, run 2: 69.32 ± 15.74, p = 0.021, paired t-test) (Figure 
7.8.2). Sucrose sweetness ratings on the other hand did not change over time.  
 
Under insulin conditions, ratings of sweetness, were different between runs for both 
sucrose and stevia solutions but only stevia differences survived multiple testing 
correction. Sucrose solution increased in sweetness over time, but was not significant 
(run 1: 74.60 ± 13.09, run 2: 80.32 ± 10.74, p = 0.031, paired t-test), whereas the 
stevia solution decreased in sweetness over time (run 1: 76.28 ± 11.99, run 2: 65.92 





Figure 7.8.2 Sweetness VAS ratings for the whole group illustrating the effects of run over time for 
sucrose and stevia solution. A) Under placebo conditions stevia solution sweetness decreased over 
time. B) Under insulin conditions stevia solution sweetness decreased over time between runs. Data 
shown in mean ± SD, * p < 0.025, *** p < 0.001, using paired t-tests (n=25). 
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7.8.1.3 Lean Group – likeness and sweetness ratings 
Within group and within drug comparisons of likeness and sweetness ratings were 
conducted to look for effects between substance’s (i.e. sucrose or stevia) and also 
runs using repeated measure ANOVA models.  
 
Within the lean group likeness and sweetness ratings for either sucrose or stevia did 
not change between run 1 ratings and run 2 ratings under placebo conditions.   
 
Within the lean group, there were no effects on likeness for either of the two 
substances (sucrose and stevia) under insulin conditions. In terms of sweetness 
there was a significant main substance effect for sweetness (F1,39 = 4.32,  p = 0.045, 
ANOVA). This effect was driven by the sweetness of sucrose solution being rated 
greater than stevia in the second run. This comparison however did not the survive 
multiple comparison correction threshold (sucrose: 75.00 ± 8.01, stevia: 60.70 ± 
17.22, t(9) = 2.50,  p = 0.034, paired t-test). 
7.8.1.4 OW Group – likeness and sweetness ratings 
For the OW group, there were no differences between any of the likeness ratings 
under placebo conditions. However, there was a significant main effect of substance 
sweetness (F1,59 = 5.10, p = 0.028, ANOVA), driven by a significantly higher rating of 
sweetness for sucrose compared to stevia solution only in the second run (sucrose: 
81.2 ± 13.28, stevia: 71.33 ± 14.55, t(14) = 4.48, p < 0.001, paired t-test) under 
placebo conditions (Figure 7.8.3.A).  
 
Within the OW, there were no effects on likeness ratings following insulin 
administration. For sweetness ratings an interaction effect was seen (run*substance 
F1,39 = 11.12,  p = 0.0015, ANOVA). Tukey test post-hoc analysis showed that this 
interaction effect was driven by a significant difference in sweetness between 
sucrose and stevia solution in the second run (sucrose: 83.87 ± 11.08, stevia: 69.4 ± 






A summary table of all the significant results highlighted from the VAS analysis are 
presented in Table 7.8.1 below. 
 
Figure 7.8.3 VAS sweetness ratings in the OW group. A) Under placebo there was a significant 
difference between sweetness ratings for stevia and sucrose solutions, which was also seen under 
insulin conditions (B). ** p < 0.01, *** p < 0.001, paired t-tests, data shown is mean ± SD, n=15 
(OW). 
Table 7.8.1 Summary of significant results from the VAS score analysis.  
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7.8.2 Whole brain analysis 
Second level within treatment paired t-tests showed no differences in BOLD 
responsivity for either placebo or insulin conditions for any of the contrast 
comparisons tested.  
 
Furthermore, within run repeated measure ANOVA models that were designed to 
look for main drug effects and interaction effects within each run separately did not 
show any significant changes for any of the contrasts tested.  
 
7.8.3 ROI analysis 
The ROI analysis looked for drug related effects across runs for each contrast 
separately. This analysis was constrained to within group comparisons. 
 
7.8.3.1 Sucrose > water cue 
Within the lean group a main drug effect was seen within the ACC (F1,39 = 5.50,  p = 
0.025, ANOVA) and vmPFC (F1,39 = 4.27, p = 0.046, ANOVA). Planned comparison 
paired t-tests however did not reveal any drug related differences from either run 1 
or run 2 BOLD estimates. The OW group did not show any significant effects for any 
of the ROIs tested for from this contrast.  
 
7.8.3.2 Stevia > water cue 
For both lean and OW groups, there were no significant effects seen for the stevia 
cue > water cue for any of the ROIs tested. 
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7.8.3.3 Sucrose > stevia cue 
For the sucrose cue > stevia cue contrast a significant main effect of run was seen 
from beta estimates extracted from the NAcc (F1,39 = 5.20, p = 0.029, ANOVA) in the 
lean group. Planned comparison analysis did not reveal any further drug related 
differences in the NAcc. No significant effects from any of the ROIs were seen from 
analysis performed in the OW group for this contrast.  
7.8.3.4 Sucrose delivery > withheld delivery 
Sucrose delivery > withheld delivery contrast did not provide any significant drug or 
run effects from any of the ROIs tested in either the lean or the OW group.  
7.8.3.5 Stevia delivery > withheld delivery 
Finally, ROI extracted parameter estimates from the stevia delivery > withheld 
delivery contrast showed a significant main effect of drug within the NAcc (F1,39 =  
4.58, p = 0.039, ANOVA) in the lean group. Planned comparison paired t-tests showed 
that NAcc BOLD estimates extracted from the second run contrast were significantly 
greater following insulin administration compared to placebo (placebo: -0.08 ± 0.21, 
insulin: 0.23 ± 0.27, t(9) = 5.32, p < 0.001, paired t-test) (Figure 7.8.4). This was the 
only ROI that produced any significant effects within the lean group.  
 
In the OW group, significant main effects of drug were seen from the estimates 
extracted from the CPu (t(14) = 10.52, p = 0.002, ANOVA. This main effect of drug  
was driven by a decrease in response to insulin administration within the first run 
(placebo: 0.57 ± 0.31, insulin: 0.07 ± 0.43, t(14) = -2.76, p = 0.015, paired t-test) 






A summary table of significant differences seen from the ROI analysis is not provided 








Figure 7.8.4 Contrast estimates extracted from the NAcc and the CPu regions from lean and OW 
groups for the stevia delivery contrast. A) ROI analysis within the lean group produced a significant 
increase for this contrast compared to placebo in the bilateral NAcc, which was observed in the second 
run only. NAcc contrast estimates were very similar for both conditions during the first run. B) The 
OW group displayed a reduced response in the CPu following insulin compared to placebo 
administration which showed a high contrast estimate. This difference was exclusive to the first run 
only. C) and D) illustrate contrast estimates for the OW and lean group for NAcc and CPu regions for 
reference. Differences were found from planned comparison paired t-tests. Data shown is mean ± 
SEM. * p < 0.025, *** p < 0.001, lean n=10, OW n=15.  
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7.9 Taste Paradigm Discussion 
 
This study explored the neural mechanisms involved in primary reward processing 
from conditioned taste stimuli and how these systems are modulated by intranasal 
insulin administration. This study showed that the effects of insulin administration 
were (in general) most prominent upon receipt of stevia solution and that intranasal 
insulin displayed differential effects in the lean group compared with the overweight 
group. Insulin related effects were seen from regions of the prefrontal cortex and 
mesolimbic dopaminergic regions associated with reward evaluation (Fuster 2001) 
and reward processing (O'Doherty et al. 2004; Pagnoni et al. 2002), respectively, 
suggestive of an insulin related role on dopaminergic transmission. Additionally, this 
analysis has provided evidence for group effects upon cue presentation which are 
influenced by intranasal administration of insulin suggesting differential sensitivity to 
central insulin action, associated with BMI in prefrontal, cognitive functioning brain 
regions.  
 
This is the first time that the primary effects of food (solution) taste and ingestion 
have been explored as part of a pharmacological investigation with intranasal insulin. 
Previous fMRI reports exploring the associations between elevated insulin and food 
related processing have largely focused on brain responsiveness to food 
cues/pictures (Guthoff et al. 2010; Kroemer et al. 2013) as a surrogate marker for 
food related neural processing. Food picture responsiveness fMRI experiments are 
useful for inferring the attractiveness or palatability of food under different 
homeostatic conditions (Goldstone et al. 2009) and in metabolic disease (Karra et al. 
2013). However, these paradigms have limited scope for determining consummatory 
effects of food as the participant is not presented with a food stimulus to consume. 
This study, on the other hand, has made use of a primary reward paradigm that 
explored the effects of intranasal insulin on the anticipation and receipt of sweet 
tasting stimuli.  
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Furthermore, this is the first time that a BOLD functional imaging protocol has been 
implemented to explore brain responsiveness to the receipt of a non-nutritive 
sweetener, Stevia. The function of non-nutritive, zero calorie, sweeteners as an 
alternative to energy dense sweeteners such as sugar for weight loss and promotion 
of health is any area of considerable debate (Mattes and Popkin 2009). This work 
does not directly add knowledge to the literature regarding weight loss and health 
promotion but does help to address the acute effects that a popular non-nutritive 
sweetener has on brain responsiveness in comparison to sucrose.  
 
On a primal level, all animal systems will ensure to attain key primary biological goals 
such as adequate nourishment and reproduction. Achieving these goals is facilitated 
through highly complex mechanisms (Goldstone 2006). Food intake is driven by three 
integrative systems, the homeostatic, hedonic and cognitive pathways, respectively.  
Homeostatic eating is largely controlled by the hypothalamus in response to 
peripheral signals regarding hunger, satiety and adiposity. Hedonic eating, on the 
other hand, is governed by the palatability and pleasure associated with eating 
certain foods and flavours. While the homeostatic system governs the body’s 
metabolic needs, the pleasure that is coupled with eating makes energy intake 
worthwhile (Kringelbach 2015) and this pleasure has been proposed to be a key 
driver in the evolution of large primate brains (Kringelbach 2004). Hedonic eating and 
the pleasure associated from eating is a multi-faceted function that incorporates 
several distinct concepts involved in processing the pleasure induced by food 
administration. These are liking (palatability of food), wanting (motivation/drive for 
food) and learning (Berridge and Kringelbach 2008). Examinations of these 
components both individually and in combination has been one of the research goals 
of investigating food-related pleasure and consumption.   
 
From the large body of relevant research, a number of models and theories relating 
to overconsumption of food in obesity and dysregulation of reward responsivity, 
have been suggested. One theory is the hypo-responsivity theory which suggests 
obese individuals show decreased activity within reward circuitry upon consumption, 
which in turn leads to repeated overeating to compensate for this deficit (Wang, 
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Volkow, and Fowler 2002; Blum et al. 1996). Alternatively, others have suggested 
that overeating associated with obesity stems from a hyper-responsivity to food 
stimuli leading to overall greater food intake (Stice et al. 2008; Davis, Strachan, and 
Berkson 2004). Both theories rely heavily on the effects of dopamine and its role in 
reward processing, specifically the pleasure aspect encoded within the striatum. 
More recently, an alternative interpretation of the literature has suggested that 
obese individuals display a reduction in reward-related cognitive inhibition rather 
than reward hypo or hyper-responsivity (Kroemer and Small 2016). Using links 
between obesity and drug addiction, Volkow et al., proposed a model of obesity that 
reflects an imbalance between circuits that drive pleasure seeking behaviour and 
circuits that regulate inhibitory control (Volkow, Wang, Fowler, et al. 2008). This 
discussion will address the circuits that contribute to reward motivated behaviours: 
reward saliency and learning, and how these circuits are affected in response to 
insulin administration and differ with regards to body weight (BMI). The cohort in 
this study are not obese, however this discussion intends to reference the relevant 
literature surrounding obesity related reward theory in support of the findings from 
this neuroimaging investigation. Furthermore, the effects of taste and 
consummatory responses to primary rewards with regards to natural and artificial 
sweeteners will also be discussed. The term ‘reward’ will be used throughout, which 
refers to the positive value assigned to a certain object, act or state (Schultz, Dayan, 
and Montague 1997). In this context, the term reward will be used to describe the 
value of the primary solution stimuli used in this task, unless stated otherwise.  
 
The analysis for this task was separated into three sub-sections. This discussion will 
aim to bring the results of these sections together in an effort to harmonise the 
findings and complement the interpretation of this functional dataset. To aid the 
reader, the findings regarding the cue phase and delivery phase will be reported 
separately and then integrated for completion and to support or oppose reward and 
obesity based models and theories mentioned. The effects of intranasal insulin will 
be discussed thoroughly with reference to relevant literature first, followed by the 
interpretation of the effects seen as a consequence of BMI.  
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7.9.1 Anticipatory response 
Experimental studies of reward processing often use conditioning paradigms to 
explore both the anticipatory phase as well as the consummatory phase. The 
presented cues used within this task were fractal images, not seen previously until 
the morning of each scan, and did not contain any patterns or characteristics that 
were predictive of the taste stimuli.  
 
From whole brain maps that combined both functional scanning runs, there were no 
significant BOLD response increases seen when the water cue event was contrasted 
against either of the sweet solution presentation cues, in any group or treatment 
session. The lack of BOLD reactivity seen from this contrast suggest that the cue for 
water was less salient given its association with the water taste stimulus. VAS ratings 
averaged across the two runs show that the palatability of water stimulus, as 
measured by how much the water taste was liked, was significantly less than both 
the sweet stimuli.  
 
These data showed significant increases in BOLD response activity common to both 
groups and treatment sessions upon presentation of both the sweet stimuli cues in 
comparison to the water stimulus cue. For all sweet > water cue contrasts and drug 
conditions regional BOLD activity was increased within both the left and right primary 
visual cortex. Previous work has shown that predictive cues coupled with higher 
value reward stimuli show greater activation within the primary visual and secondary 
(extrastriate) cortices (Anderson, Laurent, and Yantis 2014). The increased salience 
of greater reward-value cues, once learned, is thought to be augmented by 
dopaminergic activity, thus priming the brain to seek or find these learned rewards 
(Hickey, Chelazzi, and Theeuwes 2010). As mentioned previously, palatability scores 
were greater for sucrose and stevia over water stimuli so the increases in BOLD 
response in these visual regions for sweet > water cue contrasts is not surprising. The 
extrastriate cortex, makes up part of the secondary visual cortex, receiving inputs 
directly from the primary visual cortex and is involved with encoding shapes and 
edges (Okusa, Kakigi, and Osaka 2000; Vinberg and Grill-Spector 2008). The 
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complexity of shapes and patterns were similar for all the cues but with sufficient 
differences to permit visual differentiation. Cue and stimulus coupling were 
randomised amongst subjects to avoid any confounding effects of repeated cue and 
flavour across sessions thus the increased extrastriate response from these sweet 
cues is likely due to the increased likeness for sweet-tasting stimuli coupled with 
increased salience for those sweet cues.  
 
BOLD response increases originating from the dorsal region of the cerebellum in the 
overweight group were seen following placebo administration when presented with 
the stevia paired cue vs water. Recent research in rodent models have shown 
neuronal responses from populations of granular cells within the VI region of the 
cerebellum during the anticipation of sucrose solution delivery (Wagner et al. 2017). 
Regions of the middle temporal gyrus showed increased BOLD responsiveness 
following cue presentation of stevia in comparison to water within lean and 
overweight groups following placebo administration. Although not directly related to 
food reward, fMRI results from a monetary reward paradigm (Manelis et al. 2016) 
highlighted the middle temporal gyrus as an area involved in the anticipation of 
winning in comparison to losing. Although, winning money is conceptually different 
to receiving a primary food reward, some similarities in neural organisation do exist 
(Simon et al. 2015) and so these responses in the temporal gyrus seen here could be 
common to both the anticipation of food stimuli and monetary reward.   
 
Combining runs of functional data was conducted in an effort to increase statistical 
power in the first instance. Given that this paradigm examined the effects of three 
tastes: water, sucrose and stevia, it was important to collect sufficient functional data 
for each event for parametric general linear model based voxel wise analysis. Across 
both runs each participant was presented with 30 cue images for each taste and 
received the taste bolus following cue presentation 18 times, with 12 withheld 
delivery events. Whole brain, SVC and ROI analysis of combined run contrasts did not 
reveal any significant drug related effects for either sweet > water cue contrasts from 
combined run data. Observations of within treatment whole brain maps and SVC 
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analysis did, however, suggest that there were some subtle effects of both drug and 
BMI that were not detected from a whole brain voxel wise statistical comparison.  
For all taste stimuli and drug sessions, the association between fractal cues and taste 
stimuli were learnt successfully during the course of the paradigm for each 
participant, tested by asking each participant out of the scanner. Thus presentation 
of the cue elicited an ‘anticipatory’ brain response, recruiting regions not just 
involved in visual processing, but those involved in higher level reward processing 
such as the vmPFC, ACC and mOFC, all commonly associated with evaluation and 
decision making in response to rewarding stimuli (Wallis and Kennerley 2011).  
 
During the placebo session, SVC analysis did not show BOLD related increases from 
regions tested (ACC, vmPFC, NAcc, mOFC) for the sucrose > water cue presentation, 
in either BMI group. This was surprising given how much the sucrose solution was 
liked from VAS ratings and is in contrast to the results from O’Doherty et al., who 
showed that during non-pharmacological challenges the mOFC is active during 
anticipation  (O'Doherty et al. 2002). The likeness ratings for the whole group as seen 
from Figure 7.4.1.A following placebo administration showed that there was some 
variability in the VAS scores for sucrose solution, which may be reflected in the 
imaging data. More relevant perhaps is how this event was modelled. The cue 
presentation event modelled in the current taste paradigm was short (2s) and 
corresponded only to the period when the visual cue was present. Therefore, a 
limitation of this model approach could be the lack of imaging volumes used to 
capture the anticipatory phase fully, which may, arguably, begin post cue 
presentation. Despite this potential limitation, whole brain t-maps following insulin 
administration did show recruitment of regions commonly involved in anticipation 
(O'Doherty et al. 2002). These regions were highlighted by SVC results that showed 
BOLD responses for sucrose > water cues within the NAcc and the mOFC in the lean 
group suggestive of an anticipation effect, as well as an insulin related increase in 
anticipation recruitment. Stouffer et al. has shown in mice that increased central 
insulin concentrations act to enhance dopamine pre-synaptic neurotransmitter 
release in the NAcc and putamen (Stouffer et al. 2015) thereby acting as a reward 
signal. The mOFC is a region situated on the ventral surface of the prefrontal cortex. 
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The mOFC plays a role in reward evaluation, as well as the magnitude and probability 
of the related reward (Wallis and Miller 2003). As mentioned, O’Doherty et al. 
showed in humans that during the anticipation phase for sucrose solution stimulus 
there was an increased BOLD response in the mOFC when compared to the 
anticipation of a tasteless solution (O'Doherty et al. 2002). The mOFC acts as an 
integrative hub for many sensory inputs and is seen here in response to the cue 
presentation for sucrose stimulus in the lean group under insulin conditions but not 
placebo.   
  
Activation due to the presentation of the stevia cue with respect to that for water,  
revealed BOLD related increases in pre-frontal regions (ACC, vmPFC and mOFC) as 
well as the NAcc region in the lean group, following placebo administration but were 
absent under insulin conditions. Despite these observable differences from within 
treatment analyses there was not any significant differences seen from whole brain 
or ROI analysis comparisons, but suggest a trend for a ‘reward-reducing’ effect of 
insulin. Experiments in mice have shown reduced anticipatory behaviour for sweet 
solutions following insulin injection into the VTA (Labouebe et al. 2013). In addition, 
central insulin injections to the VTA in mice are coupled with suppression of food cue 
salience via decreased dopamine release in the NAcc (Mebel et al. 2012). The 
opposing insulin response trend seen between ‘sucrose > water’ and ‘stevia > water’ 
cues is interesting. Particularly as there were no effects in either the placebo 
condition or insulin condition when comparing these two flavour-cue contrasts 
(sucrose > stevia) from whole brain analysis. Averaged sweetness ratings (run 1 and 
2) for the whole group did show that, under insulin conditions only, sucrose was 
significantly sweeter than stevia but this did not affect how much these tastes were 
liked. It is worth stressing that ratings of sweetness are better related to the delivery 




7.9.2 Group differences in cue reactivity 
There were differences between groups which were only identified in the cue 
condition and were for observed upon presentation of both the sucrose and stevia 
cues vs water. The treatment dependent group differences were exclusively seen in 
response to insulin administration within the ACC and NAcc regions. The vmPFC also 
showed group wide BOLD signal differences under placebo conditions as well as 
following insulin administration. These group differences are highlighted in Summary 
Box 1.  
 
These results suggest that the ACC and NAcc are both insulin sensitive and that BMI 
has an effect on regional insulin sensitivity. The NAcc BOLD increase seen in the lean 
group but not in overweight group in response to insulin administration follows a 
similar trend seen in pre-clinical work that shows insulin’s lack of effectiveness as a 
reward signal in obese mice vs wild type littermates (Stouffer et al. 2015). Insulin 
receptors have been found within the NAcc (Schulingkamp et al. 2000; Werther et al. 
 282 
1987) and exogenous insulin administration has been shown to modulate 
dopaminergic concentrations within this region (Jones et al. 2017; Stouffer et al. 
2015). Stouffer et al. has shown in mice that increased central insulin concentrations 
enhanced dopamine synaptic neurotransmitter release in the NAcc and caudate-
putamen (Stouffer et al. 2015) thereby acting as a reward signal, in support of the 
insulin induced increase in activity within the NAcc. Interestingly, from Stouffer et al., 
the sensitivity of insulin related dopamine release from striatal neurons (NAcc, 
caudate-putamen) is diet dependent with obese rats displaying diminished insulin 
related dopamine synaptic concentrations (Stouffer et al. 2015). Although the 
participants involved in the current study are overweight and not obese, this result 
is in support of the notion that insulin may have a differential response in those with 
an increased BMI. 
 
For both sucrose and stevia solution cue > water cue contrasts the ACC provided a 
distinguishable difference between the lean and OW groups in an insulin dependent 
manner. The fractal cue used in this paradigm informs the participant which taste 
may be delivered, but the cue does not inform the participant whether the taste will 
be delivered or not. Thus the cue itself is not predictive of whether the trial will be 
paired or unpaired. Therefore this raises a possibility that upon cue presentation the 
participant will observe the cue but also try and predict the probability of receiving 
the reward (taste bolus). The ACC has been previously shown to be involved in the 
prediction of rewarding outcomes (Silvetti, Seurinck, and Verguts 2013) and also has 
been recruited during assessing the probability of receiving primary rewards 
(Vassena et al. 2014). This study however limited in interpretation power given it is 
hard to know based on the data collected what the participant is actually thinking 
during these events. It is worth highlighting though that the process being carried out 
in the ACC is not taste dependent and is also modulated by insulin within the lean 
group, suggestive of a modulatory effect of insulin in the lean group that may lead 
these individuals to think and predict the probability of receiving the reward or not, 
which may be different in the OW group.  
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BOLD activity within the vmPFC was greater in lean individuals in response to the 
stevia cue for both the placebo and insulin sessions. The exploratory correlational 
analysis illustrated a relationship between placebo vmPFC activity in response to the 
stevia cue and BMI. This relationship showed that lower BMI is associated with 
greater BOLD activity in the vmPFC following placebo administration. A similar 
relationship was seen between vmPFC BOLD estimates and BMI following insulin 
administration but did not survive the statistical threshold. The vmPFC is associated 
with valuation of stimuli, both food and non-food related (Tiedemann et al. 2017) as 
well as decision making. Halfmann et al., showed that in older adults vmPFC activity 
was associated with gambling task performance and that greater activity within the 
vmPFC correlated well with better performance from the task, i.e. greater money 
won (Halfmann et al. 2016). This increase in vmPFC activity was predictive of better 
decision making and Halfmann et al., further suggested that the vmPFC could be 
important with regards to long term decision making and that this leads to effects on 
both wealth and health (Halfmann et al. 2016). As the task implemented in the 
SNIFAR study was passive, in that participants had no choice, the effects seen are 
hard to decipher and a decision making element introduced to this paradigm would 
be helpful to explore these effects seen and if these regions of interest translate to a 
more cognitively demanding reward paradigm.  
 
These group differences do not fully support either the reward hyper-responsivity 
dopamine theory of obesity that has been suggested previously (Volkow, Wang, and 
Baler 2011; Burger and Stice 2011a). This is largely because of the lack of group 
differences seen following placebo administration within the NAcc. Furthermore, as 
the differences in cue responsivity within the NAcc were limited to stevia cue 
presentation the conclusions drawn are therefore not conclusive or applicable to all 
primary rewarding stimuli.  
 
In light of this, these results suggest a hypo-responsivity of the NAcc, a key 
dopaminergic region, to centrally increased insulin in overweight compared to 
normal weight individuals in response to a predictive cue. Furthermore, prefrontal 
regions involved in cognitive processing, reward valuation and prediction were 
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unresponsive in the presence of central insulin in the OW group in comparison to the 
lean group who provided insulin related increases within these regions. Suggesting a 
BMI related differential sensitivity to central insulin which may be key to valuation 
and prediction prior to consumption of sweet foods.  
7.9.3 Consummatory response  
Whole brain functional images that corresponded to stimulus delivery events were 
contrasted against those that corresponded to the ‘stimulus withheld’ events for 
each taste. In both BMI groups the water taste revealed significant activations within 
the bilateral somatosensory cortex and anterior insula region for the both placebo 
and insulin conditions, using combined run data. It is well known that water is not 
‘tasteless’ (Zald and Pardo 2000) and as these results show the taste of bottled 
mineral water elicits a reliable BOLD response irrespective of insulin or placebo 
challenge. Previous fMRI studies that investigated ‘taste’ often use either a tasteless 
artificial solution (Stice et al. 2008; O'Doherty et al. 2003) that mimics the ionic 
complexity saliva or distilled water (Szalay et al. 2012; Haase, Cerf-Ducastel, and 
Murphy 2009) as a control taste. In retrospect, incorporating water as a control 
solution has perhaps limited the functional contrasts that can be explored in the 
consummatory phase of the paradigm. For example, whole brain contrasts for the 
taste of sucrose vs water did not reveal any differences and likewise for stevia vs 
water, this data was not reported. Hence, for this investigation the taste responses 
were modelled as delivery minus withheld delivery for each taste. It has been 
possible to make  inferences at both the whole brain level as well as from ROI analysis 
from these modelled events. In regards to the taste of water, formal drug related 
differences or group differences were not tested in this instance.  
 
7.9.4 Sucrose and stevia delivery 
Under placebo conditions, regions of common activation elicited in response to 
delivery of both sweeteners were the left and right somatosensory and motor 
cortical regions. The spatial location of this cortical activation along the lateral 
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surface coincides with areas functionally related to the lips, tongue and jaw 
(Miyamoto et al. 2006) and would be expected to be recruited by this paradigm for 
both these contrasts. By contrasting the delivery against the withheld event, these 
regions appear quite prominently from whole brain one sample t-tests. No 
statistically significant differences between whole brain t-maps for lean and OW 
groups for both sucrose delivery and stevia delivery under placebo conditions were 
observed. It is nevertheless instructive to review some of these differences.  For 
example, under placebo conditions, the lean group showed a relatively reduced 
response in the somatosensory cortex in comparison to the overweight group for 
both the sucrose and stevia taste. So much so, that small volume correction did not 
result in any significant clusters within the lean group for the stevia delivery contrast 
and only provided a significant effect within the anterior insula from sucrose delivery. 
In contrast the OW group showed significant BOLD responses within the insula, 
amygdala, striatum and also cerebellum for stevia and sucrose delivery from small 
volume correction and whole brain interrogation, respectively.  
 
The Insula has been well documented in its role of gustatory perception and 
processing (Frank, Kullmann, and Veit 2013) within the brain and is commonly 
referred also as part of the primary gustatory cortex. The dorsal surface of the tongue 
is scattered with raised projections known as papillae which are lined with taste buds. 
Each taste bud hosts a large number of taste receptor cells with afferent axons that 
carry information along cranial nerves to the brainstem and thalamus where relay 
neurons connect with the insula cortex, amygdala and hypothalamus (Breslin 2013). 
From the insula, projections to the striatum, OFC and ACC carry the oral sensory 
information where properties regarding reward valence and other cognitive 
processes are encoded (Breslin 2013). BOLD response increases were seen within the 
cerebellum from presentation of the stevia stimulus under placebo conditions. 
Activity within the cerebellum has been observed from previous fMRI studies looking 
at taste (Zald and Pardo 2000; Small et al. 2003). Small et al., reported cerebellar 
activity associated with intensity of substances and suggested a role of the 
cerebellum to respond to taste intensity information and guide oral movements 
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(Small et al. 2003). The cerebellum was also involved following insulin administration 
for both sucrose and stevia delivery.  
 
Following insulin administration whole brain t-maps were visually similar for the OW 
group in response to both sucrose and stevia delivery contrasts. Interestingly, BOLD 
increases were seen in the right putamen from stevia solution delivery which was 
absent following placebo conditions. Lean group whole brain maps for both sucrose 
and stevia delivery contrasts presented a more widespread spatial BOLD response, 
incorporating similar regions seen in the OW group, following insulin administration 
in comparison to placebo. In response to stevia administration, the lean group 
displayed activation within the supplementary motor area (SMA) under insulin 
conditions. The SMA is well known for its role in controlling movement actions 
(Nachev et al. 2007) and therefore this response seen could be due to preparation 
for swallowing. Why this region was only seen upon stevia delivery and not sucrose 
delivery, and why was limited to both the lean group and following insulin 
administration is hard to comprehend.  
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7.9.5 Insulin effects 
 
 
Whole brain parametric analysis provided a significant interaction effect between 
treatment and group in response to stevia delivery vs withheld delivery. Insulin 
administration vs placebo displayed a differential response in lean and overweight 
groups within the prefrontal cortex, localised to the rostral ACC and mOFC. The lean 
group showed an insulin-related BOLD increase within this region in contrast to the 
OW group who demonstrated an insulin-related BOLD decrease within this prefrontal 
region compared to placebo. Whole brain paired t-tests, conducted as post hoc 
analyses were not sensitive to detect significant insulin-induced changes for either 
group.  
 
The interaction effect seen is anatomically interesting as the prefrontal cortex is 
heavily involved in cognitive functioning and decision making, as mentioned 
previously. In addition to the hedonic aspects associated with food consumption, the 
response to food taste and sight is highly dependent on higher level cognitive 
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processing. Cognitive control, via the prefrontal cortex, is key to both the 
enhancement and suppression of appetite and motivation to consume food (Dagher 
2012). The prefrontal cortex is a region with known responses to changes in insulin 
concentration. For example, increases in endogenous insulin concentrations 
following glucose ingestion have been shown to induce reductions in prefrontal 
cortex activity upon food picture presentation (Heni, Kullmann, et al. 2014) 
suggesting that this cognitive hub is an insulin sensitive brain region. In relation to 
the current study, Kullmann et al., showed an opposing interaction effect between 
intranasal insulin and group (lean and obese) for resting state cerebral blood flow 
(CBF) in the prefrontal cortex (Kullmann, Heni, Veit, Scheffler, Machann, Haring, et 
al. 2015). They showed that prefrontal cortex CBF was reduced in lean, insulin 
sensitive, individuals but was increased in obese, insulin resistant (HOMA-IR > 2.0), 
individuals in response to intranasal insulin administration compared to placebo 
(Kullmann, Heni, Veit, Scheffler, Machann, Häring, et al. 2015). The insulin induced 
reduction in the lean individuals correlated well with disinhibition measurements and 
thus the authors suggest a modulatory role for insulin within the prefrontal cortex 
(Kullmann, Heni, Veit, Scheffler, Machann, Häring, et al. 2015). On closer inspection, 
however,  the origin of the CBF interaction effect observed by these authors was 
lateralised and more superior to that observed from this taste paradigm. The region 
reported in Kullmann et al. corresponded to the middle frontal gyrus (Kullmann, 
Heni, Veit, Scheffler, Machann, Häring, et al. 2015) as opposed to the more medial 
regions of the prefrontal cortex (rostral ACC and mOFC) seen from this current 
analysis and therefore similarities between these studies should not hold significant 
weight in support or opposition of these findings. Furthermore, the taste paradigm 
employed is a complex functional task that engages reward and learning circuitry as 
well as areas involved in taste anticipation and consumption rather than a resting 
state perfusion interrogation.   
 
More relevant are studies that report activity within these regions in response to task 
based manipulation. For example, fMRI studies have shown the involvement of the 
vmPFC and rostral ACC (rACC) during encoding and predicting value of future 
rewards, particularly during decision making paradigms (Gläscher, Hampton, and 
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O'Doherty 2009). The ACC is a large anatomical structure, with the more 
frontal/rostral regions being closely linked to the cognitive evaluation of reward 
(Toda et al. 2012). The rACC in particular is known to be responsive upon receipt of 
hedonically relevant stimuli, whether the stimulus be oral or olfactory (de Araujo and 
Rolls 2004; de Araujo et al. 2005). The taste response to both fat and sucrose produce 
increases in the BOLD response within the rACC, irrespective of viscosity (de Araujo 
and Rolls 2004). Similarly, BOLD response magnitude in response to odour stimuli has 
been shown to be greater for stimuli labelled as ‘appealing’ (e.g. cheddar cheese) in 
comparison to the same odour labelled as ‘unappealing’ (e.g. body odour) (de Araujo 
et al. 2005). In the same vain, the rACC region has been shown to elicit a greater 
magnitude BOLD response to an umami  taste stimulus labelled as appealing vs the 
same umami stimulus with a less appealing label (de Araujo et al. 2003). Thus the 
rACC has a cognitive modulatory effect on appealing and unappealing stimuli. In light 
of this involvement of the rACC in taste modulation and response, the participants 
were instructed to learn the association between cue and taste. Knowledge of each 
taste was not provided until completion of the entire study and so the response in 
this region could be attributed to or associated with trying to encode the taste.  
 
The prefrontal cortex is an integrative hub with many roles and functions. The 
interaction effect observed from whole brain statistical maps for the stevia delivery 
contrast spans across multiple anatomical regions and slightly limits the 
interpretation power of this interesting result. As mentioned, whole paired t-tests 
within both groups did not reveal any significant drug related effects and thus power 
to speculate on this interaction effect is limited. Group related effects seen from the 
stevia cue, as mentioned previously, are seen within the same regions and also 
display lean related insulin increases in BOLD activity. Given the timing of events used 
in this paradigm and implemented within the 1st level model it could be argued that 
there is a carryover BOLD effect originating from the cue presentation to the bolus 
delivery.  
 
Significant drug related effects of insulin were seen from the stevia delivery vs 
withheld contrast from ROI analyses that interrogated insulin related changes from 
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functional data acquired during the first and second run separately. Combining both 
runs was important for an initial analysis however the learning and sensitisation 
elements of this task may introduce temporal characteristics that warrants analyses 
of each run separately.  
 
Ancillary VAS measures of how much each taste was liked and how sweet the 
participant found the taste bolus help to support the notion of temporal effects from 
this task. Following placebo administration, stevia solution was rated as significantly 
less sweet at the end of the second run compared to sweetness ratings made at the 
start of the first run but was not coupled with a change in likeness ratings. Under 
insulin conditions ratings of stevia sweetness also showed a strong decrease over 
time which was also coupled with a decrease in subjective liking. These results 
suggest that, firstly, there are dynamic changes in sweet taste sensitisation for stevia 
solution and secondly, that these changes are more prominent following insulin 
administration which also changed the how much stevia solution was liked. Stevia, 
as well as other non-nutritive sweeteners, activates sweet taste receptors and bitter 
taste receptors on the tongue simultaneously, in a concentration dependent manner 
(Hellfritsch et al. 2012). The decrease in stevia sweetness over time could be from an 
increase in bitterness following repeated exposure, however the bitterness of stevia 
was not assessed and therefore this cannot be confirmed. The decrease in subjective 
stevia sweetness was more pronounced following insulin administration compared 
to placebo. This pronounced decrease in sweetness was coupled by a decrease in 
likeness suggesting a decrease in the hedonic value over time, associated with central 
insulin concentrations.  
 
ROI analysis employed to interrogate the data acquired during different independent 
runs for each BMI group separately, revealed interesting findings. No effects of drug 
or run were seen for any of the cue contrasts and no effects of drug or run were seen 
either for the sucrose delivery contrast. Effects were seen, however, within 
dopaminergic regions of the mesolimbic system for the stevia delivery contrast. 
Within lean individuals a significant increase in NAcc BOLD activity was seen in 
response to insulin compared to placebo, which was only apparent in the second run 
 291 
(SUMMARY BOX 2). In contrast, in the overweight group insulin produced decreases 
in BOLD activity within the striatum (caudate and putamen) compared to placebo 
during the first run.   
 
Work on reward processing has focused on the concept of reinforcement learning 
(classical conditioning) (Schultz 2001; Rescorla and Wagner 1972) and the 
involvement of the dopaminergic system in facilitating and reinforcing reward 
seeking and approach behaviours. Midbrain dopaminergic projections from the VTA 
and substantia nigra (SN) nuclei to the striatum and pre-frontal cortex are highly 
implicated in reward processing (Schultz 2001; Rolls 2004). Particular focus has been 
on the NAcc, a region commonly known for its role in pleasure and addiction (Adinoff 
2004). With reference to cue conditioned reward paradigms the dopaminergic 
neuronal firing responses within the NAcc shift from the reward presentation 
stimulus (e.g. 0.5ml sweet bolus) to the cue presentation (e.g. fractal cue) during 
conditioning, known as temporal difference learning (Sutton 1988). A pattern similar 
to a temporal shift can be seen following placebo administration from the lean group 
NAcc plots in response to stevia delivery (Figure 7.8.4). The plot shows that over time 
(from run 1 to run 2) the NAcc activity decreases, as would be seen in the case of a 
temporal dopamine shift from reward stimulus to cue presentation, once the 
association had been learnt (Schultz 1998). Interestingly in response to increased 
central insulin concentrations in the lean group this pattern is reversed; NAcc activity 
increases over time. Insulin plays a dual role in the local mesolimbic regions. Firstly, 
insulin binds to insulin receptors on pre-synaptic striatal (NAcc and CPu) neurons and 
acts to increase pre-synaptic dopamine uptake via upregulated dopamine 
transporter activity (DAT) (Stouffer et al. 2015). Secondly, excitatory cholinergic 
interneurons that synapse onto striatal neurons display pre-synaptic insulin 
receptors. Successful binding of insulin upon these cholinergic interneurons 
increases excitability and action potential frequency thus increasing downstream 
dopaminergic release from striatal dopamine neurons (Stouffer et al. 2015). The 
latter effect is most prominent upon increased insulin concentrations and is sufficient 
to overcome the increased DAT uptake activity in response to increased striatal 
insulin concentrations. The increase in BOLD response seen from the NAcc from the 
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lean group may be explained by the excitatory effects of insulin on cholinergic 
interneurons associated with subsequent dopamine release. Cholinergic 
interneurons receive input from the thalamus and this mechanism is involved in 
directing attention, reinforcement and also learning (Smith et al. 2011). It could be 
suggested that the insulin related BOLD increase in this region is reflective of an 
informative signal, potentially due to a change in hedonic properties or valence. 
Perhaps the change in palatability and sweetness seen from VAS scores would be 
significant to elicit this attention signal.  
 
One thing that has not been explored that would supplement this data is looking at 
the negative prediction error response that would occur during omission of the taste 
bolus. As the delivery event has been contrasted with the withheld delivery event 
the contrast images produced will have contributions from both beta estimates. This 
needs further exploration to help decipher the insulin related increases witnessed 
from the NAcc in the lean group.  
 
In contrast, the OW group displayed an insulin related striatal (caudate and putamen) 
BOLD decrease in response to stevia presentation. Interestingly, from Stouffer et al., 
the sensitivity of insulin related dopamine release from striatal neurons (NAcc, 
caudate-putamen) is diet dependent with obese rats displaying diminished insulin 
related dopamine synaptic concentrations (Stouffer et al. 2015). Although the 
participants involved in the current study are overweight and not obese, this result 
is in support of the notion that insulin may have a differential response in those with 
an increased BMI. Stouffer et al., and Jones et al., both showed that under chronic 
low basal insulin concentrations the caudate-putamen showed reduced  insulin 
dependent DAT expression and activity, thus displaying an increase in net caudate-
putamen dopamine release (Stouffer et al. 2015; Jones et al. 2017). Given that central 
insulin concentrations are decreased in those with a greater fat mass (i.e. BMI) (Kern 
et al. 2006) the greater BOLD response in the caudate-putamen seen in the OW group 
under placebo conditions vs insulin would be supported (see Summary Box 2). In 
turn, the presence of increased central insulin following intranasal insulin 
administration may reinstate DAT activity thus reducing caudate-putamen 
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dopaminergic activity as seen from the data. The lean group showed no insulin 
related changes in caudate-putamen activity which may suggest that the caudate-
putamen is more sensitive to weight and fat induced changes in insulin related DAT 
sensitivity.  
 
In conclusion this task has highlighted several interesting effects that intranasal 
insulin has on primary reward. The effects of centrally acting insulin are noticeably 
differently between lean and overweight groups for some of the contrasts 
interrogated in this task. In general, insulin acts to drive different neural responses 
between lean and overweight individuals. Interestingly, the effects of intranasal 
insulin were limited to the receipt of stevia, a non-nutritive sweetener. The reasoning 
behind this could be that stevia is novel to the taste buds and that this added novelty 
is sufficient to recruit and affect areas of the brain involved in higher level cognitive 
functions akin to the reward learning process. Insulin affects were seen within the 
striatum (NAcc, caudate-putamen) and this finding helps to support central insulin’s 
role in dopaminergic signalling. Understanding the effects that this may have on 
energy related decision making and reward related deficiencies in obesity or insulin 
resistance is of great importance and continued research in this area is needed to 















Chapter 8  Evaluation of the effects of 
intranasal insulin on resting functional 
connectivity  
 
This chapter covers the resting state Blood Oxygen Level Dependent (BOLD) 
functional MRI component of the SNIFAR study that was employed to interrogate the 
effects of intranasal insulin administration on functional connectivity measures as 
well as effects of body mass index (BMI). Specific details regarding the acquisition 
parameters, pre-processing and analysis techniques employed for this component of 
the SNIFAR imaging study will be reported. For the analysis of these data, only ‘seed 
based connectivity’ inferences were made . The findings and results from this 
component are discussed with reference to previous fMRI based intranasal insulin 















8.1 Introduction  
Centrally acting insulin has been shown to have an effect on a number of centrally 
controlled functions including memory, cognition, mood modulation, reward and 
appetite control (Kullmann, Heni, Fritsche, et al. 2015; Ott et al. 2012; Tiedemann et 
al. 2017; Stouffer et al. 2015). Key to understanding these modulatory effects has 
been the implementation of intranasal insulin administration coupled with a 
combination of multi-modal fMRI techniques (Kullmann, Heni, Fritsche, et al. 2015). 
Among these techniques, a body work has been conducted to investigate the effects 
of intranasal insulin on resting state functional activity (Kullmann et al. 2013; 
Kullmann, Heni, et al. 2017; Kullmann et al. 2018). The majority of this work has 
examined changes in BOLD signal dynamics using techniques known as Amplitude of 
Low-Frequency Fluctuations (ALFF) and Fractional Amplitude of Low-Frequency 
fluctuations (fALFF) (Zuo et al. 2010).  Measures of ALFF and fALFF provide a view on 
resting, regional neuronal activity through quantifying the fraction of the total power 
of the BOLD signal that corresponds to the low frequency range (0.01 – 0.1 Hz) (Lv et 
al. 2018). Comparatively little work has been conducted to investigate the effects of 
intranasal insulin on network dynamics and functional connectivity through a seed-
based model-driven approach, which was the main aim of this component of the 
SNIFAR protocol.  
 
In this work, resting state BOLD data were acquired using a multi-echo (ME) EPI 
acquisition protocol combined with an image pre-processing and denoising 
methodology called multi-echo independent component analysis (ME-ICA). As 
described in Chapter 2 (section 2.3.4), a multi-echo EPI acquisition acquires multiple 
whole brain EPI images (in this case three) at multiple TEs following spin excitation, 
in contrast to conventional EPI BOLD acquisitions which acquire a single EPI image 
(Howseman and Bowtell 1999). The benefits of the multi-echo acquisition approach 
are two-fold. Firstly, multiple EPI images can be combined using an optimally 
weighted summation approach to increase BOLD sensitivity throughout the entire 
brain (Posse et al. 1999). And secondly, the richness of the data per excitation (TR) 
permits the implementation of a denoising technique, ME-ICA (Kundu et al. 2012), 
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which was employed in this component of the SNIFAR investigation. The details of 
the ME-ICA methodology have been explained in detail in Chapter 2 (section 2.3.4). 
 
Prior to SNIFAR study initiation, a study was conducted in a small number of healthy 
volunteers (n=8, 6M, 2F) to compare multi-echo denoising against a conventional 
single echo EPI acquisition (Wingrove et al. 2016). This work supported the use of 
ME-ICA for denoising functional timeseries compared to conventional single echo 
data, producing results that were similar to those obtained by Kundu et al., (Kundu 
et al. 2013; Kundu et al. 2012). Furthermore, using the multi-echo EPI methodology, 
data were collected to investigate two important issues: a) the optimum number of 
echo time-series to be used for denoising (3 echoes vs 4) (Wingrove, O’Daly, and 
Zelaya 2017b) and b) the differences between performing analysis on multi-echo 
data spatially normalised to standardised space (e.g. MNI), or in native subject space 
(Wingrove, O’Daly, and Zelaya 2017a). From this work, the use of three-echo data 
proved to be preferable to four-echo data with superior discrimination of BOLD and 
non-BOLD components. More specifically, four echo data in some occasions failed to 
identify non-BOLD components and therefore did not ‘denoise’ the dataset as 
efficiently as the three echo data. The data suggested that the fourth echo images, 
acquired with a long echo time (TE = 48ms) and with low signal to noise ratio (SNR), 
reduced the sensitivity of the denoising algorithm and thus three echoes turned out 
to be better in comparison (Wingrove, O’Daly, and Zelaya 2017b). Finally, analysis in 
subject space or MNI space did not show large amounts of differences as both 
performed comparatively well in terms of denoising. However, analysis conducted in 
native space is quicker and less computationally intensive due to a smaller number 
of voxels per image in the native space domain. 
 
As a result of the above, the SNIFAR study was acquired using a three echo multi-
echo sequence and analysed in native space, prior to normalisation of the final 




In this resting state BOLD investigation, data from all subjects (n=27) were included. 
In total there were 12 lean participants (BMI = 22.40 ± 1.89 (mean ± standard 
deviation)) and 15 OW participants (BMI = 27.76 ± 1.92), (mean difference in BMI = 
5.36, p < 0.001, two-tailed unpaired t-test). Groups did not differ significantly in age, 
as described in Chapter 5 (section 5.1.1) 
8.2.1 Image acquisition 
The resting state BOLD data were collected following the final anatomical image 
acquisition and were the first of the functional image series. This acquisition was 
approximately 25-30 minutes following intranasal insulin/placebo administration at 
a time when central insulin levels were close to their peak (Born et al. 2002).  
 
Whole brain functional images were acquired using a custom-built, T2* weighted 
gradient echo multi-echo echo-planar imaging (ME-EPI) pulse sequence.  A 32-
channel receive only coil and ‘array coil spatial sensitivity encoding slices’ (ASSET) 
was employed for parallel imaging. Slices were acquired in a sequential top down 
direction in the near-axial plane parallel to the anterior-posterior commissure line 
(approximately 30° from the ‘true axial’ orientation) with the following parameters: 
TR = 2000 ms, TE = 12,28 and 44 ms, flip angle = 80°, acquisition matrix size = 64 x 64, 
FOV = 211 x 211, slice thickness = 3 mm, slice gap = 0.3 mm, no. of slices = 32, in plane 
voxel size = 3.30 x 3.30 mm2. Four dummy acquisitions were used to achieve steady 
state magnetisation, which were discarded. The total number of imaging volumes 
was 192 acquired in 6:32 mins.  
8.2.2 Image Processing  
All resting state data pre-processing and seed based functional connectivity analyses 
was performed using AFNI, FSL and SPM functional imaging software packages. All 
data denoising processes were performed in subject specific space. Only for group 
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level seed-based connectivity analysis were images normalised and co-registered to 
MNI space.  
 
Multi-echo EPI data was first split into individual echo times series (using the FSL 
function ‘fslsplit’).  In each echo time series, signal outliers were removed using the 
‘3dDespike’ routine found in the ‘Analysis of Functional Neuroimages’ (AFNI) 
software suite (Cox 1996). To correct for subject motion, the first echo (TE=12ms) 
timeseries were realigned to a base volume using ‘3dVolreg’ (AFNI). Motion 
correction parameters were saved and applied to the second and third echo 
timeseries using ‘3Drotate’ (AFNI). Individual echo time series were subsequently 
corrected for slice timing acquisition differences using ‘3dTshift’ (AFNI). Brain 
extraction was performed to remove extra-cerebral signal from the first echo (using 
the ‘BET’ routine found in FSL). This ‘skull-stripped’ first echo image was then 
binarized and used as a mask to remove extra-cerebral signal from the other echo 
time series. All three ‘skull-stripped’ echo time series were concatenated along the 
z-axis for input into the ME-ICA denoising program (tedana.py, AFNI). 
8.2.3 ME-ICA denoising 
The ME-ICA denoising protocol has been previously described in Chapter 2 (section 
2.3.4). Output images from the ME-ICA processing consist of an optimally combined 
echo timeseries and a de-noised optimally combined echo timeseries. The latter de-
noised timeseries was used for the functional connectivity analysis.  
8.2.4 Spatial and temporal filtering 
Prior to seed based connectivity analysis, additional filtering was applied; deep white 
matter and CSF signal regression, bandpass filtering and spatial smoothing.  
 
Subject structural T1 images were segmented into grey matter (GM), white matter 
(WM) and cerebrospinal fluid (CSF) (FMRIB’s Automated Segmentation Tool, FAST, 
FSL, (Zhang, Brady, and Smith 2001)). WM and CSF segmentations were eroded 
(fslmaths, FSL), for extraction of deep WM and CSF time series and to avoid 
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contamination of grey matter partial volume signal, and co-registered to the 
functional time series using the inverse registration affine parameters saved 
previously. WM and CSF signal timeseries were extracted from the denoised 
optimally combined dataset and combined with the six affine motion correction 
regressors which were then regressed from the denoised timeseries (fsl_glm, FSL)(a 
total of eight regressors; WM, CSF and 6 x head motion).  
 
A temporal bandpass filter (0.01hz – 0.1hz) was applied (fslmaths, FSL) and images 
were spatially smoothed using a full width half maximum gaussian kernel of 8 x 8 x 8 
mm3. 
 
Finally, denoised and filtered timeseries were normalised to MNI space by applying 
the saved transformation steps using Advanced Normalisation Tools (ANTs)(Avants 
et al. 2011; Avants et al. 2014). 
8.2.5 Seed based connectivity analysis 
Based on several previous publications, analysis of the resting state -BOLD (rs-BOLD) 
multi-echo data was conducted to examine insulin related functional connectivity 
changes using a seed based connectivity approach using two anatomical regions; the 
insula cortex and the hippocampus. 
 
Mean signal time series data from denoised and filtered datasets were extracted for 
each subject from the defined seeds independently (3dROIstats, AFNI). A whole brain 
voxel-wise correlation was performed between the processed timeseries and the 
seed extracted time series (3dTcorr1D, AFNI) to produce a whole brain correlation 
maps (R values) for each subject. R values from these correlational maps were 
converted into z-scores using the Fisher Z-transformation (3dcalc, AFNI), to produce 





8.2.5.1 Insula seeds 
The insula has been shown to be responsive to intranasal insulin administration 
(Schilling et al. 2014) but little is known about the modulatory effects insulin may 
have on the regional functional connections of this substrate with other parts of the 
brain. Spherical seeds with a 5mm radius were created for both left and right anterior 
and posterior divisions of the insula, based on co-ordinates from Taylor et al., (Taylor, 
Seminowicz, and Davis 2009)(displayed in Figure 8.2.1, coordinates in Table 8.2.1). 
The insula cortex is particularly large in volume and with known anatomical and 
functional segregations (Kurth, Zilles, et al. 2010; Stephani et al. 2011). This was taken 
into consideration in the design stage of the analysis and the seeds were created 




Figure 8.2.1 An image showing the locations of the four insula seeds used 
in this resting state analysis overlaid onto  structural MNI image. The 
seeds in the images are smaller in volume  than the 5mm spherical seeds 
employed in the analysis. The seeds correspond to the left and right 
anterior and posterior insula, respectively.  
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8.2.5.2 Hippocampus Seeds 
The hippocampus has an abundance of insulin receptors and is thought to be crucial 
in several memory related processes (Ott et al. 2012). Hippocampal seeds were 
defined by the creation of 5mm radius spheres within the left and right anterior and 
posterior regions of the hippocampus as defined by Kahn et al., (Kahn et al. 
2008)(displayed in Figure 8.2.2).  
 
Table 8.2.1 Insula seed coordinates used in 
the resting state analysis.  
Figure 8.2.2 A table of hippocampus seed coordinates and the posterior and anterior 
hippocampus seed locations displayed onto a structural MNI image. 
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8.2.6 Group level analysis  
A random effects group level analysis was conducted to explore insulin related 
functional connectivity effects and also within treatment group effects. For each 
seed, subject specific z-maps were entered into a second level repeated measures 
factorial model (SPM-12) with three factors; subject, drug (insulin, placebo) and 
group (lean, OW). Four linear contrasts of interest were created to explore for the 
main effects of drug and any drug by group interactions:  
 
1. Insulin > Placebo (Main effect of insulin) 
2. Insulin < Placebo (Main effect of placebo) 
3. Lean Insulin > Placebo, OW Insulin < Placebo (Interaction 1) 
4. Lean Insulin < Placebo, OW Insulin > Placebo (interaction 2) 
 
The resulting statistical parametric t-maps created from this second level model were 
set to a cluster forming voxel threshold of p < 0.001 uncorrected. This seed based 
connectivity analysis was performed using a total of the eight seeds described earlier. 
The statistical threshold of the FWE correction for multiple comparisons was 
adjusted for multiple seeds and tests (0.05/8). The statistical cluster extent threshold 
was set to FWE p < 0.0063 to address the multiple seed/testing issue. Therefore, only 
clusters that survived the statistical threshold of p < 0.0063 (FWE-corrected) will be 
reported as significant. 
 
The repeated measures ANOVA model employed at the second level (known in SPM 
as a flexible factorial model) is limited to interrogate treatment related effects and 
group by treatment interactions, but not main group effects. Significant clusters 
observed from either of the interaction contrasts tested were interrogated further in 
two ways. 
 
Firstly, group effects were tested within treatment using whole brain unpaired (two-
sample) t-tests. Linear contrasts for lean vs OW were created and tested. This whole 
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brain parametric analysis used a cluster forming voxel threshold of p < 0.001 and 
significant clusters were reported based on a p < 0.05, FWE-corrected statistical 
threshold. Furthermore, one sample t-tests within group for each treatment were 
conducted and presented to visualise the network structure generated from those 
seeds that were taken through to post-hoc analysis.  
 
Secondly, treatment effects were tested within groups by creation of whole brain 
paired t-tests. Linear treatment contrasts (i.e. IN-INS > IN-PLA) within these paired t-
tests were created and tested. Whole brain paired t-tests conducted in the lean 
group were performed both with and without the addition of the HOMA-IR score 
(calculated in Chapter 5, section 5.1.5) as an additional regressor of no interest 
(nuisance covariate) within the model. This regressor was added to help account for 
some of the physiological variance witnessed at baseline in the lean group (as 
detailed in Chapter 5, section 5.1.6). This methodological addition was only 
implemented in the lean group and not the OW group. In the OW group, one of the 
participants did not provide a full blood profile and therefore baseline HOMA-IR 
scores could not be used as a nuisance regressor in this OW group analysis. 
 
For illustration purposes, all statistical t-maps are overlaid onto a T1 weighted MNI 
oriented image using MRIcroGL. Anatomical assignment of statistically significant 
clusters was done with the built-in probabilistic atlases within FSL (FMRIB Software 






8.3 Results  
8.3.1 Group level analysis 
8.3.1.1 Anterior insula – left and right 
Results from random effects group level repeated measures factorial model analysis 
did not reveal any main treatment effects or interaction effects of functional 
connectivity for either the left or right anterior insula seed correlations.   
8.3.1.2 Posterior insula seed – left and right  
For the right posterior insula, whole brain repeated measures analysis did not reveal 
any significant main treatment or interaction effects on functional connectivity.  
Whole brain results from random effects group level analysis for the left posterior 
insula produced three large clusters from the interaction 1 contrast (Lean IN-INS > 
IN-PLA, OW IN-INS < IN-PLA) (see Figure 8.3.1 and Table 8.3.1). These clusters, were 
situated around the left dorsal medial prefrontal cortex (dmPFC), left lateral occipital 
cortex and left middle temporal gyrus with the left dmPFC cluster surviving multiple 
seed correction (p < 0.05, FWE – corrected).  
Figure 8.3.1 An image showing the left posterior insula seed interaction (1) effect t-map overlaid 
onto a structural MNI image. Maps contain only clusters that survived p < 0.05, FWE – corrected 
cluster extent statistical threshold. A) Sagittal slices show statistically significant cluster 
formations in the dmPFC region, which survived multiple seed correction. B) An axial slice 
illustrating the dmPFC significant cluster. C)  Coronal and axial slices illustrating the middle 
temporal gyrus cluster which did not survive the multiple seed correction threshold. 
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8.3.1.3 Left posterior insula seed -  group effects 
Following this interaction effect whole brain unpaired t-tests were conducted to look 
for functional connectivity group differences, within treatment. This analysis did not 
reveal any significant between group effects for either the IN-PLA session or the IN-
INS session.  
8.3.1.4 Left posterior insula seed - treatment effects 
Post hoc analysis whole brain paired t-tests were conducted for the left posterior 
insula seed correlation Z-maps to explore this interaction effect.  
Paired t-tests performed in the OW group did not reveal any significant treatment 
effects.  
 
The paired t-test conducted without the addition of the HOMA-IR regressor in the 
lean group (IN-INS > IN-PLA) revealed a large significant cluster (823 voxels, p < 0.001, 
FWE-corrected) situated over the left and right precuneus/posterior cingulate cortex 
(PCC) (see Figure 8.3.2 and Table 8.3.2). 
Table 8.3.1 Whole brain statistic results from the interaction (1) effect observed from the repeated 
measures ANOVA analysis conducted for the left posterior insula seed. Cluster size refers to the 
number of voxels within the significant cluster. p values in BOLD correspond to those clusters that 




Similarly, the paired t-test conducted with HOMA-IR regressors (lean: IN-INS > IN-
PLA) revealed two large significant clusters, that both survived the multiple seed 
correction threshold (see Figure 8.3.3 and Table 8.3.3),situated over the left and right 
precuneus/PCC and the dmPFC, respectively. These whole brain post hoc analyses 
IN-INS show an increase in functional connectivity between the left posterior insula 
seed and regions of the PCC and dmPFC when compared to IN-PLA.  
Figure 8.3.2 Whole brain paired t-test, t-map for the left posterior insula seed 
(IN-INS > IN-PLA) in the lean group overlaid onto a structural MNI template. A) 
sagittal and B) axials sections show increased functional connectivity between 
the left posterior insula seed and the PCC following IN-INS vs IN-PLA. 







Figure 8.3.3 Whole brain paired t-test, t-map for the left posterior insula seed (IN-INS 
> IN-PLA) in the lean group, with the addition of HOMA-IR scores as a regressor of no 
interest overlaid onto a structural MNI template. A) sagittal and B) axials sections 
show increased functional connectivity between the left posterior insula seed with 
the PCC and dmPFC following IN-INS vs IN-PLA. 
Table 8.3.3 Whole brain statistics for the lean group left posterior insula seed connectivity paired t-
test, with additional HOMA-IR score regressor.  
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8.3.1.5 Anterior hippocampus – left and right 
No significant effects were seen from whole brain analysis for either the left or the 
right anterior hippocampal seed correlations.  
8.3.1.6 Posterior hippocampus – left and right 
Using the right posterior hippocampus as a seed region, group level whole brain 
repeated measures analysis did not reveal any main treatment effects. From the 
interaction 1 contrast (Lean IN-INS > IN-PLA, OW IN-INS < IN-PLA), a cluster was 
identified in the right somatosensory cortex but did not survive multiple seed 
correction (335 voxels, p = 0.043). Therefore, post hoc analysis was not conducted 
for this seed.  
 
Using the left posterior hippocampal seed, whole brain group level analysis showed 
that for the interaction 1 contrast (Lean IN-INS > IN-PLA, OW IN-INS < IN-PLA) 
revealed two large clusters (significant at p < 0.05, FWE) (see Figure 8.3.4 and Table 
8.3.4), one of which survived multiple seed correction and one which did not. The 
significant cluster which survived multiple comparison correction (608 voxels) was 
situated around the right somatosensory cortex and the other (406 voxels) was 














Figure 8.3.4 An image showing the left posterior hippocampus seed interaction (1) effect t-map 
overlaid onto a structural MNI image. Maps contain only clusters that survived p < 0.05, FWE – 
corrected cluster extent statistical threshold. A) Coronal slices show statistically significant 
clusters  in the left middle frontal gyrus  region, which did not survive multiple seed correction. 
B) Axial slices illustrating the left middle frontal gyrus cluster as well as the right somatosensory 
cortex significant cluster 
Table 8.3.4 Whole brain statistic results from the interaction (1) effect observed from the 
repeated measures ANOVA analysis conducted for the left posterior hippocampus seed. 
Cluster size refers to the number of voxels within the cluster. p values in BOLD correspond to 
those clusters that survived multiple seed correction threshold. Lean (n=12), OW (n=15).   
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8.3.1.7 Left posterior hippocampus seed -  group effects 
Whole brain one sample t-tests are presented in Figure 8.3.5 for each group showing 
the spatial extent of the left posterior hippocampus functional connectivity maps, for 
display purposes.  
 
Following IN-PLA there was a significant increase in functional connectivity seen 
between the left posterior hippocampus seed region and a region in the right primary 
sensory cortex in the OW group vs the lean group (see Figure 8.3.6 and Table 8.3.5). 
There were no significant increases in functional connectivity in the lean group when 







Figure 8.3.5 Whole brain one sample t-tests for each group for the left posterior hippocampus seed. 
A) lean and B) OW group functional connectivity maps, thresholded to p < 0.05, FWE-corrected level 






















Figure 8.3.6 T-map overlaid onto a structural MNI showing group differences (OW > lean) for 
the left posterior hippocampus seed, following IN-PLA administration. A) axial, B) coronal and 
C) sagittal sections showing the right somatosensory cortex cluster.  




Whole brain one sample t-test maps for both groups following IN-INS are presented 
in Figure 8.3.7. Following IN-INS there was a significant increase in functional 
connectivity seen between the hippocampus seed and a region corresponding to the 
right middle/superior frontal gyrus (Figure 8.3.7 and Table 8.3.6) in the lean group 
compared to the OW group. There were no other statistical group related differences 
seen for the IN-INS condition.  
Figure 8.3.7 t-map overlaid onto a structural MNI showing group differences (Lean > OW) for the left 
posterior hippocampus seed, following IN-INS administration. A) Sagittal and B) axial sections showing 
the right middle frontal gyrus cluster. 
Whole brain one sample t-tests for each group for the left posterior hippocampus seed. A) lean and 
B) OW group functional connectivity maps, thresholded to p < 0.05, FWE-corrected level following IN-
INS administration 
Figure 8.3.8 Whole brain one sample t-tests for each group for the left posterior 
hippocampus seed. A) lean and B) OW group functional connectivity maps, thresholded 
to p < 0.05, FWE-corrected level following IN-INS administration 
t-map overlaid onto a structural MNI showing group differences (Lean > OW) for the left 
posterior hippocampus seed, following IN-INS administration. A) Sagittal and B) axial 




8.3.1.8 Left posterior hippocampus seed - treatment effects 
Following the significant interaction effect seen from the whole group ANOVA model 
post hoc whole brain paired t-tests were then performed in the lean and OW group 
to look for within group treatment effects. Post hoc whole brain paired t-tests within 
the OW group did not reveal any significant treatment effects.  
 
Post hoc whole brain paired t-tests within the lean group (IN-INS > IN-PLA) with no 
additional regressors provided a large significant cluster (526 voxels, p = 0.001, FWE-
corrected) around the left fusiform gyrus (Figure 8.3.9 and Table 8.3.7).  
Table 8.3.6 Statistics from the left posterior hippocampus seed group differences Lean > OW, IN-
INS. 
Figure 8.3.9 t-map overlaid onto structural MNI image from lean group IN-INS > IN-PLA (paired 
t-test). A) Sagittal and B) Axial and coronal sections showing IN-INS related increase in functional 




With the addition of the HOMA-IR regressor into the paired t-test model, a significant 
cluster was obtained in the left fusiform gyrus (451 voxels, p = 0.002, FWE-corrected) 






Table 8.3.7 Whole brain statistics for the lean group left posterior hippocampus seed connectivity 
paired t-test (IN-INS > IN-PLA).    
Figure 8.3.10 t-map overlaid onto structural MNI image from lean group IN-INS > IN-
PLA (paired t-test) with the inclusion of HOMA-IR regressor into the model. A) 
Sagittal and B) Axial and coronal sections showing IN-INS related increase in 
functional connectivity within the fusiform gyrus. 
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8.3.2 Additional procedures to aid interpretation of treatment effects 
Following formation of significant clusters from treatment effect contrasts within the 
post-hoc paired t-test analyses (with HOMA-IR regressors), there were additional 
steps taken to aid interpretation of these results for both the left posterior insula and 
hippocampus seeds.  
 
Firstly, the significant clusters found from whole brain paired t-test models were used 
as masks to extract mean correlational values (Z-scores) from subject specific z-maps 
and plotted to evaluate the magnitude of the correlations. These values were plotted 
only and not used within any statistical tests to ‘supplement’ the whole brain 
statistics observed from the paired t-test analysis.  
 
Secondly, a potential drawback of seed-based correlational analysis is that an 
increase in functional connectivity between two brain regions does not inform 
underlying BOLD activity, rather an increase in correlation. To aid interpretation of 
these functional connectivity changes seen, measures of low frequency fluctuations 
(ALFF), which are useful for detecting the regional intensity of spontaneous 
fluctuations in BOLD signal (Zou et al. 2008), were obtained from significant clusters 
(from paired t-tests) and seed ROIs. With these cluster and seed measures the effects 
of insulin on ALFF can be observed, providing a better and clearer understanding of 
the mechanisms underlying the insulin related functional connectivity increases 
witnessed. 
Table 8.3.8 Whole brain statistics for the lean group left posterior hippocampus seed connectivity 
paired t-test (IN-INS > IN-PLA) with the addition of HOMA-IR scores as a regressor of no interest. 
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This was done by, firstly creating whole brain ALFF maps for each lean participant 
and each session using AFNI’s 3D resting state functional connectivity program 
(3DRSFC, AFNI). Denoised, filtered and smoothed timeseries (the final output from 
image pre-processing) were used to create a voxel-wise ALFF map (for an example 
ALFF map see Figure 8.3.11). The signal intensity from each voxel within these maps 
is equal to the total power of the BOLD signal within the range 0.01 and 0.1Hz 
measured from that voxel timeseries. Mean ALFF values were extracted from the 
significant clusters and respective seeds (using 3Dmaskave, AFNI) and the mean 
group value was plotted for each condition.  
 
Similarly to the extracted z-values as mentioned above, no formal statistical testing 
was conducted on any of the mean values extracted. All values were calculated from 
a mask of significant change and therefore any statistical analysis conducted using 
these would be biased. Therefore, only summary statistics such as the group mean 







Figure 8.3.11 Axial sections of an example ALFF map made by averaging across the lean group 
IN-PLA session (n=12). ALFF is higher in cortical areas in comparison to sub-cortical and white 
matter regions.  
 317 
8.3.3 Additional procedure analysis 
8.3.3.1 Left posterior insula – extracted correlation values 
Mean Z-scores were extracted from the significant bilateral PCC and dmPFC clusters 
obtained from the lean group post hoc paired t-test analysis with HOMA-IR covariate 
and plotted in Figure 8.3.12. From this plot it can be seen that following IN-PLA 
functional connectivity between these regions is negative, but in response to IN-INS, 
functional connectivity, as measured via correlation (Z-scores), increases from a 
negative value to a small positive value (mean z score IN-INS PCC = 0.04, mean z score 
IN-INS dmPFC = 0.09, respectively). This implies that under IN-PLA conditions the PCC 
and dmPFC are anti-correlated (negative z-score) with the left posterior insula seed 
but under IN-PLA the degree of anti-correlation changes and these regions become 
very slightly correlated (small positive z-score).  
 
Figure 8.3.12 Line plot showing the mean Z-values from the PCC and dmPFC clusters 
extracted from the left posterior insula z-maps for the lean group.  
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Mean ALFF values extracted from the PCC, dmPFC and left posterior insula seed are 
plotted in Figure 8.3.13.These plots show that firstly under IN-PLA conditions that the 
ALFF measures between all regions are quite different, with the seed displaying the 
lowest ALFF measures and the dmPFC showing the greatest ALFF score. And 
secondly, these plots show that there is very little change between ALFF for any of 
these regions in response to IN-INS compared to IN-PLA. 








Figure 8.3.13 ALFF values extracted from the left posterior insula seed, PCC and dmPFC 
clusters from both IN-PLA and IN-INS ALFF maps.  
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For illustration and interpretation purposes, mean Z-scores were extracted from the 
left fusiform gyrus cluster (created from the lean paired t-test IN-INS > IN-PLA, with 
HOMA-IR covariate) from both IN-PLA and IN-INS sessions from the lean group only 
and plotted in Figure 8.3.14. From this plots it can be seen that there is an IN-INS 
related increase in functional connectivity between the left posterior hippocampus 
and the left fusiform gyrus cluster (mean z-score IN-PLA = 0.16, mean z-score IN-INS 








Figure 8.3.14 Line plot showing the mean Z-values from the fusiform gyrus  cluster 
extracted from the left posterior hippocampus z-maps for the lean group. 
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Furthermore, mean ALFF scores were extracted from the same cluster and also from 
the left posterior hippocampus seed sphere for each treatment session and plotted 
in Figure 8.3.15. Furthermore, ALFF measurements were increased in the fusiform 
gyrus following IN-INS compared IN-PLA (mean ALFF IN-PLA = 401.71, mean ALFF IN-
INS = 475.83). ALFF measures from the left posterior hippocampus seed were much 
smaller and a small increase in ALFF in response to IN-INS compared to placebo 
(mean ALFF IN-PLA = 127.62, mean ALFF IN-INS = 132.47) was observed. From these 
data, the IN-INS increase in functional connectivity between the left posterior 
hippocampus and a region of the left fusiform gyrus in the lean group can be clearly 
seen and that coupled with this increase in functional connectivity is an increase in 




Figure 8.3.15 ALFF values extracted from the left posterior hippocampus seed, fusiform gyrus 
cluster from both IN-PLA and IN-INS ALFF maps. 
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8.4 Discussion  
Seed-based connectivity analysis performed on multi-echo denoised BOLD data 
displayed intranasal insulin associated increases in functional connectivity between 
the left posterior hippocampus and the left fusiform gyrus, which was exclusive to 
the lean/normal weight individuals. Correlational measures between the left 
posterior insula and the precuneus and dmPFC were significantly modified by IN-INS, 
again exclusively in the lean group. Resting state neuronal information is carried by 
low frequency (<0.1Hz) oscillations from the time series frequency spectrum. An 
index of these fluctuations, in addition to the synchronicity measured as functional 
connectivity, is ALFF. Regional ALFF values extracted from regions significantly 
modulated by IN-INS were used as a supplementary information to describe the IN-
INS results seen from this whole brain functional connectivity analysis.  
 
Furthermore, group differences in the left posterior hippocampus functional 
connectivity was also observed. OW individuals displayed increased functional 
connectivity between the left posterior hippocampus seed and the right sensory 
cortex following IN-PLA, whereas the lean group displayed greater functional 
connectivity between the left posterior hippocampus and the middle frontal gyrus 
following IN-INS administration. 
8.4.1 Relationships with insulin resistance as measured by HOMA-IR 
For lean group treatment analyses, a ‘default’ whole brain paired t-test model was 
constructed as well as a paired t-test model that included the HOMA-IR score for 
each session as a regressor/covariate of no interest. These scores were added to the 
model in an attempt to explain some of the between session variability. For the left 
posterior hippocampus seed based analyses the addition of HOMA-IR scores had no 
effect on the parametric maps created when compared to the model without the 
added regressor. However, the addition of HOMA-IR regressor to the left posterior 
insula seed based analyses (lean paired t-test) provided the observation of a 
significant cluster formation in the region of the dmPFC, which was not observed in 
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the ‘default’ paired t-test model. From this observation the use of additional 
measures such as HOMA-IR proved beneficial in model fitting for this posterior insula 
seed analyses. The lack of effect seen from the posterior hippocampus seed may 
suggest that the effects seen in the fusiform gyrus were modelled well in the 
standard t-test and that the added attempt to explain any subject variability with 
HOMA-IR did not aid the model fitting.  
 
This discussion will focus on interpreting each of the aforementioned results with 
reference to resting state as well as task based fMRI literature. 
8.4.2 Insula  
The insula is an anatomical substrate situated within the fold of the lateral sulcus 
within each hemisphere. The insula exhibits several features of functional 
specialisation and plays an important role in key actions such as gustatory processing 
(Frank, Kullmann, and Veit 2013), interoception, awareness and pain processing, 
providing a necessary link between sensory processing and affective system 
engagement (Craig 2009). The insula can be divided anatomically and functionally 
into the anterior and posterior sub-regions, which are bisected by the middle 
cerebral artery and are involved in functionally discrete processes (Flynn 1999). 
Furthermore, the anterior and posterior insula belong to distinct functional networks 
as described from seed based connectivity of resting state BOLD analysis with the 
anterior insula being connected with regions involved in emotional awareness and 
interoceptive functioning (Cauda et al. 2011). In comparison, the posterior insula is 
situated within a network involving sensorimotor hubs and has been thought to be 
involved in environmental monitoring and skeletal orientation (Cauda et al. 2011). 
The results from this present study showed a large effect of IN-INS on posterior insula 
connectivity and therefore the focus will be on this region and its associated 




From this multi-echo denoising data analysis it shows that, at the whole brain level,  
IN-INS increases functional connectivity between the posterior insula and two main 
hubs of the default mode network (DMN), the PCC and dmPFC, respectively (Buckner, 
Andrews-Hanna, and Schacter 2008). However, extracting Z-scores from the PCC and 
dmPFC from both sessions reveals anti-correlation (negative Z score) with the 
posterior insula seed timeseries following IN-PLA, but following IN-INS the degree of 
anti-correlation is decreased (Z score goes from negative to positive).  Therefore, the 
effect observed at the whole brain level is not necessarily an IN-INS related increase 
in functional connectivity between the posterior insula seed and the PCC and dmPFC, 
but in fact a reduction in anti-correlation between the posterior insula and the PCC 
and dmPFC. The posterior insula is typically connected with the sensorimotor 
network (Deen, Pitskel, and Pelphrey 2011) and a large amount of task based 
research has also shown the posterior insula to be involved in pain related neural 
circuitry (Segerdahl et al. 2015). The sensorimotor network which typically involves 
the middle cingulate gyrus/supplementary motor area is known to be anti-correlated 
with the DMN at rest (Deen, Pitskel, and Pelphrey 2011). ALFF measures extracted 
from each of these regions do not suggest that there is any change in neural activity 
in either the PCC, dmPFC or posterior insula, implying that there are network level 
changes within the DMN and posterior insula-related sensorimotor connectivity that 
are causing this effect. From the analysis conducted, speculations as to why this 
affect is seen can be difficult and further analysis of DMN connectivity may have to 
be conducted to better understand this result.  
8.4.3 Hippocampus 
Using the posterior hippocampus as a seed region for this functional connectivity 
analysis permitted the observation that in response to IN-INS there was an increase 
in functional connectivity between this left posterior hippocampus and a region 
within the left fusiform gyrus. The fusiform gyrus forms part of the higher level visual 
cortex, residing within the ventral temporal cortex, and is well known for its 
involvement object recognition, face perception and processing  (Downing et al. 
2005). Task based fMRI studies involving the viewing of food pictures have shown the 
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involvement of both the fusiform gyrus and the hippocampus (Pelchat et al. 2004). 
Increased BOLD activity in both the fusiform gyrus and hippocampus are related to 
viewing of high and low calorie food pictures (Wallner-Liebmann et al. 2010) and 
have been associated with liking and craving for foods even from imagining and 
mental visualisation of different foods (Pelchat et al. 2004). In addition, the fusiform 
gyrus along with the hippocampus have previously been found to be modulated 
following IN-INS administration, within a task based food picture paradigm (Guthoff 
et al. 2010). Guthoff et al., showed that regions of both the hippocampus and 
fusiform gyrus displayed IN-INS related decreases in response to viewing food 
pictures compared to IN-PLA (Guthoff et al. 2010). They further speculate that the 
fusiform gyrus and hippocampus may form a circuitry that specialises in detection of 
food-related objects as there was no IN-INS related effects in these regions when 
viewing non-food pictures (Guthoff et al. 2010). Furthermore, increased central and 
peripheral insulin concentrations, via a hyperinsulinemic-euglycemic clamp 
technique, also showed bilateral fusiform gyrus decreases in BOLD activity in 
response to food pictures (Kroemer et al. 2013).  
 
The fusiform gyrus has been termed an ‘insulin sensitive’ brain region from several 
reviews (Heni et al. 2015; Häring 2016; Kullmann et al. 2016). Within the current 
study it can be seen that there is an IN-INS related increase in connectivity between 
the left posterior hippocampus and fusiform gyrus, however whether this increase is 
driven by an overall increase or decrease in BOLD activity or neither is beyond seed 
based correlation analysis. From the seed based results alone one can speculate that 
in lean individuals, IN-INS increases connectivity between higher visual regions and 
memory related areas important for visual recognition or visual memory processing. 
Perhaps this increase in functional connectivity between these regions, seen in this 
analysis, is key to some of the reported cognitive and memory related benefits of IN-
INS administration (Ott et al. 2012). As these data were collected during the resting 
state, or put another way, not during a cognitive engaging task, it is harder to 
interpret these findings and make fully supported claims on memory and cognitive 
effects in a direct manner. But the changes observed may underpin some of the 
 325 
effects reported by other studies.  Therefore, the interpretations of these results may 
be considered conjectural in the absence of data from cognitively-engaging periods.  
Whole brain ALFF maps were created in order to provide another perspective for the 
interpretation of the results from the seed based connectivity analyses. Mean ALFF 
values extracted from the fusiform gyrus cluster show an increase in response to IN-
INS compared to IN-PLA (approximately 20%). However, for the left posterior 
hippocampus seed region the change in ALFF was not as pronounced as that of the 
fusiform, which would suggest that this increase in connectivity is driven by an insulin 
related increase in oscillatory BOLD signal in the fusiform gyrus as opposed to a 
dynamic change BOLD activity in the posterior hippocampus. Rotte et al., showed 
that participants presented increased bilateral fusiform gyrus BOLD activity in 
response to viewing unscrambled vs scrambled images during a hyperinsulinemic-
euglycemic clamp, suggesting a role for insulin in modulating fusiform gyrus activity 
for imagery in general and not just food related pictures (Rotte et al. 2005). The 
increased connectivity seen here between these regions could be suggestive of fine 
tuning the visual system for object recognition. 
  
Another speculation could be that insulin may act as a modulator to consolidate 
memories, particularly visual memories. Active learning of word pairs and also 
visualising those word pairs during memory recall increases BOLD activation within 
the fusiform gyrus and regions of the extra-striate visual network (Gais et al. 2007). 
Chronic IN-INS administration, over eight weeks showed that IN-INS treatment 
significantly improved word recall performance (Benedict et al. 2004). In light of this 
report, and coupled with fusiform gyrus involvement in memory recall paradigms, a 
suggestion that central insulin action within the fusiform gyrus coupled with an 
increased connection to the hippocampus may be key to these beneficial memory-
associated effects. More research into both these regions would need to be 
conducted in order to supplement this suggestion. As mentioned previously, 
mentally visualising images of food also shows an increase in activation within the 
fusiform gyrus (Pelchat et al. 2004). An alternative, and final suggestion could be that 
during the resting state acquisition participants engaged in more imaginary and 
mental visualisation and perhaps this could be key to memory consolidation.  
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From observing the IN-PLA functional connectivity maps created using the left 
posterior hippocampus seed (Figure 8.3.5) the OW group display a widespread 
network that extends from the temporal lobe and covers a large region of the 
occipital lobe (visual association areas) and also prefrontal and frontal cortex regions. 
On the other hand, the lean group (following IN-PLA) display a much more 
constrained coverage comparatively to the OW group. The lean group seed based 
functional connectivity maps display much less cortical network connectivity. Formal 
whole brain comparisons revealed a statistically significant increase in connectivity 
between the posterior hippocampus and the right primary sensory cortex in the OW 
group vs the lean group.  
 
Formal whole brain comparisons did reveal that following IN-INS administration 
there was a significant increase in connectivity seen between the left posterior 
hippocampus and the right superior medial frontal cortex/middle frontal gyrus in the 
lean group vs the OW group. This region has previously been shown to be insulin 
responsive in studies of cerebral blood flow (CBF) that have used IN-INS 
administration. Kullmann et al., previously showed that the right middle frontal gyrus 
CBF was decreased in insulin sensitive individuals (measured by HOMA-IR) but 
increased in insulin resistant individuals in response to IN-INS (Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015). The CBF result mentioned above suggests 
that the right superior medial frontal cortex is an insulin sensitive region in both 
individuals with peripheral insulin sensitivity and resistance.  
 
The results reported from this resting state analysis suggest a differential response 
within the superior medial frontal cortex and middle frontal gyrus to IN-INS 
administration which is in line with that seen previously (Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015). However, clearly understanding the degree 
to which these effects share similarities, will require further interrogation. Given the 
anatomical location of this difference, however, one could speculate that this 
difference in connectivity could reflect a difference in attention as the superior 
medial frontal cortex is a key hub within the central executive network (Fang et al. 
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2016). The superior frontal cortex is recruited during working memory tasks with 
shapes (Yee, Roe, and Courtney 2010). A speculation could be that IN-INS increases 
general attention and focus that could be required for cognitive engagement, an 
effect which is more pronounced in the lean group, but not supported by any direct 
behavioural data.  
 
As mentioned previously, the left posterior hippocampus functional connectivity 
maps for the lean and OW groups were visually different during IN-PLA but visually 
more similar following IN-INS. An observation such as this could demonstrate that 
under IN-PLA conditions the OW group show a high degree of functional connectivity 
within this network, which even when stimulated by IN-INS does not have capacity 
to change. On the other hand, the lean group showed a recruitment of a greater 
number of regions during IN-INS suggesting a potential for increased connectivity and 
potentially cognitive benefits. In keeping with this, the lean group may potentially 
have a more efficient resting state posterior hippocampal network capable of 
modulation, whereas the OW do not have this additional capability.  
 
In a less speculative manner the absence of drug related effect in the OW group, 
could simply suggest the functional brain networks tested were not sensitive to the 
modulatory effects of central insulin. In a more pragmatic and critical approach it is 
necessary to remind the reader that this analyses was conducted exclusively at the 
whole brain level. In light of this simplistic approach, a more thorough region of 
interest based analysis approach would perhaps be more sensitive and appropriate 
to tease apart subtle insulin related changes in the OW group, and also additional 







Chapter 9 Discussion and Concluding 
Remarks 
 
The goal of this thesis was to perform a thorough investigation into the acute 
functional effects of intra-nasally administered insulin in the brain. To this end, the 
study probed the central functional effects of insulin both at rest and during a 
paradigm designed to assess primary food related reward.  The investigations at rest 
included resting state physiology (cerebral blood flow) and functional connectivity. 
The project was carried out in lean and overweight healthy male volunteers. 
Following a detailed analysis of these data, this thesis has provided new insights into 
the central role of insulin, which will hopefully contribute to an already extensive 
wealth of published data. The SNIFAR study has benefited from a range of newly 
developed functional imaging approaches, which have contributed to provide a 
collection of novel and interesting results. In this discussion, I will summarise the 
most pertinent findings presented in the thesis, their most relevant interpretations; 
and I will also present some limitations of the study and make recommendations for 
















9.1 Analysis of Blood Samples and the Nasal Spray Device 
Employed 
The results from the demography data were illuminating, particularly the blood 
analysis results. Mean fasting HOMA-IR did not differ between groups and for the 
lean group the HOMA-IR scores did not vary with BMI suggesting a homogeneity 
within the group, characteristic of an insulin sensitive phenotype. The overweight 
group did, on the other hand, display a positive relationship between HOMA-IR and 
BMI, suggestive of a relationship between markers of peripheral metabolism and 
body weight. In the OW data, a separation between individuals with a higher HOMA-
IR and a low HOMA-IR (same range as the lean) at a BMI of 28 kg/m2  was observed.  
These HOMA-IR score correlations suggest that stratification of these two groups 
could be made at a BMI of 28 m/kg2. But given the small number of participants with 
a BMI > 28 m/kg2  it was not possible to pursue this within the present dataset. 
Furthermore, HOMA-IR in this case, assessed fasting insulin resistance which is 
considered to be largely driven by insulin’s suppressive effects on hepatic glucose 
release (Singh and Saxena 2010) and therefore does not reflect peripheral insulin-
stimulated insulin resistance or skeletal muscle insulin resistance.  
 
The study reported in this thesis utilised a commercial nasal spray device that was 
selected based after an analytical evaluation of nasal spray characteristics for nose 
to brain delivery of insulin. Characterisation of the pump was performed prior to the 
study initiation in an effort to optimise the study protocol. This is the first time that 
this type of characterisation and selection process has been conducted with insulin 
prior to a human pharmacological study. This characterisation and selection step 
should not be considered as just a complementary step, but rather, a critical 
consideration that should be encouraged for future research experiments using a less 
conventional administration procedure.  
 
The use of intranasal administration to study the central effects of insulin was 
decided based on previous reports highlighting a short transport time into the brain 
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tissue (30-40 minutes (Born et al. 2002)), the limited effect this route has on 
peripheral blood glucose concentrations (Schmid et al. 2018; Heni et al. 2012; Heni, 
Wagner, et al. 2014; Kullmann et al. 2013; Kullmann et al. 2016; Kullmann, Heni, Veit, 
Scheffler, Machann, Häring, et al. 2015) coupled with a positive safety profile using 
high dose administration (i.e. 160 IU) (Schmid et al. 2018).  
 
In this study the metabolic effects of intranasal insulin on peripheral blood measures 
were comparable to those previously reported (Guthoff et al. 2010), showing small 
decreases in plasma glucose concentration. Intranasal insulin did result in  an 
increase in serum insulin concentrations that were significant in the overweight 
group, coupled with a decrease in C-peptide concentration, strongly suggesting an 
overspill effect of insulin into the peripheral circulation, coupled with an early 
counterregulatory suppression of endogenous insulin secretion. The small decrease 
in plasma glucose associated with the absorbed insulin was not significant in the 
overweight group and therefore illustrates a degree of peripheral insulin resistance 
within this overweight group. This reduced sensitivity to peripheral insulin was 
reflected in some of the imaging data, detailed below in the following sections. In the 
lean group, there was an increase in serum insulin associated with intranasal insulin 
administration, which was not significant. Surprisingly, there was a significant 
difference between pre-scan (fasting) serum insulin concentrations between visits 
which was unexpected and biologically difficult to disentangle, as serum C-peptide 
concentrations were comparable between visits. A potential drawback of using 
serum insulin levels for determining peripheral insulin resistance is that there is no 
standardised insulin assay but as the assay used was the same for all measures it 
seems odd that this group and this visit showed a high degree of serum insulin 
variability. Comparable to the significant trend seen in the overweight group there 
was a significant reduction in serum C-peptide over time which was more 
pronounced following intranasal insulin coupled with a small but insignificant 





9.2 Taste Task  
A major element of the SNIFAR study and a considerable component of this thesis 
was the acquisition of functional data during a task that delivered small amounts of 
liquid to the participant whilst in the scanner. The ‘taste task’ used in this study is a 
complex functional paradigm which combines elements of learning, memory, 
anticipation, consummation of primary rewards (liquid bolus) and also evaluation of 
these rewards, all within a single trial of the paradigm. Anticipating the oral delivery 
of sweet stimuli engaged cognitive prefrontal regions of the brain, as well as 
dopaminergic regions. This was the case for both lean and overweight groups. 
Pharmacologically challenging the central nervous system with insulin enhanced the 
responses to the task within these regions, but only in the lean group. In contrast, 
the responses to the task in the overweight group were either absent or in the 
opposite direction (decreases), which uncovered another potentially important 
functional difference between lean and overweight individuals. The prefrontal and 
dopaminergic regions consisted of the anterior cingulate cortex, ventromedial 
prefrontal cortex and the nucleus accumbens. The results presented suggest that 
these regions are insulin sensitive in lean individuals but show impaired insulin 
sensitivity with increased body weight. The ventromedial prefrontal cortex is known 
to be involved in encoding and performing valuations of upcoming stimuli (Hare, 
Camerer, and Rangel 2009); this region was also more active in the lean group under 
both insulin and placebo conditions. The anterior cingulate cortex, an anatomical 
neighbour of the ventromedial prefrontal cortex, is involved in decision making and 
assigning value to the outcome of decisions made (Vassena et al. 2014). Although 
this task did not involve subjective decision making, these insulin related 
modulations, as well as the ventromedial PFC activity, suggest that those with a lower 
BMI might be more cognitively engaged in this task, particularly during presentation 
of cues that occur prior to delivery of sweet stimuli. The group differences in the 
anterior cingulate cortex were witnessed in anticipation to both sucrose and stevia 
based sweet solutions, whereas the ventromedial prefrontal cortex and nucleus 




According to classical conditioning literature, phasic dopaminergic neuron firing in 
the ventral tegmental area and the nucleus accumbens initially occurs in response to 
receipt of a primary sensory stimulus (Schultz 1998; Schultz, Dayan, and Montague 
1997; Rescorla and Wagner 1972). If this stimulus is preceded by a cue, then this 
response is learnt (conditioned); and this phasic dopamine response shifts from being 
triggered by the stimulus to being triggered by cue presentation.  This phenomenon 
is known as ‘temporal difference learning’ (O'Doherty et al. 2002; Schultz 2001). In 
lean individuals the BOLD response observed upon stevia cue presentation is greater 
compared to that from overweight subjects, following insulin administration. 
Coupled with increased prefrontal BOLD activity in the lean group, this finding would 
also provide support to the suggestion made on the previous page, that the lean 
group are more cognitively active and also more aware or alert to the stevia cue and 
its association with stevia taste over the combined runs (as seen from the increase in 
nucleus accumbens activity). In reference to reward deficiency theories of obesity 
(Stice et al. 2008; Burger and Stice 2011b), it could be argued that a central insulin 
challenge evokes a hypo-responsivity to food cues in overweight individuals, which 
is in contrary to classical dopamine obesity-reward theories which posit hyper-
responsivity to food cues in obese individuals (Burger and Stice 2011b). Although not 
observed under placebo conditions, but only when challenged with central insulin, it 
could be argued that healthy overweight individuals respond as a ‘reward deficient 
phenotype’ when presented with predictive food related cues. Since both peripheral 
and central insulin levels normally rise endogenously after feeding, this finding could 
point to an aberrant postprandial response in the overweight but otherwise healthy 
population.  Since this overweight group were not peripherally insulin resistant as 
measured by HOMA-IR, these results could be an example of an early stage 
dysregulation in appetite control and an early sign of prefrontal and dopaminergic 
central insulin resistance.  
 
Investigation of  the effect of the cerebral response to taste following intranasal 
insulin administration, has not been reported to date and therefore the results 
presented in this thesis have provided novel findings. Furthermore, the 
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implementation of oral stevia administration has not formed part of any functional 
taste investigations. Its inclusion in the SNIFAR study proved to be beneficial to 
further understand insulin-related and group related effects. Whole brain analysis 
revealed a significant drug by group interaction effect for the stevia delivery contrast 
within the ventromedial prefrontal cortex and rostral anterior cingulate cortex. The 
findings of this interaction consisted of insulin related increases and decreases in 
BOLD activity for lean and overweight groups, respectively. These regions have been 
shown to be more active to taste if the taste has been assigned a greater value (i.e. 
labelled as more appealing) (de Araujo et al. 2005). As previously mentioned, there 
was an insulin related increase in nucleus accumbens BOLD response upon the stevia 
cue presentation in the lean group. In keeping with this finding one could argue that 
the valence of this taste had been modulated under insulin conditions and therefore 
the taste carries increased appeal, coupled with increased BOLD responses in these 
regions. However, average (across run) palatability data (likeness score) did not show 
any changes between insulin or placebo and therefore, there is strictly no significant 
evidence to support this interpretation.  
 
A set of interesting results from this taste task were discovered through region of 
interest analysis and given the complexity of the paradigm design, this dataset was 
analysed in several ways. This proved to be a worthwhile avenue that aided the 
understanding and interpretability of the results as a whole. Analysis of drug related 
effects was first performed with the two functional runs combined and secondly, for 
each individual run, to try and address the effects of conditioning, habituation to the 
taste stimuli and temporal changes in the BOLD response. This proved fruitful and 
revealed an insulin related increase in BOLD responsiveness within the nucleus 
accumbens upon receiving stevia solution during the second half of the paradigm in 
the lean group. This result was very interesting and opposed the effect of placebo, to 
which the observed nucleus accumbens BOLD response decreased over time 
(although not significantly). Under placebo conditions the reduced response over 
time would be expected, reflecting the temporal difference in the learning element 
of the paradigm (dopamine shift from stimulus delivery to cue presentation) 
(O'Doherty et al. 2004; O'Doherty et al. 2002). The nucleus accumbens responds to 
 335 
salience, in the process of drawing attention to a stimulus and as a consequence, this 
additional attention contributes to learning. The palatability of stevia decreased over 
time in both groups for placebo conditions. However, following IN-INS, both the 
palatability (likeness) and sweetness of stevia decreased over time for both groups. 
This significant change in sweetness and palatability is perhaps salient and therefore 
the increase in BOLD activity is a reflection of encoding this salience. The change in 
palatability and sweetness could be of significance but how this change occurs in 
response to increased central insulin conditions is unknown.  
 
Contrasts from both the stevia solution predictive cues and from the delivery of the  
bolus, were common to many of the statistically significant results observed. Stevia 
solution was employed as an alternative, low energy, but sweet tasting stimulus. 
Stevia is a non-nutritive sweetener that shows beneficial postprandial blood glucose 
effects in comparison to sucrose and other popular non-nutritive sweetener brands 
(Anton et al. 2010). The results reported have shown that the subjective sweetness 
of stevia solution decreases over time, an effect which was more pronounced 
following insulin administration and was coupled with a decrease in how much the 
stevia solution was liked over time also. This finding suggests a role for insulin in taste 
perception or perhaps a top down modulatory response on taste sweetness and an 
avenue of research that would be worthwhile pursuing. To date, only one study has 
looked at the effects of intranasal insulin on sensory perception. It focused on 
olfactory sensitivity and discrimination, highlighting an insulin related decrease in 
sensitivity to a non-food odorant (Brunner, Benedict, and Freiherr 2013). It would be 
interesting to explore olfaction and oral taste and the possible modulatory effects of 
insulin in a more thorough investigation with particular food odours and cues.  
 
As the full title of the SNIFAR study suggests, one of the main aims of the investigation 
was to assess the modulatory effects of intranasal insulin on appetite control and 
reward. However, incorporating functional imaging data acquisition during periods 
of rest, permitted context-independent evaluation of the pharmacological effects. 
Additionally, interpretation on behaviour and function must however be restricted, 
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as the neurophysiological system being perturbed by the pharmacological agent 
during rest cannot, by itself, reflect behaviour.  
9.3 Cerebral Blood Flow 
A useful addition to the assessment of centrally acting agents are measures of 
regional cerebral perfusion, or blood flow (CBF) (Jenkins 2012; Mehta and O'Daly 
2011; Zelaya et al. 2016). In this study, a pseudo-continuous arterial spin labelling 
(pCASL) sequence incorporating a long label duration, was employed to identify 
intranasal insulin related changes in CBF. From the unbiased, voxel-wise whole brain 
analysis, an intranasal insulin related decrease in CBF was witnessed within the left 
posterior insula, left hippocampus, left putamen and also left parahippocampal 
gyrus, which were all limited to the overweight group only. Another interesting 
observation from this assessment of CBF was that the insulin related change in 
hippocampal and putamen CBF showed a strong correlation with saturated fat intake 
and sugar intake scores assessed with questionnaires at screening. This work showed 
that diet composition is related to regional neuronal insulin sensitivity and supports 
the suggested relationship between high fat, high carbohydrate diets and reduced 
neuronal insulin sensitivity (von Frankenberg et al. 2017). Despite this illustrated 
relationship, the information gathered to make these observations is from 
overweight individuals who are by all accounts healthy (disease free) and this must 
be borne in mind when interpretating the data in a clinical context.  With that caveat, 
these correlations do suggest that having an overweight BMI in combination with a 
diet high in saturated fat and sugar may lead to reduced insulin sensitivity within the 
hippocampus and putamen.  
 
These are the first results to demonstrate evidence of changes in hippocampal 
resting activity in response to intranasal insulin. This result provides evidence that 
this agent affects the neuronal profile within this region, which, coupled with the 
reported beneficial effects of intranasal insulin on memory and cognition in 
Alzheimer’s Disease, makes this a relevant and significant result  (Craft et al. 2012; 
Benedict et al. 2004). 
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Furthermore, another important possible interpretation of these data relies on the 
assumption that brain insulin levels rise when peripheral insulin levels rise (Banks, 
Owen, and Erickson 2012; Gray, Meijer, and Barrett 2014).  Hence, normal insulin 
sensitivity of these brain regions may be important to form memory of tastes and 
hence contribute to the control of feeding (Higgs 2005). For example, based on the 
framework set out by Higgs et al., the hippocampus works to form memories of food 
consumption and meals, to aid future decisions about what to eat, as well as when 
to next eat (Higgs et al. 2017). This was elegantly shown in amnesic individuals with 
impaired hippocampal-dependent memory formation function who consumed 
multiple meals in succession as a consequence of not remembering when they last 
ate (Higgs et al. 2008). These important results suggest that dysregulation of 
hippocampal insulin sensitivity serve as a precursor to dysregulated cognitive input 
to appetite control.  
 
It is important to note that from the intranasal insulin literature, only one study has 
shown a significant effect of intranasal insulin on weight loss, predominantly fat 
tissue loss (Hallschmid et al. 2004). This study was part of an 8-week ‘long term 
administration’ study whereby intranasal insulin (160 IU) was administered daily. The 
acute intranasal insulin administration studies that have evaluated appetite and 
reward have not reported any significant changes in total food intake; or interrogated 
these variables using ad libitum food intake. Hallschmid et al., showed that intranasal 
insulin decreased postprandial snack intake for a certain palatable snack, but that 
overall calorie intake was not affected, but they consumed more of the other snacks 
(Hallschmid et al. 2012). This lack of empirical evidence highlights two things; firstly, 
studying intranasal insulin and ad libitum food intake is necessary for future work, 
and secondly, perhaps the weight loss effects of food intake are as a result of the 
delayed effects of insulin on possible cognitive mechanisms and top down control of 
food intake (Higgs and Spetter 2018; Higgs et al. 2017).  
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9.4 Resting State Connectivity 
The resting state BOLD component of the SNIFAR study interrogated the effects of 
intranasal insulin on whole brain functional connectivity using a seed based 
connectivity approach and a newly developed denoising acquisition and processing 
methodology (multi-echo independent component analysis). The hippocampal 
region featured within this analysis, implemented as a seed region, divided into 
anterior and posterior subdivisions. Results from this analysis showed an insulin 
related increase in functional connectivity between the left posterior hippocampus 
and the left fusiform gyrus, which was limited to the lean group only. The fusiform 
gyrus is a component of the temporal visual system, typically involved in evaluating 
food pictures and tracking energy dense foods (van der Laan et al. 2011). The increase 
in connectivity between the posterior hippocampus and fusiform gyrus, observed 
following insulin administration, may underlie some of the memory associated 
benefits that were mentioned earlier in this discussion (Ott et al. 2012; Benedict et 
al. 2004). Furthermore, the lean group showed an increase in functional connectivity 
between the left posterior hippocampus and the right superior frontal gyrus in 
comparison to the overweight group under insulin conditions. The lean group 
presented with a connectivity network, (when using the left posterior hippocampus 
as a seed), which responded to insulin related modulation. The overweight group on 
the other hand presented with a similar network, under both placebo and insulin 
conditions, demonstrating a lack of modulation with increased central insulin. As the 
network seen in response to insulin in the lean group was similar to the overweight 
group under both conditions, it could be considered that this network is already 
upregulated in overweight individuals and therefore may explain the lack of insulin 





9.5 Generalised Observations  
 
From all of the experimental imaging chapters a common theme was observed. In 
most cases the analysis was kept uniform between the imaging studies employing a 
whole brain repeated measures factorial model to explore intranasal insulin vs 
placebo effects and interaction effects between group responsiveness. Not all of 
these models provided significant observations, however some did. In these cases, 
interaction effects were observed that showed intranasal insulin related increases in 
CBF and BOLD contrast in the lean group compared to placebo but displayed insulin 
related decreases in the overweight group. These observations were common 
occurrences throughout the results and highlight intrinsic differences between these 
two groups in central insulin responsiveness. This is suggestive of differential 
responding to intranasal insulin dependent on body mass index (BMI) alone and 
provides some evidence to support this basic measure as a useful tool to assess 
metabolic, hedonic and cognitive effects of appetite control.   
 
9.6 Methodological Considerations and Future Work 
In this multi-modal MRI study, two groups of healthy male individuals were studied. 
These groups were stratified based on a crude anthropometric measure (WHO 1995), 
BMI, and split into one group of normal weight (lean) and one group of overweight 
individuals (which also contained one individual who was classified as obese). BMI, 
essentially a ratio between mass and the square of a subject’s height, was used as a 
recruitment and screening tool (Nuttall 2015). These individuals were stratified into 
two groups (lean and overweight) based on these BMI measures. It could be argued 
that those individuals at the BMI threshold between normal weight and overweight 
could be differentiated at all. This may explain why some of the group effects 
reported are not substantial, and this must be considered when interpreting the 
data. Upon reflection, splitting the two groups into BMI using a larger separation may 
have been a more suitable approach.  Furthermore, a more comprehensive set of 
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measurements such as hip-waist ratio or adiposity measures such as plasma leptin 
concentration, may have provided additional information on body composition that 
may have enhanced the observed differences and aided the interpretation of the 
study results. Other than BMI the two groups were well matched for age and did not 
significantly differ on any of the screening questionnaires or measures of peripheral 
insulin resistance, assessed with the homeostatic model assessment of insulin 
resistance (Matthews, Hosker, et al. 1985; Wallace, Levy, and Matthews 2004).  
 
This functional MRI study was conducted on a relatively small sample size. 
Unfortunately, there was additional exclusion of individuals from the analysis which 
made the sample size even more reduced. Given this, the results and data reported 
here must be largely considered exploratory rather than definitive. These results 
however, are very interesting and will inform future work and investigations into the 
effects of insulin administered via the nasal cavity on brain function. 
 
The blood analysis results highlight a methodological limitation regarding the 
efficiency of nasal administration to selectively increase central concentrations with 
limited effect on peripheral blood glucose and insulin concentrations (Reger and 
Craft 2006). More recent options have been devised further to limit the systemic 
effects of insulin, such as bespoke devices and insulin formulations designed for nose 
to brain delivery such as those reviewed in (Warnken et al. 2016).  
 
Regarding the nasal administration methodology used, a few considerations must be 
acknowledged. Firstly, the placebo treatment used in this study was a saline solution, 
and although appropriate in this instance, a better placebo treatment would have 
been a formulation derived from the vehicle constituents of the insulin solution, 
which has been previously reported (Schilling et al. 2014). Secondly, the study was 
conducted from September through to April. One concern is that during the winter 
period (November, December, January, February) the cold weather may have bought 
about extra congestion within the nasal cavity associated with the common cold 
(Sanu and Eccles 2008). Efforts to only scan when the participants were healthy and 
attempts to decongest prior to commencing the nasal administration protocol were 
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made; but ridding all congestion effects is perhaps unattainable. On the other hand, 
nasal congestion resulting from allergic rhinitis (hay fever) during the spring and 
summer seasons may have had a similar effect on nasal flow, which was avoided 
entirely by not scanning during the high pollen seasons.  
 
In line with seasonal effects are the effects of food and alcohol consumption during 
the holiday periods. Several studies have shown significant weight gain and increases 
in fat mass over the winter holiday period (e.g. Christmas and New Year) (Hull, 
Hester, and Fields 2006; Diaz-Zavala et al. 2017). This is something worth considering 
as this may lead to some additional inter-subject variability, and perhaps a temporal 
physiological change reflective of a deviation from the normal baseline of certain 
participants. In reality avoiding these issues is difficult and one must hope that 
implementing short inter-scan intervals into the protocol would help prevent any 
major intra-subject variability.   
 
From an acquisition and interpretation perspective (of functional imaging data), one 
must be aware that the changes or effects witnessed are made based on surrogate 
markers of neuronal activity, i.e. neuro-vascular changes that give rise to changes in 
CBF and BOLD contrast. Inferences based on these changes must therefore be 
restricted or limited as it is not possible to interpret these data in terms of direct 
changes in neuronal activity, neurotransmission or receptor-substrate activity. In 
terms of vasoactive effects of insulin, Grichisch et al., reported no effects of 
intranasal insulin (160 IU) vs placebo on visual cortex CBF during rest and also during 
visual stimulation (checkerboard task) (Grichisch et al. 2012). This study was limited 
to a single occipital region and so cannot confirm vasoactive effects on other regions 
where insulin receptors are more dense, or present.  
 
The central effects of intranasal insulin reported in this thesis are made upon an 
assumption that exogenous insulin substrate is active within the brain tissue and it is 
these interactions that are driving the effects seen from imaging data analysis. This 
assumption is present, although not explicitly mentioned, within the published 
human intranasal insulin literature (Kullmann et al. 2016; Reger and Craft 2006), and 
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is based on work published by Born and colleagues in 2002 that showed increased 
concentration in cerebrospinal fluid (CSF) following intranasal insulin administration 
(Born et al. 2002). This work shows that CSF concentrations are increased following 
nasal administration. There is no denying that this description of nose to brain 
delivery of insulin has changed the landscape of insulin research in the brain. 
However, during the recent surge in intranasal insulin use as a research tool there 
has been very little focus on the effects of intranasal insulin on insulin receptor 
transmission within the olfactory bulb. This is an area of research that requires some 
consideration in the future.  
 
The cohort recruited for this study were healthy male volunteers who had a range of 
different weights and associated BMI scores. Those individuals stratified into the 
overweight group did not however show a peripheral insulin resistance phenotype 
as measured from HOMA-IR scores. This overweight group of volunteers were 
healthy as attained from the screening protocol, did not smoke excessively or drink 
excessively (as per the exclusion criteria) and were relatively young. As insulin 
resistance develops over time it could be suggested that it is for these reasons that 
this cohort did not display signs of peripheral insulin resistance as measured by the 
HOMA-IR model. For future work, it would be important to investigate a group of 
overweight individuals who display peripheral insulin resistance, thus using insulin 
resistance as an inclusion criteria for recruitment. Understanding the transition 
phase or identifying neural correlates associated with a phenotype of non-obese but 
insulin resistant group of individuals would be paramount to understanding what 
neural responses might pre-dispose certain individuals to weight gain or 
development of metabolic disease.   
 
Simulating real-life situations in a laboratory environment is a major limitation for 
research, especially in the investigation of food-driven reward. From the point of 
view of brain function, during food consumption in the ‘real world’ is no trivial action. 
Rather, it is a complex decision making process that takes into account an number of 
factors such as meal cost, predicted reward, logistics, convenience, mood, arousal, 
alcohol intake and appetite suppressant intake (nicotine, caffeine), to name but a 
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few (Guyenet and Schwartz 2012). This study may have benefitted from a decision 
making element in combination with anticipation, to better try and replicate the 
processes that govern food consumption (Gluck, Viswanath, and Stinson 2017) and 
explore in more detail the cognitive effects central insulin may potentially have.  
 
From a methodological standpoint the ‘taste task’ posed some challenges. 
Incorporating three taste stimuli into the design of this paradigm required a balance 
between overall scan duration, number of events/epochs for each taste stimuli, 
having an appropriate inter-trial interval and time between cue and delivery events 
whilst taking into account taste habituation effects, participant compliance and 
performance. In spite of having implemented a design that balanced all those factors, 
a retrospective examination of this paradigm showed that there are features that 
could be changed or optimised in future investigations. Firstly, the use of just two 
tastes, one control and one rewarding, would be better suited to this style of design 
as it would permit both a greater number of trials for each taste and also allow for 
greater separation of events in time. For example, a long anticipation period, (5-7s), 
prior to stimulus delivery would be advantageous and would permit adequate 
sampling of the BOLD response associated with this anticipatory phase.  This was not 
the case in the current work. Although an apparatus was developed and used to 
minimise the need for movement during the reception of the taste solutions, 
participant head movements occurred during swallowing periods which were 
modelled in the first level analysis. Standard motion correction and regression at the 
first level was implemented and the whole brain results generated were in line with 
previous literature (O'Doherty et al. 2004; O'Doherty et al. 2002; van Bloemendaal et 
al. 2015) and as expected. Previous research using a similar study design made use 
of an EEG-like cap with a single copper node attached to the neck as a fiducial marker 
(O'Doherty et al. 2004). Swallowing-related movements were detected and a 
timeseries for this fiducial marker was regressed from the time series. This seems like 
an easily implementable addition. Finally, this paradigm only probes taste initiated 
by activation of taste receptors on the tongue and does not assess the response 
associated with the ‘flavour’ experience of the stimulus. To better understand the 
effect of ‘flavour’, which is a multi-modal perception requiring the combination of 
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taste, aroma and also other sensory systems, the paradigm should be modified to 
fully model the BOLD response that follows swallowing, i.e. the post ingestion phase. 
This could be achieved by incorporating an ‘immediate swallow’, whereby the 
participant swallows the delivered bolus as soon as it is delivered, much like how you 
would drink normally (Eldeghaidy et al. 2011) This event would be followed by a 
sufficient consummatory phase, well after the swallow event, which incorporates the 
retro-nasal aroma that is produced following swallowing thus integrating taste and 
aroma to help create flavour perception (Eldeghaidy et al. 2011). By using this 
approach the movement from receiving the stimulus delivery plus swallowing would 
be combined into a single event thus reducing the number of motion provoking 
events in the design.  
 
Finally, the external environmental factors that interact and contribute to food 
processing and appetite are hard to simulate and also hard to control. Overnight 
fasting perturbs the homeostatic system and has been shown to alter the salience of 
food pictures (Dagher 2012) and also increases the preference for energy dense 
foods over low energy food pictures (Goldstone et al. 2009). The future of functional 
imaging for metabolic research will require a better understanding of the 
environmental factors that contribute to overeating and overconsumption of energy 
dense, ‘rewarding’ foods, coupled with an understanding of the decisions made to 
seek out these food types as opposed to the response upon consumption. The 
anticipation of food is a driver of hedonic reward and one which is largely controlled 
by cognitive top down modulators. How does the interplay of circulating hormones 
such as insulin, environmental factors, and past experiences converge and how does 
this multi-faceted system become dysregulated or vulnerable to dysregulation in 
certain individuals? 
9.7 Final Concluding Statements  
This thesis presented work that employed a commercial nasal pump to increase 
central insulin concentrations via the nose to brain delivery route. The 
manifestations of these increased insulin concentrations were observed through the 
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use of both resting and task based functional imaging techniques. This work has 
added knowledge to the field of intranasal insulin and presented some thought 
provoking results. It is clear from these findings alongside the previously reported 
literature that the role of insulin in appetite control and subsequent food intake is 
multi-factorial and has implications for the homeostatic, hedonic and cognitive 
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